

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number  
**WO 00/78808 A1**

(51) International Patent Classification<sup>7</sup>: C07K 14/47,  
C07H 21/04, C12N 15/63, 1/21, C12P 21/02

(74) Agents: CORUZZI, Laura, A. et al.; Pennie & Edmonds  
LLP, 1155 Avenue of the Americas, New York, NY 10036  
(US).

(21) International Application Number: PCT/US00/16883

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,  
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 19 June 2000 (19.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/336,536 18 June 1999 (18.06.1999) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: MILLENNIUM PHARMACEUTICALS,  
INC. [US/US]; 75 Sidney Street, Cambridge, MA 02139  
(US).

**Published:**

— With international search report.

(72) Inventors: LEIBY, Kevin, R.; 4 Showhegan Way, Natick,  
MA 01760 (US). McKAY, Charles; 36 Newbrook Circle,  
Newton, MA 02467 (US). BOSSONE, Steven; 958 Mass-  
achusetts Avenue, Lexington, MA 02173 (US).

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: SECRETED PROTEINS AND USES THEREOF

(57) Abstract: The invention provides isolated nucleic acid molecules, designated TANGO 253, which encode proteins contain-  
ing C1q domains and which are homologous to a human adipocyte complement-mediated protein precursor, TANGO 257, which  
encode proteins homologous to the human extracellular molecule olfactomedin, a molecule important in the maintenance, growth  
and differentiation of chemosensory cilia of olfactory neurons, INTERCEPT 258, which encode Ig domain-containing proteins that  
exhibit homology to an antigen (A33) expressed in colonic and small bowel epithelium, and TANGO 281, which encode proteins  
downregulated in megakaryocytes that fail to express the gata-1 transcription factor (a factor critical for blood cell formation) and  
can, therefore, represent direct or indirect gata-1 targets. The invention also provides antisense nucleic acid molecules, expression  
vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and  
non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still  
further provides isolated polypeptides, fusin polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic  
methods utilizing compositions of the invention are also provided.



WO 00/78808 A1

## SECRETED PROTEINS AND USES THEREOF

---

This application is a continuation-in-part of U.S. patent application Serial No. 09/336,536, filed June 18, 2000, the contents of which are incorporated herein by reference in its entirety.

### Background of the Invention

Many secreted proteins, for example, cytokines and cytokine receptors, play a vital role in the regulation of cell growth, cell differentiation, and a variety of specific cellular responses. A number of medically useful proteins, including erythropoietin, granulocyte-macrophage colony stimulating factor, human growth hormone, and various interleukins, are secreted proteins. Thus, an important goal in the design and development of new therapies is the identification and characterization of secreted and transmembrane proteins and the genes which encode them.

Many secreted proteins are receptors which bind a ligand and transduce an intracellular signal, leading to a variety of cellular responses. The identification and characterization of such a receptor enables one to identify both the ligands which bind to the receptor and the intracellular molecules and signal transduction pathways associated with the receptor, permitting one to identify or design modulators of receptor activity, *e.g.*, receptor agonists or antagonists and modulators of signal transduction.

### Summary of the Invention

The present invention is based, at least in part, on the discovery of cDNA molecules which encode the TANGO 253, 257 and 281 proteins and the INTERCEPT 258 protein, all of which are either wholly secreted or transmembrane proteins.

The TANGO 253 proteins are C1q domain-containing polypeptides that exhibit homology to a human adipocyte complement-related protein precursor.

The TANGO 257 proteins are homologous to the human extracellular molecule olfactomedin, a molecule important in the maintenance, growth and differentiation of chemosensory cilia of olfactory neurons.

The INTERCEPT 258 proteins are Ig domain-containing polypeptides that exhibit homology to an antigen (A33) expressed in colonic and small bowel epithelium, a protein that may represent a cancer cell marker.

The TANGO 281 proteins represent proteins downregulated in megakaryocytes that fail to express the gata-1 transcription factor (a factor critical for blood cell formation) and can, therefore, represent direct or indirect gata-1 targets.

5 The TANGO 253, TANGO 257, INTERCEPT 258 and TANGO 281 proteins, fragments, derivatives, and variants thereof are collectively referred to herein as "polypeptides of the invention" or "proteins of the invention." Nucleic acid molecules encoding the polypeptides or proteins of the invention are collectively referred to as "nucleic acids of the invention."

10 The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or a biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable for use as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.

15 The invention features nucleic acid molecules which are at least 30%, 35%, 40%, 45%, 50%, 55%, 65%, 75%, 85%, 95%, or 98% identical to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, or the nucleotide sequence of the cDNA insert of an EpT253 clone deposited with ATCC® as Accession Number 207222, or a complement thereof.

20 The invention features nucleic acid molecules which are at least 30%, 35%, 40%, 45%, 50%, 55%, 65%, 75%, 85%, 95%, or 98% identical to the nucleotide sequence of SEQ ID NO:8, SEQ ID NO:9, or the nucleotide sequence of the cDNA insert of an EpTm253 clone deposited with ATCC® as Accession Number 207215, or a complement thereof.

25 The invention features nucleic acid molecules which are at least 95% or 98% identical to the nucleotide sequence of SEQ ID NO:15, SEQ ID NO:16, or the nucleotide sequence of the cDNA insert of an EpT257 clone deposited with ATCC® as Accession Number 207222, or a complement thereof.

30 The invention features nucleic acid molecules which are at least 95% or 98% identical to the nucleotide sequence of SEQ ID NO:21, SEQ ID NO:22, or the nucleotide sequence of the cDNA insert of an EpTm257 clone deposited with ATCC® as Accession Number 207217, or a complement thereof.

35 The invention features nucleic acid molecules which are at least 45%, 50%, 55%, 65%, 75%, 85%, 95%, or 98% identical to the nucleotide sequence of SEQ ID NO:26, SEQ ID NO:27, or the nucleotide sequence of the cDNA insert of an EpT258 clone deposited with ATCC® as Accession Number 207222, or a complement thereof.

The invention features nucleic acid molecules which are at least 45%, 50%, 55%, 65%, 75%, 85%, 95%, or 98% identical to the nucleotide sequence of SEQ ID NO:37, SEQ ID NO:38, or the nucleotide sequence of the cDNA insert of an EpTm258 clone deposited with ATCC® as Accession Number 207221, or a complement thereof.

5       The invention features nucleic acid molecules which are at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95%, or 98% identical to the nucleotide sequence of SEQ ID NO:46, SEQ ID NO:47, or the nucleotide sequence of the cDNA insert of an EpT281 clone deposited with ATCC® as Accession Number 207222, or a complement thereof.

10       The invention features nucleic acid molecules which are at least 35%, 40%, 45%, 50%, 55%, 65%, 75%, 85%, 95%, or 98% identical to the nucleotide sequence of SEQ ID NO:56, SEQ ID NO:57, or the nucleotide sequence of the cDNA insert of an EpmT281 clone deposited with ATCC® as patent deposit Number PTA-224, or a complement thereof.

15       The invention features nucleic acid molecules which are at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% identical to the nucleotide sequence of SEQ ID NO: 1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163,  
20   165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, a complement thereof, or the non-coding strand of EpT 253, EpTm253, EpT257, EpTm257, EpT258, EpTm258, EpT281 or EpTm281 cDNA of ATCC® Accession 207222, Accession Number 207215, Accession 207217, Accession Number 207221, or patent deposit Number PTA-224, wherein said  
25   nucleic acid molecules encode polypeptides or proteins that exhibit at least one structural and/or functional feature of a polypeptide of the invention.

      The invention features nucleic acid molecules of at least 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1100, 1200 or 1300 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, the nucleotide sequence of an EpT253 cDNA of  
30   ATCC® Accession Number 207222, or a complement thereof.

      The invention features nucleic acid molecules which include a fragment of at least 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700 or 720 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2, or a complement thereof.

      The invention features nucleic acid molecules which include a fragment of at least  
35   540, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200 or 1250 contiguous

nucleotides of the nucleotide sequence of SEQ ID NO:8 the nucleotide sequence of an EpTm253 cDNA of ATCC® Accession Number 207215, or a complement thereof.

The invention features nucleic acid molecules of at least 310, 350, 400, 450, 500, 550, 600, 650 or 700 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:9, or a complement thereof.

The invention features nucleic acid molecules which include a fragment of at least 1800 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:15 or its complement.

The invention features nucleic acid molecules which include a fragment of at least 1150 or 1200 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:16, or its complement.

The invention features nucleic acid molecules which include a fragment of at least 1100, 1200, 1300, 1400, 1500, 1600 or 1700 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:21 the nucleotide sequence of an EpTm257 cDNA of ATCC® Accession Number 207217, or a complement thereof.

The invention features nucleic acid molecules which include a fragment of at least 1150 or 1200 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:22, or its complement.

The invention features nucleic acid molecules which include a fragment of at least 420, 450, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, or 1800 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:26 the nucleotide sequence of an EpT258 cDNA of ATCC® Accession Number 207222, or a complement thereof.

The invention features nucleic acid molecules which include a fragment of at least 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:27, or a complement thereof.

The invention features nucleic acid molecules which include a fragment of at least 675, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:37 the nucleotide sequence of an EpTm258 cDNA of ATCC® Accession Number 207221, or a complement thereof.

The invention features nucleic acid molecules which include a fragment of at least 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:38, or a complement thereof.

The invention features nucleic acid molecules which include a fragment of at least 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:46 the nucleotide sequence of an EpT281 cDNA of ATCC® Accession Number 207222, or a complement thereof.

The invention features nucleic acid molecules which include a fragment of at least 50, 100, 200, 300, 400, 500, 600, 700 or 750 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:47, or a complement thereof.

The invention features nucleic acid molecules which include a fragment of at least 550, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800 or 1850 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:56 the nucleotide sequence of an EpTm281 cDNA of ATCC® patent deposit Number PTA-224, or a complement thereof.

The invention features nucleic acid molecules which include a fragment of at least 50, 100, 200, 300, 400, 500, 600 or 700 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:57, or a complement thereof.

The invention features isolated nucleic acid molecules having a nucleotide sequence that is at least about 20, 50, 100, 150, 200, 250, 300, 400, 450, 500, 550, 600, 650, 700 or more contiguous nucleotides identical to the nucleic acid sequence of SEQ ID NOS: 1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, or a complement thereof, or the non-coding strand of EpT253, EpTm253, EpT257, EpTm257, EpT258, EpTm258, EpT281 or EpTm281 cDNA of ATCC® Accession 207222, Accession number 207215, Accession Number 207217, Accession Number 207221, or patent deposit number PTA-224, wherein said nucleic acid molecules encode polypeptides or proteins that exhibit at least one structural and/or functional feature of a polypeptide of the invention.

The invention also features nucleic acid molecules which include a nucleotide sequence encoding a protein having an amino acid sequence that is at least 40%, 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:3, the amino acid sequence encoded by an EpT253 cDNA of ATCC® Accession Number 207222, or a complement thereof.

The invention also features nucleic acid molecules which include a nucleotide sequence encoding a protein having an amino acid sequence that is at least 95%, or 98%

identical to the amino acid sequence of SEQ ID NO:10, the amino acid sequence encoded by an EpTm253 cDNA of ATCC® Accession Number 207115, or a complement thereof.

The invention also features nucleic acid molecules which include a nucleotide sequence encoding a protein having an amino acid sequence that is at least 88%, 90%, 95% or 98% identical to the amino acid sequence of SEQ ID NO:17, the amino acid sequence encoded by an EpT257 cDNA of ATCC® Accession Number 207222, or a complement thereof.

The invention also features nucleic acid molecules which include a nucleotide sequence encoding a protein having an amino acid sequence that is at least 88%, 90%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:23, the amino acid sequence encoded by an EpTm257 cDNA of ATCC® Accession Number 207117, or a complement thereof.

The invention also features nucleic acid molecules which include a nucleotide sequence encoding a protein having an amino acid sequence that is at least 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:28, the amino acid sequence encoded by an EpT258 cDNA of ATCC® Accession Number 207222, or a complement thereof.

The invention also features nucleic acid molecules which include a nucleotide sequence encoding a protein having an amino acid sequence that is at least 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:39, the amino acid sequence encoded by an EpTm258 cDNA of ATCC® Accession Number 207221, or a complement thereof.

The invention also features nucleic acid molecules which include a nucleotide sequence encoding a protein having an amino acid sequence that is at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:48, the amino acid sequence encoded by an EpT281 cDNA of ATCC® Accession Number 207222, or a complement thereof.

The invention also features nucleic acid molecules which include a nucleotide sequence encoding a protein having an amino acid sequence that is at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:58, the amino acid sequence encoded by an EpTm281 of ATCC® patent deposit Number PTA-224, or a complement thereof.

The invention also features nucleic acid molecules which include a nucleotide sequence encoding a polypeptide or protein having an amino acid sequence that is at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:3, 10, 17, 23, 28, 39, 48, or 58, the amino acid

sequence encoded by EpT253, EpTm253, EpT257, EpTm257, EpT258, EpTm258, EpT281, or EpTm281 of ATCC® Accession Number 207222, Accession Number 207215, Accession Number 207217, or Accession Number 207221, patent deposit Number PTA-224, or a complement thereof, wherein the polypeptide or protein encoded by the  
5 nucleotide sequence also exhibits at least one structural and/or functional feature of a polypeptide of the invention.

In preferred embodiments, the nucleic acid molecules have the nucleotide sequence of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56 or 57, or the nucleotide sequence of the cDNA clones of ATCC® Accession Number 207222, 207215, 207217,  
10 207221, 207222, or PTA-224.

Also within the invention are nucleic acid molecules which encode a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:3, or a fragment including at least 10, 15, 20, 25, 30, 50, 75, 100, 125, 150, 175, 200, 225, 230 or 240 contiguous amino acids of SEQ ID NO:3, or the amino acid sequence encoded by an EpT253 cDNA of  
15 ATCC® Accession Number 207222.

Also within the invention are nucleic acid molecules which encode a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:17, or a fragment including at least 10, 15, 20, 25, 30, 50, 75, 100, 125, 150, 175, 200, 225, 230 or 240 contiguous amino acids of SEQ ID NO:10, or the amino acid sequence encoded by an EpTm253 cDNA of  
20 ATCC® Accession Number 207215.

Also within the invention are nucleic acid molecules which encode a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:10, or a fragment including at least 360, 370, 380, 390 or 400 contiguous amino acids of SEQ ID NO:17, or the amino acid sequence encoded by an EpT257 cDNA of ATCC® Accession Number 207222.

25 Also within the invention are nucleic acid molecules which encode a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:23, or a fragment including at least 360, 370, 380, 390 or 400 contiguous amino acids of SEQ ID NO:23, or the amino acid sequence encoded by an EpTm257 cDNA of ATCC® Accession Number 207217.

Also within the invention are nucleic acid molecules which encode a fragment of a  
30 polypeptide having the amino acid sequence of SEQ ID NO:3, or a fragment including at least 15, 25, 30, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 350 or 360 contiguous amino acids of SEQ ID NO:28, or the amino acid sequence encoded by an EpT258 cDNA of ATCC® Accession Number 207222.

Also within the invention are nucleic acid molecules which encode a fragment of a  
35 polypeptide having the amino acid sequence of SEQ ID NO:39, or a fragment including at least 160, 175, 200, 225, 250, 275, 300, 350, 375 or 385 contiguous amino acids of SEQ

ID NO:39, or the amino acid sequence encoded by an EpT258 cDNA of ATCC® Accession Number 207221.

Also within the invention are nucleic acid molecules which encode a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:48, or a fragment including at least 15, 25, 30, 50, 75, 100, 125, 150, 175, 200, 225, 235 or 240 contiguous amino acids of SEQ ID NO:48, or the amino acid sequence encoded by an EpT281 cDNA of ATCC® Accession Number 207222.

Also within the invention are nucleic acid molecules which encode a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:58, or a fragment including at least 15, 25, 30, 50, 75, 100, 125, 150, 175 or 200 contiguous amino acids of SEQ ID NO:58, or the amino acid sequence encoded by an EpTm281 cDNA of ATCC® patent deposit Number PTA-224.

The invention also features nucleic acid molecules which encode a polypeptide fragment of at least 15, 25, 30, 50, 75, 100, 125, 150, 175, 200 or more contiguous amino acids of SEQ ID NO:3, 10, 17, 23, 28, 39, 48 or 58, or the amino acid sequence encoded by EpT253, EpTm253, EpT257, EpTm257, EpT258, EpTm258, EpT281 or EpTm281 of ATCC® Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221 or patent deposit Number PTA-224, wherein the fragment also exhibits at least one structural and/or functional feature of a polypeptide of the invention.

The invention includes nucleic acid molecules which encode a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164, or the amino acid sequence encoded by a cDNA of ATCC® Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221 or patent deposit Number PTA-224, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule consisting of a nucleic acid sequence encoding SEQ ID NO:3, 10, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164, or the amino acid sequence encoded by a cDNA of ATCC® Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221 or patent deposit Number PTA-224, or a complement thereof under stringent conditions.

Also within the invention are isolated polypeptides or proteins having an amino acid sequence that is at least about 40%, preferably 45%, 55%, 65%, 75%, 85%, 95% or

98% identical to the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by an EpT253 cDNA of ATCC® Accession Number 207222.

Also within the invention are isolated polypeptides or proteins having an amino acid sequence that is at least about 40%, preferably 45%, 50%, 55%, 65%, 75%, 85%, 95% or 98% identical to the amino acid sequence of SEQ ID NO:10, or the amino acid sequence encoded by an EpTm253 cDNA of ATCC® Accession Number 207215.

Also within the invention are isolated polypeptides or proteins having an amino acid sequence that is at least 88%, 90%, 95% or 98% identical to the amino acid sequence of SEQ ID NO:17, or the amino acid sequence encoded by an EpT257 cDNA of ATCC® Accession Number 207222.

Also within the invention are isolated polypeptides or proteins having an amino acid sequence that is at least 88%, 90%, 95% or 98% identical to the amino acid sequence of SEQ ID NO:23, or the amino acid sequence encoded by an EpTm257 cDNA of ATCC® Accession Number 207217.

Also within the invention are isolated polypeptides or proteins having an amino acid sequence that is at least about 30%, preferably 35%, 45%, 55%, 65%, 75%, 85%, 95% or 98% identical to the amino acid sequence of SEQ ID NO:28, or the amino acid sequence encoded by an EpT258 cDNA of ATCC® Accession Number 207222.

Also within the invention are isolated polypeptides or proteins having an amino acid sequence that is at least about 30%, preferably 35%, 40%, 45%, 50%, 55%, 65%, 75%, 85%, 95% or 98% identical to the amino acid sequence of SEQ ID NO:39, or the amino acid sequence encoded by an EpTm258 cDNA of ATCC® Accession Number 207221.

Also within the invention are isolated polypeptides or proteins having an amino acid sequence that is at least about 30%, preferably 35%, 45%, 55%, 65%, 75%, 85%, 95% or 98% identical to the amino acid sequence of SEQ ID NO:48, or the amino acid sequence encoded by an EpT281 cDNA of ATCC® Accession Number 207222.

Also within the invention are isolated polypeptides or proteins having an amino acid sequence that is at least about 30%, preferably 35%, 40%, 45%, 50%, 55%, 65%, 75%, 85%, 95% or 98% identical to the amino acid sequence of SEQ ID NO:58, or the amino acid sequence encoded by an EpTm281 cDNA of ATCC® patent deposit Number PTA-224.

The invention also features isolated polypeptides or proteins having an amino acid sequence that is at least about 30%, preferably 35%, 40%, 45%, 50%, 55%, 65%, 75%, 85%, 95% or 98% identical to the amino acid sequence of SEQ ID NO:3, 10, 17, 23, 28, 39, 48 or 58, or the amino acid sequence encoded by EpT253, EpTm253, EpT257,

EpTm257, EpT258, EpTm258, EpT281 or EpTm281 of ATCC® Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221, patent deposit Number PTA-224, wherein the protein or polypeptides also exhibit at least one structural and/or functional feature of a polypeptide of the invention.

5 Also within the invention are isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 30%, preferably 35%, 40%, 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95% or 98% identical to the nucleic acid sequence encoding SEQ ID NO:3, and isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence which  
10 hybridizes under stringent hybridization conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2, a complement thereof, or the non-coding strand of an EpT253 cDNA of ATCC® Accession Number 207222.

Also within the invention are isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 30%,  
15 preferably 35%, 40%, 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95% or 98% identical to the nucleic acid sequence encoding SEQ ID NO:10, and isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:8 or SEQ ID NO:9, a complement thereof, or the non-  
20 coding strand of an EpTm253 cDNA of ATCC® Accession Number 207215.

Also within the invention are isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95% or 98% identical to the nucleic acid sequence encoding SEQ ID NO:28, and isolated polypeptides or proteins which are encoded by a nucleic acid  
25 molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:26 or SEQ ID NO:27, a complement thereof, or the non-coding strand of an EpT258 cDNA of ATCC® Accession Number 207222.

Also within the invention are isolated polypeptides or proteins which are encoded  
30 by a nucleic acid molecule having a nucleotide sequence that is at least about 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95% or 98% identical to the nucleic acid sequence encoding SEQ ID NO:39, and isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:37 or  
35 SEQ ID NO:38, a complement thereof, or the non-coding strand of an EpTm258 cDNA of ATCC® Accession Number 207221.

Also within the invention are isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 30%, preferably 35%, 40%, 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95% or 98% identical to the nucleic acid sequence encoding SEQ ID NO:48, and isolated polypeptides or proteins  
5 which are encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:46 or SEQ ID NO:47, a complement thereof, or the non-coding strand of an EpT281 cDNA of ATCC® Accession Number 207222.

Also within the invention are isolated polypeptides or proteins which are encoded  
10 by a nucleic acid molecule having a nucleotide sequence that is at least about 30%, preferably 35%, 40%, 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95% or 98% identical to the nucleic acid sequence encoding SEQ ID NO:58, and isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having the  
15 nucleotide sequence of SEQ ID NO:56 or SEQ ID NO:57, a complement thereof, or the non-coding strand of an EpTm281 cDNA of ATCC® patent deposit Number PTA-224.

The invention also features isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 30%, preferably 35%, 40%, 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95% or 98% identical to a nucleic  
20 acid sequence encoding SEQ ID NO:3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164, isolated polypeptides or proteins which are encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having the nucleotide  
25 sequence of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 101, 103, 104, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, a complement thereof, or the non-coding strand of  
30 EpT253, EpTm253, EpT257, EpTm257, EpT258, EpTm258, EpT281, EpTm281 of ATCC® Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221, patent deposit Number PTA-224, wherein polypeptides or proteins also exhibit at least one structural and/or functional feature of a polypeptide of the invention.

35 Also within the invention are polypeptides which are naturally occurring allelic variants of a polypeptide that includes the amino acid sequence of SEQ ID NO:3, 10, 17,

23, 28, 39, 48 or 58, or the amino acid sequence encoded by a cDNA of ATCC® Accession Number 207222, Accession Number 207215, Accession Number 207217 Accession Number 207221, or patent deposit Number PTA-224, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule having the sequence of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56 or 57, or a complement thereof under stringent conditions.

The invention also features nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 or 2, or an EpT253 cDNA of ATCC® Accession Number 207222, or a complement thereof.

In other embodiments, the nucleic acid molecules are at least 450, 500, 550, 600, 650, 700, 750, 800, 1000, 1100, 1200 or 1300 contiguous nucleotides in length and hybridize under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or 2, an EpT253 cDNA of ATCC® Accession Number 207222, or a complement thereof.

The invention also features nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:8 or SEQ ID NO:9, an EpTm253 cDNA of ATCC® Accession Number 207215, or a complement thereof. In other embodiments, the nucleic acid molecules are at least 540, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1159, 1200, or 1250 contiguous nucleotides in length and hybridize under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8 or SEQ ID NO:9, an EpTm253 cDNA of ATCC® Accession Number 207215, or a complement thereof.

The invention also features nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:15 or SEQ ID NO:16, an EpT257 cDNA of ATCC® Accession Number 207222, or a complement thereof and encode a polypeptide comprising the amino acid sequence of SEQ ID NO:17, or encode a polypeptide comprising at least 360, 370, 380, 390 or 400 contiguous amino acids or SEQ ID NO:17.

The invention also features nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:21 or SEQ ID NO:22, an EpTm257 cDNA of ATCC® Accession Number 207217, or a complement thereof, and encode a polypeptide comprising the amino acid sequence of SEQ ID NO:23, or a polypeptide comprising at least 360, 370, 380, 390, or 400 contiguous amino acids of SEQ ID NO:23.

The invention also features nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:26 or

SEQ ID NO:27, an EpT258 cDNA of ATCC® Accession Number 207222, or a complement thereof. In other embodiments, the nucleic acid molecules are at least 550, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 contiguous nucleotides in length and hybridize under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:26 or SEQ ID NO:27, an EpT258 cDNA of ATCC® Accession Number 207222, or a complement thereof.

The invention also features nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:37 or SEQ ID NO:38, an EpTm258 cDNA of ATCC® Accession Number 207221, or a complement thereof. In other embodiments, the nucleic acid molecules are at least 650, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 contiguous nucleotides in length and hybridize under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:37 or SEQ ID NO:38, an EpTm258 cDNA of ATCC® Accession Number 207221, or a complement thereof.

The invention also features nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:46 or 47, an EpTm281 cDNA of ATCC® Accession Number 207222, or a complement thereof. In other embodiments, the nucleic acid molecules are at least 710, 750, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 contiguous nucleotides in length and hybridize under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:46 or SEQ ID NO:47, an EpT281 cDNA of ATCC® Accession Number 207222, or a complement thereof.

The invention also features nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:56 or 57, an EpTm281 cDNA of ATCC® patent deposit Number PTA-224, or a complement thereof. In other embodiments, the nucleic acid molecules are at least 580, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800 or 1850 contiguous nucleotides in length and hybridize under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:56 or SEQ ID NO:57, an EpTm281 cDNA of ATCC® patent deposit Number PTA-224, or a complement thereof.

The invention also features nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, or a

nucleotide sequence of EpT253, EpTm253, EpT257, EpTm257, EpT258, EpTm258, EpT281 or EpTm281 of ATCC® Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221, patent deposit Number PTA-224, or complement thereof, wherein such nucleic acid molecules encode polypeptides or  
5 proteins that exhibit at least one structural and/or functional feature of a polypeptide of the invention.

The invention also features nucleic acid molecules at least 15, preferably at least 50, at least 75, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 1000, at least 1100  
10 or at least 1200 or more contiguous nucleotides in length which hybridize under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 104, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170,  
15 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, or a nucleotide sequence of EpT253, EpTm253, EpT257, EpTm257, EpT258, EpTm258, EpT281 or EpTm281 of ATCC® Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221, patent deposit Number PTA-224, or a complement thereof, wherein said nucleic acid  
20 molecules encode polypeptides or proteins that exhibit at least one structural and/or functional feature of a polypeptide of the invention.

In one embodiment, the invention provides an isolated nucleic acid molecule which is antisense to the coding strand of a nucleic acid of the invention.

Another aspect of the invention provides vectors, *e.g.*, recombinant expression  
25 vectors, comprising a nucleic acid molecule of the invention. In another embodiment, the invention provides host cells containing such a vector or engineered to contain and/or express a nucleic acid molecule of the invention. The invention also provides methods for producing a polypeptide of the invention by culturing, in a suitable medium, a host cell of the invention such that a polypeptide of the invention is produced.

Another aspect of this invention features isolated or recombinant proteins and  
30 polypeptides of the invention. Preferred proteins and polypeptides possess at least one biological activity possessed by the corresponding naturally-occurring human polypeptide. An activity, a biological activity, or a functional activity of a polypeptide or nucleic acid of the invention refers to an activity exerted by a protein, polypeptide or nucleic acid  
35 molecule of the invention on a responsive cell as determined *in vivo* or *in vitro*, according to standard techniques. Such activities can be a direct activity, such as an association with

or an enzymatic activity on a second protein, or an indirect activity, such as a cellular signaling activity mediated by interaction of the protein with a second protein.

For TANGO 253, biological activities include, *e.g.*, (1) the ability to modulate (this term, as used herein, includes, but is not limited to, “stabilize”, promote, inhibit or disrupt, 5 protein-protein interactions (*e.g.*, homophilic and/or heterophilic), and protein-ligand interactions, *e.g.*, in receptor-ligand recognition; (2) the ability to modulate the development, differentiation, maturation, proliferation and/or activity of cells of the central nervous system such as neurons, glial cells (*e.g.*, astrocytes and oligodendrocytes), and Schwann cells; (3) the ability to modulate the development of central nervous system; 10 (4) the ability to modulate the development, differentiation, maturation, proliferation and/or activity of renal cells; (5) the ability to modulate the development, differentiation, maturation, proliferation and/or activity of testical cells, such as germ cells, leydig cells and Sertoli cells; (6) the ability to modulate the development, differentiation, maturation, proliferation and/or activity of ovarian cells; (7) ability to modulate cell-cell interactions and/or cell-extracellular matrix interactions; (8) the ability to modulate the host immune 15 response, *e.g.*, by modulating one or more elements in the serum complement cascade; (9) the ability to modulate the proliferation, differentiation and/or activity of cells that form blood vessels and coronary tissue (*e.g.*, coronary smooth muscle cells and/or blood vessel endothelial cells); (10) the ability to modulate intracellular signaling cascades (*e.g.*, signal transduction cascades); and (11) the ability to modulate adipocyte function. 20

For TANGO 257, biological activities include, *e.g.*, (1) the ability to modulate the development, differentiation, proliferation and/or activity of neuronal cells, *e.g.*, olfactory neurons (2) the ability to modulate the development, differentiation, proliferation and/or activity of pulmonary system cells, *e.g.*, lung cell types; (4) the ability to modulate the 25 development, differentiation, maturation, proliferation and/or activity of bone cells such as osteocytes, osteoblasts and osteoclasts (*e.g.*, the ability promote the development of osteocytes); (5) the ability to modulate the development of bone structures such as the skull, the basisphenoid bone, the upper and lower incisor teeth, the vertebral column, the sternum, the scapula, and the femur during embryogenesis; (6) the ability to modulate the development, differentiation, maturation, proliferation and/or activity of renal cells; (7) the 30 ability to modulate the development, differentiation, maturation, proliferation and/or activity of intestinal cells such as M cells; (8) the ability to modulate cell-cell interactions and/or cell-extracellular matrix interactions, *e.g.*, neuronal cell-extracellular matrix interactions; (9) the ability to modulate cell proliferation, *e.g.*, abnormal cell proliferation; and (10) the ability to modulate the development, differentiation, proliferation and/or 35

activity of cells that form blood vessels and coronary tissue, *e.g.*, coronary smooth muscle cells and/or blood vessel endothelial cells.

For INTERCEPT 258, biological activities include, *e.g.*, (1) the ability to modulate protein-protein interactions (*e.g.*, homophilic and/or heterophilic), and protein-ligand interactions, *e.g.*, in receptor-ligand recognition; (2) the ability to modulate cell-cell interactions; (3) the ability to modulate the host immune response; (4) the ability to modulate the development, differentiation, maturation, proliferation and/or activity of pulmonary system cells such as bronchial cells; (5) the ability to modulate the development, differentiation, maturation, proliferation and/or activity of renal cells; (5) the ability to modulate the development, differentiation, maturation, proliferation and/or activity of cardiac cells such as cardiac myocytes; (6) the ability to modulate the development of brown fat (*e.g.*, the promotion of the development of brown fat); (7) the ability to modulate the development, differentiation, maturation, proliferation and/or activity of endothelial cells; (8) the ability to modulate cell proliferation, *e.g.*, gastrointestinal tract epithelial cell proliferation; (9) the ability to modulate intracellular signaling cascades (*e.g.*, signal transduction cascades); and (10) the ability to modulate thrombosis (*e.g.*, the ability to facilitate the removal of blood clots) and/or vascularization (*e.g.*, the promotion of vascularization).

For TANGO 281, biological activities include, *e.g.*, (1) the ability to modulate, *e.g.*, stabilize, promote, inhibit or disrupt protein-protein interactions (*e.g.*, homophilic and/or heterophilic), and protein-ligand interactions, *e.g.*, in receptor-ligand recognition; (2) the ability to modulate cell-cell interactions; (3) the ability to modulate the host immune response; (4) the ability to modulate the proliferation, differentiation and/or activity of hematopoietic cells (*e.g.* megakaryocytes); (5) the ability to modulate the development, differentiation, maturation, proliferation and/or activity of pulmonary system cells; (6) the ability to modulate the development, differentiation, maturation, proliferation and/or activity of intestinal cells such as M cells; (7) the ability to modulate the development, differentiation, maturation, proliferation and/or activity of stomach cells such as cells of the gastric epithelium; (8) the ability to modulate intracellular signaling cascades (*e.g.*, signal transduction cascades); and (9) the ability to modulate platelet function (*e.g.*, the promotion of platelet aggregation).

In one embodiment, a polypeptide of the invention has an amino acid sequence sufficiently identical to an identified domain of a polypeptide of the invention. As used herein, the term "sufficiently identical" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (*e.g.*, with a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide

sequence such that the first and second amino acid or nucleotide sequences have or encode a common structural domain and/or common functional activity. For example, amino acid or nucleotide sequences which contain or encode a common structural domain having about 60% identity, preferably 65% identity, more preferably 75%, 85%, 95%, 98% or more identity are defined herein as sufficiently identical.

In one embodiment, a TANGO 253 protein includes at least one or more of the following domains: a signal sequence, a collagen domain and a C1q domain.

In one embodiment, a TANGO 257 protein includes at least a signal peptide.

In one embodiment, an INTERCEPT 258 includes at least one or more of the following domains: a signal sequence, an extracellular domain, an immunoglobulin (Ig) domain, a transmembrane domain, and an intracellular or cytoplasmic domain.

In one embodiment, a TANGO 281 protein includes at least one or more of the following domains: a signal sequence, an extracellular domain, a photosystem II 10 kD phosphoprotein domain, a transmembrane domain, and an intracellular or cytoplasmic domain.

The polypeptides of the present invention, or biologically active portions thereof, can be operably linked to a heterologous amino acid sequence to form fusion proteins. The invention further features antibodies, such as monoclonal or polyclonal antibodies, that specifically bind a polypeptide of the invention. In addition, the polypeptides of the invention or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers.

In another aspect, the present invention provides methods for detecting the presence, activity or expression of a polypeptide of the invention in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of the presence, activity or expression such that the presence activity or expression of a polypeptide of the invention is detected in the biological sample.

In another aspect, the invention provides methods for modulating activity of a polypeptide of the invention comprising contacting a cell with an agent that modulates (inhibits or stimulates) the activity or expression of a polypeptide of the invention such that activity or expression in the cell is modulated. In one embodiment, the agent is an antibody that specifically binds to a polypeptide of the invention.

In another embodiment, the agent modulates expression of a polypeptide of the invention by modulating transcription, splicing, or translation of an mRNA encoding a polypeptide of the invention. In yet another embodiment, the agent is a nucleic acid molecule having a nucleotide sequence that is antisense to the coding strand of an mRNA encoding a polypeptide of the invention.

The present invention also provides methods to treat a subject having a disorder characterized by aberrant activity of a polypeptide of the invention or aberrant expression of a nucleic acid of the invention by administering an agent which is a modulator of the activity of a polypeptide of the invention or a modulator of the expression of a nucleic acid of the invention to the subject. In one embodiment, the modulator is a protein of the invention. In another embodiment, the modulator is a nucleic acid of the invention. In other embodiments, the modulator is a peptide, peptidomimetic, or other small molecule.

The present invention also provides diagnostic assays for identifying the presence or absence of a genetic lesion or mutation characterized by at least one of: (i) aberrant modification or mutation of a gene encoding a polypeptide of the invention; (ii) mis-regulation of a gene encoding a polypeptide of the invention; and (iii) aberrant post-translational modification of the invention wherein a wild-type form of the gene encodes a protein having the activity of the polypeptide of the invention.

In another aspect, the invention provides a method for identifying a compound that binds to or modulates the activity of a polypeptide of the invention. In general, such methods entail measuring a biological activity of the polypeptide in the presence and absence of a test compound and identifying those compounds which alter the activity of the polypeptide.

The invention also features methods for identifying a compound which modulates the expression of a polypeptide or nucleic acid of the invention by measuring the expression of the polypeptide or nucleic acid in the presence and absence of the compound.

In another aspect, the invention provides substantially purified antibodies or fragments thereof, including human, humanized, chimeric and non-human antibodies or fragments thereof, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid sequence of SEQ ID NO: 3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164, or the amino acid sequence encoded by the EpT253, EpTm253, EpT257, EpTm257, EpT258, EpTm258, EpT281 or EpTm281 cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, Accession Number 207215, Accession number 207217, Accession number 207221, or patent deposit Number PTA-224.

In another aspect, the invention provides substantially purified antibodies or fragments thereof, including, *e.g.*, human, non-human, chimeric and humanized antibodies, which antibodies or fragments thereof specifically bind to a polypeptide comprising at least 15 contiguous amino acids of the amino acid sequence of SEQ ID NO:

3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164, or the amino acid sequence encoded by the EpT253, EpTm253, EpT257, EpTm257, EpT258, EpTm258, EpT281 or EpTm281 cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, Accession number 207215, Accession number 207217, Accession number 207221, or patent deposit number PTA-224, or a complement thereof.

In another aspect, the invention provides substantially purified antibodies or fragments thereof, including, *e.g.*, human, non-human, chimeric and humanized antibodies, which antibodies or fragments thereof specifically bind to a polypeptide comprising at least 95% identical to the amino acid sequence of SEQ ID NO: 3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164, or the amino acid sequence encoded by the EpT253, EpTm253, EpT257, EpTm257, EpT258, EpTm258, EpT281 or EpTm281 cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, Accession number 207215, Accession number 207217, Accession number 207221, or patent deposit number PTA-224, or a complement thereof.

In another aspect, the invention provides substantially purified antibodies or fragments thereof, including, *e.g.*, human, non-human, chimeric and humanized antibodies, which antibodies or fragments thereof specifically bind to a polypeptide encoded by a nucleic acid molecule which hybridizes to the nucleic acid molecule of SEQ ID NO: 1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 104, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192 under conditions of hybridization of 6 X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 65°C.

Any of the antibodies of the invention can be conjugated to a therapeutic moiety or to a detectable substance. Non-limiting examples of detectable substances that can be conjugated to the antibodies of the invention are an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

The invention also provides a kit containing an antibody of the invention conjugated to a detectable substance, and instructions for use. Still another aspect of the invention is a pharmaceutical composition comprising an antibody of the invention and a pharmaceutically acceptable carrier. In preferred embodiments, the pharmaceutical

composition contains an antibody of the invention, a therapeutic moiety, and a pharmaceutically acceptable carrier.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

5

#### Brief Description of the Drawings

FIGURES 1A-AB depict the cDNA sequence of human TANGO 253 (SEQ ID NO:1) and the predicted amino acid sequence of human TANGO 253 (SEQ ID NO:3). The open reading frame of SEQ ID NO:1 extends from nucleotide 188 to nucleotide 916 of SEQ ID NO:1 (SEQ ID NO:2).

10

FIGURE 2 depicts a hydropathy plot of human TANGO 253. Relatively hydrophobic regions of the protein are above the dashed horizontal line, and relatively hydrophilic regions of the protein are below the dashed horizontal line. The cysteine residues (cys) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal sequence (amino acids 1 to 15 of SEQ ID NO:3; SEQ ID NO:5) on the left from the mature protein (amino acids 16 to 243 of SEQ ID NO:3; SEQ ID NO:4) on the right. Below the hydropathy plot, the amino acid sequence of human TANGO 253 is depicted.

15

FIGURES 3A-3B depict a cDNA sequence of mouse TANGO 253 (SEQ ID NO:8) and the predicted amino acid sequences of mouse TANGO 253 (SEQ ID NO:10). The open reading frame of SEQ ID NO:10 extends from nucleotide 135 to 863 of SEQ ID NO:10 (SEQ ID NO:9).

20

FIGURE 4 depicts a hydropathy plot of mouse TANGO 253. Relatively hydrophobic regions of the protein are shown above the dashed horizontal line, and relatively hydrophilic regions of the protein are below the dashed horizontal line. The cysteine residues (cys) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal sequence (amino acids 1 to 15 of SEQ ID NO:10; SEQ ID NO:12) on the left from the mature protein (amino acids 16 to 243 of SEQ ID NO:10; SEQ ID NO:11) on the right. Below the hydropathy plot, the amino acid sequence of mouse TANGO 253 is depicted.

25

30

FIGURE 5 depicts an alignment of the amino acid sequence of human TANGO 253 (SEQ ID NO:3) and the amino acid sequence of mouse TANGO 253 (SEQ ID NO:10). The alignment demonstrates that the amino acid sequences of human and mouse TANGO 253 are 93.8% identical. This alignment was performed using the ALIGN program with a PAM120 scoring matrix, a gap length penalty of 12 and a gap penalty of 4.

35

FIGURES 6A-6B depict alignments of the amino acid sequence of human adipocyte complement-mediated protein precursor (SEQ ID NO:20; Swiss Prot Accession Number Q15848) and the amino acid sequence of human TANGO 253 (SEQ ID NO:3; 6A) or mouse TANGO 253 (SEQ ID NO:10; 6B). 6A shows the amino acid sequences of human adipocyte complement-mediated protein precursor and human TANGO 253 are 38.7% identical. 6B shows the amino acid sequences of human adipocyte complement-mediated precursor protein and mouse TANGO 253 are 38.3% identical. These alignments were performed using the ALIGN alignment program with a PAM120 scoring matrix, a gap length penalty of 12, and a gap penalty of 4.

FIGURES 7A-7C depict alignments of the nucleotide sequence of human adipocyte complement-mediated protein precursor (SEQ ID NO:32; GenBank Accession Number A1417523) and the nucleotide sequence of human TANGO 253 (SEQ ID NO:1). The nucleotide sequences of human adipocyte complement-mediated protein precursor and human TANGO 253 are 29.1% identical. These alignments were performed using the ALIGN alignment program with a PAM120 scoring matrix, a gap length penalty of 12, and a gap penalty of 4.

FIGURES 8A-8C depict alignments of the nucleotide sequence of human adipocyte complement-mediated protein precursor (SEQ ID NO:32; GenBank Accession Number A1417523) and the nucleotide sequence of mouse TANGO 253 (SEQ ID NO:8). The nucleotide sequences of human adipocyte complement-mediated protein precursor and mouse TANGO 253 are 30.4% identical. These alignments were performed using the ALIGN alignment program with a PAM120 scoring matrix, a gap length penalty of 12, and a gap penalty of 4.

FIGURES 9A-9B depict the cDNA sequence of human TANGO 257 (SEQ ID NO:15) and the predicted amino acid sequence of human TANGO 257 (SEQ ID NO:17). The open reading frame of SEQ ID NO:16 extends from nucleotide 88 to nucleotide 1305 of SEQ ID NO:15 (SEQ ID NO:16).

FIGURE 10 depicts a hydropathy plot of human TANGO 257. Relatively hydrophobic regions of the protein are shown above the dashed horizontal line, and relatively hydrophilic regions of the protein are below the dashed horizontal line. The cysteine residues (cys) and potential N-glycosylation sites (Ngly) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal sequence (amino acids 1 to 21 of SEQ ID NO:16; SEQ ID NO:19) on the left from the mature protein (amino acids 22 to 406 of SEQ ID NO:16; SEQ ID NO:18) on the right. Below the hydropathy plot, the amino acid sequence of human TANGO 257 is depicted.

FIGURES 11A-11B depict a cDNA sequence of mouse TANGO 257 (SEQ ID NO:21) and the predicted amino acid sequence of mouse TANGO 257 (SEQ ID NO:23). The open reading frame of SEQ ID NO:21 extends from nucleotide 31 to 1248 of SEQ ID NO:21 (SEQ ID NO:22).

5       FIGURE 12 depicts a hydropathy plot of mouse TANGO 257. Relatively hydrophobic regions of the protein are shown above the dashed horizontal line, and relatively hydrophilic regions of the protein are below the dashed horizontal line. The cysteine residues (cys) and potential N-glycosylation sites (Ngly) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal  
10       sequence (amino acids 1 to 21 of SEQ ID NO:23; SEQ ID NO:25) on the left from the mature protein (amino acids 22 to 406 of SEQ ID NO:23; SEQ ID NO:24) on the right. Below the hydropathy plot, the amino acid sequence of mouse TANGO 257 is depicted.

FIGURE 13 depicts an alignment of the amino acid sequence of human TANGO 257 (SEQ ID NO:17) and the amino acid sequence of mouse TANGO 257 (SEQ ID  
15       NO:23). This alignment demonstrates that the amino acid sequences of human and mouse TANGO 257 are 94.1% identical. This alignment was performed using the ALIGN program with a PAM120 scoring matrix, a gap length penalty of 12 and a gap penalty of 4.

FIGURE 14 depicts an alignment of the amino acid sequence (SEQ ID NO:43) encoded by a nucleotide sequence referred to in PCT publication WO 98/39446 as "gene  
20       64", and the amino acid sequence of human TANGO 257 (SEQ ID NO:17). Gene 64 encodes a 353 amino acid residue protein that exhibits homology with the human extracellular molecule olfactomedin, which is thought to be involved in maintenance, growth and/or differentiation of chemosensory cilia on the apical dendrites of olfactory neurons. The polypeptide encoded by gene 64 also exhibits homology to human TANGO  
25       257, which contains 406 amino acids (*i.e.*, an additional 53 amino acids carboxy to residue 353). The amino acid sequences of amino acid residues 1-353 of the gene 64-encoded polypeptide and human TANGO 257 are identical. As such, the overall amino acid sequence identity between the full length polypeptide encoded by gene 64, and the full-length human TANGO 257 polypeptide is approximately 87%. This alignment was  
30       performed using the ALIGN alignment program with a PAM120 scoring matrix, a gap length penalty of 12, and a gap penalty of 4.

FIGURES 15A-15D depict an alignment of the nucleotide sequence of gene 64 (SEQ ID NO:66; PCT Publication WO 98/39446) and the nucleotide sequence of human TANGO 257 (SEQ ID NO:15). The nucleotide sequences of gene 64 and human  
35       TANGO 257 are 93.5% identical. It is noted, however, that among the differences between the two sequences is a cytosine nucleotide at human TANGO 257 (SEQ ID

NO:15) position 1146 that results in a human TANGO 257 amino acid sequence (SEQ ID NO:17) of 406 amino acids as opposed to the gene 64 amino acid sequence of only 353 amino acids (SEQ ID NO:43). Alignment of the nucleotide sequence of the gene 64 open reading frame and that of human TANGO 257 (SEQ ID NO:16) show that the two  
5 nucleotide sequences are 87.2% identical. These alignments were performed using the ALIGN program with a PAM220 scoring matrix, a gap length penalty of 12 and a gap penalty of 4.

FIGURE 16 depicts an alignment of the acid sequence of the gene 64-encoded polypeptide (SEQ ID NO:43) and the amino acid sequence of mouse TANGO 257 (SEQ  
10 ID NO:23). The sequences exhibit an overall amino acid sequence identity of approximately 81.8%. This alignment was performed using an ALIGN program with a PAM120 scoring matrix, a gap length penalty of 12 and a gap penalty of 4.

FIGURE 17A-17C depicts an alignment of the nucleotide sequence of gene 64 (SEQ ID NO:66) and the nucleotide sequence of mouse TANGO 257 (SEQ ID NO:21).  
15 The two sequences are approximately 76.2% identical. Alignment of the nucleotide sequence of the gene 64 open reading frame and that of mouse TANGO 257 (SEQ ID NO:22) show that the two nucleotide sequences are 77.8% identical. These alignments were performed using the ALIGN program with a PAM220 scoring matrix, a gap length penalty of 12 and a gap penalty of 4.

FIGURES 18A-18B depict the cDNA sequence of human INTERCEPT 258 (SEQ  
20 ID NO:26) and the predicted amino acid sequence of INTERCEPT 258 (SEQ ID NO:28). The open reading frame of SEQ ID NO:26 extends from nucleotide 153 to nucleotide 1262 of SEQ ID NO:26 (SEQ ID NO:27).

FIGURE 19 depicts a hydropathy plot of human INTERCEPT 258. Relatively  
25 hydrophobic regions of the protein are above the dashed horizontal line, and relatively hydrophilic regions of the protein are below the dashed horizontal line. The cysteine residues (Cys) and potential N-glycosylation sites (Ngly) are indicated by short vertical lines just below the hydropathy trace. Below the hydropathy plot, the amino acid sequence of human INTERCEPT 258 is depicted.

FIGURES 20A-20B depict a cDNA sequence of mouse INTERCEPT 258 (SEQ ID  
30 NO:37) and the predicted amino acid sequence of mouse INTERCEPT 258 (SEQ ID NO:39). The open reading frame of SEQ ID NO:37 extends from nucleotide 107 TO 1288 of SEQ ID NO:60 (SEQ ID NO:38).

FIGURE 21 depicts a hydropathy plot of mouse INTERCEPT 258. Relatively  
35 hydrophobic regions of the protein are shown above the dashed horizontal line, and relatively hydrophilic regions of the protein are below the dashed horizontal line. The

cysteine residues (cys) and potential N-glycosylation sites (Ngly) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal sequence (amino acids 1 to 29 of SEQ ID NO:39; SEQ ID NO:41) on the left from the mature protein (amino acids 30 to 394 of SEQ ID NO:39; SEQ ID NO:40) on the right.

- 5 Below the hydropathy plot, the amino acid sequence of mouse INTERCEPT 258 is depicted.

FIGURE 22 depicts an alignment of the amino acid sequence of human INTERCEPT 258 (SEQ ID NO:28) and the amino acid sequence of mouse INTERCEPT 258 (SEQ ID NO:39). The alignment demonstrates that the amino acid sequences of  
10 human and mouse INTERCEPT 258 are 62.8% identical. This alignment was performed using the ALIGN program with a PAM120 scoring matrix, a gap length penalty of 12 and a gap penalty of 4.

FIGURE 23 depicts an alignment of the amino acid sequence of human A33 antigen (SEQ ID NO:67; Swiss Prot Accession Number Q99795) and the amino acid  
15 sequence of human INTERCEPT 258 (SEQ ID NO:28). The A33 antigen is a transmembrane glycoprotein and member of the Ig superfamily that may be a cancer cell marker. The amino acid sequences of A33 antigen and human INTERCEPT 258 are 23% identical. This alignment was performed using the ALIGN alignment program with a PAM120 scoring matrix, a gap length penalty of 12, and a gap penalty of 4.

FIGURES 24A-24D depict an alignment of the nucleotide sequence of human A33 antigen (SEQ ID NO:68; Gen Bank Accession Number U79725) and the nucleotide  
20 sequence of human INTERCEPT 258 (SEQ ID NO:26). These two nucleotide sequences are 40.6% identical. The nucleotide sequence of the open reading frame of human A33 antigen and that of human INTERCEPT 258 are 44% identical. These alignments were performed using the ALIGN alignment program with a PAM120 scoring matrix, a gap  
25 length penalty of 12, and a gap penalty of 4.

FIGURE 25 depicts an alignment of the amino acid sequence of human A33 antigen (SEQ ID NO:67; Swiss Prot Accession Number Q99795) and the amino acid  
30 sequence of mouse INTERCEPT 258 (SEQ ID NO:39). These two amino acid sequences have an overall amino acid identity of 23%. This alignment was performed using the ALIGN alignment program with a PAM120 scoring matrix, a gap length penalty of 12, and a gap penalty of 4.

FIGURES 26A-26D depict an alignment of the nucleotide sequence of human A33 antigen (SEQ ID NO:68; GenBank Accession Number U79725) and the nucleotide  
35 sequence of mouse INTERCEPT 258 (SEQ ID NO:37). These two nucleotide sequences are 40% identical. The nucleotide sequence of the open reading frame of human A33

antigen and that of mouse INTERCEPT 258 are 43.2% identical. These alignments were performed using the ALIGN alignment program with a PAM120 scoring matrix, a gap length penalty of 12, and a gap penalty of 4.

FIGURE 27A-27E depict an alignment of the nucleotide sequence of human  
 5 PECAM-1, an integrin expressed on endothelial cells (SEQ ID NO:72) and the nucleotide sequence of human INTERCEPT 258 (SEQ ID NO:26). These two nucleotide sequences are 40.5% identical. This alignment was performed using ALIGN alignment program with a PAM120 scoring matrix, a gap length of 12, and a gap penalty of 4.

FIGURE 28A-28B depict the cDNA sequence of human TANGO 281 (SEQ ID  
 10 NO:46) and the predicted amino acid sequence of human TANGO 281 (SEQ ID NO:48). The open reading frame of SEQ ID NO:66 extends from nucleotide 65 to nucleotide 799 of SEQ ID NO:46 (SEQ ID NO:47).

FIGURE 29 depicts a hydropathy plot of human TANGO 281. Relatively  
 15 hydrophobic regions of the protein are above the dashed horizontal line, and relatively hydrophilic regions of the protein are below the dashed horizontal line. The cysteine residues (cys) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal sequence (amino acids 1 to 38 of SEQ ID NO:48; SEQ ID NO:49) on the left from the mature protein (amino acids 39 to 245 of SEQ ID NO:48; SEQ ID NO:50) on the right. Below the hydropathy plot, the amino acid sequence  
 20 of human TANGO 281 is depicted.

FIGURE 30 depicts an alignment of the amino acid sequence of photosystem II 10  
 kD phosphoprotein domain (SEQ ID NO:69; GenBank Accession Number PF00737) and the amino acid sequence 97 to 146 of human TANGO 281 (SEQ ID NO:48). This alignment was performed using the ALIGN alignment program with a PAM120 scoring  
 25 matrix, a gap length penalty of 12, and a gap penalty of 4.

FIGURES 31A-31B depict the cDNA sequence of mouse TANGO 281 (SEQ ID  
 NO:56) and the predicted amino acid sequence of mouse TANGO 281 (SEQ ID NO:58). The open reading frame of SEQ ID NO:56 extends from nucleotide 90 to nucleotide 728 of SEQ ID NO:56 (SEQ ID NO:57).

Figure 32 depicts a hydropathy plot of mouse TANGO 281. Relatively  
 30 hydrophobic regions of the protein are above the dashed horizontal line, and relatively hydrophilic regions of the protein are below the dashed horizontal line. The cysteine residues (cys) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal sequence (amino acids 1 to 26 of SEQ ID NO:58; SEQ ID NO:59) on the left from the mature protein (amino acids 27 to 213 of SEQ ID  
 35

NO:58; SEQ ID NO:60) on the right. Below the hydropathy plot, the amino acid sequence of mouse TANGO 281 is depicted.

FIGURE 33 depicts an alignment of the amino acid sequence of human TANGO 281 (SEQ ID NO:48) and the amino acid sequence of mouse TANGO 281 (SEQ ID NO:58). The alignment demonstrates that the amino acid sequences of human and mouse TANGO 281 are 66.5% identical. This alignment was performed using the ALIGN program with a PAM120 scoring matrix, a gap length penalty of 12 and a gap penalty of 4.

#### Detailed Description of the Invention

10 The TANGO 253, TANGO 257, INTERCEPT 258 and TANGO 281 proteins and nucleic acid molecules comprise families of molecules having certain conserved structural and functional features. As used herein, the terms "family" or "families" are intended to mean two or more proteins or nucleic acid molecules having a common structural domain and having sufficient amino acid or nucleotide sequence identity as defined herein.

15 Family members can be from either the same or different species. For example, a family can comprises two or more proteins of human origin, or can comprise one or more proteins of human origin and one or more of non-human origin. Members of the same family may also have common structural domains.

For example, TANGO 253 proteins, TANGO 257 proteins, INTERCEPT 258  
20 proteins and TANGO 281 proteins of the invention have signal sequences. As used herein, a "signal sequence" includes a peptide of at least about 15 or 20 amino acid residues in length which occurs at the N-terminus of secretory and membrane-bound proteins and which contains at least about 70% hydrophobic amino acid residues such as alanine, leucine, isoleucine, phenylalanine, proline, tyrosine, tryptophan, or valine. In a  
25 preferred embodiment, a signal sequence contains at least about 10 to 40 amino acid residues, preferably about 19-34 amino acid residues, and has at least about 60-80%, more preferably 65-75%, and more preferably at least about 70% hydrophobic residues. A signal sequence serves to direct a protein containing such a sequence to a lipid bilayer. Thus, in one embodiment, a TANGO 253 protein contains a signal sequence of about  
30 amino acids 1 to 15 of SEQ ID NO:3 (SEQ ID NO:5) or about amino acids 1 to 15 of SEQ ID NO:10 (SEQ ID NO:12). In another embodiment, a TANGO 257 protein contains a signal sequence of about amino acids 1 to 21 of SEQ ID NO:17 (SEQ ID NO:19) or about amino acids 1 to 21 of SEQ ID NO:23 (SEQ ID NO:25). In another embodiment, an INTERCEPT 258 protein contains a signal sequence at about amino acids 1 to 29 of SEQ  
35 ID NO:28 (SEQ ID NO:30) or about amino acids 1 to 29 of SEQ ID NO:39 (SEQ ID NO:41). In yet another embodiment, a TANGO 281 protein contains a signal sequence of

about amino acids 1 to 38 of SEQ ID NO:48 (SEQ ID NO:49) or about amino acids 1 to 26 of SEQ ID NO:58 (SEQ ID NO:59). The signal sequence is cleaved during processing of the mature protein.

In one embodiment, TANGO 253 includes at least one RGD cell attachment site. An RGD domain contains a contiguous arginine-glycine-aspartic acid amino acid sequence and is involved in cell-cell, cell-extracellular matrix and cell adhesion interactions. In a preferred embodiment, a TANGO 253 family member has the amino acid sequence of SEQ ID NO:3 and, preferably, a RGD cell attachment site is located at about amino acid positions 77 to 79.

TANGO 253 family members can also include a collagen domain. As used herein, the term "collagen domain" refers to a protein domain containing a G-X-Y amino acid repeat motif, wherein the first amino acid residue is glycine and the second and third amino acid residues can be any residue but are preferably proline or hydroxyproline. Typically, a collagen domain contains at least about 3 to 5 G-X-Y repeats, and can contain about 3, 5, 8, 10, 12, 15, 20 or more continuous G-X-Y repeats. In one embodiment, a collagen domain can fold to form a triple helical structure.

In one embodiment, a TANGO 253 family member includes at least one collagen domain having an amino acid sequence that is at least about 40%, 50%, 60%, 70%, 80%, 90%, 95% or 98% identical to amino acids 36 to 95 of SEQ ID NO:3, which is the collagen domain of human TANGO 253 (SEQ ID NO:6), or amino acids 36 to 95 of SEQ ID NO:10, which is the collagen domain of mouse TANGO 253 (SEQ ID NO:13), while maintaining a glycine residue at the first position of G-X-Y repeats within the domain to maintain at least 3, 5, 8, 10, 12, 15 or 20 contiguous G-X-Y repeats, or while most preferably maintaining a glycine repeat at the first position of each G-X-Y repeat within the domain.

TANGO 253 family members can also include a C1q domain or at least one of the conserved amino acid motifs found therein. As used herein, the term "C1q domain" refers to a protein domain that bears homology to a C1q domain present within a member of the C1 enzyme complex. A C1q domain typically includes about 130-140 amino acid residues. C1q domains are utilized in processes involving, *e.g.*, correct protein folding and alignment and protein-protein interactions.

In one embodiment, a TANGO 253 family member includes one or more C1q domains having an amino acid sequence that is at least 45%, preferably about 50%, 55%, 60%, 70%, 75%, 80%, 90%, 95% and most preferably at least about 98% identical to amino acids 105 to 232 of SEQ ID NO:3, which is the human TANGO 253 C1q domain

(SEQ ID NO:7) or amino acids 105 to 232 of SEQ ID NO:10, which is the mouse TANGO 253 C1q domain (SEQ ID NO:14).

Embodiments of TANGO 253 family members include, but are not limited to, human, mouse and rat TANGO 253 nucleic acids and proteins. The features of the human and mouse TANGO 253 are described below. A cDNA encoding a rat TANGO 253 nucleotide sequence (SEQ ID NO:74), identified in clone jtrxa001e10t1, is 75.4% identical to human TANGO 253 (SEQ ID NO:1) in a 536 bp overlap. Further, the isolated rat TANGO 253 nucleotide sequence (SEQ ID NO:74) is 86% identical to mouse TANGO 253 (SEQ ID NO:9) in a 472 bp overlap.

Embodiments of TANGO 257 family members include, but are not limited to, human, mouse and rat TANGO 257 nucleic acids and proteins. The features of the human and mouse TANGO 257 are described below. A cDNA encoding a rat TANGO 257 nucleotide sequence (SEQ ID NO:75), identified within clone jtrxa102g06t1, is 83.8% identical to human TANGO 257 (SEQ ID NO:15) in a 734 bp overlap. Further, the isolated rat TANGO 257 nucleotide sequence (SEQ ID NO:75) is 88.4% identical to mouse TANGO 257 (SEQ ID NO:21) in a 731 bp overlap.

In one example, a TANGO 257 family member includes one or more of the following domains: (1) an extracellular domain; (2) a transmembrane domain; and (3) a cytoplasmic domain. In one embodiment, a TANGO 257 protein contains cytoplasmic domains of about amino residues 1 to 202 of SEQ ID NO:17 (SEQ ID NO:84) and about amino acid residues 338 to 406 of SEQ ID NO:17 (SEQ ID NO:92), transmembrane domains of about amino acid residues 203 to 221 of SEQ ID NO:17 (SEQ ID NO:86) and about amino acid residues 321 to 337 of SEQ ID NO:17 (SEQ ID NO:87), and an extracellular domain of about amino acid residues 222 to 320 of SEQ ID NO:17 (SEQ ID NO:88). In an alternative embodiment, a TANGO 257 protein contains an extracellular domain of about amino acid residues 1 to 320 of SEQ ID NO:17 (SEQ ID NO:89) or a mature extracellular domain of about amino acid residues 22 to 320 of SEQ ID NO:17 (SEQ ID NO:90), a transmembrane domain of about amino acid residues 321 to 337 of SEQ ID NO:17 (SEQ ID NO:87), and a cytoplasmic domain of about amino acid residues 338 to 406 of SEQ ID NO:17 (SEQ ID NO:92). In another embodiment, a mature TANGO 257 protein contains about amino acid residues 22 to 406 of SEQ ID NO:17 (SEQ ID NO:18).

In another embodiment, a TANGO 257 protein contains intracellular domains of about amino acid residues 1 to 202 of SEQ ID NO:23 (SEQ ID NO:93) and about amino acid residues 338 to 406 of SEQ ID NO:23 (SEQ ID NO:94), transmembrane domains of about amino acid residues 203 to 221 of SEQ ID NO:23 (SEQ ID NO:95) and about

amino acid residues 321 to 337 of SEQ ID NO:32 (SEQ ID NO:96), and an extracellular domain of about amino acid residues 222 to 320 of SEQ ID NO:23 (SEQ ID NO:97). In alternative embodiment, a TANGO 257 protein contains an extracellular domain of about amino acid residues 1 to 320 of SEQ ID NO:23 (SEQ ID NO:98) or a mature extracellular domain of about amino acid residues 22 to 320 of SEQ ID NO:23 (SEQ ID NO:99), a transmembrane domain of about amino acid residues 321 to 337 of SEQ ID NO:25 (SEQ ID NO:96), and an intracellular domain of about amino acid residues 338 to 406 of SEQ ID NO:23 (SEQ ID NO:94). In another embodiment, a mature TANGO 257 protein contains about amino acid residues 22 to 406 of SEQ ID NO:23 (SEQ ID NO:24).

10 In another example, an INTERCEPT 258 family member includes one or more of the following domains: (1) an extracellular domain; (2) a transmembrane domain; and (3) a cytoplasmic domain. Thus, in one embodiment, an INTERCEPT 258 protein contains extracellular domains of about amino acid residues 1 to 206 of SEQ ID NO:28 (SEQ ID NO:81) or about amino acid residues 30 to 206 of SEQ ID NO: 28 (SEQ ID NO:76) and about amino acid residues 272 to 370 of SEQ ID NO: 28 (SEQ ID NO:34), transmembrane domains of about amino acid residues 207 to 224 of SEQ ID NO:28 (SEQ ID NO:78) and about amino acid residues 247 to 271 of SEQ ID NO:28 (SEQ ID NO:33), and a cytoplasmic domain of about amino acid residues 225 to 246 of SEQ ID NO:28 (SEQ ID NO:79). In an alternative embodiment, an INTERCEPT 258 protein contains an extracellular domain of about amino acid residues 272 to 370 of SEQ ID NO:28 (SEQ ID NO:34), a transmembrane domain of about amino acid residues 247 to 271 of SEQ ID NO:28 (SEQ ID NO:33), and a cytoplasmic domain of about amino acid residues 1 to 246 of SEQ ID NO:28 (SEQ ID NO:31) or a mature cytoplasmic domain of about amino acid residues 30 to 246 of SEQ ID NO:28 (SEQ ID NO:82). In accordance with these 25 embodiments, an INTERCEPT 258 protein is a mature protein containing an extracellular, transmembrane and cytoplasmic domain of about amino acids 30 to 370 of SEQ ID NO:28 (SEQ ID NO:29).

In another embodiment, an INTERCEPT 258 protein contains an extracellular domain of about amino acids 1 to 249 of SEQ ID NO:39 (SEQ ID NO:42), or a mature extracellular domain of about amino acids 30 to 249 of SEQ ID NO:39 (SEQ ID NO:83). In another embodiment, an INTERCEPT 258 protein contains a transmembrane domain of about amino acids 250 to 274 of SEQ ID NO:39 (SEQ ID NO:44). In another embodiment, an INTERCEPT 258 protein contains a cytoplasmic domain of about amino acids 275 to 394 of SEQ ID NO:39 (SEQ ID NO:45). In accordance with these 35 embodiments, an INTERCEPT 258 protein is a mature protein containing an extracellular,

transmembrane and cytoplasmic domain of about 30 to 394 of SEQ ID NO:39 (SEQ ID NO:40).

INTERCEPT 258 family members can also include an immunoglobulin (Ig) domain contained within the extracellular domain. As used herein, the term "Ig domain" refers to a protein domain bearing homology to immunoglobulin superfamily members. An Ig domain includes about 30-90 amino acid residues, preferably about 40-80 amino acid residues, more preferably about 50-70 amino acid residues, still more preferably about 55-65 amino acid residues, and most preferably about 57 to 59 amino acid residues. In certain embodiments, an Ig domain contains a conserved cysteine residue within about 5 to 15 amino acid residues, preferably about 7 to 12 amino acid residues, and most preferably about 8 amino acid residues from its N-terminal end, and another conserved cysteine residue within about 1 to 5 amino acid residues, preferably about 2 to 4 amino acid residues, and most preferably about 3 amino acid residues from its C-terminal end.

An Ig domain typically has the following consensus sequence, beginning about 1 to 15 amino acid residues, more preferably about 3 to 10 amino acid residues, and most preferably about 5 amino acid residues from the C terminal end of the domain: (FY)-Xaa-C-Xaa-(VA)-COO-, wherein (FY) is either a phenylalanine or a tyrosine residue (preferably tyrosine), where "Xaa" is any amino acid, C is a cysteine residue, (VA) is either a valine or an alanine residue (preferably alanine), and COO- is the protein C terminus.

In one embodiment, an INTERCEPT 258 family member includes one or more Ig domains having an amino acid sequence that is at least about 55%, preferably at least about 65%, more preferably at least 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to amino acids 49 to 128 and/or amino acids 167 to 226 of SEQ ID NO:28, which are the Ig domains of human INTERCEPT 258 (these Ig domains are also represented as SEQ ID NO:35 and 36, respectively).

In another embodiment, an INTERCEPT 258 family member includes one or more Ig domains having an amino acid sequence that is at least about 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to amino acids 167 to 226 of SEQ ID NO:28 (SEQ ID NO:36), includes a conserved cysteine residue about 8 residues downstream from the N-terminus of the Ig domain, and has one or more Ig domain consensus sequences described herein. In another embodiment, an INTERCEPT 258 family member includes one or more Ig domains having an amino acid sequence that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to amino

acids 167 to 226 of SEQ ID NO:28 (SEQ ID NO:36), includes a conserved cysteine residue 8 residues downstream from the N-terminus of the Ig domain, has one or more Ig domain consensus sequences described herein, and has a conserved cysteine within the consensus sequence that forms a disulfide both with said first conserved cysteine. In yet another embodiment, an INTERCEPT 258 family member includes one or more Ig domains having an amino acid sequence that is at least 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to amino acids 167 to 226 of SEQ ID NO:28 (SEQ ID NO:36), includes a conserved cysteine residue 8 residues downstream from the N-terminus of the Ig domain, has one or more Ig domain consensus sequences described herein, has a conserved cysteine within the consensus sequence that forms a disulfide both with said first conserved cysteine, and has at least one INTERCEPT 258 biological activity as described herein.

In a preferred embodiment, an INTERCEPT 258 family member has the amino acid sequence of SEQ ID NO:28 wherein the aforementioned Ig conserved residues are located as follows: the N-terminal conserved cysteine residue is located at about amino acid position 174 (within the Ig domain SEQ ID NO:36) and the C-terminal conserved cysteine is located at about amino acid position 224 (within the Ig domain SEQ ID NO:36).

In another embodiment, an INTERCEPT 258 family member includes one or more Ig domains having an amino acid sequence that is at least about 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to amino acids 170 to 229 of SEQ ID NO:39, which is the Ig domain of mouse INTERCEPT 258 (SEQ ID NO:71). In another embodiment, an INTERCEPT 258 family member includes one or more Ig domains having an amino acid sequence that is at least about 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to amino acids 170 to 229 of SEQ ID NO:39 (SEQ ID NO:71), includes a conserved cysteine residue about 8 residues downstream from the N-terminus of the Ig domain, and has one or more Ig domain consensus sequences described herein, has a conserved cysteine within the consensus sequence that forms a disulfide both with said first conserved cysteine, and has at least one INTERCEPT 258 biological activity as described herein.

In a preferred embodiment, an INTERCEPT 258 family member has the amino acid sequence of SEQ ID NO:39 wherein the aforementioned Ig domain conserved residues are located as follows: the N-terminal conserved cysteine residue is located at

about amino acid residue position 177 (within the Ig domain SEQ ID NO:71) and the C-terminal conserved cysteine residue is located at about amino acid position 227 (within the Ig domain SEQ ID NO:71).

In another example, a TANGO 281 family member consists of one or more of the following domains: (1) an extracellular domain; (2) a transmembrane domain; and (3) a cytoplasmic domain. In one embodiment, a TANGO 281 protein contains an extracellular domain at amino acids 1 to about 123 of SEQ ID NO:48 or a mature extracellular domain at about amino acid residues 39 to 123 of SEQ ID NO:48 (SEQ ID NO:51), a transmembrane domain at about amino acid residues 124 to 148 of SEQ ID NO:48 (SEQ ID NO:52), and a cytoplasmic domain at about amino acid residues 149 to 245 of SEQ ID NO:48 (SEQ ID NO:53). In another embodiment, a mature TANGO 281 protein contains about amino acid residues 39 to 245 of SEQ ID NO: 48 (SEQ ID NO: 50). In another embodiment, a TANGO 281 family contains an extracellular domain at amino acids 1 to about 112 of SEQ ID NO:58 or a mature extracellular domain at about amino acid residues 27 to 112 of SEQ ID NO:58 (SEQ ID NO:61), a transmembrane domain at about amino acid residues 113 to 137 of SEQ ID NO:78 (SEQ ID NO:62), and a cytoplasmic domain at about amino acid residues 138 to 213 of SEQ ID NO:78 (SEQ ID NO:63). In yet another embodiment, a mature TANGO 281 protein contains about amino acid residues 27 to 213 of SEQ ID NO: 58 (SEQ ID NO: 61).

In one embodiment, a TANGO 281 family member includes a signal sequence. In a preferred embodiment, a TANGO 281 family member has the amino acid sequence of SEQ ID NO:48, and the signal sequence is located at about amino acids 1 to 38. In another preferred embodiment, a TANGO 281 family member has the amino acid sequence of SEQ ID NO:58, and the signal sequence is located at about amino acids 1 to 26.

A photosystem II 10kd phosphoprotein (PSBH) domain has been identified in the TANGO 281 proteins. The domain is also present in the chloroplast gene PSBH that encodes a 9-10kDa thylakoid membrane protein (PSII-H) which is associated with photosystem II. In one embodiment, a TANGO 281 family member includes one or more PSBH domains having an amino acid sequence that is at least about 55%, preferably at least about 65%, more preferably at least 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to amino acids 41 to 90 and/or amino acids 127 to 182 of SEQ ID NO:48, which are the PSBH domains of human TANGO 281 (these PSBH domains are also represented as SEQ ID NO:54 and 55, respectively). In another embodiment, a TANGO 281 family member includes one or more PSBH domains having an amino acid sequence that is at least about 55%, preferably at least about 65%, more

preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to amino acids 41 to 90 and/or amino acids 127 to 182 of SEQ ID NO:48, which are the PSBH domains of human TANGO 281 (these PSBH domains are also represented as SEQ ID NO:54 and 55, respectively), includes one or more PSBH domain consensus sequences described herein, and has at least one TANGO 281 biological activity as described herein.

In another embodiment, a TANGO 281 family member includes one or more PSBH domains having an amino acid sequence that is at least about 55%, preferably at least about 65%, more preferably at least 75%, yet more preferably at least about 85%, and most preferably at least about 95% to 98% identical to amino acids 42 to 91 and/or amino acids 128 to 183 of SEQ ID NO:58, which are the PSBH domains of mouse TANGO 281 (these PSBH domains are also represented as SEQ ID NO:64 and 65, respectively). In another embodiment, a TANGO 281 family member includes one or more PSBH domains having an amino acid sequence that is at least about 55%, preferably at least about 65%, more preferably at least about 75%, yet more preferably at least about 85%, and most preferably at least about 95% identical to amino acids 42 to 91 and/or amino acids 128 to 183 of SEQ ID NO:58, which are the PSBH domains of mouse TANGO 281 (these PSBH domains are also represented as SEQ ID NO:64 and 65, respectively), includes one or more PSBH domain consensus sequences described herein, and has at least one TANGO 281 biological activity as described herein.

Various features of human and mouse TANGO 253, TANGO 257, INTERCEPT 258 and TANGO 281 are summarized below.

#### Human TANGO 253

A cDNA encoding human TANGO 253 was identified by analyzing the sequences of clones present in a coronary artery smooth muscle library for sequences that encode secreted proteins. The primary cells utilized in construction of the library had been stimulated with agents that included phorbol 12-myristate 13-acetate (PMA), tumor necrosis factor (TNF), ionomycin, and cyclohexamide (CHX). This analysis led to the identification of a clone, Athma27h9, encoding full-length human TANGO 253. The human TANGO 253 cDNA of this clone is 1339 nucleotides long (Figures 1A-1B; SEQ ID NO:1). The open reading frame of this cDNA, nucleotides 188 to 916 of SEQ ID NO:1 (SEQ ID NO:2), encodes a 243 amino acid secreted protein (Figures 1A-1B; SEQ ID NO:3).

Figure 2 depicts a hydropathy plot of human TANGO 253. Relatively hydrophobic regions of the protein are shown above the horizontal line, and relatively

hydrophilic regions of the protein are below the horizontal line. The cysteine residues (cys) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal sequence (amino acids 1 to 15 of SEQ ID NO:3; SEQ ID NO:5) on the left from the mature protein (amino acids 15 to 243 of SEQ ID NO:3; SEQ ID NO:4) on the right.

The signal peptide prediction program SIGNALP (Nielsen et al., 1997, *Protein Engineering* 10:1-6) predicted that human TANGO 253 includes a 15 amino acid signal peptide (amino acid 1 to amino acid 15 of SEQ ID NO:3; SEQ ID NO:5) preceding the mature human TANGO 253 protein (corresponding to amino acid 16 to amino acid 243 of SEQ ID NO:3; SEQ ID NO:4). The molecular weight of TANGO 253 protein without post-translational modifications is 25.3 kDa prior to the cleavage of the signal peptide, 23.8 kDa after cleavage of the signal peptide.

Human TANGO 253 includes a collagen domain (at about amino acids 36 to 95 of SEQ ID NO:3; SEQ ID NO:6) and a C1q domain (at about amino acids 105 to 232 of SEQ ID NO:3; SEQ ID NO:7) containing 23 G-X-Y repeats. An RGD cell attachment site is found at amino acids 77 to 79 of SEQ ID NO:3.

Three protein kinase C phosphorylation sites are present in human TANGO 253. The first has the sequence SAK (at amino acids 107 to 109 of SEQ ID NO:3), the second has the sequence TGK (at amino acids 140 to 142 of SEQ ID NO:3), and the third has the sequence SIK (at amino acids 220 to 222 of SEQ ID NO:3). Human TANGO 253 has three N-myristylation sites. The first has the sequence GLAAGS (at amino acids 11 to 16 of SEQ ID NO:3), the second has the sequence GGRPGL (at amino acids 68 to 73 of SEQ ID NO:3) and the third has the sequence GIYASI (at amino acids 216 to 221 of SEQ ID NO:3).

Northern analysis of human TANGO 253 expression demonstrates strong expression in heart, lung, liver, kidney and pancreas, and moderate expression in brain, placenta and skeletal muscle. Liver expression reveals two human TANGO mRNA bands, one of approximately 1.3kb (which is the size observed in the other tissues) as well as a band at approximately 1kb, which may be the result of an alternative splicing event.

Secretion assays reveal a human TANGO 253 protein of approximately 30kDa. The secretion assays were performed as follows:  $8 \times 10^5$  293T cells were plated per well in a 6-well plate and the cells were incubated in growth medium (DMEM, 10% fetal bovine serum, penicillin/streptomycin) at 37°C, 5% CO<sub>2</sub> overnight. 293T cells were transfected with 2 µg of full-length TANGO 253 inserted in the pMET7 vector/well and 10 µg LipofectAMINE (GIBCO/BRL Cat. # 18324-012) /well according to the protocol for GIBCO/BRL LipofectAMINE. The transfectant was removed 5 hours later and fresh

growth medium was added to allow the cells to recover overnight. The medium was removed and each well was gently washed twice with DMEM without methionine and cysteine (ICN Cat. # 16-424-54). 1 ml DMEM without methionine and cysteine with 50  $\mu$ Ci Trans-<sup>35</sup>S (ICN Cat. # 51006) was added to each well and the cells were incubated at 37°C, 5% CO<sub>2</sub> for the appropriate time period. A 150  $\mu$ l aliquot of conditioned medium was obtained and 150  $\mu$ l of 2X SDS sample buffer was added to the aliquot. The sample was heat-inactivated and loaded on a 4-20% SDS-PAGE gel. The gel was fixed and the presence of secreted protein was detected by autoradiography.

TANGO 253 exhibits homology to an adipocyte complement-mediated protein precursor and so may be involved in adipocyte function, *e.g.*, may act as a signaling molecule for adipocyte tissue. Figure 6A shows an alignment of the human TANGO 253 amino acid sequence (SEQ ID NO:3) with the human adipocyte complement-mediated protein precursor amino acid sequence (SEQ ID NO:20). The alignment shows that there is a 38.7% overall amino acid sequence identity between human TANGO 253 and human adipocyte complement-mediated protein precursor.

Figures 7A-7C shows an alignment of the nucleotide sequence of human adipocyte complement-mediated protein precursor nucleotide sequence (SEQ ID NO:32); GenBank Accession Number A1417523) and the nucleotide sequence of human TANGO 253 (SEQ ID NO:1). The alignment shows a 29.1% overall sequence identity between the two nucleotide sequences.

The human TANGO 253 nucleotide sequence was mapped to human chromosome 11, between flanking markers D11S1356 and D11S924 using the Genebridge 4 Human Radiation hybrid mapping panel with CAAAGTGAGCTCATGCTCTCAC (SEQ ID NO:193) as the forward primer and CTCTGGTCTTGGGCAGAAATC (SEQ ID NO:194) as the reverse primer.

Clone EpT253, which encodes human TANGO 253, was deposited with the American Type Culture Collection (10801 University Boulevard, Manassas, VA 20110-2209) on April 21, 1999 and assigned Accession Number 207222. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

#### Mouse TANGO 253

A cDNA encoding mouse TANGO 253 was identified by analyzing the sequences of clones present in a mouse microglia library using a rat TANGO 253 probe from sciatic

nerve. This analysis led to the identification of a clone, AtmXale1075, encoding full-length mouse TANGO 253. The mouse TANGO 253 cDNA of this clone is 1263 nucleotides long (Figures 3A-3B; SEQ ID NO:8). The open reading frame of this cDNA, nucleotides 135 to 863 of SEQ ID NO:8 (SEQ ID NO:9), encodes a 243 amino acid  
 5 secreted protein (Figures 3A-3B; SEQ ID NO:10).

Figure 4 depicts a hydropathy plot of mouse TANGO 253. Relatively hydrophobic regions of the protein are shown above the horizontal line, and relatively hydrophilic regions of the protein are below the horizontal line. The cysteine residues (cys) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line  
 10 separates the signal sequence (amino acid 1 to amino acid 15 of SEQ ID NO:10; SEQ ID NO:12) on the left from the mature protein (amino acid 16 to amino acid 243 of SEQ ID NO:10; SEQ ID NO:11) on the right.

The signal peptide prediction program SIGNALP (Nielsen et al., 1997, Protein Engineering 10:1-6) predicted that mouse TANGO 253 includes a 15 amino acid signal  
 15 peptide (amino acid 1 to amino acid 15 of SEQ ID NO:10; SEQ ID NO:12) preceding the mature mouse TANGO 253 protein (corresponding to amino acid 16 to amino acid 243 of SEQ ID NO:10; SEQ ID NO:11). The molecular weight of mouse TANGO 253 protein without post-translational modifications is 25.4 kDa prior to the cleavage of the signal peptide, 23.9 kDa after cleavage of the signal peptide.

20 Mouse TANGO 253 includes a collagen domain (at amino acids 36 to 95 of SEQ ID NO:10; SEQ ID NO:13) and a C1q domain (at amino acids 105-232 of SEQ ID NO:10; SEQ ID NO:14).

Three protein kinase C phosphorylation sites are present in mouse TANGO 253. The first has the sequence SAK (at amino acids 107 to 109 of SEQ ID NO:10), the second  
 25 has the sequence TGK (at amino acids 140 to 142 of SEQ ID NO:10), and the third has the sequence SIK (at amino acids 220 to 222 of SEQ ID NO:10). Mouse TANGO 253 has four N-myristylation sites. The first has the sequence GLVSGS (at amino acids 11 to 16 of SEQ ID NO:10), the second has the sequence GGRPGL (at amino acids 68 to 73 of SEQ ID NO:10), the third has the sequence GQSIAS (at amino acids 172 to 177 of SEQ  
 30 ID NO:10), and the fourth has the sequence GIYASI (at amino acids 216 to 221 of SEQ ID NO:10).

As shown in Figure 5, human TANGO 253 protein and mouse TANGO 253 protein are 93.8% identical. Figure 6B shows an alignment of the mouse TANGO 253 amino acid sequence (SEQ ID NO:10) with the human adipocyte complement-mediated  
 35 protein precursor amino acid sequence (SEQ ID NO:20). The alignment shows that there

is a 38.3% overall amino acid sequence identity between mouse TANGO 253 and human adipocyte complement-mediated protein precursor.

Figures 8A-8C shows an alignment of the nucleotide sequence of human adipocyte complement-mediated protein precursor nucleotide sequence (SEQ ID NO:32); GenBank  
5 Accession Number A1417523) and the nucleotide sequence of mouse TANGO 253 (SEQ ID NO:8). The alignment shows a 30.4% overall sequence identity between the two nucleotide sequences.

*In situ* tissue screening was performed on mouse embryonic tissue (obtained from embryos at embryonic day 13.5 to postnatal day 1.5) and adult tissue to determine the  
10 expression of mouse TANGO 253 mRNA. Expression of mouse TANGO 253 during embryogenesis was ubiquitously expressed throughout the central nervous system. Strong expression of mouse TANGO 253 was detected in choroid plexus of the fourth ventricle of E18.5 and E1.5 embryos examined. Expression of mouse TANGO 253 was also detected in the lungs of E14.5 and E15.5 embryos and in the kidneys of E15.5 embryos.

15 Mouse TANGO 253 expression was detected by *in situ* hybridization in the following adult tissues: a signal was detected in the brain in the choroid plexus of the lateral and 4th ventricles, and the olfactory bulb; a signal was detected in the cortical region of the kidney consistent with the pattern of glomeruli (in particular, the cortical radial veins); a ubiquitous signal was detected in the thymus; a weak, ubiquitous signal  
20 was detected in the spleen; a moderate signal was associated with the seminiferous vesicles of the testes; a signal was detected in the ovaries; and a ubiquitous signal restricted to the zone of giant cells was detected in the placenta.

Clone EpTm253, which encodes mouse TANGO 253, was deposited with the American Type Culture Collection (10801 University Boulevard, Manassas, VA 20110-  
25 2209) on April 21, 1999 and assigned Accession Number 207215. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

30

#### Uses of TANGO 253 Nucleic acids, Polypeptides, and Modulators Thereof

As TANGO 253 was originally found in the coronary artery smooth muscle library described above, TANGO 253 nucleic acids, proteins, and modulators thereof can be used to modulate the proliferation, development, differentiation, and/or function of organs, *e.g.*,  
35 tissues and cells that form blood vessels and coronary tissue, *e.g.*, cells of the coronary connective tissue, *e.g.*, abnormal coronary smooth muscle cells and/or endothelial cells of

blood vessels. TANGO 253 nucleic acids, proteins, and modulators thereof can also be used to modulate symptoms associated with abnormal coronary function, *e.g.*, heart diseases and disorders such as atherosclerosis, coronary artery disease and plaque formation.

5           In light of the collagen domain, TANGO 253 nucleic acids, proteins and modulators thereof can be utilized to modulate (*e.g.*, stabilize, promote, inhibit or disrupt) cell/extracellular matrix (ECM) interactions, cell/cell interactions and, for example, signal transduction events associated with such interactions. For example, such TANGO 253 compositions and modulators thereof can be used to modulate binding of such ECM-  
10 associated factors as integrin and can function to modulate ligand binding to cell surface receptors. In addition, TANGO 253 nucleic acids, proteins and modulators thereof can be utilized to modulate connective tissue formation, maintenance and function, as well as to modulate symptoms associated with connective tissue-related disorders, to promote wound healing, and to reduce, slow or inhibit ameliorate connective tissue-related signs of aging,  
15 such as wrinkle formation.

          In light of the C1q domain exhibited by TANGO 253 proteins and their similarity to the collectin family, TANGO 253 nucleic acids, proteins and modulators thereof can be utilized to modulate immune-related processes such as the ability to modulate host immune response by, *e.g.*, modulating one or more elements in the serum complement  
20 cascade, including, for example activation of the cascade, formation of and/or binding to immune complexes, detection and defense against surface antigens and bacteria, and immune surveillance for rapid removal or pathogens. Such TANGO 253 compositions and modulators thereof can be utilized, *e.g.*, to ameliorate incidence of any symptoms associated with disorders that involve such immune-related processes, including, but not  
25 limited to infection and autoimmune disorders.

          In addition, such compositions and modulators thereof can be utilized to modulate folding and alignment of the collagen domain (*e.g.*, into a triple helix), disorders associated with collagen defects, including but not limited to bone disorders, *e.g.*, bone resorption disorders, or hearing, *e.g.*, inner ear, disorders, to modulate protein-protein  
30 interactions and recognition events (either homotypic or heterotypic) and cellular response events (*e.g.*, signal transduction events) associated with such interactions and recognitions, and to ameliorate symptoms associated with abnormal signaling, protein-protein interaction and/or cellular response events including, but not limited to cell proliferation disorders such as cancer, abnormal neuronal interactions, such as disorders involving  
35 abnormal synaptic activity, *e.g.*, abnormal Purkinje cell activities.

Human TANGO 253 protein contains an RGD domain. As such, TANGO 253 nucleic acids, proteins and modulators thereof can be utilized to modulate processes involved in, *e.g.*, bone development, sepsis, tumor progression, metastasis, cell migration, fertilization, and cellular interactions with the extracellular matrix required for growth, differentiation, and apoptosis, as well as cellular processes involving cell adhesion, such as cell migration.

TANGO 253 proteins exhibit similarity to adipocyte complement-related protein precursor and can act as signaling molecules for adipocyte tissue. In light of this, TANGO 253 nucleic acids, proteins and modulators thereof can be utilized to modulate adipocyte function and adipocyte-related processes and disorders such as, *e.g.*, obesity.

TANGO 253 nucleic acids, proteins, and modulators thereof can also be utilized to modulate the development, differentiation, maturation, proliferation and/or activity of cells of the central nervous system such as neurons, glial cells (*e.g.*, astrocytes and oligodendrocytes), and Schwann cells. TANGO 253 nucleic acids, polypeptides, or modulators thereof can also be used to treat disorders of the brain, such as cerebral edema, hydrocephalus, brain herniations, iatrogenic disease (due to, *e.g.*, infection, toxins, or drugs), inflammations (*e.g.*, bacterial and viral meningitis, encephalitis, and cerebral toxoplasmosis), cerebrovascular diseases (*e.g.*, hypoxia, ischemia, and infarction, intracranial hemorrhage and vascular malformations, and hypertensive encephalopathy), tumors (*e.g.*, neuroglial tumors, neuronal tumors, tumors of pineal cells, meningeal tumors, primary and secondary lymphomas, intracranial tumors, and medulloblastoma), and to treat injury or trauma to the brain.

TANGO 253 nucleic acids, proteins, and modulators thereof can also be utilized to treat renal (kidney) disorders, such as glomerular diseases (*e.g.*, acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease, such as systemic lupus erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, polycystic kidney disease, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases (*e.g.*, acute tubular necrosis and acute renal failure, polycystic renal diseasemedullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (*e.g.*, pyelonephritis, drug and toxin induced tubulointerstitial nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy), acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, gout, vascular diseases (*e.g.*, hypertension and nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal disease, diffuse cortical necrosis, and renal infarcts), or tumors (*e.g.*, renal cell carcinoma and nephroblastoma).

TANGO 253 nucleic acids, proteins and modulators thereof can, in addition to the above, be utilized to regulate or modulate development and/or differentiation of processes involved in microglial, lung, liver, kidney, pancreas, brain, placental and skeletal muscle formation and activity, as well as in ameliorating any symptom associated with a disorder of such cell types, tissues and organs.

TANGO 253 expression can be utilized as a marker (*e.g.*, an *in situ* marker) for specific tissues (*e.g.*, the brain) and/or cells (*e.g.*, neurons) in which TANGO 253 is expressed. TANGO 253 nucleic acids can also be utilized for chromosomal mapping.

#### 10 Human TANGO 257

A cDNA encoding human TANGO 257 was identified by analyzing the sequences of clones present in a coronary smooth muscle library for sequences that encode secreted proteins. This analysis led to the identification of a clone, Athma7c10, encoding full-length human TANGO 257. The human TANGO 257 cDNA of this clone is 1832 nucleotides long (Figures 9A-9B; SEQ ID NO:15). The open reading frame of this cDNA, nucleotides 88 to 1305 of SEQ ID NO:15 (SEQ ID NO:16), encodes a 406 amino acid secreted protein (Figures 9A-9B; SEQ ID NO:17).

Figure 10 depicts a hydropathy plot of human TANGO 257. Relatively hydrophobic regions of the protein are above the horizontal line, and relatively hydrophilic regions of the protein are below the horizontal line. The cysteine residues (cys) and N-glycosylation sites (Ngly) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal sequence from the mature protein described below.

The signal peptide prediction program SIGNALP (Nielsen et al., 1997, *Protein Engineering* 10:1-6) predicted that human TANGO 257 includes a 21 amino acid signal peptide (amino acid 1 to amino acid 21 of SEQ ID NO:17; SEQ ID NO:19) preceding the mature human TANGO 257 protein (corresponding to amino acid 22 to amino acid 406 of SEQ ID NO:17; SEQ ID NO:18). The molecular weight of human TANGO 257 protein without post-translational modifications is 46.0 kDa prior to the cleavage of the signal peptide, 43.8 kDa after cleavage of the signal peptide.

Two N-glycosylation sites are present in human TANGO 257. The first has the sequence NDTA and is found at amino acids 177 to 180 of SEQ ID NO:17, and the second has the sequence NRTV and is found at amino acids 248 to 251 of SEQ ID NO:17. A cAMP and cGMP dependent protein kinase phosphorylation site having the sequence RKAS is found in human TANGO 257 at amino acids 196 to 199 of SEQ ID NO:17. Five protein kinase C phosphorylation sites are present in human TANGO 257. The first has

the sequence SSR (at amino acids 48 to 50 of SEQ ID NO:17), the second has the sequence SGR (at amino acids 84 to 86 of SEQ ID NO:17), the third has the sequence SMK (at amino acids 144 to 146 of SEQ ID NO:17), the fourth has the sequence TEK (at amino acids 166 to 168 of SEQ ID NO:17) and the fifth has the sequence SLR (at amino acids 374 to 376 of SEQ ID NO:17). Five casein kinase II phosphorylation sites are present in human TANGO 257. The first has the sequence TEAD (at amino acids 78 to 81 of SEQ ID NO:17), the second has the sequence TQND (at amino acids 175 to 178 of SEQ ID NO:17), the third has the sequence TVVD (at amino acids 250 to 253 of SEQ ID NO:17), the fourth has the sequence TYID (at amino acids 272 to 275 of SEQ ID NO:17), and the fifth has the sequence TRED (at amino acids 289 to 292 of SEQ ID NO:17). Human TANGO 257 has a tyrosine kinase phosphorylation site having the sequence RLEREVDY at amino acids 89 to 96 of SEQ ID NO:17). Human TANGO 257 has three N-myristylation sites. The first has the sequence GGPGTK (at amino acids 115 to 120 of SEQ ID NO:17), the second has the sequence GGPAGL (at amino acids 152 to 157 of SEQ ID NO:17) and the third has the sequence GAHASL (at amino acids 370 to 375 of SEQ ID NO:17). Human TANGO 257 has an amidation site having the sequence KGRR at amino acids 122 to 125 of SEQ ID NO:17.

Northern analysis of human TANGO 257 expression demonstrates moderate expression in heart, liver and pancreas, and low expression in kidney, lung and skeletal muscle.

Secretion assays reveal a human TANGO 257 protein of approximately 50kDa. The secretion assays were performed as described in the human TANGO 253 section above.

The human TANGO 257 nucleotide sequence was mapped to human chromosome 1 using the Genebridge 4 Human Radiation hybrid mapping panel with GGATGATGG CTACCAGATTGTC (SEQ ID NO:195) as the forward primer and GGAACATTGAGGGTTTGGACTC (SEQ ID NO:196) as the reverse primer.

TANGO 257 is homologous to a protein encoded by a nucleic acid sequence referred to in PCT Publication WO 98/39446 as "gene 64". Figure 14 shows an alignment of the human TANGO 257 amino acid sequence (SEQ ID NO:17) with the gene 64 encoded amino acid sequence (SEQ ID NO:43). As shown in the figure, the 353 amino acid gene 64 polypeptide is identical to amino acid residues 1-353 of human TANGO 257 (SEQ ID NO:17). Human TANGO 257 contains 406 amino acids, *i.e.*, contains an additional 53 amino acid residues carboxy to residue 353. The overall amino acid sequence identity between full-length human TANGO 257 polypeptide and the gene 64-encoded polypeptide is approximately 87%.

Figures 15A-15D show an alignment of the nucleotide sequence of gene 64 (SEQ ID NO:66; PCT Publication WO 98/39446) and the nucleotide sequence of human TANGO 257 (SEQ ID NO:15). The nucleotide sequences of gene 64 and human TANGO 257 are 93.5% identical. Among the differences between the sequences is a cytosine nucleotide at human TANGO 257 (SEQ ID NO:15) position 1587 that represents an insertion relative to the corresponding gene 64 position when the gene 64 and TANGO 257 sequences are aligned. This additional cytosine results in the TANGO 257 open reading frame being 1218 base pairs encoding a polypeptide of 406 amino acid residues. In contrast, the gene 64 nucleic acid sequence encodes a polypeptide of only 353 amino acid residues, as discussed above.

Clone EpT257, which encodes human TANGO 257, was deposited with the American Type Culture Collection (10801 University Boulevard, Manassas, VA 20110-2209) on April 21, 1999 and assigned Accession Number 207222. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

#### Mouse TANGO 257

A cDNA encoding mouse TANGO 257 was identified by analyzing the sequences of clones present in a mouse microglia library using a rat TANGO 257 probe. This analysis led to the identification of a clone, Atmua102gbl, encoding full-length mouse TANGO 257. The mouse TANGO 257 cDNA of this clone is 1721 nucleotides long (Figures 11A-11B; SEQ ID NO:21). The open reading frame of this cDNA, nucleotides 31 to 1248 of SEQ ID NO:21 (SEQ ID NO:22), encodes a 406 amino acid secreted protein (Figures 11A-11B; SEQ ID NO:23).

Figure 12 depicts a hydropathy plot of mouse TANGO 257. Relatively hydrophobic regions of the protein are above the horizontal line, relatively hydrophilic regions of the protein are below the horizontal line. The cysteine residues (cys) and N-glycosylation sites (Ngly) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal sequence from the mature protein described below.

The signal peptide prediction program SIGNALP (Nielsen et al., 1997, Protein Engineering 10:1-6) predicted that mouse TANGO 257 includes a 21 amino acid signal peptide (amino acid 1 to amino acid 21 of SEQ ID NO:23; SEQ ID NO:25) preceding the mature TANGO 257 protein (corresponding to amino acid 22 to amino acid 406 of SEQ

ID NO:23; (SEQ ID NO:24). The molecular weight of mouse TANGO 257 protein without post-translational modifications is 45.8 kDa prior to the cleavage of the signal peptide, 43.6 kDa after cleavage of the signal peptide.

Two N-glycosylation sites are present in mouse TANGO 257. The first has the sequence NDTA and is found at amino acids 177 to 180 of SEQ ID NO:23, and the second has the sequence NRTV and is found at amino acids 248 to 251 of SEQ ID NO:23. A cAMP and cGMP-dependent protein kinase phosphorylation site having the sequence RKAS is found in mouse TANGO 257 at amino acids 196 to 199 of SEQ ID NO:23. Five protein kinase C phosphorylation sites are present in mouse TANGO 257. The first has the sequence SSR (at amino acids 48 to 50 of SEQ ID NO:23), the second has the sequence TLR (at amino acids 75 to 77 of SEQ ID NO:23), the third has the sequence SGR (at amino acids 84 to 86 of SEQ ID NO:23), the fourth has the sequence SMK (at amino acids 144 to 146 of SEQ ID NO:23) and the fifth has the sequence SLR (at amino acids 374 to 376 of SEQ ID NO:23). Five casein kinase II phosphorylation sites are present in mouse TANGO 257. The first has the sequence TEAD (at amino acids 78 to 81 of SEQ ID NO:23), the second has the sequence TQND (at amino acids 175 to 178 of SEQ ID NO:23), the third has the sequence TVVD (at amino acids 250 to 253 of SEQ ID NO:23), the fourth has the sequence TYID (at amino acids 272 to 275 of SEQ ID NO:23), and the fifth has the sequence TRRD (at amino acids 289 to 292 of SEQ ID NO:23). Mouse TANGO 257 has a tyrosine kinase phosphorylation site having the sequence RLEREVDY at amino acids 89 to 96 of SEQ ID NO:23. Mouse TANGO 257 has four N-myristylation sites. The first has the sequence GGPGAK (at amino acids 115 to 120 of SEQ ID NO:23), the second has the sequence GGSVGL (at amino acids 151 to 157 of SEQ ID NO:23), the third has the sequence GPGGG (at amino acids 227 to 232 of SEQ ID NO:23), and the fourth has the sequence GAHASL (at amino acids 370 to 375 of SEQ ID NO:23). Mouse TANGO 257 has an amidation site having the sequence KGRR at amino acids 122 to 125 of SEQ ID NO:23.

As shown in Figure 13, human TANGO 257 protein and mouse TANGO 257 protein are 94.1% identical.

Figure 16 shows an alignment of mouse TANGO 257 amino acid sequence (SEQ ID NO:23) with the amino acid sequence encoded by gene 64 (SEQ ID NO:43). As shown in the figure, the 253 amino acid gene 64 polypeptide and the 406 amino acid mouse TANGO 257 polypeptide are approximately 82% identical. Figures 17A-17C show an alignment of the nucleotide sequence of gene 64 (SEQ ID NO:66; PCT publication no. 98/39446) and the nucleotide

sequence of mouse TANGO 257 (SEQ ID NO:21). As shown in the figure, the two nucleotide sequences are approximately 76% identical.

*In situ* tissue screening was performed on mouse adult tissues and embryonic tissues (obtained from embryos E13.5 to P1.5) to analyze for the expression of mouse TANGO 257 mRNA. Mouse TANGO 257 expression was detected the following adult tissues: the submandibular gland; the renal papilla region of the kidney; the capsule region of the adrenal gland; and the labyrinth zone of the placenta.

In the case of embryonic expression, mouse TANGO 257 expression was detected in the bones, lungs, intestines, and kidneys. At E13.5, a signal was detected in many tissues including the developing bone structures such as the vertebrae, of the spinal column, jaw, and scapula. At E14.5, the signal pattern was very similar to that detected at E13.5. At 15.5, a signal was detected in all major bone structures, including the skull, basisphenoid bone, upper and lower incisor teeth, vertebral column, sternum, scapula, and femur. A ubiquitous signal was also detected in the lung, kidney, and intestinal tract. At 16.5 and 18.5, the signal is very similar to that detected at E15.5. At P1.5, a signal was still detected in all of the major bone structures and signal detected in the lung, kidney, and intestines has dropped to nearly background levels.

Clone EpTm257, which encodes mouse TANGO 257, was deposited with the American Type Culture Collection (10801 University Boulevard, Manassas, VA 20110-2209) on April 21, 1999 and assigned Accession Number 207117. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

25

#### Uses of TANGO 257 Nucleic acids, Polypeptides, and Modulators Thereof

As TANGO 257 was originally found in a coronary artery smooth muscle library, TANGO 257 nucleic acids, proteins, and modulators thereof can be used to modulate the proliferation, development, differentiation, and/or function of organs, *e.g.*, heart, tissues and cells that form blood vessels and coronary tissue, *e.g.*, cells of the coronary connective tissue, *e.g.*, coronary smooth muscle cells and/or endothelial cells of blood vessels. TANGO 257 nucleic acids, proteins, and modulators thereof can also be used to modulate symptoms associated with abnormal coronary function, *e.g.*, heart diseases and disorders such as atherosclerosis, coronary artery disease and plaque formation.

In light of TANGO 257's homology to the extracellular molecule olfactomedin, TANGO 257 nucleic acids, proteins and modulators thereof can be utilized to modulate

development, differentiation, proliferation and/or activity of neuronal cells, *e.g.*, olfactory neurons and to modulate neuronal activities involving maintenance, growth and/or differentiation of chemosensory cilia, modulate cell-cell interactions and cell-ECM interactions, *e.g.*, neuronal (such as olfactory) cell-ECM interactions. TANGO 257  
5 nucleic acids, proteins and modulations thereof can also be used to modulate symptoms associated with abnormal processes involving such cells and/or activities, for example neuronal function, *e.g.*, neurological disorders, neurodegenerative disorders, neuromuscular disorders, cognitive disorders, personality disorders, and motor disorders, and chemosensory disorders, such as olfactory-related disorders.

10 TANGO 257 exhibits homology to a gene referred to as "gene 64" (PCT Publication No. WO 98/39446), which is expressed primarily in fetal lung tissue. In light of this, TANGO 257 nucleic acids, proteins and modulators thereof can also be used to modulate development, differentiation, proliferation and/or activity of pulmonary system cells, *e.g.*, lung cell types, and to modulate a symptom associated with disorders of  
15 pulmonary development, differentiation and/or activity, *e.g.*, cystic fibrosis. TANGO 257 nucleic acids, proteins and modulators thereof can also be used to modulate symptoms associated with abnormal pulmonary development or function, such as lung diseases or disorders associated with abnormal pulmonary development or function, *e.g.*, cystic fibrosis. TANGO 257 nucleic acids, polypeptides, or modulators thereof can be used to  
20 treat pulmonary (lung) disorders, such as atelectasis, cystic fibrosis, rheumatoid lung disease, pulmonary congestion or edema, chronic obstructive airway disease (*e.g.*, emphysema, chronic bronchitis, bronchial asthma, and bronchiectasis), diffuse interstitial diseases (*e.g.*, sarcoidosis, pneumoconiosis, hypersensitivity pneumonitis, bronchiolitis, Goodpasture's syndrome, idiopathic pulmonary fibrosis, idiopathic pulmonary  
25 hemosiderosis, pulmonary alveolar proteinosis, desquamative interstitial pneumonitis, chronic interstitial pneumonia, fibrosing alveolitis, hamman-rich syndrome, pulmonary eosinophilia, diffuse interstitial fibrosis, Wegener's granulomatosis, lymphomatoid granulomatosis, and lipid pneumonia), or tumors (*e.g.*, bronchogenic carcinoma, bronchioloalveolar carcinoma, bronchial carcinoid, hamartoma, and mesenchymal  
30 tumors).

TANGO 257 nucleic acids, proteins and modulators thereof can also be used to modulate cell proliferation, *e.g.*, abnormal cell proliferation. Such modulation may, for example, be via modulation of one or more elements involved in signal transduction cascades.

35 TANGO 257 nucleic acids, proteins and modulators thereof can also be utilized to modulate the development, differentiation, maturation, proliferation and/or activity of

bone cells such as osteocytes, and to treat bone associated diseases or disorders. Examples of bone diseases and disorders include bone injury due to for example, trauma (*e.g.*, bone breakage, cartilage tearing), degeneration (*e.g.*, osteoporosis), degeneration of joints, *e.g.*, arthritis, *e.g.*, osteoarthritis, and bone wearing. Further, TANGO 257 nucleic acids, proteins and modulators thereof can be utilized to modulate or regulate the development of bone structures such as the skull, the basisphenoid bone, the upper and lower incisor teeth, the vertebral column, the sternum, the scapula, and the femur during embryogenesis.

TANGO 257 nucleic acids, proteins and modulators thereof can, in addition to the above, be utilized to regulate or modulate development and/or differentiation of processes involved in microglial, liver, kidney, and skeletal muscle formation and activity, as well as in ameliorating a symptom associated with a disorder of such cell types, tissues and organs.

TANGO 257 nucleic acids, polypeptides, or modulators thereof can also be used to treat renal (kidney) disorders, such as glomerular diseases (*e.g.*, acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease, such as systemic lupus erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, polycystic kidney disease, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases (*e.g.*, acute tubular necrosis and acute renal failure, polycystic renal diseasemedullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (*e.g.*, pyelonephritis, drug and toxin induced tubulointerstitial nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy), acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, gout, vascular diseases (*e.g.*, hypertension and nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal disease, diffuse cortical necrosis, and renal infarcts), or tumors (*e.g.*, renal cell carcinoma and nephroblastoma).

TANGO 257 polypeptides, nucleic acids, or modulators thereof can be used to treat intestinal disorders, such as ischemic bowel disease, infective enterocolitis, Crohn's disease, benign tumors, malignant tumors (*e.g.*, argentaffinomas, lymphomas, adenocarcinomas, and sarcomas), malabsorption syndromes (*e.g.*, celiac disease, tropical sprue, Whipple's disease, and abetalipoproteinemia), obstructive lesions, hernias, intestinal adhesions, intussusception, or volvulus.

Further, TANGO 257 expression can be utilized as a marker (*e.g.* an *in situ* marker) for specific tissues (*i.e.*, bone structures) and/or cells (*i.e.*, osteocytes) in which TANGO 257 is expressed. TANGO 257 nucleic acids can also be used for chromosomal mapping.

### Human INTERCEPT 258

A cDNA encoding human INTERCEPT 258 was identified by analyzing the sequences of clones present in a human mixed lymphocyte reaction library for sequences that encode secreted proteins. This analysis led to the identification of a clone, Ath1xtce,  
5 encoding full-length human INTERCEPT 258. The human INTERCEPT 258 cDNA of this clone is 1869 nucleotides long (Figures 18A-18B; SEQ ID NO:26). The open reading frame of this cDNA, nucleotides 153 to 1262 of SEQ ID NO:26 (SEQ ID NO:27), encodes a 370 amino acid transmembrane protein (Figures 18A-18B; SEQ ID NO:28).

Figure 19 depicts a hydropathy plot of human INTERCEPT 258. Relatively  
10 hydrophobic regions of the protein are shown above the horizontal line, and relatively hydrophilic regions of the protein are below the horizontal line. The cysteine residues (cys) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal sequence (amino acids 1 to 29 of SEQ ID NO:28; SEQ ID NO:30) on the left from the mature protein (amino acids 30 to 370 of SEQ ID NO:28;  
15 SEQ ID NO:29) on the right.

The signal peptide prediction program SIGNALP (Nielsen et al., 1997, *Protein Engineering* 10:1-6) predicted that human INTERCEPT 258 includes a 29 amino acid signal peptide (amino acid 1 to amino acid 29 of SEQ ID NO:26; SEQ ID NO:30) preceding the mature INTERCEPT 258 protein (corresponding to amino acid 30 to amino  
20 acid 370 of SEQ ID NO:26; SEQ ID NO:29). The molecular weight of human INTERCEPT 258 protein without post-translational modifications is 40.0 kDa prior to the cleavage of the signal peptide, 37.0 kDa after cleavage of the signal peptide.

Human INTERCEPT 258 contains a hydrophobic transmembrane domain at amino acids amino acids 207 to 224 of SEQ ID NO:28 (SEQ ID NO:78) and amino acids 247 to  
25 271 of SEQ ID NO:28 (SEQ ID NO:33). Human INTERCEPT 258 also contains two Ig domains, one at amino acids 49 to 128 of SEQ ID NO:28 (SEQ ID NO:35) and a second at amino acids 167 to 226 of SEQ ID NO:28 (SEQ ID NO:36).

Five N-glycosylation sites are present in human INTERCEPT 258. The first has sequence NLSL and is found at amino acids 108 to 111 of SEQ ID NO:28, the second has  
30 the sequence NUTL and is found at amino acids 169 to 172 of SEQ ID NO:28; the third has the sequence NLSS and is found at amino acids 213 to 216 of SEQ ID NO:28, the fourth has the sequence NUTL and is found at amino acids, 236 to 239 of SEQ ID NO:28, and the fifth has the sequence NGTL and is found at amino acids 307 to 310 of SEQ ID NO:28. Seven protein kinase C phosphorylation sites are present in human INTERCEPT  
35 258. The first has the sequence TSK and is found at amino acids 93 to 95 of SEQ ID NO:28, the second has the sequence SLR and is found at amino acids 110 to 112 of SEQ

ID NO:28, the third has the sequences SIK and is found at amino acids 141 to 143 of SEQ ID NO:28, the fourth has the sequence SCR and is found at amino acids 157 to 159, the fifth has the sequence SPR and is found at amino acids 176 to 179 of SEQ ID NO:28, the sixth has the sequence SAR and is found at amino acids 315 to 317 of SEQ ID NO:28, and the seventh has the sequence SPR and is found at amino acids 344 to 346 of SEQ ID NO:28. The human INTERCEPT 258 protein has seven N-myristoylation sites. The first has the sequence GUTTSK and is found at amino acids 90 to 95 of SEQ ID NO:28, the second has the sequence GANVTL and is found at amino acids 167 to 172 of SEQ ID NO:28, the third has the sequence GVVYCK and is found at amino acids 220 to 225, the fourth has the sequence GTAQCN and is found at amino acids 231 to 236 of SEQ ID NO:28, the fifth has the sequence GTLVGL and is found at amino acids 256 to 261, the sixth has the sequence GLLAGL and is found at amino acids 262 to 267 of SEQ ID NO:28, and the seventh has the sequence GTLSSU and is found at amino acids 308 to 313 of SEQ ID NO:28.

The human INTERCEPT 258 gene was mapped to human chromosome 11 using Genebridge 4 Human Radiation hybrid mapping panel with GGAGTATCCTTGGTCTACTCC (SEQ ID NO:197) as the forward primer and GAAAGTCTGGAAGGATGGAAGCT (SEQ ID NO:198) as the reverse primer.

Human multi-tissue dot blot analysis of human INTERCEPT 258 expression demonstrates strongest expression in lung, fetal lung, placenta, thyroid gland and mammary gland. Moderate expression is observed in heart, aorta, kidney, small intestine, fetal heart, fetal kidney, fetal spleen, uterus, and stomach. Weak expression is observed in whole brain, amygdala, caudate nucleus, cerebellum, cerebral cortex frontal lobe, hippocampus, medulla oblongata, occipital lobe, putamen, substantia nigra, temporal lobe, thalamus, acumens, spinal cord, skeletal muscle, colon, bladder, prostate, ovary, pancreas, pituitary gland, adrenal gland, salivary gland, liver, spleen, thymus, lymph node, bone marrow, appendix, trachea, fetal brain, fetal liver, and fetal thymus.

A human cancer cell line Northern blot analysis showed a roughly 2.0 kb INTERCEPT 258 band only in the lane containing cell line Chronic Myelogenous Leukemia (K-562). The cancerous cell lines in which INTERCEPT 258 was not expressed include promyelocytic leukemia, Hela, lymphoblastic leukemia, Burkitt's lymphoma Raji, colorectal adenocarcinoma, lung carcinoma and melanoma.

INTERCEPT 258 exhibits homology to a human A33 antigen. A33 antigen is a transmembrane glycoprotein and a member of the immunoglobulin superfamily that may represent a cancer cell marker (Heath et al., 1997, Proc. Natl. Acad. Sci. USA 94:469-474). Figure 23 shows an alignment of the human INTERCEPT 258 amino acid sequence

(SEQ ID NO:28) with the human A33 amino acid sequence (SEQ ID NO:67). The alignment shows that there is a 23.0% overall amino acid sequence identity between human INTERCEPT 258 and A33. Figures 24A-24D show an alignment of the human INTERCEPT 258 nucleotide sequence (SEQ ID NO:26) with that of human A33  
5 nucleotide sequence (SEQ ID NO:68). The alignment shows that there is a 40.6% identity between the two sequences.

Human INTERCEPT 258 nucleotide sequence (SEQ ID NO:26) exhibits homology to human PECAM-1 nucleotide sequence (SEQ ID NO:72). Figures 27A-27E show that there is an overall 40.5% identity between the two nucleotide sequences.  
10 Human INTERCEPT 258 amino acid sequence (SEQ ID NO:28) and human PECAM-1 amino acid sequence (SEQ ID NO:73) share less than 18% identity. PECAM-1 (platelet endothelial cell adhesion molecule-1) is an integrin expressed on endothelial cells.

Clone EpT258, which encodes human INTERCEPT 258, was deposited with the American Type Culture Collection (10801 University Boulevard, Manassas, VA 20110-  
15 2209) on April 21, 1999 and assigned Accession Number 207222. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

20

#### Mouse INTERCEPT 258

A cDNA encoding mouse INTERCEPT 258 was identified by analyzing the sequences of clones present in a mouse megakaryocyte library for sequences that encode secreted proteins. This analysis led to the identification of a clone, Athmeal7c8, encoding  
25 full-length mouse INTERCEPT 258. The mouse INTERCEPT 258 cDNA of this clone is 1846 nucleotides long (Figures 20A-20B; SEQ ID NO:37). The open reading frame of this cDNA, nucleotides 107 to 1288 of SEQ ID NO:37 (SEQ ID NO:38), encodes a 394 amino acid transmembrane protein (Figures 20A-20B, SEQ ID NO:39).

Figure 21 depicts a hydropathy plot for mouse INTERCEPT 258. Relatively  
30 hydrophobic regions of the protein are above the horizontal line, relatively hydrophilic regions of the protein are below the horizontal line. The cysteine residues (cys) and N-glycosylation sites (Ngly) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal sequence from the mature protein described below.

35 The signal peptide prediction program SIGNALP (Nielsen et al., 1997, *Protein Engineering* 10:1-6) predicted that mouse INTERCEPT 258 includes a 29 amino acid

signal peptide (amino acid 1 to amino acid 29 of SEQ ID NO:39; SEQ ID NO:41) preceding the mature INTERCEPT 258 protein (corresponding to amino acid 30 to amino acid 394 of SEQ ID NO:39; SEQ ID NO:40). The molecular weight INTERCEPT 258 without post-translational modifications is 41.8 kDa prior to the cleavage of the signal peptide, 38.90 kDa after cleavage of the signal peptide.

Mouse INTERCEPT 258 contains a hydrophobic transmembrane domain at amino acids 250 to 274 SEQ ID NO:39 (SEQ ID NO:44). Mouse INTERCEPT 258 also contains an Ig domain at amino acids 170 to 229 of SEQ ID NO:39 (SEQ ID NO:71).

Five N-glycosylation sites are present in mouse INTERCEPT 258. The first has sequence NVSL and is found at amino acids 111 to 114 of SEQ ID NO:39, the second has the sequence NVTL and is found at amino acids 172 to 175 of SEQ ID NO:39, the third has the sequence NLSI and is found at amino acids 216 to 219 of SEQ ID NO:39, the fourth has the sequence NVTL and is found at amino acids, 239 to 242 of SEQ ID NO:39, and the fifth has the sequence NGTL and is found at amino acids 310 to 313 of SEQ ID NO:39. Nine protein kinase C phosphorylation sites are present in mouse INTERCEPT 258. the first has the sequence TNK and is found at amino acids 96 to 98 of SEQ ID NO:39, the second has the sequence SSR and is found at amino acids 108 to 110 of SEQ ID NO:39, the third has the sequence SLR and is found at amino acids 113 to 115 of SEQ ID NO:39, the fourth has the sequence TYR and is found at amino acids 126 to 128, the fifth has the sequence SIK and is found at amino acids 144 to 146 of SEQ ID NO:39, the sixth has the sequence SPR and is found at amino acids 179 to 181 of SEQ ID NO:39, the seventh has the sequence SLK and is found at amino acids 211 and 213, the eighth has the sequence SAR and is found at amino acids 318 to 320 of SEQ ID NO:39, and the ninth has the sequence SPR and is found at amino acids 348 to 350 of SEQ ID NO:39. The mouse INTERCEPT 258 contains a casein kinase II phosphorylation site having the sequence TLEE, found at amino acids 280 to 283 of SEQ ID NO:39. The mouse INTERCEPT 258 protein has nine N-myristoylation sites. The first has the sequence GTPETS and is found at amino acids 6 to 11 of SEQ ID NO:39, the second has the sequence GVMTNK and is found at amino acids 125 to 130 of SEQ ID NO:39, the third has the sequence GTYRCS and is found at amino acids 125 to 130, the fourth has the sequence GTNVTL and is found at amino acids 170 to 175 of SEQ ID NO:39, the fifth has the sequence GVVYVCK and is found at amino acids 223 to 228, the sixth has the sequence GSKAAV and is found at amino acids 247 to 252, the seventh has the sequence GAVVGT and is found at amino acids 255 to 260 of SEQ ID NO:39, the eighth has sequence GTLSSV and is found at amino acids 311 to 316 of SEQ ID NO:39, and the

ninth has the sequence GGVSSS and is found at amino acids 367 to 372 of SEQ ID NO:39.

5 An *in situ* expression analysis of INTERCEPT 258 was performed as summarized herein. Mouse INTERCEPT 258 expression during embryogenesis (E73.5 to P1.5 were examined) was observed throughout the animal in a punctate pattern. This pattern is very similar to that seen with the molecule PECAM-1, but at a lower intensity. PECAM-1 is an integrin expressed on endothelial cells. In addition, lung and brown fat exhibited a much higher signal in a more ubiquitous pattern in all embryonic stages examined. Heart and kidney also have a higher expression, but to a lesser degree. Adult mouse INTERCEPT  
10 258 expression was seen in many tissues, often in a multifocal, punctate pattern suggestive of vessels. Expression was also predominant in many highly vascularized tissues such as ovary (especially the septol region), kidney and adrenal cortex.

In general, both embryonic and adult expression patterns were suggestive of endothelial cells being a component in the expression patterns observed. In summary,  
15 tissues in which INTERCEPT 258 expression was observed were as follows: brain, eye, harderian gland, submandibular gland, bladder, brown fat, stomach, heart, kidney, adrenal gland, colon, liver, thymus, lymph node, spleen, spinal cord, ovary, testes and placenta.

As shown in Figure 22, human INTERCEPT 258 protein and mouse INTERCEPT 258 protein are 62.8% identical.

20 Mouse INTERCEPT 258 exhibits homology to a human A33 antigen. Figure 25 shows an alignment of mouse INTERCEPT 258 amino acid sequence (SEQ ID NO:39) with the human A33 amino acid sequence (SEQ ID NO:96). The alignment shows that there is a 23% overall amino acid sequence identity between the two sequences. Figures 26A-26D show an alignment of the mouse INTERCEPT 258 nucleotide sequence (SEQ  
25 ID NO:37) with that of the human A33 nucleotide sequence (SEQ ID NO:97). The alignment shows that there is a 40% identity between these two nucleotide sequences.

Clone EpTm258, which encodes mouse INTERCEPT 258, was deposited with the American Type Culture Collection (10801 University Boulevard, Manassas, VA 20110-2209) on April 21, 1999 and assigned Accession Number 207221. This deposit will be  
30 maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

35 Uses of INTERCEPT 258 Nucleic acids, Polypeptides, and Modulators Thereof

INTERCEPT 258 was identified as being expressed in a mixed lymphocyte library. In light of this, INTERCEPT 258 nucleic acids, proteins and modulators thereof can be utilized to modulate processes involved in lymphocyte development, differentiation and activity, including, but not limited to development, differentiation and activation of T cells, including T helper, T cytotoxic and non-specific T killer cell types and subtypes, and B cells, immune functions associated with such cells, and amelioration of one or more symptoms associated with abnormal function of such cell types. Such disorders can include, but are not limited to, autoimmune disorders, such as organ specific autoimmune disorders, *e.g.*, autoimmune thyroiditis, Type I diabetes mellitus, insulin-resistant diabetes, autoimmune anemia, multiple sclerosis, and/or systemic autoimmune disorders, *e.g.*, rheumatoid arthritis, lupus or scleroderma, allergy, including allergic rhinitis and food allergies, asthma, psoriasis, graft rejection, transplantation rejection, graft versus host disease, pathogenic susceptibilities, *e.g.*, susceptibility to certain bacterial or viral pathogens, wound healing and inflammatory reactions.

INTERCEPT 258 includes one or more Ig domains. INTERCEPT 258 nucleic acids, proteins, and modulators thereof can, therefore, be used to modulate immune function, *e.g.*, by the modulation of immunoglobulins and the formation of antibodies. For the same reason, INTERCEPT 258 nucleic acids, proteins, and modulators thereof can be used to modulate immune response, leukocyte trafficking, cancer, Type I immunologic disorders, *e.g.*, anaphylaxis and/or rhinitis, by modulating the interaction between antigens and cell receptors, *e.g.*, high affinity IgE receptors.

INTERCEPT 258 exhibits homology to PECAM-1, a cell adhesion integrin molecule that has been shown to mediate cell-cell interactions, play an important role in bidirectional signal transduction, and may be involved in thrombotic, inflammatory and immunological disorders. As such, INTERCEPT 258 nucleic acids, proteins, and modulators thereof can be utilized to modulate cell/cell interactions and, for example, signal transduction events associated with such interactions. For example, such INTERCEPT 258 compositions and modulators thereof can be used to modulate binding of cellular factors or ECM-associated factors such as integrin and can function to modulate ligand binding to cell surface receptors. Further, such INTERCEPT 258 compositions and modulators thereof can be utilized to ameliorate at least one symptom associated with thrombotic disorders, *e.g.*, stroke, inflammatory processes or disorders, and immune disorders.

In light of INTERCEPT 258 expression, INTERCEPT 258 nucleic acids, proteins and modulators thereof can be utilized modulate development, differentiation, proliferation and/or activity of pulmonary system cells, *e.g.*, lung cell types, and to

modulate a symptom associated with disorders of pulmonary development, differentiation and/or activity, such as lung diseases or disorders associated with abnormal pulmonary development or function, *e.g.*, cystic fibrosis. INTERCEPT 258 nucleic acids, proteins and modulators thereof can also be utilized modulate development, differentiation, proliferation and/or activity of thyroid cells, megakaryocytes or mammary gland cells, and can further be utilized to ameliorate at least one symptom of disorders associated with, abnormal thyroid function, *e.g.*, thyroiditis or Grave's disease, abnormal megakaryocyte differentiation or function, *e.g.*, anemias or leukemias, hematological diseases such as thrombocytopenia, platelet disorders and bleeding disorders, such as hemophilia or abnormal mammary development or function.

INTERCEPT 258 nucleic acids, polypeptides, or modulators thereof can be used to treat renal (kidney) disorders, such as glomerular diseases (*e.g.*, acute and chronic glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, focal proliferative glomerulonephritis, glomerular lesions associated with systemic disease, such as systemic lupus erythematosus, Goodpasture's syndrome, multiple myeloma, diabetes, polycystic kidney disease, neoplasia, sickle cell disease, and chronic inflammatory diseases), tubular diseases (*e.g.*, acute tubular necrosis and acute renal failure, polycystic renal diseasemedullary sponge kidney, medullary cystic disease, nephrogenic diabetes, and renal tubular acidosis), tubulointerstitial diseases (*e.g.*, pyelonephritis, drug and toxin induced tubulointerstitial nephritis, hypercalcemic nephropathy, and hypokalemic nephropathy), acute and rapidly progressive renal failure, chronic renal failure, nephrolithiasis, gout, vascular diseases (*e.g.*, hypertension and nephrosclerosis, microangiopathic hemolytic anemia, atheroembolic renal disease, diffuse cortical necrosis, and renal infarcts), or tumors (*e.g.*, renal cell carcinoma and nephroblastoma).

INTERCEPT 258 nucleic acids, polypeptides, or modulators thereof can also be used to treat disorders of the brain, such as cerebral edema, hydrocephalus, brain herniations, iatrogenic disease (due to, *e.g.*, infection, toxins, or drugs), inflammations (*e.g.*, bacterial and viral meningitis, encephalitis, and cerebral toxoplasmosis), cerebrovascular diseases (*e.g.*, hypoxia, ischemia, and infarction, intracranial hemorrhage and vascular malformations, and hypertensive encephalopathy), and tumors (*e.g.*, neuroglial tumors, neuronal tumors, tumors of pineal cells, meningeal tumors, primary and secondary lymphomas, intracranial tumors, and medulloblastoma), and to treat injury or trauma to the brain.

INTERCEPT 258 nucleic acids, proteins, and modulators thereof can still further be utilized to modulate development, differentiation proliferation and/or activity of cells involved in kidney or heart formation and function. In addition, such compositions and modulators thereof can be utilized to ameliorate at least one symptom of disorders

associated with abnormal kidney or heart formation or function, including, but not limited to nephritis, coronary disease, atherosclerosis and plaque formation.

INTERCEPT 258 expression indicates that INTERCEPT 258 is involved, in addition to the above, in such processes as thermogenesis, adipocyte function, and vascularization. As such, INTERCEPT 258 nucleic acids, proteins, and modulators thereof can be utilized to modulate such processes as well as for ameliorating at least one symptom associated with such processes. Such disorders include, but are not limited to obesity, regulation of body temperature, and disorders involving abnormal vascularization, e.g., vascularization of solid tumors.

In further light of INTERCEPT 258 expression, as well as in light of its homology to A33 antigen, INTERCEPT 258 nucleic acids, proteins and modulators thereof can be utilized to modulate cell proliferation, including, for example, epithelial, e.g., gastrointestinal tract epithelial cell proliferation, and to ameliorate at least one symptom of cell proliferative disorders such as cancer, and, in particular, chronic myelogenous leukemia, colon cancers, small bowel epithelium cancers and other gastrointestinal tract cancers. Further, INTERCEPT 258 expression can be utilized as a marker for specific tissues (e.g., vascularized tissues) and/or cells (e.g., endothelial cells) in which INTERCEPT 258 is expressed. INTERCEPT 258 nucleic acids can also be utilized for chromosomal mapping.

20

#### Human TANGO 281

A cDNA encoding human TANGO 281 was identified by analyzing the sequences of clones present in a human megakaryocyte cDNA library. This analysis led to the identification of a clone, AThPb81d10, encoding full-length human TANGO 281. The human TANGO 281 cDNA of this clone is 1812 nucleotides long (Figures 28A-28B; SEQ ID NO:46). The open reading frame of this cDNA, nucleotides 65 to 799 of SEQ ID NO:46 (SEQ ID NO:47), encodes a 245 amino acid transmembrane protein (Figures 28A-28B; SEQ ID NO:48).

The signal peptide prediction program SIGNALP (Nielsen, et al. (1997) *Protein Engineering* 10:1-6) predicted that human TANGO 281 includes an 38 amino acid signal peptide (amino acid 1 to amino acid 38 of SEQ ID NO:48; SEQ ID NO:49) preceding the mature TANGO 281 protein (corresponding to amino acid 39 to amino acid 245 of SEQ ID NO:48; SEQ ID NO:50). The molecular weight of TANGO 281 without post-translational modifications is 26.5 kDa prior to the cleavage of the signal peptide, 20.2 kDa after cleavage of the signal peptide.

Human TANGO 281 is a transmembrane protein which contains one or more of the following domains: (1) an extracellular domain; (2) a transmembrane domain; and (3) a

cytoplasmic domain. The human TANGO 281 protein contains an extracellular domain at amino acids 1 to 123 of SEQ ID NO:48 or a mature extracellular domain at about amino acid residues 39 to 123 of SEQ ID NO:48 (SEQ ID NO:51), a transmembrane domain at amino acid residues 124 to 148 of SEQ ID NO:48 (SEQ ID NO:52), and a cytoplasmic domain at amino acid residues 149 to 245 of SEQ ID NO:48 (SEQ ID NO:53).

Figure 29 depicts a hydropathy plot of human TANGO 281. Relatively hydrophobic regions of the protein are shown above the horizontal line, and relatively hydrophilic regions of the protein are below the horizontal line. The cysteine residues (cys) and potential N-glycosylation sites (Ngly) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal sequence (amino acids 1 to 38 of SEQ ID NO:48; SEQ ID NO:49) on the left from the mature protein (amino acids 38 to 245 of SEQ ID NO:48; SEQ ID NO:50) on the right.

Human TANGO 281 comprises photosystem II 10 kD phosphoprotein (PSBH) domain sequences, which have been shown to be phosphorylated in a light-dependent reaction, from amino acids 41 to 90 and 127 to 182 of SEQ ID NO:48 (SEQ ID NO:54 and SEQ ID NO:55, respectively). Figure 30 depicts an alignment between the PSBH domain (SEQ ID NO:69; Accession No. PF00737) and human TANGO 281 from amino acids 97 to 146 of SEQ ID NO:48. An N-glycosylation site having the sequence NTTT is present in TANGO 281 at about amino acids 160 to 163 of SEQ ID NO:48. Two protein kinase C phosphorylation sites are present in human TANGO 281. The first has the sequence SVR (at amino acids 8 to 10 of SEQ ID NO:48), and the second has the sequence SSR (at amino acids 87 to 89 of SEQ ID NO:48). Three casein kinase II phosphorylation sites are present in human TANGO 281. The first has the sequence SIPE (at amino acids 49 to 52 of SEQ ID NO:48), the second has the sequence SCPD (at amino acids 53 to 56 of SEQ ID NO:48), and the third has the sequence SSLD (at amino acids 108 to 111 of SEQ ID NO:48). Human TANGO 281 has two N-myristylation sites. The first has the sequence GSCSSQ (at amino acids 60 to 65 of SEQ ID NO:48), and the second has the sequence GATVAI (at amino acids 119 to 124 of SEQ ID NO:48).

Nucleic acid base pairs 413 to 746 of human TANGO 281 (SEQ ID NO:46) have 81% identity to the nucleic acid sequence identified as Accession Number AV34245. Nucleic acid base pairs 438 to 746 of human TANGO 281 (SEQ ID NO:46) have 80% identity to a nucleic acid sequence referred to as "gene 31" described in PCT Publication No. WO 98/39446 (SEQ ID NO:70). "Gene 31" is characterized as being expressed primarily in brain and thymus, and to a lesser extent in such organs as liver, skin, bone and bone marrow.

Clone EpT281 was deposited with the American Type Culture Collection (10801 University Boulevard, Manassas, VA 20110-2209) on April 21, 1999 and assigned Accession

Number 207222. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. § 112.

5

#### Mouse TANGO 281

A cDNA encoding mouse TANGO 281 was identified in a normal mouse megakaryocyte library by performing expression profiling on megakaryocytes obtained from mice with a the deletion of the element of the gata-1 gene responsible for megakaryocyte-specific expression. This analysis led to the identification of a clone, Atmea49d3, encoding  
10 full-length mouse TANGO 281. The mouse TANGO 281 cDNA of this clone is 1858 nucleotides long (Figure 30; SEQ ID NO:56). The open reading frame of this cDNA, nucleotides 90 to 728 of SEQ ID NO:56 (SEQ ID NO:57), encodes a 213 amino acid transmembrane protein (Figure 30; SEQ ID NO:58).

15 The signal peptide prediction program SIGNALP (Nielsen, et al. (1997) *Protein Engineering* 10:1-6) predicted that mouse TANGO 281 includes an 26 amino acid signal peptide (amino acid 1 to amino acid 26 of SEQ ID NO:58; SEQ ID NO:59) preceding the mature TANGO 281 protein (corresponding to amino acid 27 to amino acid 213 of SEQ ID NO:58; SEQ ID NO:60). The molecular weight of mouse TANGO 281 without post-  
20 translational modifications is 22.9 kDa prior to the cleavage of the signal peptide, 20.2 kDa after cleavage of the signal peptide.

Mouse TANGO 281 is a transmembrane protein which contains one or more of the following domains: (1) an extracellular domain; (2) a transmembrane domain; and (3) a cytoplasmic domain. The mouse TANGO 281 protein contains an extracellular domain at  
25 amino acid residues 27 to 112 of SEQ ID NO:58 (SEQ ID NO:61), a transmembrane domain at amino acid residues 113 to 137 of SEQ ID NO:58 (SEQ ID NO:62), and a cytoplasmic domain at amino acid residues 138 to 213 of SEQ ID NO:58 (SEQ ID NO:63).

Figure 32 depicts a hydropathy plot of mouse TANGO 281. Relatively hydrophobic regions of the protein are shown above the horizontal line, and relatively hydrophilic regions of the protein are below the horizontal line. The cysteine residues (cys) and potential  
30 N-glycosylation sites (Ngly) are indicated by short vertical lines just below the hydropathy trace. The dashed vertical line separates the signal sequence (amino acids 1 to 26 of SEQ ID NO:58; SEQ ID NO:59) on the left from the mature protein (amino acids 27 to 213 of SEQ ID NO:58; SEQ ID NO:60) on the right.

35 Mouse TANGO 281 comprises photosystem II 10 kD phosphoprotein (PSBH) domain sequences, which have been shown to be phosphorylated in a light-dependent reaction, from

amino acids 42 to 91 and 128 to 183 of SEQ ID NO:58 (SEQ ID NO:64 and SEQ ID NO:65, respectively). Two N-glycosylation sites having the sequences NTTT (at amino acids 149 to 152 of SEQ ID NO:58) and NASS (at about amino 189 to 192 of SEQ ID NO:58) are present in TANGO 281. A glycosaminoglycan attachment site having the sequence SGFG is present in mouse TANGO 281, and protein kinase C phosphorylation site having the sequence SSR is present in mouse TANGO 281. Two casein kinase II phosphorylation sites are present in human TANGO 281. The first has the sequence TPAE (at amino acids 80 to 83 of SEQ ID NO:58), and the second has the sequence SSFD (at amino acids 97 to 100 of SEQ ID NO:58). Mouse TANGO 281 has two N-myristylation sites. The first has the sequence GSCSNQ (at amino acids 48 to 53 of SEQ ID NO:58), and the second has the sequence GATVAI (at amino acids 108 to 113 of SEQ ID NO:58).

Northern blot analysis of mouse TANGO 281 expression revealed two mRNA bands, one of approximately 1.8 kb and another approximately 1.4 kb. Expression of the 1.8 kb band was detected in the heart, spleen, lung and kidney, with the greatest abundance detected in the heart and lung, followed by the kidney and trace amounts in the spleen. Expression of the 1.4 kb band was detected in the brain, spleen, and lung. Expression of the 1.4 kb and 1.8 kb species of mouse TANGO 281 was detected in 7 day old normal mouse embryos. Neither the 1.4 kb or the 1.8 kb species of mouse TANGO 281 were detected in 11 day old normal mouse embryos. The 1.8 kb species of mouse TANGO 281 was detected in 15 day old normal mouse embryos at 20 % the level detected in 7 day old normal mouse embryos. Expression of the 1.8 kb species detected in 17 day old normal mouse embryos was comparable to the level of expression detected in 7 day old normal mouse embryos. Expression of mouse TANGO 281 expression was greatly reduced in megakaryocytes obtained from gata-1 knockout mice.

*In situ* tissue screening was performed on mouse adult and embryonic tissues to analyze for the expression of mouse TANGO 281 mRNA. Mouse TANGO 281 expression was detected predominantly in the adult lymphoid tissues such as the thymus, lymph node, and spleen. In particular, mouse TANGO 281 expression was detected in the following adult tissues: a moderate, ubiquitous signal was detected in the submandibular gland; a strong, ubiquitous signal was detected in the adrenal gland; a strong, multifocal signal was detected in the medulla of the thymus and a moderate, ubiquitous signal was detected in the cortex of the thymus; a strong signal was detected in the lymph node; a strong signal was detected in the follicles of the spleen; a weak signal was detected in the mucosal epithelium of the bladder; a strong signal was detected in the ovaries; a ubiquitous signal was detected in the placenta; a moderate signal was detected in the muscle region of the stomach; a weak signal

in a pattern outlining many of the large airways was detected in lung; a weak, ubiquitous signal was detected in the liver; and a weak, ubiquitous signal was detected in the kidney.

In the case of embryonic expression, mouse TANGO 281 expression was detected in the lung, stomach, thymus and submaxillary gland. In particular, at E16.5 a weak to moderate  
5 signal was detected in the intestine and stomach, and a moderate, ubiquitous signal was detected in the lung. At P1.5, a signal was detected in the lung, stomach, thymus, and submaxillary gland.

Figure 33 shows that there is an overall 66.5% identity between the precursor human TANGO 281 amino acid sequence and the precursor mouse TANGO 281 amino acid  
10 sequence.

Clone EpT281 was deposited with the American Type Culture Collection (10801 University Boulevard, Manassas, VA 20110-2209) on June 15, 1999 and assigned patent deposit Number PTA-224. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes  
15 of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

#### Uses of TANGO 281 Nucleic acids, Polypeptides, and Modulators Thereof

As TANGO 281 was originally found in a megakaryocyte library, TANGO 281  
20 nucleic acids, proteins, and modulators thereof can be used to modulate the proliferation, differentiation, and/or function of megakaryocytes and platelets. TANGO 281 nucleic acids, proteins, and modulators thereof can be used to treat associated hematological diseases such as thrombocytopenia, platelet disorders and bleeding disorders (*e.g.*, hemophilia). TANGO 281 nucleic acids, proteins, and modulators thereof can be used to modulate platelet  
25 aggregation and degranulation. Further, as TANGO 281 expression varies in mouse embryos during development, TANGO 281 nucleic acids, proteins, and modulators thereof can be used to modulate the development of cells, tissues or organs in embryos.

As TANGO 281 expression is greatly reduced in megakaryocytes obtained from gata-1 knockout mice compared normal mice, TANGO 281 is either a direct or indirect target of  
30 gata-1 and has profound biological implications. Gata-1 is a transcription factor involved in the development of hemapoietic cell lineages -- gata-1 expression is required for proper development of erythrocytes and megakaryocytes. Although deletion of the gata-1 gene is lethal at the embryonic stage due to a failure to form red blood cells, deletion of only the element of the gata-1 gene responsible for megakaryocyte-specific expression (a 10 kb region  
35 of genomic DNA containing a megakaryocyte specific DNase I hypersensitive) is not lethal and results in a reduction in gata-1 expression in the megakaryocyte without affecting gata-1

expression in red blood cells. The megakaryocytes of mice with this element of the gata-1 gene knocked out fail to develop into mature platelets, and the mice experience abnormal bleeding due to their profound thrombocytopenia. TANGO 281 nucleic acids, proteins, and modulators thereof can be used to treat disease and/or disorders associated with gata-1 dysfunction. In light of the reduced expression of TANGO 281 in gata-1 knockout mice, TANGO 281 expression can be utilized as a marker for modulators of gata-1 expression and/or activity.

As TANGO 281 is expressed in the heart, brain, spleen, lung, kidney, embryo and megakaryocytes, TANGO 281 nucleic acids, proteins, and modulators thereof can be used to treat disorders of these cells, tissues, or organs, *e.g.*, ischemic heart disease or atherosclerosis, head trauma, brain cancer, splenic lymphoma, splenomegaly, lung cancer, cystic fibrosis, rheumatoid lung disease, glomerulonephritis, end stage renal disease, uremia, DiGeorge syndrome, thymoma, autoimmune disorders, atresia, Crohns's disease, and various embryonic disorders. TANGO 281 nucleic acids, proteins, and modulators thereof can be used to modulate the bleeding associated with uremia. Further, TANGO 281 nucleic acids, proteins, and modulators thereof can be used to treat hypercoagulation associated with a damaged endothelium, *e.g.*, pre-eclampsia, malignant hypertension, disseminated intravascular coagulopathy, renal transplant rejection, cyclosporin toxicity, microangiopathic hemolytic anemia, and thrombotic thrombocytopenic purpura.

TANGO 281 exhibits homology to a gene referred to as "gene 31" (PCT Publication No. WO98/39446), which is expressed primarily in the brain and thymus. In light of this, TANGO 281 nucleic acids, proteins and modulators thereof can be utilized to ameliorate at least one symptom associated with central nervous (CNS) disorders, hematopoietic disorder, and disorders of the endocrine system.

Further, in light of TANGO 281's pattern of expression in mice, TANGO 281 expression can be utilized as a marker for specific tissues (*e.g.*, lymphoid tissues such as the thymus and spleen) and/or cells (*e.g.*, lymphocytes) in which INTERCEPT 281 is expressed. TANGO 281 nucleic acids can also be utilized for chromosomal mapping.

Tables 1-4 below provide a summary of the sequence information for TANGO 253, TANGO 257, INTERCEPT 258 and TANGO 281.

TABLE 1: Summary of Human TANGO 253, TANGO 257, INTERCEPT 258, and TANGO 281 Sequence Information

Gene	cDNA	ORF	Figure	Accession Number
TANGO 253	SEQ ID NO:1	SEQ ID NO:2	Figure 1	207222
TANGO 257	SEQ ID NO:15	SEQ ID NO:16	Figures 9A-9B	207222

INTERCEPT 258	SEQ ID NO:26	SEQ ID NO:27	Figure17	207222
TANGO 281	SEQ ID NO:46	SEQ ID NO:47	Figures 27	207222

5

10

15

20

25

30

35

TABLE 2: Summary of Domains of Human TANGO 253, TANGO 257, INTERCEPT 258 and TANGO 281 Proteins

Protein	Signal Sequence	Mature Protein	Extracellular	PSBH	Ig	Clq	Collagen	Transmembrane	Cytoplasmic
TANGO 253	aa 1-15 of SEQ ID NO:3 (SEQ ID NO:5)	aa 16-243 of SEQ ID NO:3 (SEQ ID NO:4)				aa 102-232 of SEQ ID NO:3 (SEQ ID NO:7)	aa 36-45 of SEQ ID NO:3 (SEQ ID NO:6)		
TANGO 257	aa 1-21 of SEQ ID NO:17 (SEQ ID NO:19)	aa 22-406 of SEQ ID NO:17 (SEQ ID NO:18)							
INTERCEPT 258	aa 1-29 of SEQ ID NO:28 (SEQ ID NO:30)	aa 30-370 of SEQ ID NO:28 (SEQ ID NO:29)	aa 30-206 of SEQ ID NO: 28 (SEQ ID NO: 76) aa 272-370 of SEQ ID NO: 28 (SEQ ID NO: 34)		aa 49-128; 167-226 of SEQ ID NO:28 (SEQ ID NO:35; SEQ ID NO:36)			aa 207-224 of SEQ ID NO:28 (SEQ ID NO:78); aa 247-271 of SEQ ID NO: 28 (SEQ ID NO: 33)	aa 225-246 of SEQ ID NO:28 (SEQ ID NO:79)
TANGO 281	aa 1-38 of SEQ ID NO:48 (SEQ ID NO:49)	aa 39-245 of SEQ ID NO:48 (SEQ ID NO:50)	aa 39-123 of SEQ ID NO:48 (SEQ ID NO:51)	aa 41-90; 12-187 of SEQ ID NO:48 (SEQ ID NO:54; SEQ ID NO:55)				aa 124-148 of SEQ ID NO:48 (SEQ ID NO:52)	aa 149-245 of SEQ ID NO:48 (SEQ ID NO:53)

TABLE 3: Summary of Mouse TANGO 253, TANGO 257, INTERCEPT 258 and TANGO 281 Sequence Information

Gene	cDNA	ORF	Figure	Accession Number
TANGO 253	SEQ ID NO:8	SEQ ID NO:9	Figures 3A-3B	207215
TANGO 257	SEQ ID NO:21	SEQ ID NO:22	Figures 11A-11B	207217
INTERCEPT 258	SEQ ID NO:37	SEQ ID NO:38	Figures 20A-20B	207221
TANGO 281	SEQ ID NO:56	SEQ ID NO:57	Figures 31A-31B	PTA-224

TABLE 4: Summary of Domains of Mouse TANGO 253, TANGO 257, INTERCEPT 258 and TANGO 281 Proteins

Protein	Signal Sequence	Mature Protein	Extracellular	PSBH	Ig	Clq	Collagen	Transmembrane	Cytoplasmic
TANGO 253	aa 1-15 of SEQ ID NO:10 (SEQ ID NO:12)	aa 16-243 of SEQ ID NO:10 (SEQ ID NO:11)				aa 105-232 of SEQ ID NO:10 (SEQ ID NO:13)	aa 36-95 of SEQ ID NO:10 (SEQ ID NO:14)		
TANGO 257	aa 1-21 of SEQ ID NO:23 (SEQ ID NO:25)	aa 22-406 of SEQ ID NO:23 (SEQ ID NO:24)							
INTERCEPT 258	aa 1-29 of SEQ ID NO:39 (SEQ ID NO:41)	aa 30-394 of SEQ ID NO:39 (SEQ ID NO:40)	30-249 of SEQ ID NO:39 (SEQ ID NO:83)		aa 170-229 of SEQ ID NO:39 (SEQ ID NO:46)			250 to 274 of SEQ ID NO:39 (SEQ ID NO:44)	275-394 of SEQ ID NO:39 (SEQ ID NO:45)
TANGO 281	aa 1-26 of SEQ ID NO:58 (SEQ ID NO:59)	aa 27-213 of SEQ ID NO:58 (SEQ ID NO:60)	aa 27-112 of SEQ ID NO:58 (SEQ ID NO:61)	aa 42-91; 128-183 of SEQ ID NO:58 (SEQ ID NO:64; SEQ ID NO:65)				aa 113-137 of SEQ ID NO:58 (SEQ ID NO:62)	aa 138-213 of SEQ ID NO:58 (SEQ ID NO:63)

Various aspects of the invention are described in further detail in the following subsections:

### I. Isolated Nucleic Acid Molecules

5 One aspect of the invention pertains to isolated nucleic acid molecules that encode a polypeptide of the invention or a biologically active portion thereof, as well as nucleic acid molecules sufficient for use as hybridization probes to identify nucleic acid molecules encoding a polypeptide of the invention and fragments of such nucleic acid molecules suitable for use as PCR primers for the amplification or mutation of nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA) and RNA molecules (*e.g.*, mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. In one embodiment, the nucleic acid molecules of the invention comprise a contiguous open reading frame encoding a polypeptide of the invention.

15 An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. Preferably, an "isolated" nucleic acid molecule is free of sequences (preferably protein encoding sequences) which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kB, 4 kB, 3 kB, 2 kB, 1 kB, 0.5 kB or 0.1 kB of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. As used herein, the term "isolated" when referring to a nucleic acid molecule does not include an isolated chromosome.

30 A nucleic acid molecule of the present invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, or a complement thereof, 35 can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequences of SEQ ID NO:1, 2,

8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, as a hybridization probe, nucleic acid molecules of the invention can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook et al., eds., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

A nucleic acid molecule of the invention can be amplified using cDNA, mRNA or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to all or a portion of a nucleic acid molecule of the invention can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, or the nucleotide sequence of the cDNA insert of a clone deposited with the ATCC® as Accession number 207222, Accession Number 207215, Accession number 207217, Accession Number 207221 or patent deposit Number PTA-224, or a portion thereof. A nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence thereby forming a stable duplex.

Moreover, a nucleic acid molecule of the invention can comprise only a portion of a nucleic acid sequence encoding a full length polypeptide of the invention for example, a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of a polypeptide of the invention. The nucleotide sequence determined from the cloning one gene allows for the generation of probes and primers designed for use in identifying and/or cloning homologues in other cell types, *e.g.*, from other tissues, as well as homologues from other mammals. The probe/primer typically comprises substantially purified oligonucleotide. In one embodiment, the oligonucleotide comprises a region of

nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably 25, more preferably about 50, 75, 100, 125, 150, 175, 200, 250, 300, 350 or 400 consecutive oligonucleotides of the sense or anti-sense sequence of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, or the nucleotide sequence of the cDNA insert of a clone deposited with the ATCC® as Accession number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221, or patent deposit Number PTA-224, or of a naturally occurring mutant of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 104, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192. In another embodiment, the oligonucleotide comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least 400, preferably 450, 500, 530, 550, 600, 700, 750, 800, 850, 900, 1000, 1100, 1200 or more consecutive oligonucleotides of the sense or antisense sequence of SEQ ID NO: 1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, or the nucleotide sequence of the cDNA insert of a clone deposited with the ATCC® as Accession number 207222, Accession number 207215, Accession number 207217, Accession Number 207221, or patent deposit Number PTA-224, or of a naturally occurring mutant of SEQ ID NO: 1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192.

In a preferred embodiment, the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 450, preferably about 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1100 or 1300 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:1, 103, 105, 107 or 109, or a naturally occurring mutant of SEQ ID NO:1, 103, 105, 107, or 109. In another preferred embodiment, the oligonucleotide typically comprises a region of

nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700 or 720 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:2, 91, 100, 101 or 80.

5 In another preferred embodiment, the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 540, preferably about 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200 or 1250 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:8, 119, 121, 123 or 125, or of a naturally occurring mutant of SEQ ID NO:8, 119, 121, 123 or 125. In

10 another preferred embodiment, the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 310, preferably about 350, 400, 450, 500, 550, 600, 650 or 700 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:9, 174, 175, 176 or 177, or of a naturally occurring mutant of SEQ ID NO:9, 174, 175, 176 or 177.

15 In another preferred embodiment, the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 1800 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:15, 111, 113, 115 or 117, or of a naturally occurring mutant of SEQ ID NO:15, 111, 113, 115 or 117. In another preferred embodiment, the oligonucleotide typically comprises a region of  
20 nucleotide sequence that hybridizes under stringent conditions to at least about 1150 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:16, 170, 171, 172 or 173, or of a naturally occurring mutant of SEQ ID NO:16, 170, 171, 172 or 173.

In another preferred embodiment, the oligonucleotide typically comprises a region  
25 of nucleotide sequence that hybridizes under stringent conditions to at least about 1100, preferably about 1200, 1300, 1400, 1500, 16500 or 1700 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:21, 127, 129, 131 or 133, or of a naturally occurring mutant of SEQ ID NO:21, 127, 129, 131 or 133. In another preferred  
embodiment, the oligonucleotide typically comprises a region of nucleotide sequence that  
30 hybridizes under stringent conditions to at least about 1150 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:22, 178, 179, 180 or 181, or of a naturally occurring mutant of SEQ ID NO:22, 178, 179, 180 or 181.

In another preferred embodiment, the oligonucleotide typically comprises a region  
of nucleotide sequence that hybridizes under stringent conditions to at least about 420,  
35 preferably about 450, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID

NO:26, 135, 137, 139 or 141, or of a naturally occurring mutant of SEQ ID NO:26, 135, 137, 139 or 141. In another preferred embodiment, the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:27, 182, 183, 184 or 185, or of a naturally occurring mutant of SEQ ID NO:27, 182, 183, 184 or 185.

In another preferred embodiment, the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 675, preferably about 700, 800, 900, 1000, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:37, 143, 145, 147 or 149, or of a naturally occurring mutant of SEQ ID NO:37, 143, 145, 147 or 149. In another preferred embodiment, the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 500, preferably about 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:38, 186, 187, 188 or 189, or of a naturally occurring mutant of SEQ ID NO:38, 186, 187, 188 or 189.

In another preferred embodiment, the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:46, 151, 153, 155 or 157, or of a naturally occurring mutant of SEQ ID NO:46, 151, 153, 155 or 157. In another preferred embodiment, the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:47, 190, 191, 192 or 77, or of a naturally occurring mutant of SEQ ID NO:47, 190, 191, 192 or 77.

In another preferred embodiment, the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 550, preferably about 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800 or 1850 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:56, 159, 161, 163 or 165, or of a naturally occurring mutant of SEQ ID NO:56, 159, 161, 163 or 165. In another preferred embodiment, the oligonucleotide typically

comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 50, 100, 200, 300, 400, 500, 600 or 700 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:57, 166, 167, 168 or 169, or of a naturally occurring mutant of SEQ ID NO:57, 166, 167, 168 or 169.

Probes based on the sequence of a nucleic acid molecule of the invention can be used to detect transcripts or genomic sequences encoding the same protein molecule encoded by a selected nucleic acid molecule. The probe comprises a label group attached thereto, *e.g.*, a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which mis-express the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, *e.g.*, detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted.

A nucleic acid fragment encoding a biologically active portion of a polypeptide of the invention can be prepared by isolating a portion of any of SEQ ID NO:3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164 expressing the encoded portion of the polypeptide protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the polypeptide.

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, or the nucleotide sequence of the cDNA insert of a clone deposited with the ATCC® as Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221 or patent deposit number PTA-224 due to degeneracy of the genetic code and thus encode the same protein as that encoded by the nucleotide sequence of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, or the nucleotide sequence of the cDNA insert of a clone deposited with the ATCC® as Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221 or patent deposit Number PTA-224.

In addition to the nucleotide sequences of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequence may exist within a population (e.g., the human population). Such genetic polymorphisms may exist among individuals within a population due to natural allelic variation.

An allele is one of a group of genes which occur alternatively at a given genetic locus. As used herein, the phrase "allelic variant" refers to a nucleotide sequence which occurs at a given locus or to a polypeptide encoded by the nucleotide sequence. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a polypeptide of the invention. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity are intended to be within the scope of the invention.

The human gene for TANGO 253 has been mapped to the long arm of chromosome 11. Flanking markers for this region are D1151356 and D115924. The Jacobsen syndrome (JBS), ED4 (ectodermal dysplasia 4), CMT4B (Charcot Marie Tooth neuropathy), PORC (porphyria, acute) loci also map to this region of the human chromosome. The APOPLP1 (apolipoprotein cluster), DRD2 (dopamine receptor 2), PGL1 (paraganglioma glomus tumors), RDX (radixin), NCAM1 (neural cell adhesion molecule), ARCN1 (archain 1), and IL-10R (IL-10 receptor) genes map to this region of the human chromosome. This region is syntenic to mouse chromosome 9. The ruf (rough fur), lu (luxoid), and atm (ataxia telangiectasia gene mutated in human being) loci also map to this region of the mouse chromosome. The ruf (rough fur), lu (luxoi), hmbs (hydroxymethylbilane synthase), IL-10R $\alpha$  (IL-10 receptor  $\alpha$ ), and drd2 (dopamine receptor 2) genes also map to this region of the mouse chromosome.

The human gene for TANGO 257 has been mapped to chromosome 1. Flanking markers for this region are WI-7614 and FB14F9. The WS2B (Waardenburg syndrome) loci also maps to this region of the human chromosome. The NGF- $\beta$  (nerve growth

factor- $\beta$ ), TSHB (thyroid stimulating hormone), and GSTM1 (glutathione S-transferase cluster) genes also map to this region of the human chromosome. This region is syntenic to mouse chromosome 3. The de (droopy ear) loci maps to this region of the mouse chromosome. The NGF- $\beta$  (nerve growth factor- $\beta$ ), TSHB (thyroid stimulating hormone),  
5 and BCAN (brevican) genes also map to this region of the mouse chromosome.

The human gene for INTERCEPT 258 has been mapped to the long arm of chromosome 11, in the region q23. Flanking markers for this region are D11S936 and D11S933. The CMT4B (Charcot Marie Tooth neuropathy), ED4 (ecotodermal dysplasia), JBS (Jacobsen Syndrome), and TCPT (thrombocytopenia) loci also map to this region of  
10 the human chromosome. The APOLP1 (apolipoprotein cluster), DRD2 (dopamine receptor), and RDX (radixin) genes also map to this region of the human chromosome. This region is syntenic to mouse chromosome 9. The atm (ataxia telangiectasia), ruf (rough fur), and vs (variable spotting) loci map to this region of the mouse chromosome. The lu (luxoid), vs (variable spotting), atm (ataxia telangiectasia), rug (rough fur), and  
15 lap1 (leucine arylaminopeptidase) genes also map to this region of the mouse chromosome.

Moreover, nucleic acid molecules encoding proteins of the invention from other species (homologues), which have a nucleotide sequence which differs from that of the human or mouse protein described herein are intended to be within the scope of the  
20 invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of a cDNA of the invention can be isolated based on their identity to the human nucleic acid molecule disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. For example, a cDNA encoding a soluble form of a  
25 membrane-bound protein of the invention isolated based on its hybridization to a nucleic acid molecule encoding all or part of the membrane-bound form. Likewise, a cDNA encoding a membrane-bound form can be isolated based on its hybridization to a nucleic acid molecule encoding all or part of the soluble form.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 1000, 1100, 1200 or 1300 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:1, 103, 105, 107 or 109, or a complement thereof.  
30

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700 or  
35

720 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:2, 80, 91, 100 or 101, or a complement thereof.

5 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 540, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200 or 1250 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:8, 119, 121, 123 or 125, or a complement thereof.

10 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 310, 350, 400, 450, 500, 550, 600, 650 or 700 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:9, 174, 175, 176 or 177, or a complement thereof.

15 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 1800 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:15, 111, 113, 115 or 117, or a complement thereof.

20 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 1150 or 1200 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:16, 170, 171, 172 or 173, or a complement thereof.

25 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 1100, 1200, 1300, 1400, 1500, 1600 or 1700 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:21, 127, 129, 131 or 133, or a complement thereof.

30 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 1150 or 1200 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:22, 178, 179, 180 or 181, or a complement thereof.

35 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 420, 450, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400,

1500, 1600, 1700, or 1800 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID No:26, 135, 137, 139 or 141, or a complement thereof.

5 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:27, 182, 183, 184 or 185, or a complement thereof.

10 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 675, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:37, 143, 145, 147 or 149, or a complement thereof.

15 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:38, 186, 187, 188 or 189, or a complement thereof.

20 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or 1800 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:46, 151, 153, 155 or 157, or a complement thereof.

25 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 50, 100, 200, 300, 400, 500, 600, 700 or 750 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:47, 77 190, 191 or 192, or a complement thereof.

30 Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 550, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800 or 1850 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:56, 159, 161, 163 or 165, or a complement thereof.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 50, 100, 200, 300, 400, 500, 600 or 700 contiguous nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:57, 166, 167, 168 or 169, or a complement thereof.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60%, 65%, 70%, preferably 75%, identical to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45° C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65° C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, or a complement thereof, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

In addition to naturally-occurring allelic variants of a nucleic acid molecule of the invention sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation thereby leading to changes in the amino acid sequence of the encoded protein, without altering the biological activity of the protein. For example, one can make nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are not conserved or only semi-conserved among homologues of various species may be non-essential for activity and thus would be likely targets for alteration. Specific examples of conservative amino acid alterations from the original amino acid sequence of SEQ ID NO:3, 10, 17, 23, 28, 39, 48 or 58 are shown in SEQ ID NO: 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164.

Alternatively, amino acid residues that are conserved among the homologues of various species (*e.g.*, mouse and human) may be essential for activity and thus would not be likely targets for alteration.

5 Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity. Such polypeptides differ in amino acid sequence from SEQ ID NO:3, 102, 104, 106 or 108, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 40%, 45%, 50%, 55%, 60%, 65%,  
10 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:3, 102, 104, 106 or 108.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity. Such polypeptides differ in amino acid sequence from SEQ  
15 ID NO:10, 118, 120, 122 or 124 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 95%, or 98% identical to the amino acid sequence of SEQ ID NO:10, 118, 120, 122 or 124.

20 Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity. Such polypeptides differ in amino acid sequence from SEQ ID NO:17, 110, 112, 114 or 116 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that  
25 includes an amino acid sequence that is at least about 88%, 90%, 95% or 98% identical to the amino acid sequence of SEQ ID NO:17, 110, 112, 114 or 116.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity. Such polypeptides differ in amino acid sequence from SEQ  
30 ID NO:23, 126, 128, 130 or 132 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 88%, 90%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:23, 126, 128, 130 or 132.

35 Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity. Such polypeptides differ in amino acid sequence from SEQ

ID NO:28, 134, 136, 138, 140, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:28, 134, 136, 138,  
5 140.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity. Such polypeptides differ in amino acid sequence from SEQ ID NO:39, 142, 144, 146 or 148, yet retain biological activity. In one embodiment, the  
10 isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:39, 142, 144, 146 or 148.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity. Such polypeptides differ in amino acid sequence from SEQ ID NO:48, 150, 152, 154, or 156, yet retain biological activity. In one embodiment, the  
15 isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID  
20 NO:48, 150, 152, 154 or 156.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a polypeptide of the invention that contain changes in amino acid residues that are not essential for activity. Such polypeptides differ in amino acid sequence from SEQ  
25 ID NO:58, 158, 160, 162 or 164, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID  
30 NO:58, 158, 160, 162 or 164.

An isolated nucleic acid molecule encoding a variant protein can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131,  
35 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184,

185, 186, 187, 188, 189, 190, 191 or 192 such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more  
5 predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar  
10 side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by  
15 saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

In a preferred embodiment, a mutant polypeptide that is a variant of a polypeptide of the invention can be assayed for: (1) the ability to form protein: protein interactions  
20 with proteins in a signaling pathway of the polypeptide of the invention; (2) the ability to bind a ligand of the polypeptide of the invention; or (3) the ability to bind to an intracellular target protein of the polypeptide of the invention. In yet another preferred embodiment, the mutant polypeptide can be assayed for the ability to modulate cellular proliferation, cellular migration or chemotaxis, or cellular differentiation.

25 The present invention encompasses antisense nucleic acid molecules, *i.e.*, molecules which are complementary to a sense nucleic acid encoding a polypeptide of the invention, *e.g.*, complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary  
30 to an entire coding strand, or to only a portion thereof, *e.g.*, all or part of the protein coding region (or open reading frame). An antisense nucleic acid molecule can be antisense to all or part of a non-coding region of the coding strand of a nucleotide sequence encoding a polypeptide of the invention. The non-coding regions ("5' and 3' untranslated regions") are the 5' and 3' sequences which flank the coding region and are  
35 not translated into amino acids.

An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides or more in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense  
5 oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate  
10 the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine,  
15 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,  
20 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense  
25 orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a selected polypeptide of the invention to thereby inhibit  
30 expression, *e.g.*, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct  
35 injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic

administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the  
5 vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

An antisense nucleic acid molecule of the invention can be an  $\alpha$ -anomeric (alpha) nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific  
10 double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other (Gaultier et al. (1987) *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue et al. (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) *FEBS Lett.* 215:327-330).

15 The invention also encompasses ribozymes. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave mRNA transcripts to thereby  
20 inhibit translation of the protein encoded by the mRNA. A ribozyme having specificity for a nucleic acid molecule encoding a polypeptide of the invention can be designed based upon the nucleotide sequence of a cDNA disclosed herein. For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a Cech et al. U.S.  
25 Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742. Alternatively, an mRNA encoding a polypeptide of the invention can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. *See, e.g.*, Bartel and Szostak (1993) *Science* 261:1411-1418.

30 The invention also encompasses nucleic acid molecules which form triple helical structures. For example, expression of a polypeptide of the invention can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the gene encoding the polypeptide (*e.g.*, the promoter and/or enhancer) to form triple helical structures that prevent transcription of the gene in target cells. *See generally* Helene  
35 (1991) *Anticancer Drug Des.* 6(6):569-84; Helene (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher (1992) *Bioassays* 14(12):807-15.

In various embodiments, the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996) *Bioorganic & Medicinal Chemistry* 4(1): 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, *e.g.*, DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996), *supra*; Perry-O'Keefe et al. (1996) *Proc. Natl. Acad. Sci. USA* 93: 14670-675.

PNAs can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g.*, inducing transcription or translation arrest or inhibiting replication. PNAs can also be used, *e.g.*, in the analysis of single base pair mutations in a gene by, *e.g.*, PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, *e.g.*, S1 nucleases (Hyrup (1996), *supra*; or as probes or primers for DNA sequence and hybridization (Hyrup (1996), *supra*; Perry-O'Keefe et al. (1996) *Proc. Natl. Acad. Sci. USA* 93: 14670-675).

In another embodiment, PNAs can be modified, *e.g.*, to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated which may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, *e.g.*, RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996), *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996), *supra*, and Finn et al. (1996) *Nucleic Acids Res.* 24(17):3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs. Compounds such as 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite can be used as a link between the PNA and the 5' end of DNA (Mag et al. (1989) *Nucleic Acids Res.* 17:5973-88). PNA monomers are then coupled in a stepwise manner to produce a

chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn et al. (1996) *Nucleic Acids Res.* 24(17):3357-63). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser et al. (1975) *Bioorganic Med. Chem. Lett.* 5:1119-11124).

5 In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (*see, e.g.*, Letsinger et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. WO 88/09810) or the blood-brain barrier (*see, e.g.*, PCT Publication No. 10 WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (*see, e.g.*, Krol et al. (1988) *Bio/Techniques* 6:958-976) or intercalating agents (*see, e.g.*, Zon (1988) *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

15

## II. Isolated Proteins and Antibodies

One aspect of the invention pertains to isolated proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise 20 antibodies directed against a polypeptide of the invention. In one embodiment, the native polypeptide can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, polypeptides of the invention are produced by recombinant DNA techniques. Alternative to recombinant expression, a polypeptide of the invention can be synthesized chemically 25 using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language "substantially 30 free of cellular material" includes preparations of protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a "contaminating protein"). When the protein or biologically 35 active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, 10%, or 5% of the

volume of the protein preparation. When the protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such preparations of the protein have less than about 30%,  
5 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the polypeptide of interest.

Biologically active portions of a polypeptide of the invention include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the protein (*e.g.*, the amino acid sequence shown in any of SEQ ID NO:4, 6,  
10 7, 13, 14, 18, 23, 28, 33, 34, 35, 36, 39, 42, 44, 45, 48, 51, 52, 53, 54, 55, 58, 61, 62, 63, 64, 65, 71, 76, 34, 78, 79, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 92, 93, 94, 95, 96, 97, 98, or 99 which include fewer amino acids than the full length protein, and exhibit at least one activity of the corresponding full-length protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the corresponding protein. A  
15 biologically active portion of a protein of the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of the native form of a polypeptide of the invention.

20 Preferred polypeptides have the amino acid sequence of SEQ ID NO:4, 6, 7, 13, 14, 18, 23, 28, 33, 34, 35, 36, 39, 42, 44, 45, 48, 51, 52, 53, 54, 55, 58, 61, 62, 63, 64, 65, 71, 76, 34, 78, 79, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 92, 93, 94, 95, 96, 97, 98, or 99. Other useful proteins are substantially identical (*e.g.*, at least about 45%, preferably 55%,  
25 65%, 75%, 85%, 95%, or 99%) to any of SEQ ID NO:4, 6, 7, 13, 14, 18, 23, 28, 33, 34, 35, 36, 39, 42, 44, 45, 48, 51, 52, 53, 54, 55, 58, 61, 62, 63, 64, 65, 71, 76, 34, 78, 79, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 92, 93, 94, 95, 96, 97, 98, or 99 and retain the functional activity of the protein of the corresponding naturally-occurring protein yet differ in amino acid sequence due to natural allelic variation or mutagenesis.

30 To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then  
35 compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is

a function of the number of identical positions shared by the sequences (i.e., % identity = # of identical positions/total # of positions (e.g., overlapping positions) x 100). In one embodiment, the two sequences are the same length.

5 The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-2268, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) *J. Mol.*  
10 *Biol.* 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to a protein molecules of the invention. To obtain gapped alignments for  
15 comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) *Nucleic Acids Res.* 25:3389-3402. Alternatively, PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules (*Id.*). When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. *See*  
20 <http://www.ncbi.nlm.nih.gov>.

Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the  
25 CGC sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Additional algorithms for sequence analysis are known in the art and include ADVANCE and ADAM as described in Torellis and Robotti (1994) *Comput. Appl. Biosci.*, 10:3-5; and FASTA described in Pearson and Lipman (1988) *Proc. Natl. Acad. Sci.* 85:2444-8. Within FASTA, ktup is a control option that sets  
30 the sensitivity and speed of the search. If ktup=2, similar regions in the two sequences being compared are found by looking at pairs of aligned residues; if ktup=1, single aligned amino acids are examined. ktup can be set to 2 or 1 for protein sequences, or from 1 to 6 for DNA sequences. The default if ktup is not specified is 2 for proteins and 6 for DNA. For a further description of FASTA parameters, see  
35 <http://bioweb.pasteur.fr/docs/man/man/fasta.1.html#sect2>, the contents of which are incorporated herein by reference.

The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.

5 The invention also provides chimeric or fusion proteins. As used herein, a "chimeric protein" or "fusion protein" comprises all or part (preferably biologically active) of a polypeptide of the invention operably linked to a heterologous polypeptide (i.e., a polypeptide other than the same polypeptide of the invention). Within the fusion protein, the term "operably linked" is intended to indicate that the polypeptide of the invention and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the N-terminus or C-terminus of the polypeptide of the invention.

15 One useful fusion protein is a GST fusion protein in which the polypeptide of the invention is fused to the C-terminus of GST sequences. Such fusion proteins can facilitate the purification of a recombinant polypeptide of the invention.

20 In another embodiment, the fusion protein contains a heterologous signal sequence at its N-terminus. For example, the native signal sequence of a polypeptide of the invention can be removed and replaced with a signal sequence from another protein. For example, the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (*Current Protocols in Molecular Biology*, Ausubel et al., eds., John Wiley & Sons, 1992). Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, California). In yet another example, useful prokaryotic heterologous signal sequences include the phoA secretory signal (Sambrook et al., *supra*) and the protein A secretory signal (Pharmacia Biotech; Piscataway, New Jersey).

30 In yet another embodiment, the fusion protein is an immunoglobulin fusion protein in which all or part of a polypeptide of the invention is fused to sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ligand (soluble or membrane-bound) and a protein on the surface of a cell (receptor), to thereby suppress signal transduction *in vivo*. The immunoglobulin fusion protein can be used to affect the bioavailability of a cognate ligand of a polypeptide of the invention. Inhibition of ligand/receptor interaction may be useful therapeutically, both for treating proliferative and differentiative disorders and for modulating (*e.g.*, promoting or inhibiting) cell survival. Moreover, the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies directed

against a polypeptide of the invention in a subject, to purify ligands and in screening assays to identify molecules which inhibit the interaction of receptors with ligands.

Chimeric and fusion proteins of the invention can be produced by standard recombinant DNA techniques. In another embodiment, the fusion gene can be synthesized  
5 by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (*see, e.g.,* Ausubel et al., *supra*). Moreover, many expression vectors are commercially available  
10 that already encode a fusion moiety (*e.g.,* a GST polypeptide). A nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the polypeptide of the invention.

A signal sequence of a polypeptide of the invention (SEQ ID NO:5, 12, 19, 25, 30,  
15 41, 49 or 59) can be used to facilitate secretion and isolation of the secreted protein or other proteins of interest. Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway. Thus, the invention pertains to the described polypeptides having a  
20 signal sequence, as well as to the signal sequence itself and to the polypeptide in the absence of the signal sequence (*i.e.,* the cleavage products). In one embodiment, a nucleic acid sequence encoding a signal sequence of the invention can be operably linked in an expression vector to a protein of interest, such as a protein which is ordinarily not secreted or is otherwise difficult to isolate. The signal sequence directs secretion of the protein,  
25 such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved. The protein can then be readily purified from the extracellular medium by art recognized methods. Alternatively, the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain.  
30

In another embodiment, the signal sequences of the present invention can be used to identify regulatory sequences, *e.g.,* promoters, enhancers, repressors. Since signal sequences are the most amino-terminal sequences of a peptide, it is expected that the nucleic acids which flank the signal sequence on its amino-terminal side will be regulatory  
35 sequences which affect transcription. Thus, a nucleotide sequence which encodes all or a portion of a signal sequence can be used as a probe to identify and isolate signal sequences

and their flanking regions, and these flanking regions can be studied to identify regulatory elements therein.

5 The present invention also pertains to variants of the polypeptides of the invention. Such variants have an altered amino acid sequence which can function as either agonists (mimetics) or as antagonists. Variants can be generated by mutagenesis, *e.g.*, discrete point mutation or truncation. An agonist can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of the protein. An antagonist of a protein can inhibit one or more of the activities of the naturally occurring form of the protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the protein of interest. Thus, specific biological effects can be elicited by treatment with a variant of limited function. Treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein can have fewer side effects in a subject relative to treatment with the naturally occurring form of the protein.

15 Variants of a protein of the invention which function as either agonists (mimetics) or as antagonists can be identified by screening combinatorial libraries of mutants, *e.g.*, truncation mutants, of the protein of the invention for agonist or antagonist activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display). There are a variety of methods which can be used to produce libraries of potential variants of the polypeptides of the invention from a degenerate oligonucleotide sequence. Methods for synthesizing degenerate oligonucleotides are known in the art (*see, e.g.*, Narang (1983) *Tetrahedron* 39:3; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 25 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477).

30 In addition, libraries of fragments of the coding sequence of a polypeptide of the invention can be used to generate a variegated population of polypeptides for screening and subsequent selection of variants. For example, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease,

and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal and internal fragments of various sizes of the protein of interest.

5 Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA  
libraries for gene products having a selected property. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming  
10 appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify variants of a protein of the invention (Arkin and Yourvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815;  
15 Delgrave et al. (1993) *Protein Engineering* 6(3):327-331).

The polypeptides of the invention can exhibit post-translational modifications, including, but not limited to glycosylations, (*e.g.*, N-linked or O-linked glycosylations), myristylations, palmitylations, acetylations and phosphorylations (*e.g.*, serine/threonine or tyrosine). In one embodiment, the TANGO 253, TANGO 257, INTERCEPT 258 or  
20 TANGO 281 polypeptides of the invention exhibit reduced levels of O-linked glycosylation and/or N-linked glycosylation relative to endogenously expressed TANGO 253, TANGO 257, INTERCEPT 258 or TANGO 281 polypeptides of the invention do not exhibit O-linked glycosylation or N-linked glycosylation. The post-translational  
25 modifications of TANGO 253, TANGO 257, INTERCEPT 258 or TANGO 281 polypeptides will vary depending upon the host cell in which in TANGO 253, TANGO 257, INTERCEPT 258 or TANGO 281 is expressed. Further, post-translational modifications of TANGO 253, TANGO 257, INTERCEPT 258 or TANGO 281 polypeptides such as glycosylation can be prevented by treating cells, *e.g.*, with  
30 tunicamycin.

An isolated polypeptide of the invention, or a fragment thereof, can be used as an immunogen to generate antibodies using standard techniques for polyclonal and monoclonal antibody preparation. The full-length polypeptide or protein can be used or, alternatively, the invention provides antigenic peptide fragments for use as immunogens.  
35 In one embodiment, an isolated polypeptide or fragment thereof which lacks N- and/or O-linked glycosylation is used as an immunogen to generate antibodies using standard techniques known to those of skill in the art. The antigenic peptide of a protein of the

invention comprises at least 8 (preferably 10, 15, 20, or 30) amino acid residues of the amino acid sequence of SEQ ID NO:3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164 and encompasses an epitope of the protein  
5 such that an antibody raised against the peptide forms a specific immune complex with the protein.

Preferred epitopes encompassed by the antigenic peptide are regions that are located on the surface of the protein, *e.g.*, hydrophilic regions. Figures 2, 4, 10, 12, 19, 21, 29 and 32, are hydropathy plots of the proteins of the invention. These plots or similar  
10 analyses can be used to identify hydrophilic regions.

An immunogen typically is used to prepare antibodies by immunizing a suitable subject, (*e.g.*, rabbit, goat, mouse or other mammal). An appropriate immunogenic preparation can contain, for example, recombinantly expressed or chemically synthesized polypeptide. The preparation can further include an adjuvant, such as Freund's complete  
15 or incomplete adjuvant, or similar immunostimulatory agent.

Accordingly, another aspect of the invention pertains to antibodies directed against a polypeptide of the invention. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin  
20 molecules, *i.e.*, molecules that contain an antigen binding site which specifically binds an antigen, such as a polypeptide of the invention *e.g.*, an epitope of a polypeptide of the invention. A molecule which specifically binds to a given polypeptide of the invention is a molecule which binds the polypeptide, but does not substantially bind other molecules in a sample, *e.g.*, a biological sample, which naturally contains the polypeptide. Examples of  
25 immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')<sub>2</sub> fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of  
30 immunoreacting with a particular epitope.

Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a polypeptide of the invention as an immunogen. Preferred polyclonal antibody compositions are ones that have been selected for antibodies directed against a polypeptide or polypeptides of the invention. Particularly preferred polyclonal  
35 antibody preparations are ones that contain only antibodies directed against a polypeptide or polypeptides of the invention. Particularly preferred immunogen compositions are

those that contain no other human proteins such as, for example, immunogen compositions made using a non-human host cell for recombinant expression of a polypeptide of the invention. In such a manner, the only human epitope or epitopes recognized by the resulting antibody compositions raised against this immunogen will be present as part of a polypeptide or polypeptides of the invention.

The antibody titer in an immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide. If desired, the antibody molecules can be isolated from the mammal (*e.g.*, from the blood) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. Alternatively, antibodies specific for a protein or polypeptide of the invention can be selected for (*e.g.*, partially purified) or purified by, *e.g.*, affinity chromatography. For example, a recombinantly expressed and purified (or partially purified) protein of the invention is produced as described herein, and covalently or non-covalently coupled to a solid support such as, for example, a chromatography column. The column can then be used to affinity purify antibodies specific for the proteins of the invention from a sample containing antibodies directed against a large number of different epitopes, thereby generating a substantially purified antibody composition, *i.e.*, one that is substantially free of contaminating antibodies. By a substantially purified antibody composition is meant, in this context, that the antibody sample contains at most only 30% (by dry weight) of contaminating antibodies directed against epitopes other than those on the desired protein or polypeptide of the invention, and preferably at most 20%, yet more preferably at most 10%, and most preferably at most 5% (by dry weight) of the sample is contaminating antibodies. A purified antibody composition means that at least 99% of the antibodies in the composition are directed against the desired protein or polypeptide of the invention.

At an appropriate time after immunization, *e.g.*, when the specific antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497, the human B cell hybridoma technique (Kozbor et al. (1983) *Immunol. Today* 4:72), the EBV-hybridoma technique (Cole et al. (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing hybridomas is well known (*see generally Current Protocols in Immunology* (1994) Coligan et al. (eds.) John Wiley & Sons, Inc., New York, NY). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind the polypeptide of interest, *e.g.*, using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody directed against a polypeptide of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with the polypeptide of interest. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™ Phage Display Kit*, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *EMBO J.* 12:725-734.

Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. (See, e.g., Cabilly et al., U.S. Patent No. 4,816,567; and Boss et al., U.S. Patent No. 4,816,397, which are incorporated herein by reference in their entirety.) Humanized antibodies are antibody molecules from non-human species having one or more complementarily determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule. (See, e.g., Queen, U.S. Patent No. 5,585,089, which is incorporated herein by reference in its entirety.) Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No. WO 87/02671; European Patent Application 184,187; European Patent Application 171,496; European Patent Application 173,494; PCT Publication No. WO 86/01533; U.S. Patent No. 4,816,567; European Patent Application 125,023; Better et al. (1988) *Science* 240:1041-1043; Liu et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu et al. (1987) *J. Immunol.* 139:3521-3526; Sun et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura et al. (1987) *Canc. Res.* 47:999-1005; Wood et al. (1985) *Nature* 314:446-449; and Shaw et al. (1988) *J. Natl. Cancer Inst.* 80:1553-1559; Morrison (1985) *Science* 229:1202-1207; Oi et al. (1986) *Bio/Techniques* 4:214; U.S.

Patent 5,225,539; Jones et al. (1986) *Nature* 321:552-525; Verhoeyan et al. (1988) *Science* 239:1534; and Beidler et al. (1988) *J. Immunol.* 141:4053-4060.

5 Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Such antibodies can be produced, for example, using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chains  
10 genes, but which can express human heavy and light chain genes. The transgenic mice are immunized in the normal fashion with a selected antigen, *e.g.*, all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology. The human immunoglobulin  
15 transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar (1995, *Int. Rev. Immunol.* 13:65-93). For a detailed discussion of this technology  
20 for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, *see, e.g.*, U.S. Patent 5,625,126; U.S. Patent 5,633,425; U.S. Patent 5,569,825; U.S. Patent 5,661,016; and U.S. Patent 5,545,806. In addition, companies such as Abgenix, Inc. (Freemont, CA), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described  
25 above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, *e.g.*, a mouse antibody, is used to guide the selection of a  
30 completely human antibody recognizing the same epitope. (Jespers et al. (1994) *Bio/technology* 12:899-903).

An antibody directed against a polypeptide of the invention (*e.g.*, monoclonal antibody) can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, such an antibody can be used to  
35 detect the protein (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. The antibodies can also be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable  
substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable  
enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or

acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material  
5 includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

Further, an antibody (or fragment thereof) can be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol,  
10 cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites  
15 (*e.g.*, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (*e.g.*, mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (*e.g.*, daunorubicin (formerly daunomycin) and  
20 doxorubicin), antibiotics (*e.g.*, dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (*e.g.*, vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical  
25 therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, d-interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for  
30 example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Techniques for conjugating a therapeutic moiety to antibodies are well known, see,  
35 *e.g.*, Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in

Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The  
5 Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., 62:119-58 (1982).

10 Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

Accordingly, in one aspect, the invention provides substantially purified antibodies or fragment thereof, including human, non-human, chimeric, and humanized antibodies, which antibodies or fragments specifically bind to a polypeptide comprising an amino acid  
15 sequence of any one of SEQ ID NOs:3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164, or an amino acid sequence encoded by the cDNA insert of a clone deposited with the ATCC® as Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221, or  
20 patent deposit Number PTA-224, or a complement thereof. In another aspect, the invention provides substantially purified antibodies or fragments thereof, including human, non-human, chimeric and humanized antibodies, which antibodies or fragments thereof specifically bind to a polypeptide comprising a fragment of at least 8 contiguous amino acid residues, preferably at least 15 contiguous amino acid residues, of the amino  
25 acid sequence of any one of SEQ ID NOs:3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, or 164.

In another aspect, the invention provides substantially purified antibodies or fragments thereof, including human, non-human, chimeric and humanized antibodies,  
30 which antibodies or fragments thereof, which antibodies or fragments thereof specifically bind to a polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence of any one of SEQ ID NOs:3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164, wherein the percent  
35 identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. In another aspect, the invention provides substantially purified antibodies or fragments

thereof, including human, non-human, chimeric and humanized antibodies, which antibodies or fragments thereof specifically bind to a polypeptide comprising an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to the nucleic acid molecule consisting of any one of SEQ ID Nos:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, or the cDNA insert of a clone deposited as ATCC® as Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession number 207221 or patent deposit Number PTA-224, or a complement thereof, under conditions of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 50°C, 55°C, 60°C or 65°C.

In various embodiments, the substantially purified antibodies or fragments thereof of the invention are polyclonal, monoclonal, Fab fragments, single chain antibodies, or F(ab')<sub>2</sub> fragments. The non-human antibodies or fragments thereof of the invention can be goat, mouse, sheep, horse, chicken, rabbit or rat antibodies or antibodies fragments. In a preferred embodiment, the antibodies of the invention are monoclonal antibodies that specifically bind to a polypeptide of the invention.

The substantially purified antibodies or fragments thereof specifically bind to a signal peptide, a secreted sequence, an extracellular domain, a transmembrane or a cytoplasmic domain cytoplasmic membrane of a polypeptide of the invention. In a particularly preferred embodiment, the substantially purified antibodies or fragments thereof of the invention specifically bind to a secreted sequence or an extracellular domain of the amino acid sequence of SEQ ID NO:3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164, or the amino acid sequence encoded by the EpT253, EpTm253, EpT257, EpTm257, EpT258, EpTm258, EpT281 or EpTm281 cDNA insert of ATCC® Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221, or patent deposit Number PTA-224, or a complement thereof. In one embodiment, the extracellular domain to which the antibody or antibody fragment binds comprises at least 8 contiguous amino acid residues, preferably at least 10 or at least 15 contiguous amino acid residues, of amino acid residues 30 to 206 of SEQ ID NO:28 (SEQ ID NO:76), amino acid residues 272 to 370 of SEQ ID NO:28 (SEQ ID NO:34); amino acid residues 30 to 249 of SEQ ID NO:39 (SEQ ID NO: 83), amino acid residues 39 to 123 of SEQ ID NO:48 (SEQ ID NO:50), or amino acid residues 27 to 112 of SEQ ID NO:58 (SEQ ID NO:61).

Any of the antibodies of the invention can be conjugated to a therapeutic moiety or to a detectable substance. Non-limiting examples of detectable substances that can be conjugated to the antibodies of the invention are an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

The invention also provides a kit containing an antibody of the invention conjugated to a detectable substance, and instructions for use. Still another aspect of the invention is a pharmaceutical composition comprising an antibody of the invention and a pharmaceutically acceptable carrier. In preferred embodiments, the pharmaceutical composition contains an antibody of the invention, a therapeutic moiety, and a pharmaceutically acceptable carrier.

Still another aspect of the invention is a method of making an antibody that specifically recognizes TANGO 253, TANGO 257, INTERCEPT 258, and TANGO 281, the method comprising immunizing a mammal with a polypeptide. In one embodiment, the polypeptide used as an immunogen comprises an amino acid sequence of any one of SEQ ID NOs:3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164, or an amino acid sequence encoded by the cDNA insert of a clone deposited with the ATCC® as Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221, or patent deposit Number PTA-224. In another embodiment, the polypeptide used as an immunogen comprises a fragment of at least 15 amino acid residues, preferably at least 25 amino acid residues, of the amino acid sequence of any one of SEQ ID NOs:3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164, or an amino acid sequence which is at least 85%, preferably at least 95% identical to the amino acid sequence of any one of SEQ ID NOs:3, 10, 17, 23, 28, 39, 48, 58, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162 or 164, wherein the percent identity is determined using the ALIGN program of the GCG software package with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4.

In another embodiment, the polypeptide used as an immunogen comprises an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to the nucleic acid molecule consisting of any one of SEQ ID NOs:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56, 57, 77, 80, 91, 100, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153,

155, 157, 159, 161, 163, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191 or 192, or the cDNA insert of a clone deposited with the ATCC® as Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221, or patent  
5 deposit Number PTA-224, or a complement thereof, under conditions of hybridization of 6X SSC at 45°C and washing in 0.2 X SSC, 0.1% SDS at 50°C, 55°C, 60°C or 65°C. After immunization, a sample is collected from the mammal that contains an antibody that specifically recognizes TANGO 253, TANGO 257, INTERCEPT 258 or TANGO 281, a fragment thereof, or allelic variant thereof. Preferably, the polypeptide is recombinantly  
10 produced using a non-human host cell. Optionally, the antibodies can be further purified from the sample using techniques well known to those of skill in the art. The method can further comprise producing a monoclonal antibody- producing cell from the cells of the mammal. Optionally, antibodies are collected from the antibody-producing cell.

15  
III. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a polypeptide of the invention (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting  
20 another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of  
25 replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, expression vectors, are capable of directing the expression of genes to which they are operably linked. In general, expression vectors of utility in recombinant DNA  
30 techniques are often in the form of plasmids (vectors). However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the  
35 invention in a form suitable for expression of the nucleic acid in a host cell. This means that the recombinant expression vectors include one or more regulatory sequences,

selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide  
5 sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA  
10 (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of  
15 expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein.

The recombinant expression vectors of the invention can be designed for expression of a polypeptide of the invention in prokaryotic (*e.g.*, *E. coli*) or eukaryotic  
20 cells (*e.g.*, insect cells (using baculovirus expression vectors), yeast cells or mammalian cells). Suitable host cells are discussed further in Goeddel, *supra*. Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with  
25 vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the  
30 recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.  
35 Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRITS

(Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

5 Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann et al., (1988) *Gene* 69:301-315) and pET 11d (Studier et al., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident  $\lambda$  prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

15 One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada et al. (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

20 In another embodiment, the expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari et al. (1987) *EMBO J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz et al. (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and pPicZ (Invitrogen Corp, San Diego, CA).

25 Alternatively, the expression vector is a baculovirus expression vector. Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*, Sf 9 cells) include the pAc series (Smith et al. (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

30 In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed (1987) *Nature* 329:840) and pMT2PC (Kaufman et al. (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2,

35

cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook et al., *supra*.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g.,  
5 tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and  
10 Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji et al. (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) *Science* 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No.  
15 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the mouse *hox* promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the beta-fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA  
20 molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operably linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to the mRNA encoding a polypeptide of the invention. Regulatory  
25 sequences operably linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant  
30 plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub et al. (*Reviews - Trends in Genetics*, Vol. 1(1) 1986).

35 Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms

refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

5 A host cell can be any prokaryotic (*e.g.*, *E. coli*) or eukaryotic cell (*e.g.*, insect cells, yeast or mammalian cells).

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (*supra*), and other laboratory manuals.

15 For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, for resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectables markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

In another embodiment, the expression characteristics of an endogenous (*e.g.*, TANGO 253, TANGO 257, INTERCEPT 258 and TANGO 281 genes) within a cell, cell line or microorganism may be modified by inserting a DNA regulatory element heterologous to the endogenous gene of interest into the genome of a cell, stable cell line or cloned microorganism such that the inserted regulatory element is operatively linked with the endogenous gene (*e.g.*, TANGO 253, TANGO 257, INTERCEPT 258 and TANGO 281 genes) and controls, modulates or activates. For example, endogenous TANGO 253, TANGO 257, INTERCEPT 258 and TANGO 281 genes which are normally "transcriptionally silent", *i.e.*, a TANGO 253, TANGO 257, INTERCEPT 258 and TANGO 281 genes which is normally not expressed, or are expressed only at very low levels in a cell line or microorganism, may be activated by inserting a regulatory element which is capable of promoting the expression of a normally expressed gene product in that cell line or microorganism. Alternatively, transcriptionally silent, endogenous TANGO

253, TANGO 257, INTERCEPT 258 and TANGO 281 genes may be activated by insertion of a promiscuous regulatory element that works across cell types.

5 A heterologous regulatory element may be inserted into a stable cell line or cloned microorganism, such that it is operatively linked with endogenous TANGO 253, TANGO 257, INTERCEPT 258 and TANGO 281 genes, using techniques, such as targeted homologous recombination, which are well known to those of skill in the art, and described *e.g.*, in Chappel, U.S. Patent No. 5,272,071; PCT publication No. WO 91/06667, published May 16, 1991.

10 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce a polypeptide of the invention. Accordingly, the invention further provides methods for producing a polypeptide of the invention using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding a polypeptide of the invention has been introduced) in a suitable medium such that the polypeptide is produced. In another  
15 embodiment, the method further comprises isolating the polypeptide from the medium or the host cell.

The host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized  
20 oocyte or an embryonic stem cell into which a sequence encoding a polypeptide of the invention has been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous sequences encoding a polypeptide of the invention have been introduced into their genome or homologous recombinant animals in which endogenous encoding a polypeptide of the invention sequences have been altered. Such  
25 animals are useful for studying the function and/or activity of the polypeptide and for identifying and/or evaluating modulators of polypeptide activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep,  
30 dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, an "homologous recombinant animal" is a non-human animal, preferably a  
35 mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA

molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

5 A transgenic animal of the invention can be created by introducing nucleic acid encoding a polypeptide of the invention (or a homologue thereof) into the male pronuclei of a fertilized oocyte, *e.g.*, by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the polypeptide of the invention to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, U.S. Patent No. 4,873,191 and in Hogan, *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986) and Wakayama *et al.*, (1999), *Proc. Natl. Acad. Sci. USA*, 96:14984-14989. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of mRNA encoding the transgene in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying the transgene can further be bred to other transgenic animals carrying other transgenes.

To create an homologous recombinant animal, a vector is prepared which contains at least a portion of a gene encoding a polypeptide of the invention into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the gene. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous protein). In the homologous recombination vector, the altered portion of the gene is flanked at its 5' and 3' ends by additional nucleic acid of the gene to allow for homologous recombination to occur between the exogenous gene carried by the vector and an endogenous gene in an embryonic stem cell. The additional flanking nucleic acid sequences are of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (*see, e.g.*, Thomas and Capecchi (1987) *Cell* 51:503 for a description of homologous

recombination vectors). The vector is introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced gene has homologously recombined with the endogenous gene are selected (*see, e.g.*, Li et al. (1992) *Cell* 69:915). The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse) to form aggregation chimeras (*see, e.g.*, Bradley in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) *Current Opinion in Bio/Technology* 2:823-829 and in PCT Publication Nos. WO 90/11354, WO 91/01140, WO 92/0968, and WO 93/04169.

In another embodiment, transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, *see, e.g.*, Lakso et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. (1991) *Science* 251:1351-1355. If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, *e.g.*, by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut et al. (1997) *Nature* 385:810-813 and PCT Publication NOS. WO 97/07668 and WO 97/07669.

#### IV. Pharmaceutical Compositions

The nucleic acid molecules, polypeptides, and antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any

and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is  
5 incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

The invention includes methods for preparing pharmaceutical compositions for modulating the expression or activity of a polypeptide or nucleic acid of the invention. Such methods comprise formulating a pharmaceutically acceptable carrier with an agent  
10 which modulates expression or activity of a polypeptide or nucleic acid of the invention. Such compositions can further include additional active agents. Thus, the invention further includes methods for preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a polypeptide or nucleic acid of the invention and one or more additional active  
15 compounds.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for  
20 parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as  
25 acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous  
30 solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF; Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition  
35 must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a

solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of  
5 dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable  
10 compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (*e.g.*, a polypeptide or antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered  
15 sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any  
20 additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared  
25 using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.

Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such  
30 as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.  
35

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

5 Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active  
10 compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention  
15 enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides,  
20 polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be  
25 prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to  
30 be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding  
35 such an active compound for the treatment of individuals.

For antibodies, the preferred dosage is 0.1 mg/kg to 100 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is usually appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (*e.g.*, into the brain). A method for lipidation of antibodies is described by Cruikshank et al. ((1997) *J. Acquired Immune Deficiency Syndromes and Human Retrovirology* 14:193).

As defined herein, a therapeutically effective amount of protein or polypeptide (*i.e.*, an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight.

The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments. In a preferred example, a subject is treated with antibody, protein, or polypeptide in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of antibody, protein, or polypeptide used for treatment may increase or decrease over the course of a particular treatment. Changes in dosage may result and become apparent from the results of diagnostic assays as described herein.

The present invention encompasses agents which modulate expression or activity. An agent may, for example, be a small molecule. For example, such small molecules include, but are not limited to, peptides, peptidomimetics, amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (*i.e.*, including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole,

organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

It is understood that appropriate doses of small molecule agents depends upon a number of factors within the ken of the ordinarily skilled physician, veterinarian, or researcher. The dose(s) of the small molecule will vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the composition is to be administered, if applicable, and the effect which the practitioner desires the small molecule to have upon the nucleic acid or polypeptide of the invention. Exemplary doses include milligram or microgram amounts of the small molecule per kilogram of subject or sample weight (*e.g.*, about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is furthermore understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. Such appropriate doses may be determined using the assays described herein. When one or more of these small molecules is to be administered to an animal (*e.g.*, a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (U.S. Patent 5,328,470) or by stereotactic injection (*see, e.g.*, Chen et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

## V. Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) detection assays (*e.g.*, chromosomal mapping, tissue typing, forensic biology); c) 5 predictive medicine (*e.g.*, diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenomics); and d) methods of treatment (*e.g.*, therapeutic and prophylactic). The isolated nucleic acid molecules of the invention can be used to express proteins (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect mRNA (*e.g.*, in a biological sample) or a genetic lesion, and to modulate activity of a 10 polypeptide of the invention. In addition, the polypeptides of the invention can be used to screen drugs or compounds which modulate activity or expression of a polypeptide of the invention as well as to treat disorders characterized by insufficient or excessive production of a protein of the invention or production of a form of a protein of the invention which has decreased or aberrant activity compared to the wild type protein. In addition, the 15 antibodies of the invention can be used to detect and isolate a protein of the and modulate activity of a protein of the invention.

This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

20

### A. Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) which bind to polypeptide of the 25 invention or have a stimulatory or inhibitory effect on, for example, expression or activity of a polypeptide of the invention.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of a 30 polypeptide of the invention or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic 35 library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide,

non-peptide oligomer or small molecule libraries of compounds (Lam (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:6909; Erb et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann et al. (1994). *J. Med. Chem.* 37:2678; Cho et al. (1993) *Science* 261:1303; Carrell et al. (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carrell et al. (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and Gallop et al. (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (e.g., Houghten (1992) *Bio/Techniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (U.S. Patent No. 5,223,409), spores (Patent NOS. 5,571,698; 5,403,484; and 5,223,409), plasmids (Cull et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:1865-1869) or phage (Scott and Smith (1990) *Science* 249:386-390; Devlin (1990) *Science* 249:404-406; Cwirla et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6378-6382; and Felici (1991) *J. Mol. Biol.* 222:301-310).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of a polypeptide of the invention, or a biologically active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to the polypeptide determined. The cell, for example, can be a yeast cell or a cell of mammalian origin. Determining the ability of the test compound to bind to the polypeptide can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the polypeptide or biologically active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, test compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In a preferred embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of a polypeptide of the invention, or a biologically active portion thereof, on the cell surface with a known compound which binds the polypeptide to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the ability of the test compound to preferentially

bind to the polypeptide or a biologically active portion thereof as compared to the known compound.

5 In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of a polypeptide of the invention, or a biologically active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the polypeptide or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of the polypeptide or a biologically active portion thereof can be accomplished, for example, by determining the ability of the polypeptide protein to bind to  
10 or interact with a target molecule.

Determining the ability of a polypeptide of the invention to bind to or interact with a target molecule can be accomplished by one of the methods described above for determining direct binding. As used herein, a "target molecule" is a molecule with which a selected polypeptide (*e.g.*, a polypeptide of the invention) binds or interacts with in  
15 nature, for example, a molecule on the surface of a cell which expresses the selected protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A target molecule can be a polypeptide of the invention or some other polypeptide or protein. For example, a target molecule can be a component of a signal  
20 transduction pathway which facilitates transduction of an extracellular signal (*e.g.*, a signal generated by binding of a compound to a polypeptide of the invention) through the cell membrane and into the cell or a second intercellular protein which has catalytic activity or a protein which facilitates the association of downstream signaling molecules with a polypeptide of the invention. Determining the ability of a polypeptide of the invention to  
25 bind to or interact with a target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*e.g.*, intracellular  $\text{Ca}^{2+}$ , diacylglycerol, IP3, etc.), detecting catalytic/enzymatic activity of the target on an appropriate substrate, detecting the induction of a reporter gene (*e.g.*, a regulatory element  
30 that is responsive to a polypeptide of the invention operably linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a cellular response, for example, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the present invention is a cell-free assay  
35 comprising contacting a polypeptide of the invention or biologically active portion thereof with a test compound and determining the ability of the test compound to bind to the polypeptide or biologically active portion thereof. Binding of the test compound to the

polypeptide can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the polypeptide of the invention or biologically active portion thereof with a known compound which binds the polypeptide to form an assay mixture, contacting the assay mixture with a test compound, and  
5 determining the ability of the test compound to interact with the polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the ability of the test compound to preferentially bind to the polypeptide or biologically active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-free assay comprising contacting a  
10 polypeptide of the invention or biologically active portion thereof with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the polypeptide or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of the polypeptide can be accomplished, for example, by determining the ability of the polypeptide to bind to a  
15 target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of the polypeptide can be accomplished by determining the ability of the polypeptide of the invention to further modulate the target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be  
20 determined as previously described.

In yet another embodiment, the cell-free assay comprises contacting a polypeptide of the invention or biologically active portion thereof with a known compound which binds the polypeptide to form an assay mixture, contacting the assay mixture with a test  
25 compound, and determining the ability of the test compound to interact with the polypeptide, wherein determining the ability of the test compound to interact with the polypeptide comprises determining the ability of the polypeptide to preferentially bind to or modulate the activity of a target molecule.

The cell-free assays of the present invention are amenable to use of both a soluble  
30 form or the membrane-bound form of a polypeptide of the invention. In the case of cell-free assays comprising the membrane-bound form of the polypeptide, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of the polypeptide is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-octylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton X-100, Triton X-114, Thesit, Isotridecypoly(ethylene glycol ether)<sub>n</sub>,  
35 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS),

3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane sulfonate.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either the polypeptide of the invention or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to the polypeptide, or interaction of the polypeptide with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase fusion proteins or glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical; St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or A polypeptide of the invention, and the mixture incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components and complex formation is measured either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of binding or activity of the polypeptide of the invention can be determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the polypeptide of the invention or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated polypeptide of the invention or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (*e.g.*, biotinylation kit, Pierce Chemicals; Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with the polypeptide of the invention or target molecules but which do not interfere with binding of the polypeptide of the invention to its target molecule can be derivatized to the wells of the plate, and unbound target or polypeptide of the invention trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the polypeptide of the invention or target

molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the polypeptide of the invention or target molecule.

5 In another embodiment, modulators of expression of a polypeptide of the invention are identified in a method in which a cell is contacted with a candidate compound and the expression of the selected mRNA or protein (*i.e.*, the mRNA or protein corresponding to a polypeptide or nucleic acid of the invention) in the cell is determined. The level of expression of the selected mRNA or protein in the presence of the candidate compound is compared to the level of expression of the selected mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of expression of the polypeptide of the invention based on this comparison. For example, 10 when expression of the selected mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of the selected mRNA or protein expression. Alternatively, when expression of the selected mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of the selected mRNA or protein expression. The level of the selected mRNA or protein expression in the cells can be determined by methods described herein. 15

20 In yet another aspect of the invention, a polypeptide of the inventions can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (*see, e.g.*, U.S. Patent No. 5,283,317; Zervos et al. (1993) *Cell* 72:223-232; Madura et al. (1993) *J. Biol. Chem.* 268:12046-12054; Bartel et al. (1993) *Bio/Techniques* 14:920-924; Iwabuchi et al. (1993) *Oncogene* 8:1693-1696; and PCT Publication No. WO 94/10300), to identify other proteins, which bind to or interact with the polypeptide of the invention and modulate activity of the polypeptide of the invention. Such binding proteins are also likely to be 25 involved in the propagation of signals by the polypeptide of the inventions as, for example, upstream or downstream elements of a signaling pathway involving the polypeptide of the invention.

30 This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

#### B. Detection Assays

35 Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a

chromosome and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.

5

### 1. Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. Accordingly, nucleic acid molecules described herein or fragments thereof, can be used to map the location of the corresponding genes on a chromosome. The mapping of the sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the sequence of a gene of the invention. Computer analysis of the sequence of a gene of the invention can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the gene sequences will yield an amplified fragment. For a review of this technique, see D'Eustachio et al. ((1983) *Science* 220:919-924).

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the nucleic acid sequences of the invention to design oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map a gene to its chromosome include *in situ* hybridization (described in Fan et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6223-27), pre-screening with labeled flow-sorted chromosomes (CITE), and pre-selection by hybridization to chromosome specific cDNA libraries. Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. For a review of this technique, see Verma et al., (Human Chromosomes: A Manual of Basic Techniques (Pergamon Press, New York, 1988)).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to

noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

5 Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes),  
10 described in, *e.g.*, Egeland et al. (1987) *Nature* 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with a gene of the invention can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected  
15 individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to  
20 confirm the presence of a mutation and to distinguish mutations from polymorphisms.

Furthermore, the nucleic acid sequences disclosed herein can be used to perform searches against "mapping databases", *e.g.*, BLAST-type search, such that the chromosome position of the gene is identified by sequence homology or identity with known sequence fragments which have been mapped to chromosomes.

25 In the instant case, the human gene for INTERCEPT 258 has been mapped to the long arm of chromosome 11, in the region q23. Flanking markers for this region are D11S936 and D11S933. The CMT4B (Charcot Marie Tooth neuropathy), ED4 (ecotodermal dysplasia), JBS (Jacobsen Syndrome), TCPT (thrombocytopenia) loci also map to this region of the human chromosome. The APOLP1 (apoplipoprotein cluster),  
30 DRD2 (dopamine receptor), and RDX (radixin) genes also map to this region of the human chromosome. This region is syntenic to mouse chromosome 9. The atm (ataxia telangiectasia), ruf (rough fur), and vs (variable spotting) loci map to this region of the mouse chromosome. The lu (luxoid), vs (variable spotting), atm (ataxia telangiectasia), rug (rough fur), and lap1 (leucine arylaminopeptidase) genes also map to this region of the  
35 mouse chromosome.

A polypeptide and fragments and sequences thereof and antibodies specific thereto can be used to map the location of the gene encoding the polypeptide on a chromosome. This mapping can be carried out by specifically detecting the presence of the polypeptide in members of a panel of somatic cell hybrids between cells of a first species of animal  
5 from which the protein originates and cells from a second species of animal and then determining which somatic cell hybrid(s) expresses the polypeptide and noting the chromosome(s) from the first species of animal that it contains. For examples of this technique, see Pajunen *et al.* (1988) *Cytogenet. Cell Genet.* 47:37-41 and Van Keuren *et al.* (1986) *Hum. Genet.* 74:34-40. Alternatively, the presence of the polypeptide in the  
10 somatic cell hybrids can be determined by assaying an activity or property of the polypeptide, for example, enzymatic activity, as described in Bordelon-Riser *et al.* (1979) *Somatic Cell Genetics* 5:597-613 and Owerbach *et al.* (1978) *Proc. Natl. Acad. Sci. USA* 75:5640-5644.

## 15 2. Tissue Typing

The nucleic acid sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification  
20 of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP  
25 (described in U.S. Patent 5,272,057).

Furthermore, the sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the nucleic acid sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These  
30 primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from  
35 tissue. The nucleic acid sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these

sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency at about once per each 500 bases. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes.

5 Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences of SEQ ID NO:1, 8, 15, 21, 26, 37, 46 or 56, can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID  
10 NO:2, 9, 16, 22, 27, 38, 47 or 57 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

If a panel of reagents from the nucleic acid sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database,  
15 positive identification of the individual, living or dead, can be made from extremely small tissue samples.

### 3. Use of Partial Gene Sequences in Forensic Biology

20 DNA-based identification techniques can also be used in forensic biology. Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, *e.g.*, hair or skin, or  
25 body fluids, *e.g.*, blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.

The sequences of the present invention can be used to provide polynucleotide reagents, *e.g.*, PCR primers, targeted to specific loci in the human genome, which can  
30 enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (i.e. another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to noncoding regions are particularly appropriate for this  
35 use as greater numbers of polymorphisms occur in the noncoding regions, making it easier to differentiate individuals using this technique. Examples of polynucleotide reagents

include the nucleic acid sequences of the invention or portions thereof, *e.g.*, fragments derived from noncoding regions having a length of at least 20 or 30 bases.

The nucleic acid sequences described herein can further be used to provide polynucleotide reagents, *e.g.*, labeled or labelable probes which can be used in, for example, an *in situ* hybridization technique, to identify a specific tissue, *e.g.*, brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such probes can be used to identify tissue by species and/or by organ type.

### C. Predictive Medicine

The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining TANGO 253, TANGO 257, INTERCEPT 258, or TANGO 281 protein and/or nucleic acid expression as well as TANGO 253, TANGO 257, INTERCEPT 258, or TANGO 281 activity, in the context of a biological sample (*e.g.*, blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant or unwanted TANGO 253, TANGO 257, INTERCEPT 258, or TANGO 281 expression or activity. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with TANGO 253, TANGO 257, INTERCEPT 258, or TANGO 281 protein, nucleic acid expression or activity. For example, mutations in a TANGO 253, TANGO 257, INTERCEPT 258, or TANGO 281 gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with TANGO 253, TANGO 257, INTERCEPT 258, or TANGO 281 protein, nucleic acid expression or activity.

As an alternative to making determinations based on the absolute expression level of selected genes, determinations may be based on the normalized expression levels of these genes. Expression levels are normalized by correcting the absolute expression level of a TANGO 253, TANGO 257, INTERCEPT 258, or TANGO 281 gene by comparing its expression to the expression of a gene that is not a TANGO 253, TANGO 257, INTERCEPT 258, or TANGO 281 gene, *e.g.*, a housekeeping gene that is constitutively expressed. Suitable genes for normalization include housekeeping genes such as the actin

gene. This normalization allows the comparison of the expression level in one sample, *e.g.*, a patient sample, to another sample, *e.g.*, a sample from an individual without a particular disease or disorder, or a sample from a healthy individual, or between samples from different sources.

5           Alternatively, the expression level can be provided as a relative expression level. To determine a relative expression level of a gene, the level of expression of the gene is determined for 10 or more samples of different cell isolates (*e.g.*, neural cell isolates, glial cell isolates, immune cell isolates, platelet isolates, megakaryocyte isolates, endothelial cell isolates, and osteocyte isolates) preferably 50 or more samples, prior to the  
10       determination of the expression level for the sample in question. The mean expression level of each of the genes assayed in the larger number of samples is determined and this is used as a baseline expression level for the gene(s) in question. The expression level of the gene determined for the test sample (absolute level of expression) is then divided by  
15       the mean expression value obtained for that gene. This provides a relative expression level and aids in identifying extreme cases of diseases and disorders such as obesity, coronary disorders (*e.g.*, atherosclerosis), neuronal disorders, pulmonary disorders, renal disorders, and bleeding disorders.

          Preferably, the samples used in the baseline determination will be from diseased or from non-diseased cells of the appropriate cell type or tissue. The choice of the cell source  
20       is dependent on the use of the relative expression level. Using expression found in normal tissues as a mean expression score aids in validating whether the TANGO 253, TANGO 257, INTERCEPT 258, or TANGO 281 gene assayed is specific (versus normal cells). Such a use is particularly important in identifying whether a TANGO 253, TANGO 257,  
25       INTERCEPT 258, or TANGO 281 gene can serve as a target gene. In addition, as more data is accumulated, the mean expression value can be revised, providing improved relative expression values based on accumulated data. Expression data from cells provides a means for grading the severity of the disease or disorder state.

          Another aspect of the invention pertains to monitoring the influence of agents (*e.g.*,  
30       drugs, compounds) on the expression or activity of TANGO 253, TANGO 257, INTERCEPT 258, or TANGO 281 in clinical trials. These and other agents are described in further detail in the following sections.

#### 35       1.     Diagnostic Assays

          An exemplary method for detecting the presence or absence of a polypeptide or nucleic acid of the invention in a biological sample involves obtaining a biological sample

from a test subject and contacting the biological sample with a compound or an agent capable of detecting a polypeptide or nucleic acid (*e.g.*, mRNA, genomic DNA) of the invention such that the presence of a polypeptide or nucleic acid of the invention is detected in the biological sample. A preferred agent for detecting mRNA or genomic  
5 DNA encoding a polypeptide of the invention is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic DNA encoding a polypeptide of the invention. The nucleic acid probe can be, for example, a full-length cDNA, such as the nucleic acid of SEQ ID NO:1, 2, 8, 9, 15, 16, 21, 22, 26, 27, 37, 38, 46, 47, 56 or 57, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and  
10 sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a polypeptide of the invention. Other suitable probes for use in the diagnostic assays of the invention are described herein.

A preferred agent for detecting a polypeptide of the invention is an antibody capable of binding to a polypeptide of the invention, preferably an antibody with a  
15 detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')<sub>2</sub>) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another  
20 reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That  
25 is, the detection method of the invention can be used to detect mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of a polypeptide of the invention include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and  
30 immunofluorescence. *In vitro* techniques for detection of genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of a polypeptide of the invention include introducing into a subject a labeled antibody directed against the polypeptide. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

35 In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test

subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

5 In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting a polypeptide of the invention or mRNA or genomic DNA encoding a polypeptide of the invention, such that the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide is detected in the biological sample, and comparing the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide in the control sample with the presence of the polypeptide or mRNA or genomic DNA encoding the polypeptide in the test sample.

10 The invention also encompasses kits for detecting the presence of a polypeptide or nucleic acid of the invention in a biological sample (a test sample). Such kits can be used to determine if a subject is suffering from or is at increased risk of developing a disorder associated with aberrant expression of a polypeptide of the invention, as discussed, for example, in sections above relating to uses of the sequences of the invention.

For example, kits can be used to determine if a subject is suffering from or is at increased risk of disorders such as coronary disorders (*e.g.*, heart diseases and disorders such as atherosclerosis, coronary artery disease and plaque formation), and adipocyte-related disorders (*e.g.*, obesity), which are associated with aberrant TANGO 253 expression. In another example, kits can be used to determine if a subject is suffering from or is at increased risk of disorders such as coronary disorders (*e.g.*, heart diseases and disorders such as atherosclerosis, coronary artery disease and plaque formation), olfactory disorders, neurological disorders (*e.g.*, neurodegenerative disorders, neuromuscular disorders, cognitive disorders, personality disorders, and motor disorder) and pulmonary disorders, (*e.g.*, cystic fibrosis), which are associated with aberrant TANGO 257 expression. In another example, kits can be used to determine if a subject is suffering from or is at increased risk of disorders such as Type I immunologic disorders, (*e.g.*, anaphylaxis and rhinitis), which are associated with aberrant INTERCEPT 258 expression. In another example, kits can be used to determine if a subject is suffering from or is at increased risk of disorders such as immunological disorders, (*e.g.* thrombocytopenia and platelet disorders), developmental disorders, coronary disorders, *e.g.*, ischemic heart disease or atherosclerosis, neurological disorders, (*e.g.*, head trauma and brain cancer), pulmonary disorders, (*e.g.*, lung cancer, cystic fibrosis and rheumatoid lung disease), kidney disorders, (*e.g.*, glomerulonephritis and end stage renal disease), autoimmune disorders, (*e.g.*, Crohn's disease) and embryonic disorders, which are associated with aberrant TANGO 281 expression. The kit, for example, can comprise a labeled compound

or agent capable of detecting the polypeptide or mRNA encoding the polypeptide in a biological sample and means for determining the amount of the polypeptide or mRNA in the sample (*e.g.*, an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide). Kits can also include  
5 instructions for observing that the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of the polypeptide if the amount of the polypeptide or mRNA encoding the polypeptide is above or below a normal level.

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (*e.g.*, attached to a solid support) which binds to a polypeptide of the invention; and,  
10 optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable agent.

For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, *e.g.*, a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide of the invention or (2) a pair of primers useful for  
15 amplifying a nucleic acid molecule encoding a polypeptide of the invention. The kit can also comprise, *e.g.*, a buffering agent, a preservative, or a protein stabilizing agent. The kit can also comprise components necessary for detecting the detectable agent (*e.g.*, an enzyme or a substrate). The kit can also contain a control sample or a series of control  
20 samples which can be assayed and compared to the test sample contained. Each component of the kit is usually enclosed within an individual container and all of the various containers are within a single package along with instructions for observing whether the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of the polypeptide.

25

## 2. Prognostic Assays

The methods described herein can furthermore be utilized as diagnostic or prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with aberrant expression or activity of a polypeptide of the invention. For  
30 example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with aberrant expression or activity of a polypeptide of the invention, *e.g.*, coronary disorders, pulmonary disorders, kidney disorders or embryonic disorders. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk  
35 for developing such a disease or disorder. Thus, the present invention provides a method in which a test sample is obtained from a subject and a polypeptide or nucleic acid (*e.g.*,

mRNA, genomic DNA) of the invention is detected, wherein the presence of the polypeptide or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant expression or activity of the polypeptide. As used herein, a "test sample" refers to a biological sample obtained from a subject of  
5 interest. For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

The prognostic assays described herein, for example, can be used to identify a subject having or at risk of developing disorders such as disorders discussed, for example, in Sections above relating to uses of the sequences of the invention.

10 For example, such disorders can include coronary disorders (*e.g.*, heart diseases and disorders such as atherosclerosis, coronary artery disease and plaque formation) and adipocyte disorders (*e.g.*, obesity), which are associated with aberrant TANGO 253 expression. In another example, prognostic assays described herein, can be used to  
15 identify a subject having or at risk of developing disorders such as coronary disorders (*e.g.*, heart diseases and disorders such as atherosclerosis, coronary artery disease and plaque formation), olfactory disorders, neurological disorders (*e.g.*, neurodegenerate disorders, neuromuscular disorders, cognitive disorders, personality disorders, and motor disorders), and pulmonary disorders, (*e.g.*, cystic fibrosis), which are associated with  
20 aberrant TANGO 257 expression. In another example, prognostic assays described herein, can be used to identify a subject having or at risk of developing disorders such as Type I immunologic disorders, (*e.g.*, anaphylaxis and rhinitis), which are associated with aberrant INTERCEPT 258 expression. In another example, prognostic assays described herein, for  
25 example, can be used to identify a subject having or at risk of developing disorders such as immunological disorders, (*e.g.* thrombocytopenia and platelet disorders), developmental disorders, coronary disorders, (*e.g.*, ischemic heart disease and atherosclerosis), neurological disorders, (*e.g.*, head trauma and brain cancer), pulmonary disorders, (*e.g.*, lung cancer, cystic fibrosis and rheumatoid lung disease), kidney disorders, (*e.g.*, glomerulonephritis and end stage renal disease), autoimmune disorders, (*e.g.*, Crohn's  
30 disease) and embryonic disorders, which are associated with aberrant TANGO 281 expression.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to  
35 treat a disease or disorder associated with aberrant expression or activity of a polypeptide of the invention. For example, such methods can be used to determine whether a subject can be effectively treated with a specific agent or class of agents (*e.g.*, agents of a type

which decrease activity of the polypeptide). Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant expression or activity of a polypeptide of the invention in which a test sample is obtained and the polypeptide or nucleic acid encoding the polypeptide is detected (e.g., wherein the presence of the polypeptide or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant expression or activity of the polypeptide).

The methods of the invention can also be used to detect genetic lesions or mutations in a gene of the invention, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized aberrant expression or activity of a polypeptide of the invention. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion or mutation characterized by at least one of an alteration affecting the integrity of a gene encoding the polypeptide of the invention, or the mis-expression of the gene encoding the polypeptide of the invention. For example, such genetic lesions or mutations can be detected by ascertaining the existence of at least one of: 1) a deletion of one or more nucleotides from the gene; 2) an addition of one or more nucleotides to the gene; 3) a substitution of one or more nucleotides of the gene; 4) a chromosomal rearrangement of the gene; 5) an alteration in the level of a messenger RNA transcript of the gene; 6) an aberrant modification of the gene, such as of the methylation pattern of the genomic DNA; 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of the gene; 8) a non-wild type level of a the protein encoded by the gene; 9) an allelic loss of the gene; and 10) an inappropriate post-translational modification of the protein encoded by the gene. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a gene.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (*see, e.g.,* U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (*see, e.g.,* Landegran et al. (1988) *Science* 241:1077-1080; and Nakazawa et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:360-364), the latter of which can be particularly useful for detecting point mutations in a gene (*see, e.g.,* Abravaya et al. (1995) *Nucleic Acids Res.* 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to the selected gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an

amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

5           Alternative amplification methods include: self sustained sequence replication (Guatelli et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh, et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) *Bio/Technology* 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using  
10 techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

          In an alternative embodiment, mutations in a selected gene from a sample cell can  
15 be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific  
20 ribozymes (*see, e.g.*, U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

          In other embodiments, genetic mutations can be identified by hybridizing a sample and control nucleic acids, *e.g.*, DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin et al. (1996) *Human Mutation* 7:244-255;  
25 Kozal et al. (1996) *Nature Medicine* 2:753-759). For example, genetic mutations can be identified in two-dimensional arrays containing light-generated DNA probes as described in Cronin et al., *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows  
30 the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

35           In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the selected gene and detect mutations by comparing

the sequence of the sample nucleic acids with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) *Proc. Natl. Acad. Sci. USA* 74:560) or Sanger ((1977) *Proc. Natl. Acad. Sci. USA* 74:5463). It is also contemplated that any of a variety of  
5 automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) *Bio/Techniques* 19:448), including sequencing by mass spectrometry ( *see, e.g.*, PCT Publication No. WO 94/16101; Cohen et al. (1996) *Adv. Chromatogr.* 36:127-162; and Griffin et al. (1993) *Appl. Biochem. Biotechnol.* 38:147-159).

Other methods for detecting mutations in a selected gene include methods in which  
10 protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers et al. (1985) *Science* 230:1242). In general, the technique of mismatch cleavage entails providing heteroduplexes formed by hybridizing (labeled) RNA or DNA containing the wild-type sequence with potentially mutant RNA or  
15 DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. RNA/DNA duplexes can be treated with RNase to digest mismatched regions, and DNA/DNA hybrids can be treated with S1 nuclease to digest mismatched regions.

In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated  
20 with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. *See, e.g.*, Cotton et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:4397; Saleeba et al. (1992) *Methods Enzymol.* 217:286-295. In a preferred embodiment, the control DNA or  
25 RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations  
30 in cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu et al. (1994) *Carcinogenesis* 15:1657-1662). According to an exemplary embodiment, a probe based on a selected sequence, *e.g.*, a wild-type sequence, is hybridized to a cDNA or other DNA product from a test cell(s).  
35 The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. *See, e.g.*, U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:2766; see also  
5 Cotton (1993) *Mutat. Res.* 285:125-144; Hayashi (1992) *Genet. Anal. Tech. Appl.* 9:73-79). Single-stranded DNA fragments of sample and control nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, and the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or  
10 detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) *Trends Genet.* 7:5).

15 In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) *Nature* 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a 'GC clamp of approximately 40 bp of  
20 high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) *Biophys. Chem.* 265:12753).

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective  
25 primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) *Nature* 324:163); Saiki et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different  
30 mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology which depends on selective PCR amplification may be used in conjunction with the instant invention.  
35 Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs et al. (1989) *Nucleic Acids Res.* 17:2437-2448) or at the extreme 3'

end of one primer where, under appropriate conditions, mismatch can prevent or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In addition, it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini et al. (1992) *Mol. Cell Probes* 6:1). It is anticipated that in certain  
5 embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) *Proc. Natl. Acad. Sci. USA* 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

10 The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.*, in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a gene encoding a polypeptide of the invention. Furthermore, any cell type or tissue, *e.g.*,  
15 chondrocytes, in which the polypeptide of the invention is expressed may be utilized in the prognostic assays described herein.

### 3. Pharmacogenomics

20 Agents, or modulators which have a stimulatory or inhibitory effect on activity or expression of a polypeptide of the invention as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders associated with aberrant activity of the polypeptide. In conjunction with such treatment, the pharmacogenomics (*i.e.*, the study of the relationship between an  
25 individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (*e.g.*, drugs) for prophylactic or  
30 therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of a polypeptide of the invention, expression of a nucleic acid of the invention, or mutation content of a gene of the invention in an individual can be determined to thereby select appropriate agent(s) for therapeutic or  
35 prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. *See, e.g., Linder (1997) Clin. Chem.* 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body are referred to as "altered drug action." Genetic conditions transmitted as single factors altering the way the body acts on drugs are referred to as "altered drug metabolism". These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19*) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, a PM will show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the activity of a polypeptide of the invention, expression of a nucleic acid encoding the polypeptide, or mutation content of a gene encoding the polypeptide in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a

modulator of activity or expression of the polypeptide, such as a modulator identified by one of the exemplary screening assays described herein.

5       4.     Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of a polypeptide of the invention (*e.g.*, the ability to modulate aberrant cell proliferation, chemotaxis, and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent, as  
10     determined by a screening assay as described herein, to increase gene expression, protein levels or protein activity, can be monitored in clinical trials of subjects exhibiting decreased gene expression, protein levels, or protein activity. Alternatively, the effectiveness of an agent, as determined by a screening assay, to decrease gene expression, protein levels or protein activity, can be monitored in clinical trials of subjects exhibiting  
15     increased gene expression, protein levels, or protein activity. In such clinical trials, expression or activity of a polypeptide of the invention and preferably, that of other polypeptide that have been implicated in for example, a cellular proliferation disorder, can be used as a marker of the immune responsiveness of a particular cell.

For example, and not by way of limitation, genes, including those of the invention,  
20     that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) which modulates activity or expression of a polypeptide of the invention (*e.g.*, as identified in a screening assay described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of a gene of the  
25     invention and other genes implicated in the disorder. The levels of gene expression (*i.e.*, a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of a gene of the invention or other genes. In this way, the gene expression pattern can serve as a marker,  
30     indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist,  
35     peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a

pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of the polypeptide or nucleic acid of the invention in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level the of the polypeptide or nucleic acid of the invention in the  
5 post-administration samples; (v) comparing the level of the polypeptide or nucleic acid of the invention in the pre-administration sample with the level of the polypeptide or nucleic acid of the invention in the post-administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of the  
10 polypeptide to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of the polypeptide to lower levels than detected, i.e., to decrease the effectiveness of the agent.

15 C. Methods of Treatment

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant expression or activity of a polypeptide of the invention, as discussed, for  
20 example, in sections above relating to uses of the sequences of the invention.

For example, disorders characterized by aberrant expression or activity of the polypeptides of the invention include immunologic disorders, coronary disorders, pulmonary disorders, neurological disorders, kidney disorders, and autoimmune disorders. The nucleic acids, polypeptides, and modulators thereof of the invention can be used to  
25 treat immunologic diseases and disorders, including but not limited to, allergic disorders (*e.g.*, anaphylaxis and allergic asthma) autoimmune and inflammatory disorders (*e.g.*, atopic dermatitis). Polypeptides of the invention can be used to treat diseases associated with bacterial infection (*e.g.*, tuberculosis, *e.g.*, pulmonary tuberculosis), inflammatory arthropathy, and bone and cartilage degenerative diseases and disorders (*e.g.*, arthritis,  
30 *e.g.*, rheumatoid arthritis). Polypeptides of the invention can be used to treat pulmonary disorders such as lung cancer, cystic fibrosis and rheumatoid lung diseases. Polypeptides of the invention can be used to treat coronary disorders, such as ischemic heart disease, atherosclerosis and plague formation. Polypeptides of the invention can also be used to treat neurological disorders such as neurodegenerate disorders, neuromuscular disorders  
35 and cognitive disorders. Polypeptides of the invention can also be used to treat kidney disorders such as glomerulonephritis and end stage renal disease. Further, polypeptides of

the invention can be used to treat autoimmune disorders such as Crohns disease, and other disorders described herein.

5       1.     Prophylactic Methods

          In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant expression or activity of a polypeptide of the invention, by administering to the subject an agent which modulates expression or at least one activity of the polypeptide. Subjects at risk for a disease which is caused or  
10       contributed to by aberrant expression or activity of a polypeptide of the invention can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of  
15       aberrancy, for example, an agonist or antagonist agent can be used for treating the subject. For example, an antagonist of a TANGO 253, TANGO 257, INTERCEPT 258 or TANGO 281 proteins may be used to treat an immunologic disorder, *e.g.*, rheumatoid arthritis. The appropriate agent can be determined based on screening assays described herein.

20       2.     Therapeutic Methods

          Another aspect of the invention pertains to methods of modulating expression or activity of a polypeptide of the invention for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or  
25       more of the activities of the polypeptide. An agent that modulates activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of the polypeptide, a peptide, a peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more of the biological activities of the polypeptide. Examples of such stimulatory agents include the active polypeptide of the invention and a nucleic acid molecule encoding the polypeptide of the invention that has  
30       been introduced into the cell. In another embodiment, the agent inhibits one or more of the biological activities of the polypeptide of the invention. Examples of such inhibitory agents include antisense nucleic acid molecules and antibodies. These modulatory methods can be performed *in vitro* (*e.g.*, by culturing the cell with the agent) or,  
35       alternatively, *in vivo* (*e.g.*, by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a polypeptide of the invention. In one

embodiment, the method involves administering an agent (*e.g.*, an agent identified by a screening assay described herein), or combination of agents that modulates (*e.g.*, upregulates or downregulates) expression or activity. In another embodiment, the method involves administering a polypeptide of the invention or a nucleic acid molecule of the invention as therapy to compensate for reduced or aberrant expression or activity of the polypeptide.

Stimulation of activity is desirable in situations in which activity or expression is abnormally low or downregulated and/or in which increased activity is likely to have a beneficial effect. Conversely, inhibition of activity is desirable in situations in which activity or expression is abnormally high or upregulated and/or in which decreased activity is likely to have a beneficial effect.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference.

#### Deposit of Clones

Clones containing cDNA molecules encoding human TANGO 253, (clone EpT253) human TANGO 257 (EpT257), human INTERCEPT 258 (clone EpT258) and human TANGO 281 (clone EpT 281) were deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA, 20110-2209, on April 21, 1999 as Accession Number 207222, as part of a composite deposit representing a mixture of strains, each carrying one recombinant plasmid harboring a particular cDNA clone.

For this composite deposit, to distinguish the strains and isolate a strain harboring a particular cDNA clone, an aliquot of the mixture can be streaked out to single colonies on nutrient medium (*e.g.*, LB plates) supplemented with 100g/ml ampicillin, single colonies grown, and then plasmid DNA extracted using a standard miniprep procedure. Next, a sample of the DNA miniprep can be digested with a combination of the restriction enzymes *Sall*, *NotI*, *XbaI* and *EcorV* and the resultant products resolved on a 0.8% agarose gel using standard DNA electrophoresis conditions. The digest liberates fragments as follows:

Human TANGO 253 (clone EpT253): 1.3 kb

Human TANGO 257 (clone EpT257): 1.8 kb

Human INTERCEPT 258 (clone EpT258): 1.0 kb and 0.85 kb (human INTERCEPT 258 has a *EcoRV* cut site at about bp 1004).

Human TANGO 281 (clone EpT281): 0.9 kb and 0.9kb (human TANGO 281 Has an *XbaI* cut site at about bp 900).

5

The identity of the strains can be inferred from the fragments liberated.

Clones containing cDNA molecules encoding mouse INTERCEPT 258 were deposited with the American Type Culture Collection (Manassas, VA) on April 21, 1999 as Accession Number 207221, as part of a composite deposit representing a mixture of five strains, each carrying one recombinant plasmid harboring a particular cDNA clone.

To distinguish the strains and isolate a strain harboring a particular cDNA clone, an aliquot of the mixture can be streaked out to single colonies on nutrient medium (e.g., LB plates) supplemented with 100µg/ml ampicillin, single colonies grown, and then plasmid DNA extracted using a standard miniprep procedure. Next, a sample of the DNA miniprep can be digested with a combination of the restriction enzymes *Sall*, and *NotI*, and the resultant products resolved on a 0.8% agarose gel using standard DNA electrophoresis conditions. The digest liberates fragments as follows:

20

Mouse INTERCEPT 258 (clone EpT258): 1.8 kb

The identity of the strains can be inferred from the fragments liberated.

25

A clone containing a cDNA molecule encoding mouse TANGO 253 (Clone EpTm 253) was deposited with American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, on April 21, 1999 as Accession Number 207215.

A clone containing a cDNA molecule encoding mouse TANGO 257 (Clone EpTm 257) was deposited with American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, on April 21, 1999 as Accession Number 207217.

A clone containing a cDNA molecule encoding mouse TANGO 281 (Clone EpTm 281) was deposited with American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, on June 15, 1999 as patent deposit Number PTA-224.

35

All publications, patents and patent applications mentioned in this specification are herein incorporated by reference into the specification to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference.

#### Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

MICROORGANISMS	
Optional Sheet in connection with the microorganism referred to on pages __, lines ____ of the description *	
<b>A. IDENTIFICATION OF DEPOSIT *</b> Further deposits are identified on an additional sheet *	
Name of depositary institution * <b>American Type Culture Collection</b>	
Address of depositary institution (including postal code and country) * <b>10801 University Blvd. Manassas, VA 20110-2209 US</b>	
Date of deposit * <u>April 21, 1999</u> Accession Number * <u>207215</u>	
<b>B. ADDITIONAL INDICATIONS *</b> (leave blank if not applicable). This information is continued on a separate attached sheet	
<b>C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *</b> (if the indications are not all designated States)	
<b>D. SEPARATE FURNISHING OF INDICATIONS *</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")	
<b>E.</b> <input type="checkbox"/> This sheet was received with the International application when filed (to be checked by the receiving Office)	
<div style="text-align: right;">_____ (Authorized Officer)</div>	
<input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau *	
was _____ (Authorized Officer)	

Form PCT/RO/134 (January 1981)

International Application No: PCT/

Form PCT/RO/134 (cont.)

**American Type Culture Collection**

10801 University Blvd.  
Manassas, VA 20110-2209  
US

<u>Accession No.</u>	<u>Date of Deposit</u>
207217	April 21, 1999
207221	April 21, 1999
207222	April 21, 1999
207222	April 21, 1999
207222	April 21, 1999
207222	April 21, 1999
PTA-224	June 15, 1999

What is claimed is:

1. An isolated nucleic acid molecule selected from the group consisting of:
  - a) a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to the nucleotide sequence of SEQ ID NO:1, 2, 26, 27, 46, 47, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, or a complement thereof;
  - b) a nucleic acid molecule comprising a fragment of at least 300 nucleotides of the nucleotide sequence of SEQ ID NO:1, 2, 15, 16, 26, 27, 46, 47, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, or a complement thereof;
  - c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:3, 17, 28, 48, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222;
  - d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:3, 28, 48, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:3, 28, 48, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222;
  - e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:3, 17, 28, 48, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:2, 16, 27, 47, or a complement thereof under stringent conditions;
  - f) a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:21, 22, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207217, or a complement thereof;
  - g) a nucleic acid molecule comprising a fragment of at least 300 nucleotides of the nucleotide sequence of SEQ ID NO:21, 22, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207217, or a complement thereof;

h) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:23, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207217;

i) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:23, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207217, wherein the fragment comprises at least 360 contiguous amino acids of SEQ ID NO:23, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207217;

j) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:23, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207217, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:22, or a complement thereof under stringent conditions;

k) a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to the nucleotide sequence of SEQ ID NO:37, 38, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207221, or a complement thereof;

l) a nucleic acid molecule comprising a fragment of at least 300 nucleotides of the nucleotide sequence of SEQ ID NO:37, 38, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207221, or a complement thereof;

m) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:39, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207221;

n) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:39, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207221, wherein the fragment comprises at least 160 contiguous amino acids of SEQ ID NO:39, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207221;

o) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:39, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as

Accession Number 207217, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:38, or a complement thereof under stringent conditions;

p) a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to the nucleotide sequence of SEQ ID NO:8, 9, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207215, or a complement thereof;

q) a nucleic acid molecule comprising a fragment of at least 300 nucleotides of the nucleotide sequence of SEQ ID NO:8, 9, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207215, or a complement thereof;

r) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:10, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207215;

s) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:10, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207215, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:10, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207215;

t) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:10, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207215, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:9, or a complement thereof under stringent conditions;

u) a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:15, 16, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, or a complement thereof;

v) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:17, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, wherein the fragment comprises at least 360 contiguous amino acids of SEQ ID NO:17, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222.

w) a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to the nucleotide sequence of SEQ ID NO:56, 57, the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-224, or a complement thereof;

x) a nucleic acid molecule comprising a fragment of at least 300 nucleotides of the nucleotide sequence of SEQ ID NO:56, 57, the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-224, or a complement thereof;

y) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:58, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-224;

z) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:58, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-224, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:58, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-224;

aa) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:58, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-224, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:57, or a complement thereof under stringent conditions.

2. The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of:

a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, 2, 15, 16, 26, 27, 46, 47, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, or a complement thereof;

b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:3, 17, 28, 48, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222;

c) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:21, 22, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207217, or a complement thereof;

d) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:23, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207217;

e) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:37, 38, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207221, or a complement thereof;

f) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:39, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207221;

g) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:8, 9, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207215, or a complement thereof;

h) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:10, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222.

i) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:56, 57, the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-224, or a complement thereof;

j) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:58, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-224.

3. The nucleic acid molecule of claim 1 further comprising vector nucleic acid sequences.

4. The nucleic acid molecule of claim 1 further comprising nucleic acid sequences encoding a heterologous polypeptide.

5. A host cell which contains the nucleic acid molecule of claim 1.

6. The host cell of claim 5 which is a mammalian host cell.

7. A non-human mammalian host cell containing the nucleic acid molecule of claim 1.
8. An isolated polypeptide selected from the group consisting of:
  - a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:3, 10, 17, 23, 28, 39, 48, 58, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:3, 10, 17, 23, 28, 39, 48, 58;
  - b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:3, 10, 17, 23, 28, 39, 48, 58, or the amino acid sequence encoded by the cDNA insert of plasmids deposited with the ATCC® as Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221, patent deposit Number PTA-224 wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:2, 9, 16, 22, 27, 38, 47, 57, or a complement thereof under stringent conditions; and
  - c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:2, 9, 27, 38, 47, 57, or at least 98% to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:2, 9, 27, 38, 47, 57, or a complement thereof.
9. The isolated polypeptide of claim 8 comprising the amino acid sequence of SEQ ID NO:3, 10, 17, 23, 28, 39, 48, 58.
10. The polypeptide of claim 8 further comprising heterologous amino acid sequences.
11. An antibody which selectively binds to a polypeptide of claim 8.
12. A method for producing a polypeptide selected from the group consisting of:
  - a) a polypeptide comprising the amino acid sequence of SEQ ID NO:3, 10, 17, 23, 28, 39, 48, 58, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, Accession Number

207215, Accession Number 207217, Accession Number 207221, or patent deposit Number PTA-224;

b) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO:3, 10, 17, 23, 28, 39, 48, 58, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221, or patent deposit Number PTA-224, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:3, 10, 17, 23, 28, 39, 48, 58, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221 or patent deposit Number PTA-224; and

c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:3, 10, 17, 23, 28, 39, 48, 58, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207222, Accession Number 207215, Accession Number 207217, Accession Number 207221, or patent deposit Number PTA-224, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, 8, 15, 21, 26, 37, 46, 56, or a complement thereof under stringent conditions;

comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is expressed.

13. A method for detecting the presence of a polypeptide of claim 8 in a sample, comprising:

- a) contacting the sample with a compound which selectively binds to a polypeptide of claim 8; and
- b) determining whether the compound binds to the polypeptide in the sample.

14. The method of claim 13, wherein the compound which binds to the polypeptide is an antibody.

15. A kit comprising a compound which selectively binds to a polypeptide of claim 8 and instructions for use.

16. A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of:
- a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
  - b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.
17. The method of claim 16, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.
18. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 1 and instructions for use.
19. A method for identifying a compound which binds to a polypeptide of claim 8 comprising the steps of:
- a) contacting a polypeptide, or a cell expressing a polypeptide of claim 8 with a test compound; and
  - b) determining whether the polypeptide binds to the test compound.
20. The method of claim 19, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:
- a) detection of binding by direct detecting of test compound/polypeptide binding;
  - b) detection of binding using a competition binding assay;
  - c) detection of binding using an assay for TANGO 253, TANGO 257, INTERCEPT 258, TANGO 281-mediated signal transduction.
21. A method for modulating the activity of a polypeptide of claim 8 comprising contacting a polypeptide or a cell expressing a polypeptide of claim 8 with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

22. A method for identifying a compound which modulates the activity of a polypeptide of claim 8, comprising:


- a) contacting a polypeptide of claim 8 with a test compound; and
- b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

GTCGACCCACGCGTCCGGGACTGGGGTGACGGCAGGGCAGGGGGCGCCTGGCCGGGGAGAAAGCGCGGGGGCTGGAGCAC 79  
 CACCAACTGGAGGGTCCGGAGTAGCGAGCGCCCCGAAGGAGGCCATCGGGGAGCCGGGAGGGGGGACTGCGAGAGGACC 158  
 M R P L L V L L L L G L 12  
 CCGGCGTCCGGGCTCCCGGTGCCAGCGCT ATG AGG CCA CTC CTC GTC CTG CTG CTC CTG GGC CTG 223  
 A A G S P P L D D N K I P S L C P G H P 32  
 GCG GCC GGC TCG CCC CCA CTG GAC GAC AAC AAG ATC CCC AGC CTC TGC CCG GGC CAC CCC 283  
 G L P G T P G H H G S Q G L P G R D G R 52  
 GGC CTT CCA GGC ACG CCG GGC CAC CAT GGC AGC CAG GGC TTG CCG GGC CGC GAT GGC CGC 343  
 D G R D G A P G A P G E K G E G G R P G 72  
 GAC GGC CGC GAC GGC GCG CCC GGG GCT CCG GGA GAG AAA GGC GAG GGC GGC AGG CG GGA 403  
 L P G P R G D P G P R G E A G P A G P T 92  
 CTG CCG GGA CCT CGA GGG GAC CCC GGG CCG CGA GGA GAG GCG GGA CCC GCG GGC CCC ACC 463  
 G P A G E C S V P P R S A F S A K R S E 112  
 GGG CCT GCC GGC GAG TGC TCG GTG CCT CCG CGA TCC GCC TTC AGC GCC AAG CGC TCC GAG 523  
 S R V P P P S D A P L P F D R V L V N E 132  
 AGC CGG GTG CCT CCG CCG TCT GAC GCA CCC TTG CCC TTC GAC CGC GTG CTG GTG AAC GAG 583  
 Q G H Y D A V T G K F T C Q V P G V Y Y 152  
 CAG GGA CAT TAC GAC GCC GTC ACC GGC AAG TTC ACC TGC CAG GTG CCT GGC GTC TAC TAC 643  
 F A V H A T V Y R A S L Q F D L V K N G 172  
 TTC GCC GTC CAT GCC ACC GTC TAC CGG GCC AGC CTG CAG TTT GAT CTG GTG AAG AAT GGC 703  
 E S I A S F F Q F F G G W P K P A S L S 192  
 GAA TCC ATT GCC TCT TTC TTC CAG TTT TTC GGG GGG TGG CCC AAG CCA GCC TCG CTC TCG 763  
 G G A M V R L E P E D Q V W V Q V G V G 212  
 GGG GGG GCC ATG GTG AGG CTG GAG CCT GAG GAC CAA GTG TGG GTG CAG GTG GGT GTG GGT 823  
 D Y I G I Y A S I K T D S T F S G F L V 232  
 GAC TAC ATT GGC ATC TAT GCC AGC ATC AAG ACA GAC AGC ACC TTC TCC GGA TTT CTG GTG 883  
 Y S D W H S S P V F A \* 244  
 TAC TCC GAC TGG CAC AGC TCC CCA GTC TTT GCT TAG 919  
 TGCCCACTGCAAAGTGAGCTCATGCTCTCACTCCTAGAAGGAGGGTGTGAGGCTGACAACCTGGTCATCCAGGAGGGCT 998  
 GGCCCCCTGGAATATTGTGAATGACTAGGGAGGTGGGGTAGAGCACTCTCCGTCTGCTGCTGGCAAGGAATGGGAAC 1077

FIG. 1A

AGTGGCTGTCTGCGATCAGGTCTGGCAGCATGGGGCAGTGGCTGGATTTCTGCCCAAGACCAGAGGAGTGTGCTGTGCT 1156  
GGCAAGTGTAAGTCCCCCAGTTGCTCTGGTCCAGGAGCCACGGTGGGGTGCTCTCTTCCTGGTCCTCTGCTTCTCTGG 1235  
ATCCTCCCCACCCCCTCCTGCTCCTGGGGCCGGCCCTTTTCTCAGAGATCACTCAATAAACCTAAGAACCCTCCAAAAA 1314  
AAAAAAAAAAAAAAAAAGGGCGGCCGC 1339

**FIG. 1B**



MRPLLVLALLGLAAGSPPLDDNKIPSLCPGHPGLPGTPGHHGSQGLPGRDGRDGRDGAPG  
APGEKGEGGRPGLPGPRGDPGPRGEAGPAGPTGPAGECSVPPRSAFSKRSESRVPPPSD  
APLPFDRVLVNEQQGHYDAVTGKFTCQVPGVYYFAVHATVYRASLQFDLVKNGESIASFFQ  
FFGGWPKPASLSGGAMVRLEPEDQVWVQVGVDYIGIYASIKTDSTFSGFLVYSDWHSSP  
VFA


**FIG. 2**

GTCGACCCACGCGTCCGCGCTGTGAAGCCAGCAAGGAGCAACCAGAAGCTAGGAGTCAGTCAGCAAGGACAGGGGCTGC 79  
 CTGCCTACAGACTACAAGAGAGGTTCTGAGTCTGAGCCTCCGGGGTCACCACC 6  
 M R P L L A 6  
 ATG AGG CCA CTT CTT GCC 152  
 L L L L G L V S G S P P L D D N K I P S 26  
 CTT CTG CTT CTG GGT CTG GTG TCA GGC TCT CCT CCT CTG GAC GAC AAC AAG ATC CCC AGC 212  
 L C P G Q P G L P G T P G H H G S Q G L 46  
 CTG TGT CCC GGG CAG CCC GGC CTT CCA GGC ACA CCA GGT CAC CAT GGC AGC CAA GGC CTG 272  
 P G R D G R D G R D G A P G A P G E K G 66  
 CCT GGC CGT GAC GGC CGT GAT GGC CGC GAC GGT GCA CCC GGA GCT CCG GGA GAG AAA GGC 332  
 E G G R P G L P G P R G E P G P R G E A 86  
 GAG GGC GGG AGA CCG GGA CTA CCT GGC CCA CGT GGG GAG CCC GGG CCG CGT GGA GAG GCA 392  
 G P M G A I G P A G E C S V P P R S A F 106  
 GGG CCC ATG GGG GCT ATC GGG CCT GCG GGG GAG TGC TCG GTA CCC CCA CGA TCA GCC TTC 452  
 S A K R S E S R V P P P A D T P L P F D 126  
 AGT GCC AAG CGA TCC GAG AGC CGG GTA CCT CCG CCA GCC GAC ACA CCC CTA CCT TTC GAC 512  
 R V L L N E Q G H Y D P T T G K F T C Q 146  
 CGT GTG CTG CTA AAT GAG CAG GGC CAT TAC GAC CCC ACT ACT GGC AAG TTC ACC TGC CAA 572  
 V P G V Y Y F A V H A T V Y R A S L Q F 166  
 GTG CCT GGC GTC TAC TAC TTT GCT GTG CAC GCC ACT GTC TAC CGG GCC AGC TTG CAG TTT 632  
 D L V K N G Q S I A S F F Q Y F G G W P 186  
 CAT CTT GTC AAA AAC GGG CAG TCC ATC GCC TCT TTC TTC CAG TAT TTT GGG GGG TGG CCC 692  
 K P A S L S G G A M V R L E P E D Q V W 206  
 AAG CCA GCC TCG CTC TCA GGG GGT GCG ATG GTA AGG CTA GAA CCT GAG GAC CAG GTG TGG 752  
 V Q V G V G D Y I G I Y A S I K T D S T 226  
 GTG CAG GTG GGC GTG GGT GAT TAC ATT GGC ATC TAT GCC AGC ATC AAG ACA GAC AGT ACC 812  
 F S G F L V Y S D W H S S P V F A \* 244  
 TTC TCT GGA TTT CTC GTC TAT TCT GAC TGG CAC AGC TCC CCA GTC TTC GCT TAA 866  
 AACACAGTGAACCCGGAGCTGGCATTGCTCCTCAGTGGAGGGTGTGACACTAACCCGCGCAGCGCATACCAGGAGGGC 945  
 TGGCCCCCTGGAATATTGTGAATGACTTAGGAAGAGAGGGAGCCACTTCCAGTCCCACTGCTGGCAATGAATGGAGACA 1024  
 GCGTGTCTGAGGTCAAGACAGCGTGGAGCAGTGGCTGGGTTTCTGCCAGGACTTTAGAATGCAGTAGGCTGGCAGCTG 1103  
 TGGGTCTGCCCCAGGACTCCAAGGTGGGATGCTCCATTCTAGTCTGTGTCCCTCTAGGTCCCTGACTCCATCTCT 1182

FIG. 3A

GCTGCTCCAGGGCAGGCCTTTTCTCAGAGGTCACCTTAATAAACCTAAAATCCTCAAAAAAAAAAAAAAGGGCGGCC 1261  
GC 1263

**FIG. 3B**



>mT253

MRPLLALLLLGLVSGSPPLDDNKIPSLCPGQPGLPGTPGHHGSQGLPGRDGRDGRDGA.PG  
APGEKGEGGRPGLPGPRGEPGPRGEAGPMGAIGPAGECSVPPRSAFSAKRSESRVPPPAD  
TPLPFDRVLLNEQGHYDPTTGKFTCQVPGVYYFAVHATVYRASLQFDLVKNGQSIASFFQ  
YFGGWPKPASLSGGAMVRLEPEDQVWVQVGVDYIGIYASIKTDSTFSGFLVYSDWHSSP  
VFA

**FIG. 4**

ALIGN calculates a global alignment of two sequences

version 2.0uPlease cite: Myers and Miller, CABIOS (1989)

> ht253 a.a. 243 aa vs.

> mT253 a.a. 243 aa

scoring matrix: paml20.mat, gap penalties: -12/-4

93.8% identity; Global alignment score: 1239

```

      10      20      30      40      50      60      70
inputs MRPLLVL LLLGLAAGSPPLDDNKIPSLCPGHPGLPGTPGHHSQQLPGRDGRDGRDGAPGAPGEKGEGR
      .....
      MRPLLAL LLLGLVSGSPPLDDNKIPSLCPGQPGLPGTTPGHHSQQLPGRDGRDGRDGAPGAPGEKGEGR
      10      20      30      40      50      60      70

      80      90     100     110     120     130     140
inputs PGLPGPRGDPGPRGEAGPAGPTGPAGECSVPPRSAFSAKRSESRVPPSDAPLPFDRVLVNEQGHYDAVT
      .....
      PGLPGPRGEPGPRGEAGPMGAIGPAGECSVPPRSAFSAKRSESRVPPADTLPFDRVLLNEQGHYDPTT
      80      90     100     110     120     130     140

      150     160     170     180     190     200     210
inputs GKFTCQVPGVYFAVHATVYRASLQFDLVKNGESIASFFQFFGGWPKPASLSGGAMVRLPEQVWVQVG
      .....
      GKFTCQVPGVYFAVHATVYRASLQFDLVKNGQSIAFFQYFGGWPKPASLSGGAMVRLPEQVWVQVG
      150     160     170     180     190     200     210

      220     230     240
inputs VGDYIGIYASIKTDSTFSGFLVYSDWHSSPVFA
      .....
      VGDYIGIYASIKTDSTFSGFLVYSDWHSSPVFA
      220     230     240

```

**FIG. 5**

ALIGN calculates a global alignment of two sequences

version 2.0u Please cite: Myers and Miller, CABIOS (1989)  
 > ht253 a.a. 243 aa vs.  
 > SwissProt Q15848 - (untitled) 244 aa  
 scoring matrix: pam120.mat, gap penalties: -12/-4  
 38.7% identity; Global alignment score: 262

```

      10      20      30      40      50      60
inputs MRPL-LVLLLGLAA---GSPPLDDNKIPSL----CPG-HPGLPGTPGHHGSQGLPGRDGRDGRDGAPGA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      MLLLGAVLLLLLALPGHDQETTTQGPVLLPLPKGACTGWMAGIPGHPGHNGAPGRDGRDGTPEKEKEKGD
      10      20      30      40      50      60      70

      70      80      90      100     110     120     130
inputs PGEKEGGRPGLPGPRGDPGPRGEAGPAGPTGPAGECSVPPRSAFSAKRSESRVPPPSDAPLPFDRVLVN
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      PGLIGPKGDIGETGVPGAEGPRGFPGIQGRKGEPGEGAYVYRSAFSVGL-ETYVTIP-NMPIRFTKIFYN
      80      90      100     110     120     130

      140     150     160     170     180     190     200
inputs EQGHYDAVTGKFTCQVPGVYFVAVHATVYRASLQFDLVKNGESIASFFQFFGGWPKPASLSGGAMVRLEP
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      QQNHYDGSTGKFHCNIPGLYYFAYHITVYMKDVKVSLFKKDKAMLFTYDQYQE-NNVDQASGSVLLHLEV
      140     150     160     170     180     190     200

      210     220     230     240
inputs EDQVWVQV-GVGDIYIGIYASIKTDSTFSGFLVYSDWHSSPVFA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GDQVWLQVYGEGERNGLYADNDNDSTFTGFLLY---HDT---N
      210     220     230     240

```

FIG. 6A

ALIGN calculates a global alignment of two sequences

version 2.0u Please cite: Myers and Miller, CABIOS (1989)

> mT253 a.a. 243 aa vs.

> SwissProt Q15848 - (untitled) 244 aa

scoring matrix: pam120.mat, gap penalties: -12/-4

38.3% identity; Global alignment score: 264

```

      10      20      30      40      50      60
inputs MRPLLALLLLGLVSGSPPLDDNKIPSL-----CPG-QPGLPGTPGHHSQGLPGRDGRDGRDGAPGA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      MLLLGAVLLLLALPGHDQETTTQGPVLLPLPKGACTGWMAGIPGHPGHNGAPGRDGRDGTPEKGEKGD
      10      20      30      40      50      60      70

      70      80      90      100     110     120     130
inputs PGEKGEGRPGPLPGPRGEPGPRGEAGPMGAIGPAGECSVPPRSAFSAKRSESrvppPADTPLPFDRVLLN
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      PGLIGPKGDIGETGVPGAEGPRGFPGIQGRKGEPGEGAYVYRSFASVGL-ETVVTIP-NMPIRFTKIFYN
      80      90      100     110     120     130

      140     150     160     170     180     190     200
inputs EQGHYDPTTGKFTCQVPGVYYFAVHATVYRASLQFDLVKNGQSIASFFQYFGGWPKPASLSGGAMVRLEP
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      QQNHYDGSTGKFHCNIPGLYYFAYHITVYMKDVKVSFLFKDKAMLFYDQYQE-NNVDQASGSVLLHLEV
      140     150     160     170     180     190     200

      210     220     230     240
inputs EDQVWVQV-GVGDIYIGIYASIKTDSTFSGFLVYSDWHSSPVFA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GDQVWLQVYGEGERNGLYADNDNDSTFTGFLLY---HDT---N
      210     220     230     240

```

FIG. 6B

ALIGN calculates a global alignment of two sequences

version 2.0u Please cite: Myers and Miller, CABIOS (1989)

> ht253 n.a. 1339 aa vs.

> adipocyte n.a. (AI417523) 653 aa

scoring matrix: pam120.mat, gap penalties: -12/-4

29.1% identity; Global alignment score: -1168

```

      10      20      30      40      50      60      70
inputs  GTCGACCCACGCGTCCGGGACTGGGGTGACGGCAGGGCAGGGGGCGCCTGGCCGGGAGAAGCGCGGGGG
      : .      : : : : : : : : : : : : : : : : : : : : : : : :
      TTTTTT---GCAT--GTAACTTTTTTATTGA---GGCA-----CAACAAGGCATTGTAAGTTGCCTGGA
      10      20      30      40      50

      80      90      100      110      120      130      140
inputs  CTGGAGCACCACCAACTGGAGGGTCCGGAGTAGCGAGCGCCCCGAAGGAGGCCATCGGGGAGCCGGGAGG
      : : : : : : : : : : : : : : : : : : : : : : : :
      CTTGAG-----GCAGT-----CAGTTTAGTAAGCT---GAA-----CGTTAATACAGTTAA
      60      70      80      90

      150      160      170      180      190      200      210
inputs  GGGGACTGCGAGAGGACCCCGGCGTCCGGGCTCCCGGTGCCAGCGCTATGAGGCCACTCCTCGTCTCTGCT
      : : . . : : : : : : : : : : : : : : : : : :
      GGATTAAG-----TGCAAACAATATA---CATTC-----ACA
      100      110      120

      220      230      240      250      260      270      280
inputs  GCTCCTGGGCCTGGCGGCCGGCTCGCCCCCACTGGACGACAACAAGATCCCCAGCCTCTGCCCGGGGCAC
      : : : : : : : : : : : : : : : : : : : : : : : :
      GCT--TGA--CTAGCGA--GGCT-----ACATCA--CAATTTATAAAG---TGCCAGA-----
      130      140      150      160      170

      290      300      310      320      330      340      350
inputs  CCCGGCCTTCCAGGCACGCCGGGCCACCATGGCAGCCAGGGCTTGCCGGGCCGCGATGGCCGCGACGGCC
      : : : : : : : : : : : : : : : : : : : : : : : :
      -----TT--AGT--GCTAA-----TTGTCAITCA--GCTTG-----ATTTTTCAC-----
      180      190      200

      360      370      380      390      400      410      420
inputs  GCGACGGCGCGCCCCGGGGCTCCGGGAGAGAAAGGCGAGGGCGGGAGGCCGGGACTGCCGGGACCTCGAGG
      : : : : : : : : : : : : : : : : : : : : : : : :
      -----CTCAGGAAGGAAAA--CAAAAAAGTAAG-----ACC--TCCTC-----
      210      220      230

      430      440      450      460      470      480      490
inputs  GGACCCCGGGCCGCGAGGAGGGCGGGACCCGCGGGGCCACCGGGCCTGCCGGGGAGTGCTCGGTGCCT
      : : : : : : : : : : : : : : : : : : : : : : : :
      -----CCTCTAGGAA-----
      240

      500      510      520      530      540      550      560
inputs  CCGCGATCCGCGCTTCAGCGCCAAGCGCTCGAGAGCCGGGTGCCTCCGCGGTCTGACGCACCCTTGCCCT
      : : : : : : : : : : : : : : : : : : : : : : : :

```

FIG. 7A

```

-----CAAAAAACATTTTCCT-----AAACCAA
                      250      260                      270

      570      580      590      600      610      620      630
inputs TCGACCGCGTGCTGGTGAACGAGCAGGGACATTACGACGCCGTCACCGGCAAGTTCACCTGCCAGGTGCC
      :... :      :... : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TCAGTC-----ATGA--GGGCAAAGAC--TACTTTTCCTTCA-----ATC-CCA--CTAAT---
                      280      290      300                      310

      640      650      660      670      680      690      700
inputs TGGGGTCTACTACTTCGCGTCCATGCCACCGTCTACCGGGCCAGCCTGCAGTTTGATCTGGTGAAGAAT
      :... :      :... : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TAGAA-----CACCATCC-----TTTTAT-----T
      320                      330

      710      720      730      740      750      760      770
inputs GGCGAATCCATTGCCTCTTTCTTCCAGTTTTTCGGGGGGTGGCCCAAGCCAGCCTCGCTCTCGGGGGGGG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GTCAATACTGT---ACTGACTTTCAAT-----CTTG-----
      340      350      360

      780      790      800      810      820      830      840
inputs CCATGGTGAGGCTGGAGCCTGAGGACCAAGTGTGGGTGCAGGTGGGTGTGGGTGACTACATTGGCATCTA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      --ATAAAGAAGAT--AGCCTGAAAAC-----GTAGAATAT-----
      370      380                      390

      850      860      870      880      890      900      910
inputs TGCCAGCATCAAGACAGACAGCACCTTCTCCGGATTCTGGTGTACTCCGACTGGCACAGCTCCCCAGTC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TTCCAGCTACT-----TCCATAAAT-----TGCTCCCCTGT-
      400                      410                      420

      920      930      940      950      960      970      980
inputs TTTGCTTAGTGCCCACTGCAAAGTGAGCTCATGCTCTCACTCCTAGAAGGAGGGTGTGAGGCTGACAACC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      -----GCAGACGT--
      430

      990      1000      1010      1020      1030      1040      1050
inputs TGGTCATCCAGGAGGGCTGGCCCCCCTGGAATATTGTGAATGACTAGGGAGGTGGGGTAGAGCACTCTCC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      -----AACCATAT--CTGGTCTCCCTGGAA-----GAGCTGAAGAATTGCATGAT--
      440      450                      460      470

      1060      1070      1080      1090      1100      1110      1120
inputs GTCCTGCTGCTGGCAAGGAATGGGAACAGTGGCTGTCTGCGATCAGGTCTGGCAGCATGGGGCAGTGGCT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      -----TGCTAGCA-----GTTTCA-TGG---TCTG-GAGCA---C---CATCATTTGG-CATAGGCT
      480      490      500      510      520

      1130      1140      1150      1160      1170      1180      1190

```

FIG. 7B

```

inputs GGATTTCTGCCCAAGACCAGAGGAGTGTGCTGTGCTGGCAAGTGTAAGTCCCCCAGTTGCTCTGGTCCAG
      :...      :.....      ::  :.  ...  .....      :...  .:  .:  :...
      GATA-----CCAAGACCT-----CTT--CATTCTTCANTGAG-----GTTG-AC--ATACAG
                        530                        540      550                        560

            1200      1210      1220      1230      1240      1250      1260
inputs GAGCCCACGGTGGGGTGCTCTCTTCCTGGTCCTCTGCTTCTCTGGATCCTCCCCACCCCCTCCTGCTCCT
      .::  ::      :...:  :::  :  :  :...:  :  .....      :  ..  .:  :
      TGGCACAT-----TCACTGCCAG--CTTTTACATGTGAAAAA-----TGAAAAACGT
                570                        580      590                        600

            1270      1280      1290      1300      1310      1320      1330
inputs GGGGCCCGCCCTTTTCTCAGAGATCACTCAATAAACCTAAGAACCCTCCAAAAAAAAAAAAAAAAAAG
      .:  :...      :...:  .:  ::  :...:  ::      :...:  .....  :...
      AGTGCCA-----TTCACCTTGG--CA---ATTAAATCTA-----CCAAAGCTGAGATCAA-----
        610                620      630                640      650

inputs GGCGGCCGC
      -----

```

FIG. 7C

ALIGN calculates a global alignment of two sequences

version 2.0u Please cite: Myers and Miller, CABIOS (1989)

> mt253 n.a.

1263 aa vs.

> adipocyte n.a. (AI417523)

653 aa

scoring matrix: pam120.mat, gap penalties: -12/-4

30.4% identity; Global alignment score: -840

```

      10      20      30      40      50      60      70
inputs  GTCGACCCACGCGTCCGCGCTGTGAAGCCAGCAAGGAGCAACCAGAAGCTAGGAGTCAGTCAGCAAGGAC
      :
      :      :      :      :      :      :      :      :      :      :      :
      TT-----TTT-----TGCATGTAACCTT-----TTTATTGAGGCA--CAACAAGG-C
                        10              20              30

      80      90      100      110      120      130      140
inputs  AGGGGCTGCCTGCCTACAGACTACAAGAGAGGTTCTGAGTCTGAGCCTCCGGGGTCACCACCATGAGG
      :      :      :      :      :      :      :      :      :      :
      ATTG-----TAACT-----TGCCTGGA-----CTTGAGG
      40              50              60

      150      160      170      180      190      200      210
inputs  CCACTTCTTGCCCTTCTGCTTCTGGGTCTGGTGTCTAGGCTCTCCTCCTCTGGACGACAACAAGATCCCA
      :      :      :      :      :      :      :      :      :      :
      CAG-----TCAGTTT-----AGTAAG-----CTGAACGTTAATA-----
                        70              80              90

      220      230      240      250      260      270      280
inputs  GCCTGTGTCCCGGGCAGCCCGGCCCTTCCAGGCACACCAGGTCACCATGGCAGCCAAGGCCTGCCTGGCCG
      :      :      :      :      :      :      :      :      :      :
      --CAGTTA--AGGA-----TTAAGTGCAAACAATAT-----ACATTACAGCTTGACTAGC-G
                        100              110              120              130              140

      290      300      310      320      330      340      350
inputs  TGACGGCCGTGATGGCCCGACGGTGCACCCGGAGCTCCGGGAGAGAAAGGCGAGGGCGGGAGACCGGGA
      :      :      :      :      :      :      :      :      :      :
      AGGCTAC-----ATCACAATTTATAAAGTGC-----CAGATTA---GTG
                        150              160              170

      360      370      380      390      400      410      420
inputs  CTACCTGGCCCCACGTGGGGAGCCCGGGCGCGTGGAGAGGCAGGGCCCATGGGGGCTATCGGGCCTGCGG
      :      :      :      :      :      :      :      :      :      :
      CTAATTGTCATTCA-----GCTTGATTTTCA-----CCTCAGGAA-----GGAAAACAA
      180      190              200              210              220

      430      440      450      460      470      480      490
inputs  GGGAGTGCTCGGTACCCCCACGATCAGCCTTCAGTGCCAAGCGATCCGAGAGCCGGGTACCTCCGCCAGC
      :      :      :      :      :      :      :      :      :      :
      AAAAGTA---AGGACCTCCTC-----CCT-----CTAG-GAACAAAAAAC-ATTTTCCTA-----
      230              240              250              260

      500      510      520      530      540      550      560
inputs  CGACACACCCCTACCTTTTCGACCGTGTGCTGCTAAATGAGCAGGGCCATTACGACCCCACTACTGGCAAG
      :      :      :      :      :      :      :      :      :      :
      :      :      :      :      :      :      :      :      :      :

```

FIG. 8A

```

-----AACCAATCAGTCATGAG-GGCAAAGACTACTTTTCCTT--CAATCCCCTAAT---TAG
          270      280      290      300      310

          570      580      590      600      610      620      630
inputs  TTCACCTGCCAAGTGCCTGGCGTCTACTACTTTGCTGTGCACGCCACTGTCTACCGGGCCAGCTTGCAGT
        ..... :... :. : : ..... :.....
        AACACCATCCTTTTA--TTG-----TCAATACTGT-----ACTGACTT-----
        320      330      340      350

          640      650      660      670      680      690      700
inputs  TTGATCTTGTCAAAAACGGGCAGTCCATCGCCTCTTTCTTCCAGTATTTTGGGGGTGGCCCAAGCCAGC
          ..... :.....
          -----TCAATCTT-----GATAAAGAAGATAGCC-----
          360      370

          710      720      730      740      750      760      770
inputs  CTCGCTCTCAGGGGGTGCATGGTAAGGCTAGAACCTGAGGACCAGGTGTGGGTGCAGGTGGGCGTGGGT
          ..... :. :..... : :.....
          -----TGAAAACGTAGAA-----TATTTCCAG-----C-----TAC-----
          380      390      400

          780      790      800      810      820      830      840
inputs  GATTACATTGGCATCTATGCCAGCATCAAGACAGACAGTACCTTCTCTGGATTTCTCGTCTATTCTGACT
          : : ..... : : : : ..... :..... : : : : : : : : : :
          --TTCCATAAATTGCT--CC--C--CTGTGCAGACGTAACCATATCTGG--TCTC--C-----CT
          410      420      430      440      450

          850      860      870      880      890      900      910
inputs  GGCACAGCTCCCCAGTCTTCGCTTAAACACAGTGAACCGGAGCTGGCACTTGCTCCTCAGTGGAGGGT
          : : : : : : : : : : ..... : : : : : : : : : :
          GGAAGAGCTGA--AGAATT-GCATGATT-----GCTAGCAGTTTC-----ATGGT
          460      470      480      490

          920      930      940      950      960      970      980
inputs  GTGACACTAACCCGCGCAGCGCATACCAGGAGGGCTGGCCCCCTGGAATATTGTGAATGACTTAGGAAGA
          ..... : : : : : : : : : : ..... : : : : : : : :
          -----CTGGA-----GCACC-----ATCATTGGCATAGGCTGA
          500      510      520

          990      1000      1010      1020      1030      1040      1050
inputs  GAGGGAGCCACTTCCAGTCCCACTGCTGGCAATGAATGGAGACAGGCTGTCTGAGGTCAAGACAGCGTGG
          ..... : : : : : : : : : : ..... : : : : : : : :
          -----TACCAAGACCTCTTCATTCTT-----CAN-----TGAGGT--TGACA-----
          530      540      550

          1060      1070      1080      1090      1100      1110      1120
inputs  AGCAGTGGCTGGGTTTCTGCCAGGACTTTAGAATGCAGTAGGCTGGCAGCTGTGGGTCTGGCCCAGGA
          ..... : : : : : : : : : : ..... : : : : : : : :
          TACAGTGGCACATTCACTGCC--AGCTTT--TACA-----TGTGAAAAATGA--AAAA
          560      570      580      590      600

          1130      1140      1150      1160      1170      1180      1190

```

FIG. 8B

```
inputs CTCCAAGGTGGGATGCTCCATTCTAGTCCTGTGTCCCCTCTAGGTCCCTGACTCCATCTCTGCTGCTCC
:   ...:::   :::::   .:::.   : ::   :. . :: :
C---GTAGTG-----CCATTC-----ACTTGG-----CAAT---TAAATCTAC
      610                               620                               630

      1200      1210      1220      1230      1240      1250      1260
inputs CAGGGCAGGCCTTTTCTCAGAGGTCACCTAATAAACCTAAAATCCTCAAAAAAAAAAAAAAAGGGCGGC
:.....:   :::   :.....
CAAAGCTG-----AGA-----TCAA-----
640                               650

inputs CGC
```


FIG. 8C

GTCGACCCACGCGTCCGCGGACGCGTGGGTGAGGGGAAGAGGCTGACTGTACGTTTCCTTCTACTCTGGCACCCTCTCC	79
M G P S T P L L I L F L L S W S G	17
AGGCTGCC ATG GGG CCC AGC ACC CCT CTC CTC ATC TTG TTC CTT TTG TCA TGG TCG GGA	138
P L Q G Q Q H H L V E Y M E R R L A A L	37
CCC CTC CAA GGA CAG CAG CAC CAC CTT GTG GAG TAC ATG GAA CGC CGA CTA GCT GCT TTA	198
E E R L A Q C Q D Q S S R H A A E L R D	57
GAG GAA CGG CTG GCC CAG TGC CAG GAC CAG AGT AGT CGG CAT GCT GCT GAG CTG CGG GAC	258
F K N K M L P L L E V A E K E R E A L R	77
TTC AAG AAC AAG ATG CTG CCA CTG CTG GAG GTG GCA GAG AAG GAG CGG GAG GCA CTC AGA	318
T E A D T I S G R V D R L E R E V D Y L	97
ACT GAG GCC GAC ACC ATC TCC GGG AGA GTG GAT CGT CTG GAG CGG GAG GTA GAC TAT CTG	378
E T Q N P A L P C V E F D E K V T G G P	117
GAG ACC CAG AAC CCA GCT CTG CCC TGT GTA GAG TTT GAT GAG AAG GTG ACT GGA GGC CCT	438
G T K G K G R R N E K Y D M V T D C G Y	137
GGG ACC AAA GGC AAG GGA AGA AGG AAT GAG AAG TAC GAT ATG GTG ACA GAC TGT GGC TAC	498
T I S Q V R S M K I L K R F G G P A G L	157
ACA ATC TCT CAA GTG AGA TCA ATG AAG ATT CTG AAG CGA TTT GGT GGC CCA GCT GGT CTA	558
W T K D P L G Q T E K I Y V L D G T Q N	177
TGG ACC AAG GAT CCA CTG GGG CAA ACA GAG AAG ATC TAC GTG TTA GAT GGG ACA CAG AAT	618
D T A F V F P R L R D F T L A M A A R K	197
GAC ACA GCC TTT GTC TTC CCA AGG CTG CGT GAC TTC ACC CTT GCC ATG GCT GCC CGG AAA	678
A S R V R V P F P W V G T G Q L V Y G G	217
GCT TCC CGA GTC CGG GTG CCC TTC CCC TGG GTA GGC ACA GGG CAG CTG GTA TAT GGT GGC	738
F L Y F A R R P P G R P G G G G E M E N	237
TTT CTT TAT TTT GCT CGG AGG CCT CCT GGA AGA CCT GGT GGA GGT GGT GAG ATG GAG AAC	798
T L Q L I K F H L A N R T V V D S S V F	257
ACT TTG CAG CTA ATC AAA TTC CAC CTG GCA AAC CGA ACA GTG GTG GAC AGC TCA GTA TTC	858
P A E G L I P P Y G L T A D T Y I D L A	277
CCA GCA GAG GGG CTG ATC CCC CCC TAC GGC TTG ACA GCA GAC ACC TAC ATC GAC CTG GCA	918
A D E E G L W A V Y A T R E D D R H L C	297
GCT GAT GAG GAA GGT CTT TGG GCT GTC TAT GCC ACC CGG GAG GAT GAC AGG CAC TTG TGT	978
L A K L D P Q T L D T E Q Q W D T P C P	317

FIG. 9A

CTG GCC AAG TTA GAT CCA CAG ACA CTG GAC ACA GAG CAG CAG TGG GAC ACA CCA TGT CCC	1038
R E N A E A A F V I C G T L Y V V Y N _ T	337
AGA GAG AAT GCT GAG GCT GCC TTT GTC ATC TGT GGG ACC CTC TAT GTC GTC TAT AAC ACC	1098
R P A S R A R I Q C S F D A S G T L T P	357
CGT CCT GCC AGT CGG GCC CGC ATC CAG TGC TCC TTT GAT GCC AGC GGC ACC CTG ACC CCT	1158
E R A A L P Y F P R R Y G A H A S L R Y	377
GAA CGG GCA GCA CTC CCT TAT TTT CCC CGC AGA TAT GGT GCC CAT GCC AGC CTC CGC TAT	1218
N P R E R Q L Y A W D D G Y Q I V Y K L	397
AAC CCC CGA GAA CGC CAG CTC TAT GCC TGG GAT GAT GGC TAC CAG ATT GTC TAT AAG CTG	1278
E M R K K E E E V *	407
GAG ATG AGG AAG AAA GAG GAG GAG GTT TGA	1308
GGAGCTAGCCTTGTTTTTGCATCTTTCTCACTCCCATACATTTATATTATATCCCCACTAAATTTCTTGTTCCCTCATT	1387
CTTCAAATGTGGGCCAGTTGTGGCTCAAATCCTCTATATTTTAGCCAATGGCAATCAAATTCCTTCAGCTCCTTTGTT	1466
TCATACGGAACCTCCAGATCCTGAGTAATCCTTTTAGAGCCCGAAGAGTCAAAACCCTCAATGTTCCCTCCTGCTCTCCT	1545
GCCCCATGTCAACAAATTTCAAGGCTAAGGATGCCCCAGACCCAGGGCTCTAACCTTGATGCGGGCAGGCCAGGGAGC	1624
AGGCAGCAGTGTTCTTCCCCTCAGAGTGACTTGGGGAGGGAGAAATAGGAGGAGACGTCCAGCTCTGTCCTCTCTTCCT	1703
CACTCCTCCCTTCAGTGTCCTGAGGAACAGGACTTTCTCCACATTGTTTTGTATTGCAACATTTTGCATTAAAAGGAAA	1782
ATCCACTGCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGGGCGGCCGC	1831

FIG. 9B



MGPSTPLLILFLLSWGPLQGQHHLVEYMERRLAAL EERLAQCQDQSSRHAAELRDFKN  
KMLPLLEVAEKEREALRTEADTISGRVDRLEREVDYLETQNPALPCVEFDEKVTGGPGTK  
GKGRRNEKYDMVTDCGYTISQVRSMKILKRFGGPAGLWTKDPLGQTEKIYVLDGTQNDTA  
FVFPRLRDFTLAMAARKASRVVPFPWVG TGQLVYGGFLYFARRPPGRPGGGGEMENTLQ  
LIKFH LANRTVVDSSVFP AEGLIPPYGLTADTYIDLADEEGLWAVYATREDDRHLC LAK  
LDPQTL DTEQQWDTPCPRENAEAAFV ICGTLYVVYNTRPASRARIQCSFDASGTLTPERA  
ALPYFP RRYGAHASLRYNPRERQLYAWDDGYQIVYKLEMRKKEEV


**FIG. 10**

										M	G	P	S	A	P	L	L	L	L	F	F		12
GTCGACCCACGCGTCCGACTTAAGGCTGCC	ATG	GGG	CCC	AGT	GCT	CCT	CTG	CTG	CTC	CTC	TTC	TTT											66
L	S	W	T	G	P	L	Q	G	Q	Q	H	H	L	V	E	Y	M	E	R				32
TTG	TCA	TGG	ACG	GGA	CCC	CTT	CAG	GGA	CAG	CAG	CAC	CAC	CTT	GTG	GAG	TAC	ATG	GAA	CGC				126
R	L	A	A	L	E	E	R	L	A	Q	C	Q	D	Q	S	S	R	H	A				52
CGA	CTA	GCT	GCC	TTA	GAG	GAA	CGG	CTG	GCC	CAA	TGC	CAG	GAT	CAG	AGT	AGT	CGG	CAT	GCT				186
A	E	L	R	D	F	K	N	K	M	L	P	L	L	E	V	A	E	K	E				72
GCC	GAG	CTT	CGG	GAC	TTC	AAA	AAC	AAG	ATG	TTG	CCT	CTC	CTG	GAG	GTG	GCA	GAG	AAG	GAG				246
R	E	T	L	R	T	E	A	D	S	I	S	G	R	V	D	R	L	E	R				92
CGG	GAG	ACC	CTC	AGA	ACT	GAA	GCA	GAC	TCC	ATC	TCA	GGA	AGA	GTG	GAC	CGT	CTT	GAA	AGG				306
E	V	D	Y	L	E	T	Q	N	P	A	L	P	C	V	E	L	D	E	K				112
GAG	GTA	GAC	TAT	CTG	GAG	ACA	CAG	AAC	CCA	GCT	TTG	CCC	TGT	GTA	GAG	CTG	GAT	GAG	AAG				366
V	T	G	G	P	G	A	K	G	K	G	R	R	N	E	K	Y	D	M	V				132
GTG	ACT	GGA	GGT	CCT	GGA	GCC	AAA	GGC	AAG	GGC	CGA	AGA	AAT	GAG	AAA	TAC	GAT	ATG	GTG				426
T	D	C	S	Y	T	V	A	Q	V	R	S	M	K	I	L	K	R	F	G				152
ACG	GAC	TGT	AGC	TAC	ACA	GTC	GCT	CAG	GTG	AGG	TCA	ATG	AAG	ATC	CTG	AAG	CGG	TTT	GGT				486
G	S	V	G	L	W	T	K	D	P	L	G	P	A	E	K	I	Y	V	L				172
GGT	TCA	GTT	GGC	CTA	TGG	ACC	AAG	GAT	CCG	CTG	GGG	CCA	GCA	GAG	AAG	ATC	TAC	GTG	TTA				546
D	G	T	Q	N	D	T	A	F	V	F	P	R	L	R	D	F	T	L	A				192
GAC	GGC	ACC	CAG	AAC	GAC	ACG	GCT	TTT	GTG	TTC	CCA	AGG	CTG	CGT	GAC	TTC	ACC	CTT	GCC				606
M	A	A	R	K	A	S	R	I	R	V	P	F	P	W	V	G	T	G	Q				212
ATG	GCT	GCC	CGG	AAA	GCT	TCC	CGA	ATT	CGG	GTG	CCC	TTC	CCC	TGG	GTA	GGC	ACG	GGG	CAG				666
L	V	Y	G	G	F	L	Y	Y	A	R	R	P	P	G	G	P	G	G	G				232
CTG	GTG	TAC	GGT	GGC	TTC	CTT	TAT	TAT	GCT	CGA	AGG	CCT	CCT	GGA	GGA	CCT	GGA	GGG	GGT				726
G	E	L	E	N	T	L	Q	L	I	K	F	H	L	A	N	R	T	V	V				252
GGT	GAA	TTG	GAG	AAC	ACT	CTG	CAG	CTG	ATC	AAA	TTT	CAC	TTG	GCA	AAC	CGA	ACA	GTG	GTG				786
D	S	S	V	F	P	A	E	S	L	I	P	P	Y	G	L	T	A	D	T				272
GAT	AGC	TCA	GTG	TTC	CCT	GCA	GAG	AGC	CTG	ATA	CCC	CCC	TAC	GGC	CTG	ACA	GCA	GAT	ACA				846
Y	I	D	L	A	A	D	E	E	G	L	W	A	V	Y	A	T	R	D	D				292
TAT	ATC	GAC	CTG	GCA	GCT	GAT	GAG	GAG	GGC	CTG	TGG	GCT	GTC	TAT	GCC	ACT	CGA	GAT	GAT				906
D	R	H	L	C	L	A	K	L	D	P	Q	T	L	D	T	E	Q	Q	W				312
GAC	AGG	CAT	TTG	TGT	CTA	GCC	AAG	TTA	GAC	CCA	CAG	ACA	CTT	GAC	ACA	GAG	CAG	CAG	TGG				966
D	T	P	C	P	R	E	N	A	E	A	A	F	V	I	C	G	T	L	Y				332

FIG. 11A

GAC ACA CCA TGT CCC AGA GAG AAC GCA GAG GCT GCG TTT GTC ATC TGT GGG ACC CTG TAC	1026
V V Y N T R P A S R A R I Q C S F D A S	352
GTT GTC TAT AAC ACC CGC CCT GCC AGT AGG GCT CGT ATT CAG TGT TCC TTC GAT GCC AGT	1086
G T L A P E R A A L S Y F P R R Y G A H	372
GGT ACT CTC GCC CCT GAA AGG GCA GCA CTC TCC TAT TTT CCA CGC CGA TAT GGT GCC CAT	1146
A S L R Y N P R E R Q L Y A W D D G Y Q	392
GCC AGC CTT CGC TAT AAC CCC CGT GAG CGC CAG CTG TAT GCC TGG GAT GAT GGC TAC CAG	1206
I V Y K L E M K K K E E E V *	407
ATT GTC TAC AAA TTG GAG ATG AAG AAG AAG GAG GAG GAA GTT TAA	1251
GCAGCTAGCCTTGTGCTCTTGATTCTTATGCCAGACATTTATATTCCTGTGAGCTCTCCTGCAGTTCATCCTTCAAAA	1330
CGAAGGCCAGTGGTGGTAGCTCATATACCCTAATTTCTAAAGGACAACCAAATTCTCAAGCCCCTCTGTTTTATGCAGA	1409
ACTCCAGATCCTGGGTAGCATTTTAGAACTGAACAGCAAACAAACACCCTAAATCTTCACTCCTGCCTTATGTCCACAA	1488
AGTTTAGTTCCAAACTCAGAGCCCTGTCCTTTGGAGAGGGTCAACCCAGACAGCAGGCGACAGCATTCTTGCCCTCAG	1567
TATGACCGAAGGGAGAGAACTCAGAGACAAAGCTGCCCTCCCTCCCTTCCCCCTCCAGTGTAGGGGAGAATGGGGCTTT	1646
CCGCACATCACTTTGTATGGTAACAGTTTGCACTTAAAAGGAAAACCCACCAAAAAAAAAAAAAAAAAAAGGGCGGCCGC	1721

FIG. 11B



>mT257

MGPSAPLLLLFFLSWTGPLQGQHHLVEYMERRLAALERLAQCQDQSSRHAAELRDFKN  
KMLPLLEVAEKERETLRTEADSI SGRVDRLEREVDYLETQNPALPCVELDEKVTGGPGAK  
GKGRRNEKYDMVTDCSYTVAQVRSMKILKRFGGSVGLWTKDPLGPAEKIYVLDGTQNDTA  
FVFPRLRDFTLAMAARKASRIRVFPWVG TGQLVYGGFLYYARRPPGGPGGGGELENTLQ  
LIKFH LANRTVVDSSVFPAESLIPPYGLTADTYIDLADEEGLWAVYATRDDDRHLC LAK  
LDPQTLDT EQQWDTPCPRENAEAA FVICGTLYVVYNTRPASRARIQCSFDASGTLAPER A  
ALSYFPRRYGAHASLRYNPRERQLYAWDDGYQIVYKLEMKKKEEV

**FIG. 12**

ALIGN calculates a global alignment of two sequences  
 version 2.0uPlease cite: Myers and Miller, CABIOS (1989)  
 > ht257 a.a. 406 aa vs.  
 > mt257a.a. 406 aa  
 scoring matrix: pam120.mat, gap penalties: -12/-4  
 94.1% identity; Global alignment score: 2097

```

      10      20      30      40      50      60      70
inputs MGPSTPLLILFLLSWSGPLQGQQHHLVEYMERRLAALAEERLAQCQDQSSRHAAELRDFKMKMLPILLEVAE
      .....
      MGPSAPLLLLLFFLSWTGPIQGQQHHLVEYMERRLAALAEERLAQCQDQSSRHAAELRDFKMKMLPILLEVAE
      10      20      30      40      50      60      70

      80      90     100     110     120     130     140
inputs KEREALRTEADTISGRVDRLEREVDYLETQNPAIPCFVEFDEKVTGGPGTKGKGRNEKYDMVTDCGYTIS
      .....
      KERETLRTEADTISGRVDRLEREVDYLETQNPAIPCFVELDEKVTGGPGAKGKGRNEKYDMVTDCSYTVA
      80      90     100     110     120     130     140

      150     160     170     180     190     200     210
inputs QVRSMKILKRFGGPAGLWTKDPLGQTEKIYVLDGTQNDTAFVFPRLRDFTLAMAARKASRVRVPFPWVGT
      .....
      QVRSMKILKRFGGSVGLWTKDPLGPAEKIYVLDGTQNDTAFVFPRLRDFTLAMAARKASRIRVPFPWVGT
      150     160     170     180     190     200     210

      220     230     240     250     260     270     280
inputs GQLVYGGFLYFARRPPGRPGGGEMENTLQLIKFHLANRTVVDSSVFPAGLIPPYGLTADTYIDLADE
      .....
      GQLVYGGFLYYARRPPGGPGGGGELENTLQLIKFHLANRTVVDSSVFPAESLIPPYGLTADTYIDLADE
      220     230     240     250     260     270     280

      290     300     310     320     330     340     350
inputs EGLWAVYATREDDRHLCIAKLDPQTLDEQQWDTPCPRENAEAAVFCGTLYVVYNTRPASRARIQCSFD
      .....
      EGLWAVYATRDDRHLCIAKLDPQTLDEQQWDTPCPRENAEAAVFCGTLYVVYNTRPASRARIQCSFD
      290     300     310     320     330     340     350

      360     370     380     390     400
inputs ASGTLTPERAALPYFPRRYGAHASLRYNPRERQLYAWDDGYQIVYKLEMKKKEEV
      .....
      ASGTLAPERAALSYPFRRYGAHASLRYNPRERQLYAWDDGYQIVYKLEMKKKEEV
      360     370     380     390     400

```

FIG. 13

	10	20	30	40	50	60	70
inputs	MGPSTPLLILFLLSWSGPLQGQHHLVEYMERRLAALAEERLAQCQDQSSRHAAELRDFKXKMLPLLEVAE						
	10	20	30	40	50	60	70
	MGPSTPLLILFLLSWSGPLQGQHHLVEYMERRLAALAEERLAQCQDQSSRHAAELRDFKXKMLPLLEVAE						
	80	90	100	110	120	130	140
inputs	KEREALRTEADTISGRVDRLEREVDYLETQNPALPCVEFDEKVTGGPGTKGKGRRNEKYDMVTDGTYTIS						
	80	90	100	110	120	130	140
	KEREALRTEADTISGRVDRLEREVDYLETQNPALPCVEFDEKVTGGPGTKGKGRRNEKYDMVTDGTYTIS						
	150	160	170	180	190	200	210
inputs	QVRSMKILKRFGGPAGLWTKDPLGQTEKIYVLDGTQNDTAFVFPRLRDFTLAMAARKASRVVPFPWVGT						
	150	160	170	180	190	200	210
	QVRSMKILKRFGGPAGLWTKDPLGQTEKIYVLDGTQNDTAFVFPRLRDFTLAMAARKASRVVPFPWVGT						
	220	230	240	250	260	270	280
inputs	GQLVYGGFLYFARRPPGRPGGGEMENTLQLIKFHLNRTVVDSSVFPAGGLIPPYGLTADTYIDLADE						
	220	230	240	250	260	270	280
	GQLVYGGFLYFARRPPGRPGGGEMENTLQLIKFHLNRTVVDSSVFPAGGLIPPYGLTADTYIDLADE						
	290	300	310	320	330	340	350
inputs	EGLWAVYATREDDRHLCLAKLDPQTLDTQQWDTPCPRENAEAAVFICGTLVYVYNTRPASRRARIQCSFD						
	290	300	310	320	330	340	350
	EGLWAVYATREDDRHLCLAKLDPQTLDTQQWDTPCPRENAEAAVFICGTLVYVYNTRPASRRARIQCSFD						
	360	370	380	390	400		
inputs	ASGTLTPERAALPYFPRRYGAHASLRYNPRERQLYAWDDGYQIVYKLEMRKKEEV						
	ASGPX-----						

23/61

ALIGN calculates a global alignment of two sequences

version 2.0>Please cite: Myers and Miller, CABIOS (1989)

> T252 a.

1832 aa vs.

> ac02146

1925 aa

scoring matrix: paml20.mat, gap penalties: -12/-4

93.5% identity; Global alignment score: 9158

```

      10      20      30      40      50      60
inputs  GTCGACCCACGCGTCC---GCGGACGCGTGGG--TGAGGGGAAGAGGCTGACTGTACGTTCTCTTCTACTC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      -----CCC-CGCCTCAAAGCTAACCCTCGGGCTTGAGGGGAAGANGCTGACTGTACGTTCTCTTCTACTC
      10      20      30      40      50      60

      70      80      90      100     110     120     130
inputs  TGGCACCACCTCTCCAGGCTGCCATGGGGCCAGCACCCTCTCCTCATCTTGTTCCCTTTTGTTCATGGTTCG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TGGCACCACCTCTCCAGGCTGCCATGGGGCCAGCACCCTCTCCTCATCTTGTTCCCTTTTGTTCATGGTTCG
      70      80      90      100     110     120     130

      140     150     160     170     180     190     200
inputs  GGACCCCTCCAAGGACAGCAGCACCACCTTGTTGGAGTACATGGAACGCCGACTAGCTGCTTTAGAGGAAC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GGACCCCTCCAAGGACAGCAGCACCACCTTGTTGGAGTACATGGAACGCCGACTAGCTGCTTTAGAGGAAC
      140     150     160     170     180     190     200

      210     220     230     240     250     260     270
inputs  GGCTGGCCCAAGTCCAGGACCAGAGTAGTCGGCATGCTGCTGAGCTGCGGGACTTCAAGAACAAGATGCT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GGCTGGCCCAAGTCCAGGACCAGAGTAGTCGGCATGCTGCTGAGCTGCGGGACTTCAAGAACAAGATGCT
      210     220     230     240     250     260     270

      280     290     300     310     320     330     340
inputs  -GCCACTGCTGGAGGTGGCAGAGAAGGAGCGGGAGGCACTCAGAACTGAGGCCGACACCATCTCCGGGAG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      NGCCACTGCTGGAGGTGGCAGAGAAGGAGCGGGAGGCACTCAGAACTGAGGCCGACACCATCTCCGGGAG
      280     290     300     310     320     330     340

      350     360     370     380     390     400     410
inputs  AGTGGATCGTCTGGAGCGGGAGGTAGACTATCTGGAGACCCAGAACCCAGCTCTGCCCTGTGTAGAGTTT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      AGTGGATCGTCTGGAGCGGGAGGTAGACTATCTGGAGACCCAGAACCCAGCTCTGCCCTGTGTAGAGTTT
      350     360     370     380     390     400     410

      420     430     440     450     460     470     480
inputs  GATGAGAAGGTGACTGGAGGCCCTGGGACCAAAGGCAAGGGAAGAAGGAATGAGAAGTACGATATGGTGA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GATGAGAAGGTGACTGGAGGCCCTGGGACCAAAGGCAAGGGAAGAAGGAATGAGAAGTACGATATGGTGA
      420     430     440     450     460     470     480

      490     500     510     520     530     540     550

```

FIG. 15A

**FIG. 15B**

```

AATGCTGAGGCTGCCTTTTTCATCTGTGGGACCCCTCTATGTCTGTCTATAACACCCGTCCTGCCAGTCGGG
1050      1060      1070      1080      1090      1100      1110 -

1120      1130      1140      1150      1160      1170      1180
inputs CCCGCATCCAGTGCTCCTTTTGATGCCAGCGGCACCCTGACCCCTGAACGGGCAGCACTCCCTTATTTTCC
:
:
:
CCCGCATCCAGTGCTCCTTTTGATGCCAGCGG-ACCCTGACCCCTGAACGGGCAGCACTCCCTTATTTTCC
1120      1130      1140      1150      1160      1170      1180

1190      1200      1210      1220      1230      1240      1250
inputs CCGCAGATATGGTGCCCATGCCAGCCTCCGCTATAACCCCCGAGAACGCCAGCTCTATGCCTGGGATGAT
:
:
:
CCGCAGATATGGTGCCCATGCCAGCCTCCGCTATAACCCCCGAGAACGCCAGCTCTATGCCTGGGATGAT
1190      1200      1210      1220      1230      1240      1250

1260      1270      1280      1290      1300      1310      1320
inputs GGCTACCAGATTGTCTATAAGCTGGAGATGAGGAAGAAAGAGGAGGAGTTTGAGGAGCTAGCCTTGTTT
:
:
:
CGCTACCAGATTGTCTATAAGCTGGAGATGAGGAAGAAAGAGGAGGAGTTTGAGGAGCTAGCCTTGTTT
1260      1270      1280      1290      1300      1310      1320

1330      1340      1350      1360      1370      1380      1390
inputs TTTGCATCTTTCTCACTCCCATACATTTATATTATATCCCCACTAAATTTCTTGTTCTCATCTCTCAA
:
:
:
TTTGCATCTTTCTCACTCCCATACATTTATATTATATCCCCACTAAATTTCTTGTTCTCATCTCTCAA
1330      1340      1350      1360      1370      1380      1390

1400      1410      1420      1430      1440      1450      1460
inputs TGTGGGCCAGTTGTGGCTCAAATCCTCTATATTTTAGCCAATGGCAATCAAATTCTTTCAGCTCCTTTG
:
:
:
TGTGGGCCAGTTGTGGCTCAAATCCTCTATATTTTAGCCAATGGCAATCAAATTCTTTCAGCTCCTTTG
1400      1410      1420      1430      1440      1450      1460

1470      1480      1490      1500      1510      1520      1530
inputs TTTCATACGGAAGTCCAGATCCTGAGTAATCCTTTTAGAGCCCGAAGAGTCAAAACCCCTCAATGTTCCCT
:
:
:
TTTCATACGGAAGTCCAGATCCTGAGTAATCCTTTTAGAGCCCGAAGAGTCAAAACCCCTCAATGTTCCCT
1470      1480      1490      1500      1510      1520      1530

1540      1550      1560      1570      1580      1590      1600
inputs CCTGCTCTCCTGCCCCATGTCAACAAATTTTCAGGCTAAGGATGCCCCAGACCCAGGGCTCTAACCTTGT
:
:
:
CCTGCTCTCCTGCCCCATGTCAACAAATTTTCAGGCTAAGGATGCCCC-AGACCCAGGGCTCTAACCTTGT
1540      1550      1560      1570      1580      1590      1600

1610      1620      1630      1640      1650      1660      1670
inputs ATGCGGGCAGGCCAGGGAGCAGGCAGCAGTGTCTTCCCCCTCAGAGTGACTTGGGGAGGGAGAAATAGG
:
:
:
ATGCGGGCAGGCCAGGGAGCAGGCAGCAGTGTCTTCCCCCTCAGAGTGACTTGGGGAGGGAGAAATAGG
1610      1620      1630      1640      1650      1660      1670

```

FIG. 15C

```

      1680      1690      1700      1710      1720      1730      1740
inputs AGGAGACGTCCAGCTCTGTCCTCTCTTCTCACTCCTCCCTTCAGTGTCTGAGGAACAGGACTTTCTCC
      .....
      AGGAGACGTCCAGCTCTGTCCTCTCTTCTCACTCCTCCCTTCAGTGTCTGAGGAACAGGACTTTCTCC
      1680      1690      1700      1710      1720      1730      1740

      1750      1760      1770      1780      1790      1800      1810
inputs ACATTGTTTTGTATTGCAACATTTTGCATTAAAAGGAAAATCCACTGCTAAAAAAAAAAAAAAAAAAAA
      .....
      ACATTGTTTTGTATTGCAACATTTTGCATTAAAAGGAAAATCCANAAAAAAAAAAAAAAAAAAAAAA
      1750      1760      1770      1780      1790      1800      1810

      1820                                  1830
inputs AAAAAAAGG-----GCGGCCGC-----
      .....
      AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACTGCGGCCGCTGTCCCTTCTG
      1820      1830      1840      1850      1860      1870      1880

inputs -----

      TCGTCTTCTCGCAGCCGTACCCTTCTGTCGTCTTCTCGCAGCC
      1890      1900      1910      1920

```

FIG. 15D

ALIGN calculates a global alignment of two sequences  
 version 2.0u Please cite: Myers and Miller, CABIOS (1989)  
 > mT257a.a. 406 aa vs.  
 > Patent Protein W75120 - (untitled) 355 aa  
 scoring matrix: pam120.mat, gap penalties: -12/-4  
 81.8% identity; Global alignment score: 1599

```

      10      20      30      40      50      60      70
inputs  MGPSAPLLLLFFLSWTGPLQGQHHLVEYMERRLAALAEERLAQCQDQSSRHAAELRDFKNKMLPLLEVAE
      .....
      MGPSTPLLLILFLLSWSGPLQGQHHLVEYMERRLAALAEERLAQCQDQSSRHAAELRDFKNKMLPLLEVAE
      10      20      30      40      50      60      70

      80      90     100     110     120     130     140
inputs  KERETLRTEADSISSRVDRLEREVDYLETQNPALPCVELDEKVTGGPGAKGKGRNEKYDMVTDCSYTVA
      .....
      KEREALRTEADTISGRVDRLEREVDYLETQNPALPCVEFDEKVTGGPGTKGKGRNEKYDMVTDCGYTIS
      80      90     100     110     120     130     140

      150     160     170     180     190     200     210
inputs  QVRSMKILKRFGGSVGLWTKDPLGPAEKIYVLDGTQNDTAFVFPRLRDFTLAMAARKASRIRVPFPWVGT
      .....
      QVRSMKILKRFGGPAGLWTKDPLGQTEKIYVLDGTQNDTAFVFPRLRDFTLAMAARKASRVVPFPWVGT
      150     160     170     180     190     200     210

      220     230     240     250     260     270     280
inputs  GQLVYGGFLYYARRPPGGPGGGGELENTLQLIKFHLANRTVVDSSVFPAESLIPPYGLTADTYIDLADE
      .....
      GQLVYGGFLYFARRPPGRPGGGGEMENTLQLIKFHLANRTVVDSSVFPAEGLIPPYGLTADTYIDLADE
      220     230     240     250     260     270     280

      290     300     310     320     330     340     350
inputs  EGLWAVYATRDDRHLCLAKLDPQTLDEQQWDTPCPRENAEAAAFVICGTLVYVYNTRPASRARIQCSFD
      .....
      EGLWAVYATREDDRHLCLAKLDPQTLDEQQWDTPCPRENAEAAAFVICGTLVYVYNTRPASRARIQCSFD
      290     300     310     320     330     340     350

      360     370     380     390     400
inputs  ASGTLAPERAALSYFPRRYGAHASLRYNPRERQLYAWDDGYQIVYKLEMKKKEEV
      : : :
      ASGPX-----

```

FIG. 16

ALIGN calculates a global alignment of two sequences  
 version 2.0uplease cite: Myers and Miller, CABIOS (1989)  
 > mt257 n.a. 1721 aa vs.  
 > Patent Nucleotide V34217 - (untitled) 1890 aa  
 scoring matrix: paml20.mat, gap penalties: -12/-4  
 76.2% identity; Global alignment score: 6493

```

              10              20
inputs GT-----CGACCCAC---GCGTCC-----GACTTAAGG-----
      ::      ::      ::      ::      ::      ::      ::      ::
      GAGCAGGAGAGAAGGCACCGCCCCACCCCGCCTCCAAAGCTAACCCCTCGGGCTTGAGGGGAAGAGGCTGA
          10          20          30          40          50          60          70

              30          40          50
inputs -----CTGCCATGGGGCCAGTGCTCCTCTGCTGCTCCT
      ::      ::      ::      ::      ::      ::      ::      ::
      CTGTACGTTCTTCTACTCTGGCACCCTCTCCAGGCTGCCATGGGGCCAGCACCCCTCTCCTCATCTT
          80          90          100          110          120          130          140

              60          70          80          90          100          110          120
inputs CTTCTTTTGTTCATGGACGGGACCCCTTCAGGGACAGCAGCACCACCTTGTTGGAGTACATGGAACGCCGA
      ::      ::      ::      ::      ::      ::      ::      ::
      GTTCCTTTTGTTCATGGTCGGGACCCCTCCAAGGACAGCAGCACCACCTTGTTGGAGTACATGGAACGCCGA
          150          160          170          180          190          200          210

              130          140          150          160          170          180          190
inputs CTAGCTGCCTTAGAGGAACGGCTGGCCCAATGCCAGGATCAGAGTAGTCGGCATGCTGCCGAGCTTCGGG
      ::      ::      ::      ::      ::      ::      ::      ::
      CTAGCTGCTTTAGAGGAACGGCTGGCCCAATGCCAGGATCAGAGTAGTCGGCATGCTGCTGAGCTGCCGG
          220          230          240          250          260          270          280

              200          210          220          230          240          250          260
inputs ACTTCAAAAACAAGATGTTGCCTCTCCTGGAGGTGGCAGAGAAGGAGCGGGAGACCCTCAGAACTGAAGC
      ::      ::      ::      ::      ::      ::      ::      ::
      ACTTCAAGAACAAGATGCTGCCACTGCTGGAGGTGGCAGAGAAGGAGCGGGAGGCACTCAGAACTGAGGC
          290          300          310          320          330          340          350

              270          280          290          300          310          320          330
inputs AGACTCCATCTCAGGAAGAGTGGACCGTCTTGAAAGGGAGGTAGACTATCTGGAGACACAGAACCCAGCT
      ::      ::      ::      ::      ::      ::      ::      ::
      CGACACCATCTCCGGGAGAGTGGATCGTCTGGAGCGGGAGGTAGACTATCTGGAGACCCAGAACCCAGCT
          360          370          380          390          400          410          420

              340          350          360          370          380          390          400
inputs TTGCCCTGTGTAGAGCTGGATGAGAAGGTGACTGGAGGTCTGGAGCCAAAGGCAAGGGCCGAAGAAATG
      ::      ::      ::      ::      ::      ::      ::      ::
      CTGCCCTGTGTAGAGTTGATGAGAAGGTGACTGGAGGCCCTGGGACCAAGGCAAGGGAAGGAAGGAATG
          430          440          450          460          470          480          490

              410          420          430          440          450          460          470
inputs AGAAATACGATATGGTGACGGACTGTAGCTACACAGTCTGCTCAGGTGAGGTCAATGAAGATCCTGAAGCG
      ::      ::      ::      ::      ::      ::      ::      ::
      AGAAGTACGATATGGTGACAGACTGTGGCTACACAATCTCTCAAGTGAGATCAATGAAGATTCTGAAGCG
          500          510          520          530          540          550          560

              480          490          500          510          520          530          540
inputs GTTTGGTGGTTTCAGTTGGCCTATGGACCAAGGATCCGCTGGGGCCAGCAGAGAAGATCTACGTGTTAGAC
      ::      ::      ::      ::      ::      ::      ::      ::
      ATTTGGTGGGCCAGCTGGTCTATGGACCAAGGATCCACTGGGGCAAACAGAGAAGATCTACGTGTTAGAT
          570          580          590          600          610          620          630

              550          560          570          580          590          600          610
inputs GGCACCCAGAACGACACGGCTTTTGTCTTCCCAAGGCTGCGTGACTTCACCCCTTGCCATGGCTGCCCGGA
      ::      ::      ::      ::      ::      ::      ::      ::
      GGGACACAGAATGACACAGCCTTTGTCTTCCCAAGGCTGCGTGACTTCACCCCTTGCCATGGCTGCCCGGA
          640          650          660          670          680          690          700

              620          630          640          650          660          670          680
inputs AAGCTTCCCGAATTCGGGTGCCCTTCCCTTGGGTAGGCACGGGCGAGCTGGTGTACGGTGGCTTCCTTTA
      ::      ::      ::      ::      ::      ::      ::      ::

```

FIG. 17A

**FIG. 17B**


**FIG. 17C**

GTCGACCCACGCGTNCNTCCAGCGTNCGGAGCCGCCCTGGGTGTCAGCGGCTCGGCTCCCGCGCACGCTCCGGCCGTCG																				79
CGCAGCCTCGGCACCTGCAGGTCCGTGCGTCCCGCGGCTGGCGCCCCCTGACTCCGTCCCGGCCAGGGAGGGCC ATG																				155
I S L P G P L V T N L X R F L F L G L S																				21
ATT TCC CTC CCG GGG CCC CTG GTG ACC AAC TTG NTG CGG TTT TTG TTC CTG GGG CTG AGT																				215
A L A P P S R A Q L Q L H L P A N R L Q																				41
GCC CTC GCG CCC CCC TCG CGG GCC CAG CTG CAA CTG CAC TTG CCC GCC AAC CGG TTG CAG																				275
A V E E G E S G A S A W Y T L H R E V S																				61
GCG GTG GAG GAG GGG GAA AGT GGT GCT TCA GCA TGG TAC ACC TTG CAC AGG GAG GTG TCT																				335
S S Q P W E V P F V M W F F K Q K E K E																				81
TCA TCC CAG CCA TGG GAG GTG CCC TTT GTG ATG TGG TTC TTC AAA CAG AAA GAA AAG GAG																				395
D Q V L S Y I N G V T T S K P G V S L V																				101
GAT CAG GTG TTG TCC TAC ATC AAT GGG GTC ACA ACA AGC AAA CCT GGA GTA TCC TTG GTC																				455
Y S M P S R N L S L R V E G L Q E K D S																				121
TAC TCC ATG CCC TCC CGG AAC CTG TCC CTG CGG GTG GAG GGT CTC CAG GAG AAA GAC TCT																				515
G P Y S C S V N V Q D K Q G K S R G H S																				141
GGC CCC TAC AGC TGC TCC GTG AAT GTG CAA GAC AAA CAA GGC AAA TCT AGG GGC CAC AGC																				575
I K T L E L N V L V P P A P P S C R L Q																				161
ATC AAA ACC TTA GAA CTC AAT GTA CTG GTT CCT CCA GCT CCT CCA TCC TGC CGT CTC CAG																				635
G V P H V G A N V T L S C Q S P R S K P																				181
GGT GTG CCC CAT GTG GGG GCA AAC GTG ACC CTG AGC TGC CAG TCT CCA AGG AGT AAG CCC																				695
A V Q Y Q W D R Q L P S F Q T F F A P A																				201
GCT GTC CAA TAC CAG TGG GAT CGG CAG CTT CCA TCC TTC CAG ACT TTC TTT GCA CCA GCA																				755
L D V I R G S L S L T N L S S S M A G V																				221
TTA GAT GTC ATC CGT GGG TCT TTA AGC CTC ACC AAC CTT TCG TCT TCC ATG GCT GGA GTC																				815
Y V C K A H N E V G T A Q C N V T L E V																				241
TAT GTC TGC AAG GCC CAC AAT GAG GTG GGC ACT GCC CAA TGT AAT GTG ACG CTG GAA GTG																				875
S T G P G A A V V A E A V V G T L V G L																				261
AGC ACA GGG CCT GGA GCT GCA GTG GTT GCT GAA GCT GTT GTG GGT ACC CTG GTT GGA CTG																				935
G L L A G L V L L Y H R R G K A L E E P																				281
GGG TTG CTG GCT GGG CTG GTC CTC TTG TAC CAC CGC CGG GGC AAG GCC CTG GAG GAG CCA																				995
A N D I K E D A I A P R T L P W P K S S																				301

FIG. 18A

GCC AAT GAT ATC AAG GAG GAT GCC ATT GCT CCC CGG ACC CTG CCC TGG CCC AAG AGC TCA	1055
D T I S K N G T L S S V T S A R A L R -P	321
GAC ACA ATC TCC AAG AAT GGG ACC CTT TCC TCT GTC ACC TCC GCA CGA GCC CTC CGG CCA	1115
P H G P P R P G A L T P T P S L S S Q A	341
CCC CAT GGC CCT CCC AGG CCT GGT GCA TTG ACC CCC ACG CCC AGT CTA TCC AGC CAG GCC	1175
L P S P R H A H D R W G P P S T N I P H	361
CTG CCC TCA CCA AGA CAT GCC CAC GAC AGA TGG GGC CCA CCC TCA ACC AAT ATC CCC CAT	1235
P W W G F F L W L *	371
CCC TGG TGG GGT TTT TTC CTT TGG CTT TGA	1265
GCCGCATGGGTGCTGNGCCTGTGATGGNGCCTGCCAGAGTCAAGCTGGCTCTCTGGTATGATGACCCACCACTCATT	1344
GGCTAAAGGATTTGGGGTCTCTCCTTCCTATAAGGGTCACCTCTAGCACAGAGGCCTGAGTCATGGGAAAGAGTCACAC	1423
TCCTGACCCCTTAGTACTCTGCCCCACCTCTCTTTACTGTGGGAAAACCATCTCAGTAAGACCTAAGTGTCCAGGAGAC	1502
AGAAGGAGAAGAGGAAGTGGATCTGGAATTGGGAGGAGCCTCCACCCACCCCTGACTCCTCCTTATGAAGCCAGCTGCT	1581
3AAATTAGCTACTCACCAAGAGTGAGGGGCAGAGACTTCCAGTCACTGAGTCTCCCAGGCCCCCTTGATCTGTACCCCA	1660
1CCCTATCTAACACCACCCCTTGGCTCCCACTCCAGCTCCCTGTATTGATATAACCTGTCAGGCTGGCTTGGTTAGGTTT	1739
1ACTGGGGCAGAGGATAGGGAATCTCTTATTAAACTAACATGAAATATGTGTTGTTTTTCATTTGCAAATTTAAATAAA	1818
GATACATAATGTTTGTATGAGATAAGAAAAAAAAAAAAAAAAAGGGCGGCCGC	1869

FIG. 18B



MISLPGPLVTNLXRFLFLGLSALAPPSRAQLQLHLPANRLQAVEEGESGASAWYTLHREV  
SSSQPWEVPFVMWFFKQKEKEDQVLSYINGVTTSKPGVSLVYSMPSRNLSLRVEGLQEKD  
SGPYSCSVNVQDKQGKSRGHSIKTLELNVLPAPPSCRLQGVPHVGANVTLSQCSPRSK  
PAVQYQWDRQLPSFQTFAPALDVIRGSLSLTNLSSSMAGVYVCKAHNEVGTAQCNTLE  
VSTGPGAAVVAEAVVGTLVGLGLLAGLVLLYHRRGKALEEPANDIKEDAIAPRTLWPWPKS  
SDTISKNGTLSSVTSARALRPPHGP RP GAL TPTPSLSSQALPSPRHAHDRWGPPSTNIP  
HPWWGFFLWL


**FIG. 19**

GTCGACCCACGCGTCCGGTGACATTTCGGGTTGCCGCCGCTCACCCACAACACCTGTAGACACCGTGTGTCCAACCTCTC																				79
																				13
CCTGAGTACTCCGGGCCAAGGAGGGCC	M	I	L	Q	A	G	T	P	E	T	S	L	L							145
ATG ATT CTT CAG GCT GGA ACC CCC GAG ACC AGC TTG CTG																				
R V L F L G L S T L A A F S R A Q M E L																				33
CGG GTT TTG TTC CTG GGA CTG AGT ACC CTT GCT GCC TTC TCC CGA GCT CAG ATG GAG TTG																				205
H V P P G L N K L E A V E G E E V V L P																				53
CAC GTG CCC CCG GGC CTC AAC AAA TTG GAA GCG GTA GAG GGA GAA GAA GTG GTG CTC CCC																				265
A W Y T M A R E E S W S H P R E V P I L																				73
GCC TGG TAC ACG ATG GCA CGG GAG GAG TCG TGG TCC CAC CCC CGG GAG GTG CCC ATC CTG																				325
I W F L E Q E G K E P N Q V L S Y I N G																				93
ATC TGG TTC TTG GAA CAA GAA GGG AAG GAA CCA AAC CAG GTG TTG TCT TAC ATT AAT GGA																				385
V M T N K P G T A L V H S I S S R N V S																				113
GTC ATG ACA AAT AAA CCT GGA ACA GCC CTG GTC CAC TCT ATC TCT TCA CGG AAT GTG TCC																				445
L R L G A L Q E G D S G T Y R C S V N V																				133
CTG CGC CTG GGG GCA CTC CAG GAG GGA GAC TCT GGG ACT TAC CGC TGT TCT GTC AAT GTG																				505
Q N D E G K S I G H S I K S I E L K V L																				153
CAG AAT GAT GAA GGC AAA AGT ATA GGC CAC AGC ATC AAA AGC ATA GAG CTC AAA GTG CTG																				565
V P P A P P S C S L Q G V P Y V G T N V																				173
GTT CCT CCA GCT CCT CCA TCC TGT AGT TTA CAG GGT GTA CCC TAT GTC GGG ACC AAT GTG																				625
T L N C K S P R S K P T A Q Y Q W E R L																				193
ACC CTG AAC TGC AAG TCC CCA AGG AGT AAA CCT ACT GCT CAG TAC CAG TGG GAG AGG CTG																				685
A P S S Q V F F G P A L D A V R G S L K																				213
GCC CCA TCC TCC CAG GTC TTC TTT GGA CCA GCC TTA GAT GCT GTT CGT GGA TCT TTA AAG																				745
L T N L S I A M S G V Y V C K A Q N R V																				233
CTC ACT AAC CTT TCC ATT GCC ATG TCT GGA GTC TAT GTC TGC AAG GCT CAA AAC AGA GTG																				805
G F A K C N V T L D V M T G S K A A V V																				253
3GC TTT GCC AAG TGC AAC GTG ACC TTG GAC GTG ATG ACA GGG TCC AAG GCT GCA GTG GTC																				865
A G A V V G T F V G L V L I A G L V L L																				273
3CT GGA GCA GTT GTG GGC ACT TTT GTT GGG TTG GTG CTG ATA GCT GGG CTG GTC CTG TTG																				925
Y Q R R S K T L E E L A N D I K E D A I																				293
3AC CAG CGC CGG AGC AAG ACC TTG GAA GAG CTG GCC AAT GAT ATC AAG GAA GAT GCC ATT																				985
A P R T L P W T K G S D T I S K N G T L																				313
3CT CCC CGG ACC TTG CCT TGG ACC AAA GGC TCA GAC ACA ATC TCC AAG AAT GGG ACA CTT																				1045

FIG. 20A

S	S	V	T	S	A	R	A	L	R	P	P	K	A	A	P	P	R	P	G	333
TCT	TCG	GTC	ACC	TCA	GCA	CGA	GCT	CTG	CGG	CCA	CCC	AAG	GCT	GCT	CCT	CCA	AGA	CCT	GGC	1105
T	F	T	P	T	P	S	V	S	S	Q	A	L	S	S	P	R	L	P	R	353
ACA	TTT	ACT	CCC	ACA	CCC	AGT	GTC	TCT	AGC	CAG	GCC	CTG	TCC	TCA	CCA	AGA	CTG	CCC	AGG	1165
V	D	E	P	P	P	Q	A	V	S	L	T	P	G	G	V	S	S	S	A	373
GTA	GAT	GAA	CCC	CCA	CCT	CAG	GCA	GTG	TCC	CTG	ACC	CCA	GGT	GGG	GTG	TCT	TCT	TCT	GCT	1225
L	S	R	M	G	A	V	P	V	M	V	P	A	Q	S	Q	A	G	S	L	393
CTG	AGC	CGC	ATG	GGT	GCT	GTG	CCT	GTG	ATG	GTG	CCT	GCA	CAG	AGT	CAG	GCT	GGG	TCT	CTT	1285
V																				395
GTG	TGA																			1291
TAGCCCAGGCACTCATTAGCTACATCTGGTATCTGACCTTTCTGTAAAGGTCTCCTTGTGGCACAGAGGACTCAATCTT																				1370
GGGAGGATGCCCCACATTCTAGACCTCCAGTCCTTTGCTCCTACCTCCTTCTATTGTTGGAATACTGGGCCTCAGTAAGA																				1449
TTAAAATCTGGGTCAAAGGACAAAAGGAGGAAATGGACCTGAGGTAGGGGGTTGGGAGTGAGGAGGCTTCACTTCCTCC																				1528
TGCTTCTCCCTGAAGCCAGATGAATGCTGCGGAAGATCGGCTACCCTCCAAGGGCTCTGGAGGAGACTGCCAGTCAGT																				1607
ATGCCCCTGGCTCTGTGATCTGTACAACACCCTTATCTAATGCTGTCCTTTGCCGTTGCTCCATCTCCCTGTATTAA																				1686
ATAACCTGTCCTGCTGGCTTGGCTGGGTTTTGTTGTAGCAGGGGGATAGGAAAGACATTTTAAAATCTGACTTGAAAT																				1765
GATGTTTTTGTGTTTTTATTTTGCAAATTTCAATAAAGATACATCGCATTGTCATGGAAAAAAAAAAAAAAAAAGGGCGGCC																				1844
																				1846

FIG. 20B



>mT258  
MILQAGTPETSLRLVFLGLSTLAASFRAQMELHVPPGLNKLEAVEGEEVVLPAWYTMAR  
EESWSHPREVPILIWFLEQEGKEPNQVLSYINGVMTNKP GTALVHSISSRNVSRLGALQ  
EGDSGT YRC SVNVQND EGKSI GHSIKSIELKVLVPPAPPSCSLQGVPYVGTNVTLNCKSP  
RSKPTAQYQWERLAPSSQVFFGPALDAVRGSLKLTNLSIAMSGVYVCKAQNRVGFACNV  
TLDVMTGSKAAVVAGAVVGTFVGLVLIAGLVLLYQRRSKTLEELANDIKEDAIAPRTL PW  
TKGSDTISKNGTLSSVTSARALRPPKAAPRPGTFTPTPSVSSQALSSPRLPRVDEPP PQ  
AVSLTPGGVSSSALSRMGAVPVMVPAQSQAGSLV

**FIG. 21**

ALIGN calculates a global alignment of two sequences  
 version 2.0uPlease cite: Myers and Miller, CABIOS (1989)  
 > hT258a.a. 370 aa vs.  
 > mT258 a.a. 394 aa  
 scoring matrix: pam120.mat, gap penalties: -12/-4  
 62.8% identity; Global alignment score: 1085

```

      10      20      30      40      50      60
inputs MISLPGPLVTNLXRFLFLGLSALAPPSRAQLQLHLPA--NRLQAVEEGESGASAWYTLHREVSSSQPWEV
      ::  ::  :::: ::::: ::::: ::::: ::::: ::::: ::::: :::::
      MILQAGTPETSLRLVFLGLSTLAAFSRAQMELVHVPGLNKLAVEGEEVLPAWYTHAREESWSHPREV
      10      20      30      40      50      60      70

      70      80      90      100     110     120     130
inputs PFVMWFFKQKEKE-DQVLSYINGVTTSKPGVSLVYSMPSRNLSLRVEGLQEKGSGPYSCSVNVQDKQKGS
      ::::: ::  ::::: ::::: ::::: ::::: ::::: ::::: :::::
      PILIWFLEQEGKEPNQVLSYINGVMTNKPGTALVHSISSRNVSRLRGALQEGDSGTYRCSNVNQNDKGS
      80      90      100     110     120     130     140

      140     150     160     170     180     190     200
inputs RGHSIKTELENLVLPAPPSCRLQGVPHGANVTLSQSPRSKPAVQYQWDRQLPSFQTFAPALDVRIG
      ::::: ::::: ::::: ::::: ::::: ::::: :::::
      IGHSIKSIELKVLVLPAPPSCSLQGVPHYVGTNVTLNCKSPRSKPTAQYQWERLAPSSQVFFGPALDAVRG
      150     160     170     180     190     200     210

      210     220     230     240     250     260     270
inputs SLSLTNLSSSMAGVYVCKAHNEVGTAQCQNTLEVSTGPGAAVVAEAVVGTLVGLGLLAGLVLLYHRRGKA
      :: ::::: ::::: ::::: ::::: ::::: ::::: :::::
      SLKLTNLISIAMSGVYVCKAQN RVGFAKCNVTLDVMTGSKAAVVAGAVVGTFFVGLVLIAGLVLLYQRRSKT
      220     230     240     250     260     270     280

      280     290     300     310     320     330     340
inputs LEEPANDIKEDAIAPRTLWPWKSSDTISKNGTLSSVTSARALRPPHG-PPRPGALTPTPSLSSQALPSPR
      :: ::::: ::::: ::::: ::::: ::::: ::::: :::::
      LEELANDIKEDAIAPRTLWPWKSSDTISKNGTLSSVTSARALRPPKAAPPRPGTFTPTPSVSSQALSSPR
      290     300     310     320     330     340     350

      350     360     370
inputs HAK-----DRWGPPSTNIPHPWGGFFLWL
      .. :: :: :: :: :: :: ::
      LPRVDEPPPPQAVSLTPGGVSSSALSRMGAVPVMVPAQSQAGSL-V
      360     370     380     390

```

FIG. 22

```

10      20      30      40      50      60
inputs MISLPGLVTNLXRFLFLGLSALAPPSRAQLQLHLPANRLQAVEEG-ESGASAWYTLHREVSSSQPWEVP
...      ...      ...      ...      ...      ...
MVGKMWPVLWTLCA-VRVTVD AISVETPQDV-LRASQGKSVTL PCTYHTSTSSREGLIQWDKLLLTHTER
10      20      30      40      50      60

70      80      90      100     110     120     130
inputs FVMWFFKQKEKEDQVLSYINGVTTSTKPGVSLVYSMPSRNLSLRVEGLQEKDSGPYSCSVNVQDKQGKSRG
...      ...      ...      ...      ...      ...      ...
VVIWPFPSNKN-----YIHG-ELYKNRVSISNNAEQSDASITIDQLTMADNGTYECSVSLMSDLE---G
70      80      90      100     110     120

140     150     160     170     180     190     200
inputs HSIKTLELNVLVPPAPPSCRLQGVP HVGANVTLSQCSPRSKPAVQYQWDR--QLPSFQTFPAPALDVIRG
..      .      :      :      :      :      :      :      :      :      :      :      :      :
NTKSRVRLLVLVPPSKPECGIEGETIIGNNIQLTCQSKEGSPTPQYSWKRYNINLQEQPLAQPASGQ---
130     140     150     160     170     180     190

210     220     230     240     250     260     270
inputs SLSLTNLSSSMAGVYVCKAHNEVGTAQCNTLEVSTGP-GAAVVAEAVVGLTVGLGLLAGLVLLYHRRGK
...      ...      ...      ...      ...      ...      ...
PVS LKNISTDTSGYYICTSSNEEGTQFCNITVAVRSPSMNVALYVGIAGVVAALIIIGIIYCCCCRGRK
200     210     220     230     240     250     260

280     290     300     310     320     330     340
inputs ALEEPANDIKEDAIAPRTLWPWKSSDTISKNGTLSSVTSARALRPPHGP RP GALTP TPSLSSQALPSPR
..      .      :      :      :      :      :      :      :      :      :      :
--DDNTED-KEDA-----RPNREAYEEP-PEQLRELSREREEEE-DDYR
270      280      290      300

350     360     370
inputs HAHDRWGPPSTNIPHPWWGFFLWL
..      .      :
QEEQR--STGRES PDH-----LDQ
310

```

**39/61**

ALIGN calculates a global alignment of two sequences  
 version 2.0u Please cite: Myers and Miller, CABIOS (1989)  
 > hT258 n.a. 1869 aa vs.  
 > GenBank U79725 - Human A33 antigen precursor mR 2793 aa  
 scoring matrix: pam120.mat, gap penalties: -12/-4  
 40.6% identity; Global alignment score: 1182

```

      10      20
inputs  GTCGACCC-----ACGCGTNCNT-----CCAG-----C-----
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      --CTACCCCTTTGTGAGCAGTCTAGGACTTTGTACACCTGTTAAGTAGGGAGAAGGCAGGGAGGTGGCT
      10      20      30      40      50      60

      30      40      50
inputs  -----GTNC-----GGAG-----CCGC-----CCT-----GGGTGTCA-GCG-GC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GGTTTAAGGGGAAGTTGAGGGAAGTAGGGAAGACTCCTCTTGGGACCTTTGGAGTAGGTGACACATGAGC
      70      80      90      100      110      120      130

      60      70      80      90
inputs  TCGGCTCCCGCGCAC--GC--TCCGGCCGT---CGCGC-AGCCT---CGGCA---C---C-----
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CCAGCCCCAGCTCACCTGCCAATCCAGCTGAGGAGCTCACCTGCCAATCCAGCTGAGGCTGGGCAGAGGT
      140      150      160      170      180      190      200

      100      110      120
inputs  -----TGCAGG-----TCC-----GTGC--GTCCCG---CGGCTGGCGCC---CCTG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GGGTGAGAAGAGGGAAAATTGCAGGGACCTCCAGTTGGGCCAGGCCAGAAGCTGCTGTAGCTTTAACCAG
      210      220      230      240      250      260      270

      130      140      150
inputs  AC---TCCGTCC-----CGGCCAGGGA-----GGGC-----CATGA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      ACAGCTCAGACCTGTCTGGAGGCTGCCAGTGACAGGTTAGGTTTAGGGCAGAGAAGAAGCAAGACCATGG
      280      290      300      310      320      330      340

      160      170      180
inputs  TTT-----CC-----CTCCCGGGGCC---CCTGGTGACCAAC-----TTGN
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TGGGGAAGATGTGGCCTGTGTTGTGGACACTCTGTGCAGTCAGGGTGACCGTCGATGCCATCTCTGTGGA
      350      360      370      380      390      400      410

      190      200      210      220
inputs  TGC-----GGTTTTGTTC-----CTGGGCTGAGTG---CCCT-C---GCGCC---CC-----
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      AACTCCGCAGGACGTTCTTCGGGCTTCGCAGGGAAGAGTGTACCCCTGCCCTGCACCTACCACACTTCC
      420      430      440      450      460      470      480

      230      240      250      260
inputs  -CCTC-----GCGGGCC---CA-----GCTGCAACT-GCACTTGC-----CCGCC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      ACCTCCAGTCGAGAGGGACTTATTCAATGGGATAAGCTCCTCCTCACTCATACGGAAGGGTGGTCATCT
      490      500      510      520      530      540      550

      270      280      290      300      310      320
inputs  AACCGGTTGCAGGCGGTGG-----AGGAGGG---GGAAAGTGGTGCTTCAGCATGGTACACCTTGC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GGCCGTTTCAAACAATACTACATCCATGGTGAGCTTTATAAGAATCGCGTCAGCATATCCAACAATGC
      560      570      580      590      600      610      620

      330      340      350      360
inputs  A---CAGGGAGGTGTCTTCATC-CCA-----GCCATGGGAGG---TGC-CCTT--TGTGATGT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TGAGCAGTCCGATGCCCTCCATCACCATTGATCAGCTGACCATGGCTGACAAAGGCACCTACGAGTGTCT
      630      640      650      660      670      680      690

      370      380      390      400      410
inputs  GGTTC-----TCAAAC--AGAAAGAAAAGGAGGATCAGGTGT-----TGTCT-----
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

FIG. 24A

```

GTCTCGCTGATGTTCAGACCTGGAGGGCAACACCAAGTCACGTGTCCGCCTGTTGGTCCTCGTGCCACCCCT
700      710      720      730      740      750      760

inputs -----ACATCAA-----TGGGGTCA-CAACAAGCAAACCTG--GAGTATC
      420      430      440
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CCAAACCAGAATGCGGCATCGAGGGAGAGACCATAATTGGGAACAACATCCAGCTGACCTGCCAATCAAA
770      780      790      800      810      820      830

      450      460      470      480
inputs CTTGGTCTACTCCATGCCCTC-----CCGGAA-----CCTGTG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GGAGGGCT-CACCAACCCCTCAGTACAGCTGGAAGAGGTACAACATCCTGAATCAGGAGCAGCCCTGGC
840      850      860      870      880      890      900

      490      500      510      520
inputs CCTGC-----GGGT-GGAGGGTCTCC-AGGAGAAAGACTC---TGGCCC-----CTACAGCTG-
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CCAGCCAGCCTCAGGTGAGCCTGTCTCCCTGAAGAATATCTCCACAGACACATCGGGTTACTACATCTGT
910      920      930      940      950      960      970

      530      540      550      560      570
inputs --CTCCGTGAATGTGCAAGACAAACAAG---GCAA-ATCTAGG-GGCCA-CAG-----CAT---CA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      ACCTCCAGCAATGAGGAGGGGACGCAGTTCTGCAACATCACGGTGGCCGTCAGATCTCCCTCCATGAACG
980      990      1000      1010      1020      1030      1040

      580      590      600      610      620
inputs AAACC---TTAG-----AACTCAATGTAC-TGGTT-----CCTC-----CA---GCTCCTCCATC---CTG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TGGCCCTGTATGTGGGCATCGCGGTGGGCGTGGTTGCAGCCCTCATTATCATTGGCATCATCATCTACTG
1050      1060      1070      1080      1090      1100      1110

      630      640      650      660      670
inputs C---CGTCT-CCAGGGTGTG--C-----CCCATGTG---GGGGCAAACGTGACC---CTGAGCTGCCAGT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CTGCTGCTGCCGAGGGAAGGACGACAACACTGAAGACAAGGAGGATGCAAGGCCGAACCGGGAAGCCTAT
1120      1130      1140      1150      1160      1170      1180

      680      690      700      710
inputs -----CTCCAAGG-AG-TAAGCCCGCTGTCCAA-----TAC---CAGTGGG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GAGGAGCCACCAGAGCAGCTAAGAGAACCTTCCAGAGAGAGGGAGGAGGAGGATGACTACAGGCAAGAAG
1190      1200      1210      1220      1230      1240      1250

      720      730      740      750      760
inputs ATCGG-----CA---GCTTCCATCC---TTCCAG-ACCTTCTTTG-CA---CCAGCATTAGATGTCATCC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      AGCAGAGGAGCACTGGGCGTGAATCCCGGACCACCTCGACCAGTGACAGGCCAGCAGCAGAGGGCGGCG
1260      1270      1280      1290      1300      1310      1320

      770      780      790      800      810      820
inputs GTGGG-----TCTTTAAGCCTCA-CCAA---CCTTTCTGCTTCCATGGCTGGAGTCTA-TGT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GAGGAAGGGTTAGGGGTTCACTTCTCCCGCTTCTGGCCCTCCCTTCTCCTTTCTAAGCCCTGTCTCTCTGT
1330      1340      1350      1360      1370      1380      1390

      830      840      850      860      870
inputs CTGCAAGGCCCA--CAATGAGGTGGGCA---CTGCCC-AATGTAA--TGTG-----AC---GCTGG-----
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CCTTCCATCCAGACATTGATGGGGACATTTCTTCCCACTGTCAGCTGTGGGGAACATGGCTGGCCTGG
1400      1410      1420      1430      1440      1450      1460

      880      890      900      910      920      930
inputs -AAGTGAG-CACAGGCTCTGGAGCTGCAAGCTGTGTGTTGGGTACCCT---GGTTG-GACT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TAAGGGGGTCCCTGTGC-TGATCCCTGACCTCACTGTC-CTGTGAAGTAACCCCTCCTGGCTGTGACA
1470      1480      1490      1500      1510      1520      1530

      940      950      960      970      980

```

FIG. 24B

```

inputs GGGGTTGCTGGCTGGGC-----TGGTCCT--CTTGTACCACCGC-----CGG---GGCAAG-GC-
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CCTGGTGC GGCGCTGGCCCTCACTCAAGACCAGGCTGCAGCCTCCACTTCCTCGTAGTTGGCAGGAGCT
      1540      1550      1560      1570      1580      1590      1600

      990      1000      1010      1020
inputs CCTGGAGG---AGC-CAG-----CCAAT--GATATC---AAGGAGG--ATGCCAT-----
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CCTGGAAGCACAGCGCTGAGCATGGGGCGCTCCCACTCAGAACTCTCCAGGGAGGCGATGCCAGCCTTGG
      1610      1620      1630      1640      1650      1660      1670

      1030      1040      1050
inputs -----TGTCCTCCCGGA---CCCTGC-CCTGG-----C-CCAAGAG-----CTCAG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GGGGTGGGGGCTGTCTGCTCACCTGTGTGCCAGCACCTGGAGGGGACCAGGTGGAGGGTTTGCACTC
      1680      1690      1700      1710      1720      1730      1740

      1060      1070      1080      1090
inputs -ACACAATCTCCAAGAATG-----GGACCCT--TT-----CCTCTGT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CACACATCTTTCTTGAATGAATGAAAGAATAAGTGAGTATGCTTGGGCGCTGCATTGGCCTGGCCTCCAG
      1750      1760      1770      1780      1790      1800      1810

      1100      1110      1120
inputs CACC-----TCCGCACGAGCC---CT-CCGG-----CCA---CCC-C-----ATGGCC--C
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CTCCCACTCCCTTTCCAACCTCACTTCCCGTAGCTGCCAGTATGTTCCAAACCTCCTGGGAAGGCCACC
      1820      1830      1840      1850      1860      1870      1880

      1130      1140      1150      1160      1170
inputs TCCCAGGCCTGGTGCATTGACCC-----CCACGCCCAGTCTATC-CAGCCAGGC-----
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TCCCACCTCTGTGCACAGGCCCTGGGGAGCTTTGCCACACACTTTCATCTCTGCCTGTCAATATCG
      1890      1900      1910      1920      1930      1940      1950

      1180      1190      1200      1210      1220      1230
inputs --CCTGCCCTCACCAAGACATGCCCACGACAGATGGGG--CCC--ACCCTCAACCAATATCCCCATCCC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TACCTGTCC-CTCCAGGCCATCTCAAATCACAAGGATTTCTCTAACCCTATCCTAATTGTCCACATACG
      1960      1970      1980      1990      2000      2010      2020

      1240      1250      1260      1270      1280
inputs TGGTGG-----GGTTT--TTTCCTTTGGCTT---TGAGCCGCATGG---GT--GCTGNGC-----
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TGGAAACAATCCTGTTACTCTGTCCACGTCCAATCATGGGCCACAAGGCACAGTCTTCTGAGCGAGTGC
      2030      2040      2050      2060      2070      2080      2090

      1290      1300      1310      1320      1330
inputs ----CTGTGATGGNGC--CTGC-CCA-GAGTCAAG--CTGGCTCTC-TGG--TATGATGACCC-----C
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TCTCACTGTATTAGAGCGCCAGCTCCTTGGGGCAGGGCCTGGGCCTCATGGCTTTTGCTTTCCCTGAAGC
      2100      2110      2120      2130      2140      2150      2160

      1340      1350      1360      1370      1380
inputs AC-----CACTCAT---TGG---CTAAAG--GATTTGGGGTCTCTCCTTCCTATAAGGGT---
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CCTAGTAGCTGGCGCCCATCCTAGTGGGCACCTTAAGCTTAATTGGGGAAACTGCTTTGATTGGTTGTGCC
      2170      2180      2190      2200      2210      2220      2230

      1390      1400      1410      1420      1430
inputs --CAC--CTCTAG-CAC----AGA-GGCCTGAGTCATGGGAAAGAGTCACACTCCTGACCC-----TTAG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TTCCCTTCTCTGGTCTCCTTGAGATGATCGTAGACACAGGGATGATTCCAC-CCAAACCCACGTTTCA
      2240      2250      2260      2270      2280      2290      2300

      1440      1450      1460      1470      1480      1490      1500
inputs TACTCTGCCCCACCTCTCTTTACTGTGGGAAACCA-TCTCAGTAAGACCTAAGTGTCCAGGAGACAGA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TTCAGTGAGTTAAACACGAATTGATTTAAAGTGAACACACACAAGGGAGCTTGCTTG-CAGATGGTCTGA
      2310      2320      2330      2340      2350      2360      2370

```

FIG. 24C

```

      1510      1520      1530      1540      1550      1560
inputs AG----GAGAAGAGGAAGT-----GGATCTGGAATTGGGAGGAGCCTCCACCCACCCCTGACTCCTC
      .      .:.: .:~:~:~: .:~:~:~: .:~:~:~: .:~:~:~: .:~:~:~: .:~:~:~:
      GTTCTTGTGTCCTGGTAATTCCTCTCCAGGCCAGAATAATTGGCATGTCTCCTCAACCCACATGGGGTTC
      2380      2390      2400      2410      2420      2430      2440

      1570      1580      1590      1600      1610      1620
inputs CTTATGAAGCCAGCTGCTGAAATTAGCTACTCA--CCAAG---AG---TGAGGGGCA-GAGACTTC----
      :. :. :. :.~:~:~: :.~:~:~: .:~:~:~: .:~:~:~: .:~:~:~: .:~:~:~:
      CTGGTTGTTCTGTCATCCCGATACCTCAGCCCTGGCCCTGCCAGCCCATTTGGGCTCTGGTTTTCTGGT
      2450      2460      2470      2480      2490      2500      2510

      1630      1640      1650      1660      1670
inputs ----CAGTCACTGAGTC--TCCCA-GGCCCCCTT-----GATCTGTACCCACCCCTATCTAACAC
      :.~:~:~: :.~:~:~: :.~:~:~: .:~:~:~: .:~:~:~: .:~:~:~: .:~:~:~:
      GGGGCTGTC-CTGCTGCCCTCCCACAGCCTCCTTCTGTTTGTGAGCATTCTTCTACTCTTGAGAGCTC
      2520      2530      2540      2550      2560      2570      2580

      1680      1690      1700      1710      1720      1730
inputs ---CACCCTT--GGCTCCCA----CTCCAGCTCCCTGTATTGATATAACCTGTCAG--GCTGGCTTGGTT
      :. :. :. :.~:~:~: .:~:~:~: .:~:~:~: .:~:~:~: .:~:~:~: .:~:~:~:
      AGGCAGCGTTAGGGCTGCTTAGGTCTCATGGACCAGTGGCTGGTCTCACCCAACTGCAGTTTACTATTGC
      2590      2600      2610      2620      2630      2640      2650

      1740      1750      1760      1770      1780      1790
inputs AGGTTTTACTGGG-GCAGAGGATAGGGAATC-----TCTTATTAAACTAAC-ATGAAATATGTGTTGT
      .. :.~:~:~:~:~:~: :.~:~:~:~:~:~: .:~:~:~:~:~:~: .:~:~:~:~:~:~:
      TATCTTTTCTGGATGATCAGAAAAATAATTCCATAAATCTATTGTCTACTTGCGATTTTTTAAAAAATGT
      2660      2670      2680      2690      2700      2710      2720

      1800      1810      1820      1830      1840      1850      1860
inputs TTTCATTTGCAAATTTAAATAAAG--ATACATAATGTTTGTATGAGATAAGAAAAAAAAAAAAAGGG
      :.~:~:~: .:~:~:~:~:~:~: .:~:~:~:~:~:~: .:~:~:~:~:~:~: .:~:~:~:~:~:~:
      ATATTTTATATATATTGTTAAATCCTTTGCTTCAT-TCCAAATGCTTTCAGTAATAATAAATTTGTGGG
      2730      2740      2750      2760      2770      2780      2790

inputs CGGCCGC
      :.
      TGG----

```

FIG. 24D

ALIGN calculates a global alignment of two sequences  
 version 2.0uPlease cite: Myers and Miller, CABIOS (1989)  
 > mT258 a.a. 394 aa vs.  
 > SwissProt Q99795 - (untitled) 319 aa  
 scoring matrix: pam120.mat, gap penalties: -12/-4  
 23.0% identity; Global alignment score: -149

```

      10      20      30      40      50      60      70
inputs MILQAGTPETSLLRVLFGLSTLAAFSRAQMELHVPPGLNKLEAVEGEEVVLPAWYTMAREESWSHPREV
      ..      .  ::      :: :      .  .  :      .  : :  ::      :  .  .
      MV-----GKMWPVLW---TLC AVRVTVD AISVETPQDVLRSQGKSVTL PCTYHTSTSSREGLIQWD
              10              20              30              40              50

      80      90      100      110      120      130      140
inputs PILIWFLEQEGKEPNQVLSYINGVMTNKP GTALVHSSRNVSRLGALQEGDSGTYRCSVNQNDEGKS
      . . . . . :      . . . . . :      . . . . . :      . . . . . :      . . . . . :
      KLLLTHTERVVIWPF SNKNYIHGELYKNR-VSISNNAEQSDASITIDQLTMADNGTYECSVSLMSDLE--
      60      70      80      90      100      110      120

      150      160      170      180      190      200      210
inputs IGHSIKSIELKVLVPPAPPSCSLQVVPYVGTNVTLNCKSPRSKPTAQYQWERLAPSSQVFFGPALDAVRG
      . . . : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      -GNTKSRVRLVLVPPSKPECGIEGETIIGNNIQLTCQSKEGSPTPQYSWKRYNINQE--QPLAQPASG
      130      140      150      160      170      180      190

      220      230      240      250      260      270
inputs -SLKLTNLSIAMSGVYVCKAQNRVGF AKCNVTLDMVTGS-KAAVVAGAVVGTFVGLVLIAGLVLLYQRRS
      . . : : : : : : : : : : : : : : : : : : : : : : : : : :
      QPVS LKNISTDTSGYYICTSSNEEGTQFCNITVAVRSPSMNVALYVGI AVGVVAALIIIG--IIIIYCCCC
      200      210      220      230      240      250      260

      280      290      300      310      320      330      340
inputs KTL EELANDIKEDAIAPRTL PWT KGSDTISKNGTLSSVTSARALRPPKAAPPRPGTFTPTPSVSSQALSS
      . . . . : : : : : : : : : : : : : : : : : : : : : :
      RGKDDNTED-KEDA-----RPNREAYEEPPEQ-----LRELRSR
      270              280              290

      350      360      370      380      390
inputs PRLPRVDEPPPPQAVSLTPGGVSSSALS RMGAVPVMVPAQSQAGSLV
      :      .  .  :      .  :      .  .  :      .  .  :
      EREE--EDDYRQEEQRSTGRES PDHLDQ-----
      300      310

```

FIG. 25

ALIGN calculates a global alignment of two sequences  
 version 2.0>Please cite: Myers and Miller, CABIOS (1989)  
 > mT258 n.a. 1846 aa vs.  
 > GenBank U79725 - Human A33 antigen precursor mR 2793 aa  
 scoring matrix: pam120.mat, gap penalties: -12/-4  
 40.0% identity; Global alignment score: 908

```

              10          20          30
inputs  GTCGACCC-----ACGC-GTC-----CG--GTGCAC--ATT-----C--GGGTTGCCGCC
      :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
      --CTACCCCTTTGTGAGCAGTCTAGGACTTTGTACACCTGTTAAGTAGGGAGAAGGCAGGGGAGGTGGCT
              10          20          30          40          50          60

              40          50          60          70
inputs  G-----CT-----CACC-CACAACACCTGTAGAC-----AC-CGTGTGT
      :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
      GGTTTAAGGGGAAGTTGAGGGAAGTAGGGAAGACTCCTCTTGGGACCTTTGGAGTAGGTGACACATGAGC
              70          80          90          100          110          120          130

              80          90          100          110
inputs  CCAAC-----TCTCC-----CTGAGTA-CTC-----CGGGCCA---AGG-AGGGCCATGAT
      :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
      CCAGCCCCAGCTCACCTGCCAATCCAGCTGAGGAGCTCACCTGCCAATCCAGCTGAGGCTGGGCAGAGGT
              140          150          160          170          180          190          200

              120          130          140          150          160
inputs  TCTTCAG-----GCTGGAACCCCGA---GACCAG-C---TGCTGCGGGTT-TGTTCTCTG
      :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
      GGGTGAGAAGAGGAAAATTGCAGGGACCTCCAGTTGGGCCAGGCCAGAAGCTGCTGTAGCTTTAACGAG
              210          220          230          240          250          260          270

              170          180          190          200          210
inputs  G-GACTGAGTACCCTTGCTGCCTTCTCCCGAGCTCAGATGGAGTT---GCA-----CGTGCCC--
      :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
      ACAGCTCAGA--CCTGTCTGGAGGCTGCCAGTGACAGGTTAGGTTTAGGGCAGAGAAGAAGCAAGACCAT
              280          290          300          310          320          330          340

              220          230          240          250
inputs  -----CC-----GGGC-CTCAA--CAAATTGGAAG-CGGTAGAGGGAGAAGAAGTG
      :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
      GGTGGGAAGATGTGGCCTGTGTGTGGACACTCTGTGCAGTCAGGGTGACCGTCGATGCCATCTCTGTG
              350          360          370          380          390          400          410

              260          270          280          290          300
inputs  GTGCTCCCCGCTG--GTACA-CGA--TGGCACGGGAGGAGT-----CGTGGTCC-----
      :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
      GAA-ACTCCGAGGACGTTCTTCGGGCTTCGCAGGGAAGAGTGTACCCCTGCCCTGCACCTACCACACT
              420          430          440          450          460          470          480

              310          320          330          340          350
inputs  --CACC-CC---CGGGAGGTGCCCATCCT---GATCTGTTCT-----TGGAACAAGAAGGGAAGGAA
      :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
      TCCACCTCCAGTCGAGAGGGACTTATTCAATGGGATAAGCTCCTCCTCACTCATACGGAAGGGTGGTCA
              490          500          510          520          530          540          550

              360          370          380          390          400
inputs  CCAAACAGGTGTGTCTTA-----CATTAAATGGAGTCATGACAAATAAACCTG---
      :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
      TCTGGCCGTTTTCAAACAAAACTACATCCATGGTGAGCTTTATAAGAATCGGTCAGCATATCCACAA
              560          570          580          590          600          610          620

              410          420          430          440          450
inputs  ---GAACAGCCCTGGTCCAC--TCT-----ATCT-----CTTCACGGAATGTGTC--CCTGCG-----
      :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
      TGCTGAGCAGTCGATGCCTCCATCACCATTGATCAGCTGACCATGGCTGACAAACGGCACCTACGAGTGT
              630          640          650          660          670          680          690

              460          470          480          490          500
inputs  -C-----CTGGGGCACTCCAGGAGGGAGACTCTGGGAC---TTACCGCTGTTCTGTCAATGTGC---
      :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :

```

FIG. 26A

**FIG. 26B**

```

inputs GCTCCC---CGGACCTTGCCTT-----GGACCAA-----AGGCTC-----AGACACAA
      .:..:   :.:.: :.: :   :.:.: :.: :   :.: :   :.: :   :.: :   :.: :
      ACACCTGGTGGGGCCTGGCCCTCACTCAAGACCAGGCTGCAGCCTCCACTTCCCTCGTAGTTGGCAGGA
      1540      1550      1560      1570      1580      1590      1600

      1030      1040      1050      1060      1070      1080
inputs TCTCCAAGAATGG-GACACTTT-CTTCGGTCACCTCAGCAC-GAGCTCT-----GCG--GCCACCCA
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
      GCTCCTGGAAGCACAGCGCTGAGCATGGGGCGCTCCCACTCAGAACTCTCCAGGGAGGCGATGCCAGCCT
      1610      1620      1630      1640      1650      1660      1670

      1090      1100      1110
inputs AGG-----CTGCTC--CT-----CCAAGACCTGG-----CAC-----ATTTACT
      .:..:   :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
      TGGGGGGTGGGGGCTGTCCTGCTCACCTGTGTGCCAGCACCTGGAGGGGCACCAGGTGGAGGGTTTGCA
      1680      1690      1700      1710      1720      1730      1740

      1120      1130      1140      1150
inputs C-CCACAC--C---C-----AGTGT-----CTCTAGCCAGGCCCTGTCTCT---CAC
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
      CTCCACACATCTTTCTTGAATGAATGAAAGAATAAGTGAGTATGCTTGGGCCCTGCATTGGCCTGGCCTC
      1750      1760      1770      1780      1790      1800      1810

      1160      1170      1180      1190      1200      1210
inputs CAAGACT---GCCCAGGGTAGATGAACC-CCCACCTCAGGCAGT--GTCCCTGACCC--CAGGTGGGGTT
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
      CAGTCCCACTCCCTTTCCAACCTCACTTCCCGTAGCTGCCAGTATGTTCCAAACCTCTCTGGGAAGGCC
      1820      1830      1840      1850      1860      1870      1880

      1220      1230      1240      1250
inputs TCTTC-----TTCTGCTCTGAGCC-----GCATGGG-----TGCTGTGCCTGT-GATG
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
      ACCTCCCACTCCTGCTGCACAGGCCCTGGGGAGCTTTTGGCCACACACTTTCCATCTCTGCCTGTCAATA
      1890      1900      1910      1920      1930      1940      1950

      1260      1270      1280      1290      1300      1310
inputs --GTGCCTG---CACAGAGTCAGGCT-GGGTCTCTTGTGTGA---TAGCCACAGGCACTCATTAGCTACAT
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
      TCGTACCTGTCCCTCCAGGCCATCTCAAATCACAAGGATTCTCTAACCCTATC-CTAATTGTCCACAT
      1960      1970      1980      1990      2000      2010      2020

      1320      1330      1340      1350      1360      1370
inputs -C-TGGTATCTGACCT--TTCTGTAAAGGTC-TCCTT--GTGGCACAGAGGACTCAATCTT--GGGAGGA
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
      ACGTGGAAACAATCCTGTTACTCTGTCCACGTCCAATCATGGGCCACAGGCACAGTCTTCTGAGCGAG
      2030      2040      2050      2060      2070      2080      2090

      1380      1390      1400      1410      1420
inputs TGCCACACA--TTCTAGACCTCCAG-TCCTTTG--CT---CCTA--CCTC---CTT---CTAT--TGT
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
      TGCTCTCACTGTATTAGAGCGCCAGCTCCTTGGGGCAGGGCCTGGGCCTCATGGCTTTTGTCTTCCCTGA
      2100      2110      2120      2130      2140      2150      2160

      1430      1440      1450
inputs TG---GAATACTGG-GCC--TC--AGTAAG-ACTAAA-----ATCTG-----
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
      AGCCCTAGTAGCTGGCGCCCATCCTAGTGGGCACCTTAAGCTTAATTGGGGAAGTCTTTGATTGGTTGT
      2170      2180      2190      2200      2210      2220      2230

      1460      1470      1480
inputs -----GGTCA-----AAGGACAAAAGGAGGAAAT-----GGACC-----
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
      GCCTTCCCTTCTCTGGTCTCCTTGAGATGATCGTAGACACAGGGATGATTCCCACCCAAACCCACGTATT
      2240      2250      2260      2270      2280      2290      2300

      1490      1500      1510      1520      1530
inputs -----TGAGGTAGG---GGGTTGGGAGTGAGGAGGCT-TCACTT-----CCTCCCTGCT---TCT-
      :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.: :.:
      CATTCACTGAGTTAAACACGAATTGATTAAAGTGAACACACACAAGGGAGCTTGCTTGACAGATGGTCTG
      2310      2320      2330      2340      2350      2360      2370

```

FIG. 26C

**FIG. 26D**

ALIGN calculates a global alignment of two sequences

version 2.0u Please cite: Myers and Miller, CABIOS (1989)

> ht258 n.a.

1869 aa vs.

> pecan n.a.

2557 aa

scoring matrix: paml20.mat, gap penalties: -12/-4

40.5% identity; Global alignment score: 1546

```

                                10          20
inputs  G---TC-----GACC-----CAC---GCGTNCNTC-CAGCGTN-----
      :  ::          ::::          :::   :: .  ::  :::: .
      GAATTCCGGGAGAAGTGACCAGAGCAATTTCTGCTTTTACAGGGCGGGTTTCTCAACGGTGACTTGTGG
          10          20          30          40          50          60          70

          30          40          50          60          70          80
inputs  -CGGAGCCGCC--CTGGG--TGTCAGCGGCTCGGCTCCCGCGCACGCT---CCGGC---CGTCGC-----
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GCAGTGCCTTCTGCTGAGCGAGTCAT-GGCCCCAAGGCAGAACTAACTGTGCCTGCAGTCTTCACTCTCA
          80          90          100          110          120          130

          90          100          110          120          130
inputs  ----GCAGCCTCGGCA--CCTGCAGGTCCG---TGCCTCCCG-----CGGCTGGCGCCCCCTGACTCCGTC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GGATGCAGCCGAGGTGGGCCCCAAGGGGCCACGATGTGGCTTGGAGTCTGCTGACCCTTCTG-CTCTGTT
      140          150          160          170          180          190          200

          140          150          160          170          180
inputs  CCGGCCAGGGAGGGCCATGATTTCCCT--CCCGG--GGCC-----CCTGGTGA-CCAAC-----T
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CAAGCCTTG-AGGGTCAAGAAACTCTTTCACAATCAACAGTGTGACATGAAGAGCCTGCCGGACTGGA
      210          220          230          240          250          260          270

          190          200          210          220          230
inputs  TGNTGCGGTTT---TTGTTCTTGGGGCTG-AGTGC--C-C-----TC-GCGCCCCC-CTCGCG---GGCC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CGGTGCAAAATGGGAAGAACCTGACCCTGCAGTGCTTCGCGGATGTCAGCACCACCTCTCACGTCAAGCC
      280          290          300          310          320          330          340

          240          250          260          270          280
inputs  -CAGCTGCAACTGC-----ACTTGC-----C-----CGCCAACCGGTTGCAGGCGGTG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TCAGCACCAGATGCTGTTCTATAAGGATGACGTGCTGTTTACAACTCTCCTCCATGAAGAGCACAGAG
      350          360          370          380          390          400          410

          290          300          310          320          330          340
inputs  GAGGAGGGGGA-----AAGT--GGTGCTTCAGCA-TGGTACACCT---TGCACAGGGAGGTGTCTTCATC
      .. : .. : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      AGTTATTTTATTCCTGAAGTCCGGATCTATGACTCAGGGACATATAAATGTACTGTGAT-TGTGAACAAC
      420          430          440          450          460          470          480

          350          360          370          380          390
inputs  CCAG-----CCA-TGGGAGGTGCC--CTTT--GTGATGTGGTTCTTCAAACAGAAAGAAAGGAGGATC
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

FIG. 27A

```

AAAGAGAAAACCACTGCAGAGTACCAGCTGTTGGTGGAGGAGTGCCAGTCCCAGGGTGACACTGGACA
490      500      510      520      530      540      550

400      410      420      430      440      450
inputs AGGTGTTGTCTACATCAATGGGGTCA-----CAACAAG-CAAACCTGGAGTAT-----CCTTGG-T
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      AGAAAGAGGCCATCCAAGGTGGGATCGTGAGGGTCAACTGTTCTGTCCCAGAGGAAAAGGCCCAATACA
560      570      580      590      600      610      620

460      470      480      490      500
inputs CTACTC-----CATGCCCTCCCGAACC--TGTCCCTGC-GGGTGGAGGG-----TCTC-----
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CTTCACAATTGAAAACTTGAAGTAAATGAAAAATGGTCAAGCTGAAAAGAGAGAAGAATTCTCGAGAC
630      640      650      660      670      680      690

510      520      530      540      550
inputs CAGGAGAAAG--ACTCTGG---CCCCTAC---AGCTGCTCCGTGAATGTGC-----AAGACAAACAA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CAGAATTTTGTGATACTGGAATTCCCCGTTGAGGAACAGGACCGCGTTTATCCTTCCGATGTCAAGCTA
700      710      720      730      740      750      760

560      570      580      590
inputs GG--CAAATCTAGGGGCCA---CAG-CATCAAAA---CCTTA-----GAACTCAATG-----
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      GGATCATTTCTGGGATCCATATGCAGACCTCAGAATCTACCAAGAGTGAAGTGGTCAACCGTGACGGAATC
770      780      790      800      810      820      830

600      610      620      630
inputs -TACT-----GGTTCCTC--CAGCTCCTCC-----ATCCTG-----C-CGTCTCCA--GGGTG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CTTCTCTACACCCAAGTTCACATCAGCCCCACCGGAATGATCATGGAAGGAGCTCAGCTCCACATTAAG
840      850      860      870      880      890      900

640      650      660      670      680      690
inputs TGCCCCATG-TGGGGGCAAACGTGACCCTG-AGCTGCCAG---TC-----TC-----CAAGGAGTAAG
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TGCACCATTCAGTGACTCACCTGGCCCAGGAGTTTCCAGAAATCATAATTCAGAAGGACAAGGCGATTG
910      920      930      940      950      960      970

700      710      720
inputs ---CCC-----GCTGT--C-----CAATACCAGTG-GGATC-----GGCAGCTT
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      TGGCCCCAACAGACATGGCAACAAGGCTGTGTACTCAGTCATGGCCATGGTGGAGCACAGTGGCAACTA
980      990      1000      1010      1020      1030      1040

730      740      750      760      770
inputs C-CATCCT-----TCCAGAC---TTTCTTTG--CACCAGCATTAGATGTCATCCGTG--GGTCTTTA
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
      CACGTGCAAAGTGGAGTCCAGCCGCATATCCAAGGTGAGCAGCATC-GTGGTCAACATAACAGAATATT
1050      1060      1070      1080      1090      1100      1110

780      790      800      810      820      830

```

FIG. 27B



**FIG. 27D**

**FIG. 27E**

## TANGO 281

Input file AthPb81d10.seq; Output File AthPb81d10.pat  
Sequence length 1812


GTCGACCCACGCGTCCGGCGGAGGTTGTGGCTGCACCGTGGTCCTGGGCTTGGTCCTGGGCTTG	M	R	L	3																
ATG	CGT	CTG	73																	
F	V	R	P	S	V	R	P	A	M	A	A	P	A	P	S	P	W	T	L	23
TTT	GTC	CGT	CCG	TCC	GTC	CGT	CCC	GCC	ATG	GCT	GCG	CCG	GCG	CCC	TCT	CCG	TGG	ACC	CTT	133
S	L	L	L	L	L	L	L	P	S	P	G	A	H	G	E	L	C	R	P	43
TCG	CTG	CTG	CTG	TTG	TTG	CTA	CTG	CCG	TCT	CCG	GGT	GCC	CAT	GGC	GAG	CTG	TGC	AGG	CCC	193
F	G	E	D	N	S	I	P	E	S	C	P	D	F	C	C	G	S	C	S	63
TTC	GGT	GAA	GAC	AAT	TCG	ATC	CCA	GAG	TCC	TGT	CCT	GAC	TTC	TGT	TGT	GGC	TCC	TGT	TCC	253
S	Q	Y	C	C	S	D	V	L	K	K	I	Q	W	N	E	E	M	C	P	83
AGC	CAA	TAC	TGC	TGC	TCT	GAC	GTG	CTG	AAG	AAA	ATC	CAG	TGG	AAT	GAG	GAA	ATG	TGC	CCT	313
E	P	E	S	S	R	F	S	A	H	P	E	T	P	E	Q	L	G	S	A	103
GAG	CCA	GAG	TCC	AGC	AGA	TTT	TCC	GCC	CAC	CCG	GAG	ACA	CCA	GAA	CAG	CTG	GGT	TCA	GCG	373
L	K	Y	Q	S	S	L	D	S	D	N	M	P	G	F	G	A	T	V	A	123
CTG	AAG	TAT	CAG	TCC	AGT	CTT	GAC	AGT	GAC	AAC	ATG	CCA	GGG	TTC	GGA	GCG	ACC	GTG	GCC	433
I	G	L	T	V	F	V	V	F	I	A	T	I	I	V	C	F	T	C	S	143
ATC	GGC	CTG	ACC	GTC	TTC	GTG	GTG	TTT	ATC	GCT	ACC	ATC	ATT	GTG	TGC	TTT	ACC	TGC	TCC	493
C	C	C	L	Y	K	M	C	C	R	P	R	P	V	V	S	N	T	T	T	163
TGC	TGC	TGT	CTA	TAT	AAG	ATG	TGC	TGC	CGC	CCA	CGA	CCT	GTC	GTG	TCC	AAC	ACC	ACA	ACT	553
T	T	V	V	H	T	A	Y	P	Q	P	Q	P	V	A	P	S	Y	P	G	183
ACT	ACC	GTG	GTT	CAC	ACC	GCT	TAC	CCT	CAG	CCT	CAA	CCT	GTG	GCC	CCC	AGC	TAT	CCT	GGA	613
P	T	Y	Q	G	Y	H	P	M	P	P	Q	P	G	M	P	A	A	P	Y	203
CCA	ACA	TAC	CAG	GGC	TAC	CAT	CCC	ATG	CCC	CCC	CAG	CCA	GGA	ATG	CCA	GCA	GCA	CCC	TAC	673
P	T	Q	Y	P	P	P	Y	L	A	Q	P	T	G	P	P	A	Y	H	E	223
CCA	ACG	CAG	TAC	CCT	CCA	CCC	TAC	CTG	GCC	CAG	CCC	ACA	GGG	CCA	CCA	GCC	TAT	CAT	GAG	733
T	L	A	G	A	S	Q	P	P	Y	N	P	A	Y	M	D	P	P	K	A	243
ACG	TTG	GCT	GGA	GCC	AGC	CAG	CCT	CCA	TAC	AAC	CCG	GCC	TAC	ATG	GAT	CCC	CCA	AAG	GCA	793
V	P	*	246																	
GTT	CCC	TGA	802																	

GCCTGCCCCCAGCCTCTTTGGCTAACATTTGATTATGTCATGTGTGTGTGAGTGCTATGCAGAGTTCTTTACTGCTGTC	881
TGTGGTGCCTGTGCTTGTCTAGACATGTGGCTTCCTCTGCTGATGACCAGGTAGGCACAAATCTTACCAGTGCTGGTT	960
GGGACCAATCTGTTTTCTTCCTCACTTGAAATTGTAATTTCTGAAATTTCAAGTAAATTAAAAACAATAGGGTAGGAGG	1039
TATTTCCCGCTTCACCCCAAGGTGACCAGCCATAGCCTGCCACACATAGGAGAGCAAGCTTTTTGTGGGTCCATGTCCT	1118
GCTTTGGGGAGTAGCCAGCTAGCTGCTGCTATGGGTTTATTTCCAGGGCTTGGCTGCATTTAGCTGGACAGAGAACAAG	1197
GGGCCTCAGTGGCAGTGGGTGAGTACTGATGTCAGAGCACACTAGGCAGAGAGCCCCGTCCTCCATCAGCTGTCT	1276
GTCTGGACGGTCCCACTGTCTTTCTGGGACTATGTAGAGGGCCACATGTATTCACTATTCAGGCTCCAGTGGCTTCCA	1355
GGCCAGGGGCTCTGTCTACTACACACTCTGGTTTCTCCCTACAGTGTCTTTTACGATTAGCCAAACATATTGCCTGT	1434
TTTTTGTATCCAGATGTGTGATAATTGGTGAGGTTGAAATCCTTGGTTCCTGGAGAACAGGAAACCTGACCTCTGACAG	1513

FIG. 28A

TCCGTTTCCCTTGACACCAGCTTCATAGAATACCTGACTCCTGTACTACAGTCCAGTTTGTTCAGTAGCAGGGACACC 1592  
AGGGCCAGGGGTTATCTGGACCAAGGGTGGGGGTGGAGAGCCTGGATGGTAGCTCTGGACCAGATGTGAATGCCTCCAT 1671  
ATTCCCTGTTGGTTCCTGTTTCACTGGCTGTTTTAGTTTTGTGTTAATTGGTGTTCCTGAGCATTCAAACCTCCGCACCC 1750  
TCGTTTATAATAAATGAATATTTGGAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1812

**FIG. 28B**



>hT281  
MRLFVRPSVRPAMAAPAPSPWTL SLLLLLLLPSPGAHGE LCRPFGEDNSIPESCPDFCCG  
SCSSQYCCSDVLKKIQWNEEMCPEPESSRFS AHPETPEQLGSALKYQSSLDSDNMPGFGA  
TVAIGLTVFVFIATIIVCF TCSCCCLYKMCCRPRPVVSNTTTT VVHTAYPQPQPVAPS  
YPGPTYQGYHPMP PQGMPAAPYPTQYPPPYLAQPTGPPAYHETLAGASQPPYNPAYMDP  
PKAVP

**FIG. 29**

Alignments of top-scoring domains:

PSBH: domain 1 of 1, from 97 to 146: score 5.5, E = 8.5

```

      *->ktalgeLkPlnseyGKvaPgWGttplmgvfmalfavFLliileiYn
            +lg+ Lk   s      +Pg+G t+ +g  +++f+vF+ i+  +
ht281    97    PEQLGSALKYQSSLDSDNMPGFGATVAIG--LTVFVVFIATIIVCFT 141
                                     ssvll<-*
                                     s
ht281    142 CCCCC . 146

```

**FIG. 30**

Input file T281Atmea49d3; Output File T281Atmea49d3.pat  
Sequence length 1858

```

3TCGACCCACGCGTCCGCGCGGAGGTTGCGGCGGCACCGTGGTCTTGGGCTTGGTCCGTCTGTTCGTCCGTCCGTTGGT 79
      M  A  A  P  A  P  S  L  W  T  L  L  L  L  L  L  L  L  17
TGTCCTCCGCC ATG GCT GCG CCG GCG CCC TCT CTG TGG ACC CTA TTG CTG CTG CTG TTG CTG 140
      L  P  P  P  P  G  A  H  G  E  L  C  R  P  F  G  E  D  N  S  37
TG CCG CCG CCT CCG GGT GCC CAT GGT GAG CTG TGC AGG CCC TTT GGT GAA GAC AAT TCG 200
      I  P  V  F  C  P  D  F  C  C  G  S  C  S  N  Q  Y  C  C  S  57
TC CCA GTG TTC TGT CCT GAT TTC TGT TGT GGT TCC TGT TCC AAC CAA TAC TGC TGC TCG 260
      D  V  L  R  K  I  Q  W  N  E  E  M  C  P  E  P  E  S  S  R  77
AC GTG CTG AGG AAA ATC CAG TGG AAT GAG GAA ATG TGT CCT GAG CCA GAG TCC AGC AGA 320
      F  S  T  P  A  E  E  T  P  E  H  L  G  S  A  L  K  F  R  S  97
TT TCC ACC CCC GCG GAG GAG ACA CCC GAA CAT CTG GGT TCA GCG CTG AAA TTT CGA TCC 380
      S  F  D  S  D  P  M  S  G  F  G  A  T  V  A  I  G  V  T  I  117
GT TTT GAC AGT GAC CCT ATG TCA GGG TTC GGA GCG ACC GTC GCC ATT GGC GTG ACC ATC 440
      F  V  V  F  I  A  T  I  I  I  C  F  T  C  S  C  C  C  L  Y  137
TT GTG GTG TTT ATT GCC ACT ATC ATC ATC TGC TTC ACC TGC TCC TGC TGC TGT CTG TAT 500
      K  M  C  C  P  Q  R  P  V  V  T  N  T  T  T  T  T  V  V  H  157
AG ATG TGC TGC CCC CAA CGC CCT GTC GTG ACC AAC ACC ACA ACT ACT ACC GTG GTT CAT 560
      A  P  Y  P  Q  P  Q  P  Q  P  V  A  P  S  Y  P  G  P  T  Y  177
TC CCT TAC CCT CAG CCT CAA CCT CAA CCT GTG GCC CCC AGC TAT CCT GGA CCA ACA TAC 620
      D  G  Y  H  P  M  P  P  P  A  R  N  A  S  S  T  L  P  N  A  197
AG GGC TAC CAT CCC ATG CCC CCC CCA GCC AGG AAT GCC AGC AGC ACC CTA CCC AAC GCA 680
      P  T  T  L  P  G  P  A  H  R  A  A  T  L  P  *  214
A CCC ACC ACC CTA CCT GGC CCA GCC CAC AGG GCC GCC ACC CTA CCA TGA 731


CCTTGGCTGGAGCCAGCCAGCCTCCATACAACCCGACCTACATGGATTCCCTAAAGACAATTCCCTGAACCTGCCCC 810
GCCTCTTTGGCTGCCATTTATGTCGTGTGTGAGTGAGTGATACGCAGAGTTCTTTACTGCTGTCTGTGGTGTGTGTG 889
TTGTCTAGACATGTGGCTTCCTCTGCTGTTGACCAGGTAGGCGCAAGTCTTACCAGTGTGGGTGCGGACCAACCTGT 968
TCTTCCTCACTTGAAATTGTACTTTCTGAAATTTCAAGCAAATTA AAAACAATAAGGTAGGAGGTATTTCCCACGTC 1047
CCCAAGGTGACCAGCCATGGCCTGTCATACTTAGGAGAGCAAGCTTTTGGCGGTACAGAGCAGGCTTTGGGGGGTA 1126
CAGCTAGCTGCTGCTAGGCCTTTATTCCCAGGGTTTGGCTGCATTGGCAGTGAGGCAGGTGGCTGGGGGTGACACCA 1205
TGACAAGGGGACTCAGTGGCAGGGGGTACACCAGGCAGAACACCATACTCTCCATCAGCTGTCTGTCTGGATGT 1284

```

**FIG. 31A**

ACTGTCCTTCCCGGGGCTGTATAGAGGGCCACATGTGTTCACTATTCAGGCTCCACTGGGGGAATTTTCCTACCTTTG 1363  
TGGCTTGGCTCCTGCTCCCAGGCCAGGGACCTCGGTCTGTCTACTACACACTCTGGTTTCTCCCTGCACTGTCTTTTT 1442  
CTGTTAGCCAAACATTTTGCCTGTTTTCTGTCTCCAGATGTGTGATAATTGGTGTGAGGTTGAAATCCCTGGTTCCTG 1521  
AGGACAGACAACCTGACCTCCGACTGTCAGTTTCCCTTGACACCATCTTCATAGAAATACCTGACTCCTGTACCACAG 1600  
TCAGTTTGTCCCAGTAGCAGGGACACCAAGGCCAATGGGTTATCTGGACCAAAGGTGGGGTGGAGGGCCTAGATGGTA 1679  
TCCGGCCCAGATGTGAATACCTCCATATTCCCTGTTGGTTCCCTGTTTCACTGGCTGTTTTAGCTTTGTGTTGATTGG 1758  
TTTCTGAGCATTTCAGACTCCGCACCCTCATTTCTAATAAATGCAACATTGGAAAAAAAAAAAAAAAAAAAAAAAAA 1837  
AAAAAAAAAAGGGCGGCCGC 1858

**FIG. 31B**



•mT281  
MAAPAPSLWTLLLLLLLLPPPPGAHGE LCRPFGEDNSIPVFCPDFCCGSCSNQYCCSDVL  
RKIQWNEEMCPEPSSRFSTPAEETPEHLGSALKFRSSFDSDPMSGFGATVAIGVTIFVV  
FIATIIICFTCSCCC LYKMCCPQRPVVNTTTTTTVVHAPYPQPQPQPVAPSYPGPTYQGY  
HPMPPPARNASSTLPNAVPTTLPGPAHRAATLP

**FIG. 32**

ALIGN calculates a global alignment of two sequences

version 2.0uPlease cite: Myers and Miller, CABIOS (1989)

> hT281 a.a. 245 aa vs.

> mT281 a.a. 213 aa

scoring matrix: pam120.mat, gap penalties: -12/-4

66.5% identity; Global alignment score: 739

```

      10      20      30      40      50      60      70
inputs MRLFVRPSVRPAMAAPAPSPWTL SLLLLLLLSPGAH GELCRPFGEDNSIPESCPDFCCGSCSSQYCCSD
      :      :      :      :      :      :      :
M-----AAPAPSLWTL SLLLLLLLPPPPGAH GELCRPFGEDNSIPVFCPDFCCGSCSNQYCCSD
      10      20      30      40      50

      80      90      100      110      120      130
inputs VLKKIQWNEEMCPEPESSRFS AHPE-TPEQLGSALKYQSSLDSDNMPGFGATVAIGLTVFVVFIIIVC
      :      :      :      :      :      :
VLRKIQWNEEMCPEPESSRFS TPAEETPEHLGSALKFRSSFDSDPMSGFGATVAIGVTIFVVFIIIC
      60      70      80      90      100      110      120

      140      150      160      170      180      190      200
inputs FTCSCCCLYKMCCRPRPVVSNTTTT VVHTAYPQPQP--VAPSYPGPTYQGYHPMPQP GMPAAPYPTQY
      :      :      :      :      :      :
FTCSCCCLYKMCCPQRPVVTNTTTT VVHAPYPQPQPQPVAPSYPGPTYQGYHPMP-----PARN
      130      140      150      160      170      180

      210      220      230      240
inputs PPPYLAQPTGPPAYHETLAGASQPPYNPAYMDPPKAVP
      :      :      :      :
ASSTL--PNAVPT--TLPGPAHRA-----ATLP
      190      200      210

```

FIG. 33

## SEQUENCE LISTING

&lt;110&gt; Millennium Pharmaceuticals, Inc.

&lt;120&gt; SECRETED PROTEINS AND USES THEREOF

&lt;130&gt; 7853-210-228

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; 09/336,536

&lt;151&gt; 1999-06-18

&lt;160&gt; 198

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 1338

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

```

gtcgacccac gcggtccggga ctgggggtgac ggcagggcag gggggcgctg gccggggaga 60
agcgcggggg ctggagcacc accaactgga ggggtccggag tagcgagcgc cccgaaggag 120
gccatcgggg agccgggagg ggggactgag agaggacccc ggcgtccggg ctcccgggtgc 180
cagcgctatg aggccactcc tcgtcctgct gctcctgggc ctggcggccg gctcgccccc 240
actggacgac aacaagatcc ccagcctctg cccggggcac cccggccttc caggcacgcc 300
gggccaccat ggcagccagg gcttgccggg ccgcgatggc cgcgacggcc gcgacggcgc 360
gcccgggggt ccgggagaga aaggcgaggg cgggaggcgg gactgccggg acctcgaggg 420
gaccccgggc cgcgaggaga ggcgggaccc gcggggccca ccgggcctgc cggggagtgc 480
tcgggtgcct cgcgatccgc cttcagcgcc aagcgctccg agagccgggt gcctccgccg 540
tctgacgcac ccttgccctt cgaccgcgtg ctggtgaacg agcagggaca ttacgacgcc 600
gtcaccggca agttcacctg ccagggtgct ggggtctact acttcgccgt ccattgccacc 660
gtctaccggg ccagcctgca gtttgatctg gtgaagaatg gcgaatccat tgcctctttc 720
ttccagtttt tcgggggggtg gcccagcca gcctcgctct cggggggggc catggtgagg 780
ctggagccctg aggaccaagt gtgggtgcag gtgggtgtgg gtgactacat tggcatctat 840
gccagcatca agacagacag caccttctcc ggatttctgg tgtactccga ctggcacagc 900
tcccagttct ttgcttagtg cccactgcaa agtgagctca tgctctcact cctagaagga 960
gggtgtgagg ctgacaacct ggatcatccg gagggctggc cccctggaa tattgtgaat 1020
gactagggag gtggggtaga gcactctccg tctgtctgct ggcaaggaat gggaacagtg 1080
gctgtctgag atcaggtctg gcagcatggg gcagtggctg gatttctgcc caagaccaga 1140
ggagtgtgct gtgctggcaa gtgtaagtc cccagttgct ctggtccagg agcccacggg 1200
ggggtgctct cttcctgggc ctctgcttct ctggatcctc cccacccct cctgctcctg 1260
gggccggccc ttttctcaga gatcactcaa taaacctaa aaccctcaa aaaaaaaaaa 1320
aaaaaaaaag gcggccgc                                     1338

```

&lt;210&gt; 2

&lt;211&gt; 728

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

atgaggccac tctcgtcct gctgctcctg ggccctggcgg ccggctcgcc cccactggac 60

```

```

gacaacaaga tccccagcct ctgcccgggg caccgccggc ttccaggcac gccggggccac 120
catggcagcc agggcttgcc gggccgcgat ggccgcgacg gccgcgacgg cgcgcccggg 180
gctccgggag agaaaggcga gggcgggagg cgggactgcc gggacctcga ggggaccccg 240
ggccgcgagg agaggcggga cccgcggggc ccaccggggc tgccggggag tgctcgggtg 300
ctccgcgacg cgccttcagc gccaaagcgt ccgagagccg ggtgcctccg ccgtctgacg 360
cacccttgcc cttcgaccgc gtgctggtga acgagcaggg acattacgac gccgtcaccg 420
gcaagttcac ctgccaggtg cctgggggtct actacttcgc cgtccatgcc accgtctacc 480
gggccagcct gcagtttgat ctggtgaaga atggcgaatc cattgcctct ttcttccagt 540
ttttcggggg gtggcccaag ccagcctcgc tctcgggggg ggccatggtg aggtcggagc 600
ctgaggacca agtgtgggtg caggtgggtg tgggtgacta cattggcatc tatgccagca 660
tcaagacaga cagcaccttc tccgatttc tgggtgtact cgactggcac agctccccag 720
tctttgct 728

```

&lt;210&gt; 3

&lt;211&gt; 243

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

```

Met Arg Pro Leu Leu Val Leu Leu Leu Leu Gly Leu Ala Ala Gly Ser
  1              5              10              15

Pro Pro Leu Asp Asp Asn Lys Ile Pro Ser Leu Cys Pro Gly His Pro
      20              25              30

Gly Leu Pro Gly Thr Pro Gly His His Gly Ser Gln Gly Leu Pro Gly
      35              40              45

Arg Asp Gly Arg Asp Gly Arg Asp Gly Ala Pro Gly Ala Pro Gly Glu
      50              55              60

Lys Gly Glu Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Asp Pro
      65              70              75              80

Gly Pro Arg Gly Glu Ala Gly Pro Ala Gly Pro Thr Gly Pro Ala Gly
      85              90              95

Glu Cys Ser Val Pro Pro Arg Ser Ala Phe Ser Ala Lys Arg Ser Glu
      100              105              110

Ser Arg Val Pro Pro Pro Ser Asp Ala Pro Leu Pro Phe Asp Arg Val
      115              120              125

Leu Val Asn Glu Gln Gly His Tyr Asp Ala Val Thr Gly Lys Phe Thr
      130              135              140

Cys Gln Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val Tyr
      145              150              155              160

Arg Ala Ser Leu Gln Phe Asp Leu Val Lys Asn Gly Glu Ser Ile Ala
      165              170              175

Ser Phe Phe Gln Phe Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu Ser
      180              185              190

Gly Gly Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val Gln
      195              200              205

```

Val Gly Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr Asp  
 210 215 220

Ser Thr Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser Pro  
 225 230 235 240

Val Phe Ala

<210> 4  
 <211> 228  
 <212> PRT  
 <213> Homo sapiens

<400> 4  
 Ser Pro Pro Leu Asp Asp Asn Lys Ile Pro Ser Leu Cys Pro Gly His  
 1 5 10 15

Pro Gly Leu Pro Gly Thr Pro Gly His His Gly Ser Gln Gly Leu Pro  
 20 25 30

Gly Arg Asp Gly Arg Asp Gly Arg Asp Gly Ala Pro Gly Ala Pro Gly  
 35 40 45

Glu Lys Gly Glu Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Asp  
 50 55 60

Pro Gly Pro Arg Gly Glu Ala Gly Pro Ala Gly Pro Thr Gly Pro Ala  
 65 70 75 80

Gly Glu Cys Ser Val Pro Pro Arg Ser Ala Phe Ser Ala Lys Arg Ser  
 85 90 95

Glu Ser Arg Val Pro Pro Pro Ser Asp Ala Pro Leu Pro Phe Asp Arg  
 100 105 110

Val Leu Val Asn Glu Gln Gly His Tyr Asp Ala Val Thr Gly Lys Phe  
 115 120 125

Thr Cys Gln Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val  
 130 135 140

Tyr Arg Ala Ser Leu Gln Phe Asp Leu Val Lys Asn Gly Glu Ser Ile  
 145 150 155 160

Ala Ser Phe Phe Gln Phe Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu  
 165 170 175

Ser Gly Gly Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val  
 180 185 190

Gln Val Gly Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr  
 195 200 205

Asp Ser Thr Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser  
 210 215 220

Pro Val Phe Ala  
225

<210> 5  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 5  
Met Arg Pro Leu Leu Val Leu Leu Leu Leu Gly Leu Ala Ala Gly  
1 5 10 15

<210> 6  
<211> 60  
<212> PRT  
<213> Homo sapiens

<400> 6  
Gly Thr Pro Gly His His Gly Ser Gln Gly Leu Pro Gly Arg Asp Gly  
1 5 10 15  
Arg Asp Gly Arg Asp Gly Ala Pro Gly Ala Pro Gly Glu Lys Gly Glu  
20 25 30  
Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Asp Pro Gly Pro Arg  
35 40 45  
Gly Glu Ala Gly Pro Ala Gly Pro Thr Gly Pro Ala  
50 55 60

<210> 7  
<211> 128  
<212> PRT  
<213> Homo sapiens

<400> 7  
Ala Phe Ser Ala Lys Arg Ser Glu Ser Arg Val Pro Pro Pro Ser Asp  
1 5 10 15  
Ala Pro Leu Pro Phe Asp Arg Val Leu Val Asn Glu Gln Gly His Tyr  
20 25 30  
Asp Ala Val Thr Gly Lys Phe Thr Cys Gln Val Pro Gly Val Tyr Tyr  
35 40 45  
Phe Ala Val His Ala Thr Val Tyr Arg Ala Ser Leu Gln Phe Asp Leu  
50 55 60  
Val Lys Asn Gly Glu Ser Ile Ala Ser Phe Phe Gln Phe Phe Gly Gly  
65 70 75 80  
Trp Pro Lys Pro Ala Ser Leu Ser Gly Gly Ala Met Val Arg Leu Glu  
85 90 95  
Pro Glu Asp Gln Val Trp Val Gln Val Gly Val Gly Asp Tyr Ile Gly

100

105

110

Ile Tyr Ala Ser Ile Lys Thr Asp Ser Thr Phe Ser Gly Phe Leu Val  
 115 120 125

&lt;210&gt; 8

&lt;211&gt; 1263

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 8

```

gtcgacccac gcggtccgcgc tgtgaagcca gcaaggagca accagaagct aggagtcagt 60
cagcaaggac aggggctgcc tgcctacaga ctacaagaga ggttcctgga gtctgagcct 120
ccggggtcac caccatgagg ccacttcttg cccttctgct tctgggtctg gtgtcaggct 180
ctcctcctct ggacgacaac aagatcccca gcctgtgtcc cgggcagccc ggccttccag 240
gcacaccagg tcacatggc agccaaggcc tgcttgccg tgacggccgt gatggccgcg 300
acggtgcacc cggagctccg ggagagaaag gcgagggcgg gagaccgga ctacctggcc 360
cacgtgggga gcccgggccc cgtggagagg cagggcccat gggggctatc gggcctgcgg 420
gggagtgtct ggtaccccca cgatcagcct tcagtgccaa gcgatccgag agccgggtac 480
ctccgccagc cgacacaccc ctacctttcg accgtgtgct gctaaatgag cagggccatt 540
acgacccccc tactggcaag ttcacctgcc aagtgcctgg cgtctactac tttgctgtgc 600
acgccactgt ctaccgggcc agcttgagct ttgatcttgt caaaaacggg cagtccatcg 660
cctctttctt ccagtatttt ggggggtggc ccaagccagc ctgctctca ggggggtgca 720
tggttaaggct agaacctgag gaccaggtgt ggggtgcagg gggcgtgggt gattacattg 780
gcatctatgc cagcatcaag acagacagta ccttctctgg atttctctgc tattctgact 840
ggcacagctc cccagtcttc gcttaaaaca cagtgaacct ggagctggca cttgtctctc 900
agtggagggt gtgacactaa cccgcgcagc gcataccagg agggctggcc ccctggaata 960
ttgtgaatga cttaggaaga gagggagcca cttccagtc cactgctggc aatgaatgga 1020
gacaggctgt ctgagggtcaa gacagcgtgg agcagtggct ggggtttctgc ccaggacttt 1080
agaatgcagt aggctggcag ctgtgggtcc tggcccagga ctccaagggt ggatgctcca 1140
ttcctagtc tgtgtccct ctaggtccct gactccatct ctgctgctcc cagggcaggc 1200
ctttttctca gaggtcactt aataaaccta aaatcctcaa aaaaaaaaaa aaagggcgcc 1260
cgc 1263

```

&lt;210&gt; 9

&lt;211&gt; 729

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 9

```

atgaggccac ttcttgccct tctgcttctg ggtctggtgt caggctctcc tcctctggac 60
gacaacaaga tccccagcct gtgtcccggg cagcccggcc ttccaggcac accaggtcac 120
catggcagcc aaggcctgcc tggccgtgac ggccgtgatg gccgcgacgg tgcacccgga 180
gctccgggag agaaaggcga gggcgggaga ccgggactac ctggcccacg tggggagccc 240
gggcccgtg gagaggcagg gcccatgggg gctatcgggc ctgcggggga gtgctcggtg 300
ccccacgat cagccttcag tgccaagcga tccgagagcc ggggtacctc gccagccgac 360
acaccctac ctttcgaccg tgtgctgcta aatgagcagg gccattacga cccactact 420
ggcaagttca cctgccaaagt gcctggcgtc tactactttg ctgtgcacgc cactgtctac 480
cgggccagct tgcagtttga tcttgtcaaa aacgggcagt ccatcgctc tttcttccag 540
tattttgggg ggtggcccaa gccagcctcg ctctcagggg gtgcgatggt aaggctagaa 600
cctgaggacc aggtgtgggt gcagggtggc gtgggtgatt acattggcat ctatgccagc 660
atcaagacag acagtacctt ctctggattt ctcgtctatt ctgactggca cagctcccca 720
gtcttcgct 729

```

&lt;210&gt; 10

&lt;211&gt; 243

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 10

Met Arg Pro Leu Leu Ala Leu Leu Leu Leu Gly Leu Val Ser Gly Ser  
 1 5 10 15  
 Pro Pro Leu Asp Asp Asn Lys Ile Pro Ser Leu Cys Pro Gly Gln Pro  
 20 25 30  
 Gly Leu Pro Gly Thr Pro Gly His His Gly Ser Gln Gly Leu Pro Gly  
 35 40 45  
 Arg Asp Gly Arg Asp Gly Arg Asp Gly Ala Pro Gly Ala Pro Gly Glu  
 50 55 60  
 Lys Gly Glu Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Glu Pro  
 65 70 75 80  
 Gly Pro Arg Gly Glu Ala Gly Pro Met Gly Ala Ile Gly Pro Ala Gly  
 85 90 95  
 Glu Cys Ser Val Pro Pro Arg Ser Ala Phe Ser Ala Lys Arg Ser Glu  
 100 105 110  
 Ser Arg Val Pro Pro Pro Ala Asp Thr Pro Leu Pro Phe Asp Arg Val  
 115 120 125  
 Leu Leu Asn Glu Gln Gly His Tyr Asp Pro Thr Thr Gly Lys Phe Thr  
 130 135 140  
 Cys Gln Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val Tyr  
 145 150 155 160  
 Arg Ala Ser Leu Gln Phe Asp Leu Val Lys Asn Gly Gln Ser Ile Ala  
 165 170 175  
 Ser Phe Phe Gln Tyr Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu Ser  
 180 185 190  
 Gly Gly Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val Gln  
 195 200 205  
 Val Gly Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr Asp  
 210 215 220  
 Ser Thr Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser Pro  
 225 230 235 240  
 Val Phe Ala

&lt;210&gt; 11

&lt;211&gt; 228

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 11

Ser Pro Pro Leu Asp Asp Asn Lys Ile Pro Ser Leu Cys Pro Gly Gln  
 1 5 10 15

Pro Gly Leu Pro Gly Thr Pro Gly His His Gly Ser Gln Gly Leu Pro  
                   20                                  25                                  30  
 Gly Arg Asp Gly Arg Asp Gly Arg Asp Gly Ala Pro Gly Ala Pro Gly  
                   35                                  40                                  45  
 Glu Lys Gly Glu Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Glu  
                   50                                  55                                  60  
 Pro Gly Pro Arg Gly Glu Ala Gly Pro Met Gly Ala Ile Gly Pro Ala  
                   65                                  70                                  75                                  80  
 Gly Glu Cys Ser Val Pro Pro Arg Ser Ala Phe Ser Ala Lys Arg Ser  
                                   85                                  90                                  95  
 Glu Ser Arg Val Pro Pro Pro Ala Asp Thr Pro Leu Pro Phe Asp Arg  
                                   100                                  105                                  110  
 Val Leu Leu Asn Glu Gln Gly His Tyr Asp Pro Thr Thr Gly Lys Phe  
                                   115                                  120                                  125  
 Thr Cys Gln Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val  
                                   130                                  135                                  140  
 Tyr Arg Ala Ser Leu Gln Phe Asp Leu Val Lys Asn Gly Gln Ser Ile  
                                   145                                  150                                  155                                  160  
 Ala Ser Phe Phe Gln Tyr Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu  
                                   165                                  170                                  175  
 Ser Gly Gly Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val  
                                   180                                  185                                  190  
 Gln Val Gly Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr  
                                   195                                  200                                  205  
 Asp Ser Thr Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser  
                                   210                                  215                                  220  
 Pro Val Phe Ala  
 225

<210> 12  
 <211> 15  
 <212> PRT  
 <213> Mus musculus

<400> 12  
 Met Arg Pro Leu Leu Ala Leu Leu Leu Leu Gly Leu Val Ser Gly  
           1                                  5                                  10                                  15

<210> 13  
 <211> 60  
 <212> PRT  
 <213> Mus musculus

&lt;400&gt; 13

Gly Thr Pro Gly His His Gly Ser Gln Gly Leu Pro Gly Arg Asp Gly  
 1 5 10 15  
 Arg Asp Gly Arg Asp Gly Ala Pro Gly Ala Pro Gly Glu Lys Gly Glu  
 20 25 30  
 Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Glu Pro Gly Pro Arg  
 35 40 45  
 Gly Glu Ala Gly Pro Met Gly Ala Ile Gly Pro Ala  
 50 55 60

&lt;210&gt; 14

&lt;211&gt; 128

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 14

Ala Phe Ser Ala Lys Arg Ser Glu Ser Arg Val Pro Pro Pro Ala Asp  
 1 5 10 15  
 Thr Pro Leu Pro Phe Asp Arg Val Leu Leu Asn Glu Gln Gly His Tyr  
 20 25 30  
 Asp Pro Thr Thr Gly Lys Phe Thr Cys Gln Val Pro Gly Val Tyr Tyr  
 35 40 45  
 Phe Ala Val His Ala Thr Val Tyr Arg Ala Ser Leu Gln Phe Asp Leu  
 50 55 60  
 Val Lys Asn Gly Gln Ser Ile Ala Ser Phe Phe Gln Tyr Phe Gly Gly  
 65 70 75 80  
 Trp Pro Lys Pro Ala Ser Leu Ser Gly Gly Ala Met Val Arg Leu Glu  
 85 90 95  
 Pro Glu Asp Gln Val Trp Val Gln Val Gly Val Gly Asp Tyr Ile Gly  
 100 105 110  
 Ile Tyr Ala Ser Ile Lys Thr Asp Ser Thr Phe Ser Gly Phe Leu Val  
 115 120 125

&lt;210&gt; 15

&lt;211&gt; 1831

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

gtcgaccac gcgtccgcgg acgcgtgggt gaggggaaga ggctgactgt acgttccttc 60  
 tactctggca ccactctcca ggctgccatg gggcccagca cccctctcct catcttggtc 120  
 cttttgtcat ggctcgggacc cctccaagga cagcagcacc accttggtga gtacatggaa 180  
 cgccgactag ctgctttaga ggaacggctg gccagtgcc aggaccagag tagtcggcat 240  
 gctgctgagc tgcgggactt caagaacaag atgctgccac tgctggaggt ggcagagaag 300  
 gagcgggagg cactcagaac tgaggccgac accatctccg ggagagtga tcgtctggag 360  
 cgggaggtag actatctgga gaccagaac ccagctctgc cctgtgtaga gtttgatgag 420

```

aaggtgactg gaggccctgg gaccaaaggc aaggggaagaa ggaatgagaa gtacgatatg 480
gtgacagact gtggctacac aatctctcaa gtgagatcaa tgaagattct gaagcgattt 540
ggtggcccag ctggtctatg gaccaaggat ccactggggc aaacagagaa gatctacgtg 600
ttagatggga cacagaatga cacagccttt gtcttcccaa ggctgcgtga cttcaccctt 660
gccatggctg cccggaaagc ttcccagctc cgggtgccct tcccctgggt aggcacaggg 720
cagctggtat atgggtggctt tctttatttt gctcggaggc ctcctggaag acctgggtga 780
ggtggtgaga tggagaacac tttgcagcta atcaaattcc acctggcaaa ccgaacagtg 840
gtggacagct cagtattccc agcagagggg ctgatcccc cctacggctt gacagcagac 900
acctacatcg acctggcagc tgatgaggaa ggtctttggg ctgtctatgc caccggggag 960
gatgacaggc acttgtgtct ggccaagtta gatccacaga cactggacac agagcagcag 1020
tggaacacac catgtcccag agagaatgct gaggtgcct ttgtcatctg tgggaccctc 1080
tatgtcgtct ataacacccg tcctgccagt cgggcccgc tccagtgtc ctttgatgcc 1140
agcggcacc tgaacctga acgggcagca ctcccttatt tccccgcag atatgggtgc 1200
catgccagcc tccgtataaa cccccgagaa cgccagctct atgcctggga tgatggctac 1260
cagattgtct ataagctgga gatgaggaa aaagaggagg aggtttgagg agctagcctt 1320
gttttttgca tctttctcac tcccatacat ttatattata tccccactaa atttcttgtt 1380
cctcattctt caaatgtggg ccagttgtgg ctcaaactct ctatatTTTT agccaatggc 1440
aatcaaattc tttcagctcc tttgtttcat acggaactcc agatcctgag taatcctttt 1500
agagcccga gagtcaaac cctcaatgtt ccctcctgct ctctgcccc atgtcaacaa 1560
atttcaggct aaggatgcc cagaccagc gctctaacct tgtatgcggg caggcccagg 1620
gagcaggcag cagtgttctt cccctcagag tgacttgggg agggagaaat agggagagac 1680
gtccagctct gtctctctt cctcactcct cccttcagtg tccctgaggaa caggactttc 1740
tccacattgt tttgtattgc aacattttgc attaaaagga aaatccactg ctaaaaaaaaa 1800
aaaaaaaaa aaaaaaaaaa agggcgggcg c 1831

```

&lt;210&gt; 16

&lt;211&gt; 1218

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

```

atggggccca gcacccctct cctcatcttg ttccttttgt catggtcggg acccctccaa 60
ggacagcagc accaccttgt ggagtacatg gaacgccgac tagctgcttt agaggaacgg 120
ctggcccagt gccaggacca gagtagtcgg catgctgctg agctgcggga cttcaagaac 180
aagatgctgc cactgctgga ggtggcagag aaggagcggg aggcactcag aactgaggcc 240
gacaccatct cggggagagt ggatcgtctg gagcgggagg tagactatct ggagaccгаа 300
aaccagctc tgccctgtgt agagtttgat gagaaggaga ctggaggccc tgggaccaaа 360
ggcaagggaa gaaggaatga gaagtacgat atggtgacag actgtggcta cacaatctct 420
caagtgaat caatgaagat tctgaagcga tttgggtggc cagctggtct atggaccaag 480
gatccactgg ggcaaacaga gaagatctac gtgttagatg ggacacagaa tgacacagcc 540
tttgccttcc caaggctgcg tgacttcacc cttgccatgg ctgcccggaa agcttcccga 600
gtccgggtgc ccttccccct ggtaggcaca gggcagctgg tatatggtgg ctttctttat 660
tttgctcggg ggccctcctg aagacctggt ggaggtggtg agatggagaa cactttgcag 720
ctaatacaat tccacctggc aaaccgaaca gtggtggaca gctcagtatt cccagcagag 780
gggctgatcc cccctacagg cttgacagca gacacctaca tgcacctggc agctgatgag 840
gaaggtcttt gggctgtcta tgccaccggg gaggatgaca ggcacttgtg tctggccaag 900
ttagatccac agacactgga cacagagcag cagtgggaca caccatgtcc cagagagaat 960
gctgaggctg cctttgtcat ctgtgggaac ctctatgtcg tctataacac ccgtcctgcc 1020
agtccggccc gcatccagtg ctcccttgat gccagcggca ccctgacccc tgaacgggca 1080
gcactccctt attttccccg cagatatggt gcccatgcca gcctccgcta taacccccga 1140
gaacgccagc tctatgcctg ggatgatggc taccagattg tctataagct ggagatgagg 1200
aagaaagagg aggaggtt 1218

```

&lt;210&gt; 17

&lt;211&gt; 406

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 17

Met Gly Pro Ser Thr Pro Leu Leu Ile Leu Phe Leu Leu Ser Trp Ser  
 1 5 10 15

Gly Pro Leu Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg  
 20 25 30

Arg Leu Ala Ala Leu Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser  
 35 40 45

Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro  
 50 55 60

Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Ala Leu Arg Thr Glu Ala  
 65 70 75 80

Asp Thr Ile Ser Gly Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr  
 85 90 95

Leu Glu Thr Gln Asn Pro Ala Leu Pro Cys Val Glu Phe Asp Glu Lys  
 100 105 110

Val Thr Gly Gly Pro Gly Thr Lys Gly Lys Gly Arg Arg Asn Glu Lys  
 115 120 125

Tyr Asp Met Val Thr Asp Cys Gly Tyr Thr Ile Ser Gln Val Arg Ser  
 130 135 140

Met Lys Ile Leu Lys Arg Phe Gly Gly Pro Ala Gly Leu Trp Thr Lys  
 145 150 155 160

Asp Pro Leu Gly Gln Thr Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln  
 165 170 175

Asn Asp Thr Ala Phe Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala  
 180 185 190

Met Ala Ala Arg Lys Ala Ser Arg Val Arg Val Pro Phe Pro Trp Val  
 195 200 205

Gly Thr Gly Gln Leu Val Tyr Gly Gly Phe Leu Tyr Phe Ala Arg Arg  
 210 215 220

Pro Pro Gly Arg Pro Gly Gly Gly Gly Glu Met Glu Asn Thr Leu Gln  
 225 230 235 240

Leu Ile Lys Phe His Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val  
 245 250 255

Phe Pro Ala Glu Gly Leu Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr  
 260 265 270

Tyr Ile Asp Leu Ala Ala Asp Glu Glu Gly Leu Trp Ala Val Tyr Ala  
 275 280 285

Thr Arg Glu Asp Asp Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln  
 290 295 300

Thr Leu Asp Thr Glu Gln Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn  
 305 310 315 320  
 Ala Glu Ala Ala Phe Val Ile Cys Gly Thr Leu Tyr Val Val Tyr Asn  
 325 330 335  
 Thr Arg Pro Ala Ser Arg Ala Arg Ile Gln Cys Ser Phe Asp Ala Ser  
 340 345 350  
 Gly Thr Leu Thr Pro Glu Arg Ala Ala Leu Pro Tyr Phe Pro Arg Arg  
 355 360 365  
 Tyr Gly Ala His Ala Ser Leu Arg Tyr Asn Pro Arg Glu Arg Gln Leu  
 370 375 380  
 Tyr Ala Trp Asp Asp Gly Tyr Gln Ile Val Tyr Lys Leu Glu Met Arg  
 385 390 395 400  
 Lys Lys Glu Glu Glu Val  
 405

<210> 18  
 <211> 385  
 <212> PRT  
 <213> Homo sapiens

<400> 18  
 Gln Gln His His Leu Val Glu Tyr Met Glu Arg Arg Leu Ala Ala Leu  
 1 5 10 15  
 Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser Ser Arg His Ala Ala  
 20 25 30  
 Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro Leu Leu Glu Val Ala  
 35 40 45  
 Glu Lys Glu Arg Glu Ala Leu Arg Thr Glu Ala Asp Thr Ile Ser Gly  
 50 55 60  
 Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr Leu Glu Thr Gln Asn  
 65 70 75 80  
 Pro Ala Leu Pro Cys Val Glu Phe Asp Glu Lys Val Thr Gly Gly Pro  
 85 90 95  
 Gly Thr Lys Gly Lys Gly Arg Arg Asn Glu Lys Tyr Asp Met Val Thr  
 100 105 110  
 Asp Cys Gly Tyr Thr Ile Ser Gln Val Arg Ser Met Lys Ile Leu Lys  
 115 120 125  
 Arg Phe Gly Gly Pro Ala Gly Leu Trp Thr Lys Asp Pro Leu Gly Gln  
 130 135 140  
 Thr Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln Asn Asp Thr Ala Phe  
 145 150 155 160

Val	Phe	Pro	Arg	Leu	Arg	Asp	Phe	Thr	Leu	Ala	Met	Ala	Ala	Arg	Lys	
				165					170					175		
Ala	Ser	Arg	Val	Arg	Val	Pro	Phe	Pro	Trp	Val	Gly	Thr	Gly	Gln	Leu	
				180					185					190		
Val	Tyr	Gly	Gly	Phe	Leu	Tyr	Phe	Ala	Arg	Arg	Pro	Pro	Gly	Arg	Pro	
				195					200					205		
Gly	Gly	Gly	Gly	Glu	Met	Glu	Asn	Thr	Leu	Gln	Leu	Ile	Lys	Phe	His	
				210					215					220		
Leu	Ala	Asn	Arg	Thr	Val	Val	Asp	Ser	Ser	Val	Phe	Pro	Ala	Glu	Gly	
				225					230					235		
Leu	Ile	Pro	Pro	Tyr	Gly	Leu	Thr	Ala	Asp	Thr	Tyr	Ile	Asp	Leu	Ala	
				245					250					255		
Ala	Asp	Glu	Glu	Gly	Leu	Trp	Ala	Val	Tyr	Ala	Thr	Arg	Glu	Asp	Asp	
				260					265					270		
Arg	His	Leu	Cys	Leu	Ala	Lys	Leu	Asp	Pro	Gln	Thr	Leu	Asp	Thr	Glu	
				275					280					285		
Gln	Gln	Trp	Asp	Thr	Pro	Cys	Pro	Arg	Glu	Asn	Ala	Glu	Ala	Ala	Phe	
				290					295					300		
Val	Ile	Cys	Gly	Thr	Leu	Tyr	Val	Val	Tyr	Asn	Thr	Arg	Pro	Ala	Ser	
				305					310					315		
Arg	Ala	Arg	Ile	Gln	Cys	Ser	Phe	Asp	Ala	Ser	Gly	Thr	Leu	Thr	Pro	
				325					330					335		
Glu	Arg	Ala	Ala	Leu	Pro	Tyr	Phe	Pro	Arg	Arg	Tyr	Gly	Ala	His	Ala	
				340					345					350		
Ser	Leu	Arg	Tyr	Asn	Pro	Arg	Glu	Arg	Gln	Leu	Tyr	Ala	Trp	Asp	Asp	
				355					360					365		
Gly	Tyr	Gln	Ile	Val	Tyr	Lys	Leu	Glu	Met	Arg	Lys	Lys	Glu	Glu	Glu	
				370					375					380		
Val																
385																

```
<210> 19
<211> 21
<212> PRT
<213> Homo sapiens
```

```
<400> 19
Met Gly Pro Ser Thr Pro Leu Leu Ile Leu Phe Leu Leu Ser Trp Ser
  1                               5          10          15
Gly Pro Leu Gln Gly
          20
```

<210> 20  
 <211> 244  
 <212> PRT  
 <213> Homo sapiens

<400> 20

```

Met Leu Leu Leu Gly Ala Val Leu Leu Leu Leu Ala Leu Pro Gly His
  1           5           10           15

Asp Gln Glu Thr Thr Thr Gln Gly Pro Gly Val Leu Leu Pro Leu Pro
          20           25           30

Lys Gly Ala Cys Thr Gly Trp Met Ala Gly Ile Pro Gly His Pro Gly
      35           40           45

His Asn Gly Ala Pro Gly Arg Asp Gly Arg Asp Gly Thr Pro Gly Glu
      50           55           60

Lys Gly Glu Lys Gly Asp Pro Gly Leu Ile Gly Pro Lys Gly Asp Ile
      65           70           75           80

Gly Glu Thr Gly Val Pro Gly Ala Glu Gly Pro Arg Gly Phe Pro Gly
          85           90           95

Ile Gln Gly Arg Lys Gly Glu Pro Gly Glu Gly Ala Tyr Val Tyr Arg
      100           105           110

Ser Ala Phe Ser Val Gly Leu Glu Thr Tyr Val Thr Ile Pro Asn Met
      115           120           125

Pro Ile Arg Phe Thr Lys Ile Phe Tyr Asn Gln Gln Asn His Tyr Asp
      130           135           140

Gly Ser Thr Gly Lys Phe His Cys Asn Ile Pro Gly Leu Tyr Tyr Phe
      145           150           155           160

Ala Tyr His Ile Thr Val Tyr Met Lys Asp Val Lys Val Ser Leu Phe
          165           170           175

Lys Lys Asp Lys Ala Met Leu Phe Thr Tyr Asp Gln Tyr Gln Glu Asn
      180           185           190

Asn Val Asp Gln Ala Ser Gly Ser Val Leu Leu His Leu Glu Val Gly
      195           200           205

Asp Gln Val Trp Leu Gln Val Tyr Gly Glu Gly Glu Arg Asn Gly Leu
      210           215           220

Tyr Ala Asp Asn Asp Asn Asp Ser Thr Phe Thr Gly Phe Leu Leu Tyr
      225           230           235           240

His Asp Thr Asn
```

<210> 21  
 <211> 1721  
 <212> DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 21

```

gtcgacccac gcgtccgact taaggctgcc atggggccca gtgctcctct gctgctcctc 60
ttctttttgt catggacggg accccttcag ggacagcagc accaccttgt ggagtacatg 120
gaacgccgac tagctgcctt agaggaacgg ctggcccaat gccaggatca gagtagtcgg 180
catgctgccg agcttcggga cttcaaaaac aagatgttgc ctctcctgga ggtggcagag 240
aaggagcggg agaccctcag aactgaagca gactccatct caggaagagt ggaccgtctt 300
gaaagggagg tagactatct ggagacacag aaccagctt tgccctgtgt agagctggat 360
gagaaggtga ctggaggtcc tggagccaaa ggcaagggcc gaagaaatga gaaatacgat 420
atggtgacgg actgtagcta cacagtcgct cagggtgaggt caatgaagat cctgaagcgg 480
tttgggtggt cagttggcct atggaccaag gatccgctgg ggccagcaga gaagatctac 540
gtgttagacg gcaccagaa cgacacggct tttgtcttcc caaggctgcg tgacttcacc 600
cttgccatgg ctgcccggaa agcttcccga attcgggtgc ccttcccctg ggtaggcacg 660
gggcagctgg tgtacggtgg cttcctttat tatgctcgaa ggccctcctg aggacctgga 720
gggggtggtg aattggagaa cactctgcag ctgatcaaat ttcacttggc aaaccgaaca 780
gtggtggata gctcagtgtt ccctgcagag agcctgatac cccctacgg cctgacagca 840
gatacatata tcgacctggc agctgatgag gagggcctgt gggctgtcta tgccactcga 900
gatgatgaca ggcatttgtg tctagccaag ttagaccac agacacttga cacagagcag 960
cagtgggaca caccatgtcc cagagagaac gcagaggctg cgtttgtcat ctgtgggacc 1020
ctgtacgttg tctataacac ccgccctgcc agtagggctc gtattcagtg ttccttcgat 1080
gccagtggta ctctcgcccc tgaaagggca gcactctcct attttccacg ccgatatggt 1140
gcccagcca gccttcgcta taacccccgt gagcgccagc tgtatgcctg ggatgatggc 1200
taccagattg tctacaaatt ggagatgaag aagaaggagg aggaagttta agcagctagc 1260
cttgtgctct tgattcttat gccagacat ttatattcct gtgagctctc ctgcagttca 1320
tccttcaaaa cgaaggccag tgggtggtagc tcatataccc taatttctaa aggacaacca 1380
aattctcaag cccctctgtt ttatgcagaa ctccagatcc tgggtagcat tttagaactg 1440
aacagcaaac aaacacccta aatcttctact cctgccttat gtccacaaag ttttagttcca 1500
aactcagagc cctgtccttt ggagagggtc aaccacagac agcaggcgac agcattcttg 1560
ccctcagtat gaccgaaggg agagaactca gagacaaagc tgccctccct cccttcccc 1620
tccagtgtag gggagaatgg ggctttcccc acatcacttt gtatggtaac agtttgcatt 1680
aaaaggaaaa cccacaaaaa aaaaaaaaaa agggcgggccg c 1721

```

&lt;210&gt; 22

&lt;211&gt; 1218

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 22

```

atggggccca gtgctcctct gctgctcctc ttctttttgt catggacggg accccttcag 60
ggacagcagc accaccttgt ggagtacatg gaacgccgac tagctgcctt agaggaacgg 120
ctggcccaat gccaggatca gagtagtcgg catgctgccg agcttcggga cttcaaaaac 180
aagatgttgc ctctcctgga ggtggcagag aaggagcggg agaccctcag aactgaagca 240
gactccatct caggaagagt ggaccgtctt gaaagggagg tagactatct ggagacacag 300
aaccagctt tgccctgtgt agagctggat gagaaggtga ctggaggtcc tggagccaaa 360
ggcaagggcc gaagaaatga gaaatacgat atggtgacgg actgtagcta cacagtcgct 420
cagggtgaggt caatgaagat cctgaagcgg tttgggtggt cagttggcct atggaccaag 480
gatccgctgg ggccagcaga gaagatctac gtgttagacg gcaccagaa cgacacggct 540
tttgtcttcc caaggctgcg tgacttcacc cttgccatgg ctgcccggaa agcttcccga 600
attcgggtgc ccttcccctg ggtaggcacg gggcagctgg tgtacggtgg cttcctttat 660
tatgctcgaa ggccctcctg aggacctgga ggggggtggt aattggagaa cactctgcag 720
ctgatcaaat ttcacttggc aaaccgaaca gtggtggata gctcagtgtt ccctgcagag 780
agcctgatac cccctacgg cctgacagca gatacatata tcgacctggc agctgatgag 840
gagggcctgt gggtgtgcta tgccactcga catgatgaca ggcatttgtg tctagccaag 900
ttagaccac agacacttga cacagagcag catgtggaca caccatgtcc cagagagaac 960
gcagaggctg cgtttgtcat ctgtgggacc ctgtacgttg tctataacac ccgccctgcc 1020
agtagggctc gtattcagtg ttccttcgat gccagtggta ctctcgcccc tgaaagggca 1080
gcactctcct attttccacg ccgatatggt gcccagcca gccttcgcta taacccccgt 1140

```

gagcgccagc tgtatgcctg ggatgatggc taccagattg tctacaaatt ggagatgaag 1200  
aagaaggagg aggaagtt 1218

<210> 23

<211> 406

<212> PRT

<213> Mus musculus

<400> 23

Met Gly Pro Ser Ala Pro Leu Leu Leu Leu Phe Phe Leu Ser Trp Thr  
1 5 10 15

Gly Pro Leu Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg  
20 25 30

Arg Leu Ala Ala Leu Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser  
35 40 45

Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro  
50 55 60

Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Thr Leu Arg Thr Glu Ala  
65 70 75 80

Asp Ser Ile Ser Gly Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr  
85 90 95

Leu Glu Thr Gln Asn Pro Ala Leu Pro Cys Val Glu Leu Asp Glu Lys  
100 105 110

Val Thr Gly Gly Pro Gly Ala Lys Gly Lys Gly Arg Arg Asn Glu Lys  
115 120 125

Tyr Asp Met Val Thr Asp Cys Ser Tyr Thr Val Ala Gln Val Arg Ser  
130 135 140

Met Lys Ile Leu Lys Arg Phe Gly Gly Ser Val Gly Leu Trp Thr Lys  
145 150 155 160

Asp Pro Leu Gly Pro Ala Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln  
165 170 175

Asn Asp Thr Ala Phe Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala  
180 185 190

Met Ala Ala Arg Lys Ala Ser Arg Ile Arg Val Pro Phe Pro Trp Val  
195 200 205

Gly Thr Gly Gln Leu Val Tyr Gly Gly Phe Leu Tyr Tyr Ala Arg Arg  
210 215 220

Pro Pro Gly Gly Pro Gly Gly Gly Gly Glu Leu Glu Asn Thr Leu Gln  
225 230 235 240

Leu Ile Lys Phe His Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val  
245 250 255

Phe Pro Ala Glu Ser Leu Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr

260 265 270  
 Tyr Ile Asp Leu Ala Ala Asp Glu Glu Gly Leu Trp Ala Val Tyr Ala  
 275 280 285  
 Thr Arg Asp Asp Asp Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln  
 290 295 300  
 Thr Leu Asp Thr Glu Gln Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn  
 305 310 315 320  
 Ala Glu Ala Ala Phe Val Ile Cys Gly Thr Leu Tyr Val Val Tyr Asn  
 325 330 335  
 Thr Arg Pro Ala Ser Arg Ala Arg Ile Gln Cys Ser Phe Asp Ala Ser  
 340 345 350  
 Gly Thr Leu Ala Pro Glu Arg Ala Ala Leu Ser Tyr Phe Pro Arg Arg  
 355 360 365  
 Tyr Gly Ala His Ala Ser Leu Arg Tyr Asn Pro Arg Glu Arg Gln Leu  
 370 375 380  
 Tyr Ala Trp Asp Asp Gly Tyr Gln Ile Val Tyr Lys Leu Glu Met Lys  
 385 390 395 400  
 Lys Lys Glu Glu Glu Val  
 405

<210> 24  
 <211> 385  
 <212> PRT  
 <213> Mus musculus

<400> 24  
 Gln Gln His His Leu Val Glu Tyr Met Glu Arg Arg Leu Ala Ala Leu  
 1 5 10 15  
 Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser Ser Arg His Ala Ala  
 20 25 30  
 Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro Leu Leu Glu Val Ala  
 35 40 45  
 Glu Lys Glu Arg Glu Thr Leu Arg Thr Glu Ala Asp Ser Ile Ser Gly  
 50 55 60  
 Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr Leu Glu Thr Gln Asn  
 65 70 75 80  
 Pro Ala Leu Pro Cys Val Glu Leu Asp Glu Lys Val Thr Gly Gly Pro  
 85 90 95  
 Gly Ala Lys Gly Lys Gly Arg Arg Asn Glu Lys Tyr Asp Met Val Thr  
 100 105 110  
 Asp Cys Ser Tyr Thr Val Ala Gln Val Arg Ser Met Lys Ile Leu Lys

115	120	125
Arg Phe Gly Gly Ser Val Gly Leu Trp Thr Lys Asp Pro Leu Gly Pro 130 135 140		
Ala Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln Asn Asp Thr Ala Phe 145 150 155 160		
Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala Met Ala Ala Arg Lys 165 170 175		
Ala Ser Arg Ile Arg Val Pro Phe Pro Trp Val Gly Thr Gly Gln Leu 180 185 190		
Val Tyr Gly Gly Phe Leu Tyr Tyr Ala Arg Arg Pro Pro Gly Gly Pro 195 200 205		
Gly Gly Gly Gly Glu Leu Glu Asn Thr Leu Gln Leu Ile Lys Phe His 210 215 220		
Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val Phe Pro Ala Glu Ser 225 230 235 240		
Leu Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr Tyr Ile Asp Leu Ala 245 250 255		
Ala Asp Glu Glu Gly Leu Trp Ala Val Tyr Ala Thr Arg Asp Asp Asp 260 265 270		
Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln Thr Leu Asp Thr Glu 275 280 285		
Gln Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn Ala Glu Ala Ala Phe 290 295 300		
Val Ile Cys Gly Thr Leu Tyr Val Val Tyr Asn Thr Arg Pro Ala Ser 305 310 315 320		
Arg Ala Arg Ile Gln Cys Ser Phe Asp Ala Ser Gly Thr Leu Ala Pro 325 330 335		
Glu Arg Ala Ala Leu Ser Tyr Phe Pro Arg Arg Tyr Gly Ala His Ala 340 345 350		
Ser Leu Arg Tyr Asn Pro Arg Glu Arg Gln Leu Tyr Ala Trp Asp Asp 355 360 365		
Gly Tyr Gln Ile Val Tyr Lys Leu Glu Met Lys Lys Lys Glu Glu Glu 370 375 380		
Val 385		

&lt;210&gt; 25

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 25

Met Gly Pro Ser Ala Pro Leu Leu Leu Leu Phe Phe Leu Ser Trp Thr  
 1 5 10 15

Gly Pro Leu Gln Gly  
 20

&lt;210&gt; 26

&lt;211&gt; 1869

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; all "n" positions

&lt;223&gt; n=a, c, g, or t

&lt;400&gt; 26

```

gtcgacccac gcgtncntcc agcgtncgga gccgacctgg gtgtcagcgg ctcggtctcc 60
gcgcacgctc cggccgtcgc gcagcctcgg cacctgcagg tccgtgcgtc ccgcggctgg 120
cgccccgtac tccgtcccgg ccaggaggag ccattgattc cctcccgggg cccctgggtga 180
ccaacttgnt gcggtttttg ttcctggggc tgagtgcctt cgcgcccccc tcgcggggccc 240
agctgcaact gcacttgccc gccaaaccgt tgcaggcggg ggaggagggg gaaagtgggtg 300
cttcagcatg gtacaccttg cacaggaggg tgtcttcatt ccagccatgg gaggtgcctt 360
ttgtgatgtg gttcttcaaa cagaaagaaa aggaggatca ggtgttgttc tacatcaatg 420
gggtcacaac aagcaaacct ggagtatcct tgggtctact catgccctcc cggaacctgt 480
ccctgcgggt ggagggtctc caggagaaaag actctggccc ctacagctgc tccgtgaatg 540
tgcaagacaa acaaggcaaa tctagggggc acagcatcaa aaccttagaa ctcaatgtac 600
tggttcctcc agctcctcca tcctgccgtc tccagggtgt gcccattgtg ggggcaaacg 660
tgacctgag ctgccagtct ccaaggagta agcccgctgt ccaataccag tgggatcggc 720
agcttccatc cttccagact ttctttgcac cagcattaga tgtcatccgt gggctcttaa 780
gcctcaccaa ctttctgtct tccatggctg gagtctatgt ctgcaaggcc cacaatgagg 840
tgggcactgc ccaatgtaat gtgacgctgg aagtgagcac agggcctgga gctgcagtgg 900
ttgtctgaag tggtgtgggt accctgggtg gactggggtt gctgggtggg ctggctctct 960
tgtaccaccg ccgggggcaag gccctggagg agccagccaa tgatatcaag gaggatgcca 1020
ttgtctcccg gacctgccc tggcccaaga gctcagacac aatctccaag aatgggacct 1080
tttctctgt cacctccgca cgagccctcc ggccacccca tggccctccc aggcctgggtg 1140
cattgacccc cagccccagt ctatccagcc aggcctgcc ctaccaaga catgccacg 1200
acagatgggg cccaccctca accaatatcc cccatccctg gtggggtttt ttcctttggc 1260
tttgagccgc atgggtgctg ngcctgtgat ggngcctgcc cagagtcaag ctggctctct 1320
ggatgatga cccaccact cattggctaa aggatttggg gtctctcctt cctataaggg 1380
tcacctctag cacagaggcc tgagtcattg gaaagagtca cactcctgac ccttagtact 1440
ctgccccac ctctctttac tgtgggaaaa ccatctcagt aagacctaa tgtccaggag 1500
acagaaggag aagaggaagt ggatctggaa ttgggaggag cctccacca cccctgactc 1560
ctccttatga agccagctgc tgaaattagc tactaccaaa gagtgagggg cagagacttc 1620
cagtcactga gtctcccagg ccccttctgt ctgtacccca cccctatcta acaccacct 1680
tggctccccc tccagctccc tgtattgata taacctgtca ggctggcttg gttagggttt 1740
actggggcag aggataggga atctcttatt aaaactaaca tgaaatatgt gttgttttca 1800
tttgcaaat taaataaaga tacataatgt ttgtatgaga taagaaaaaa aaaaaaaaaa 1860
ggcgccgc 1869

```

&lt;210&gt; 27

&lt;211&gt; 1110

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

<221> modified\_base  
 <222> all "n" positions  
 <223> n=a, c, g, or t

<400> 27  
 atgatttccc tcccggggcc cctggtgacc aacttgntgc ggtttttgtt cctggggctg 60  
 agtgcctcgc cgccccctc gcgggcccag ctgcaactgc acttgcccgc caaccgggtg 120  
 caggcggtgg aggaggggga aagtgggtgct tcagcatggt acaccttgca cagggaggtg 180  
 tcttcatccc agccatggga ggtgcccttt gtgatgtggt tcttcaaaca gaaagaaaag 240  
 gaggatcagg tgttgtccta catcaatggg gtcacaacaa gcaaacctgg agtatccttg 300  
 gtctactcca tgccctcccg gaacctgtcc ctgcgggtgg aggggtctcca ggagaaagac 360  
 tctggccccct acagctgctc cgtgaatgtg caagacaaac aaggcaaata taggggccac 420  
 agcatcaaaa ccttagaact caatgtactg gttcctccag ctccctccatc ctgccgtctc 480  
 cagggtgtgc cccatgtggg ggcaaactg accctgagct gccagtctcc aaggagtaag 540  
 cccgctgtcc aataccagtg ggatcggcag cttccatcct tccagacttt ctttgcacca 600  
 gcattagatg tcatccgtgg gtctttaagc ctcaccaacc tttcgtcttc catggctgga 660  
 gtctatgtct gcaaggccca caatgaggtg ggcactgccc aatgtaatgt gacgctggaa 720  
 gtgagcacag ggcctggagc tgcagtgtt gctgaagctg ttgtgggtac cctggttgga 780  
 ctgggggtgc tggctgggct ggtcctcttg taccaccgcc ggggcaaggc cctggaggag 840  
 ccagccaatg atatcaagga ggatgccatt gctccccgga cctgcccctg gccaagagc 900  
 tcagacacaa tctccaagaa tgggaccctt tctctgtca cctccgcacg agccctccgg 960  
 ccaccccatg gccctcccag gcctgggtgca ttgaccccca cgcccagctc atccagccag 1020  
 gccctgccct caccaagaca tgccacgac agatggggcc caccctcaac caatatcccc 1080  
 catccctggg ggggtttttt cctttggctt 1110

<210> 28  
 <211> 370  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (13)  
 <223> Xaa=unknown amino acid

<400> 28  
 Met Ile Ser Leu Pro Gly Pro Leu Val Thr Asn Leu Xaa Arg Phe Leu  
 1 5 10 15  
 Phe Leu Gly Leu Ser Ala Leu Ala Pro Pro Ser Arg Ala Gln Leu Gln  
 20 25 30  
 Leu His Leu Pro Ala Asn Arg Leu Gln Ala Val Glu Glu Gly Glu Ser  
 35 40 45  
 Gly Ala Ser Ala Trp Tyr Thr Leu His Arg Glu Val Ser Ser Ser Gln  
 50 55 60  
 Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe Lys Gln Lys Glu Lys  
 65 70 75 80  
 Glu Asp Gln Val Leu Ser Tyr Ile Asn Gly Val Thr Thr Ser Lys Pro  
 85 90 95  
 Gly Val Ser Leu Val Tyr Ser Met Pro Ser Arg Asn Leu Ser Leu Arg  
 100 105 110  
 Val Glu Gly Leu Gln Glu Lys Asp Ser Gly Pro Tyr Ser Cys Ser Val

115	120	125
Asn Val Gln Asp Lys Gln Gly Lys Ser Arg Gly His Ser Ile Lys Thr 130	135	140
Leu Glu Leu Asn Val Leu Val Pro Pro Ala Pro Pro Ser Cys Arg Leu 145	150	155 160
Gln Gly Val Pro His Val Gly Ala Asn Val Thr Leu Ser Cys Gln Ser 165	170	175
Pro Arg Ser Lys Pro Ala Val Gln Tyr Gln Trp Asp Arg Gln Leu Pro 180	185	190
Ser Phe Gln Thr Phe Phe Ala Pro Ala Leu Asp Val Ile Arg Gly Ser 195	200	205
Leu Ser Leu Thr Asn Leu Ser Ser Ser Met Ala Gly Val Tyr Val Cys 210	215	220
Lys Ala His Asn Glu Val Gly Thr Ala Gln Cys Asn Val Thr Leu Glu 225	230	235 240
Val Ser Thr Gly Pro Gly Ala Ala Val Val Ala Glu Ala Val Val Gly 245	250	255
Thr Leu Val Gly Leu Gly Leu Leu Ala Gly Leu Val Leu Leu Tyr His 260	265	270
Arg Arg Gly Lys Ala Leu Glu Glu Pro Ala Asn Asp Ile Lys Glu Asp 275	280	285
Ala Ile Ala Pro Arg Thr Leu Pro Trp Pro Lys Ser Ser Asp Thr Ile 290	295	300
Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg Ala Leu Arg 305	310	315 320
Pro Pro His Gly Pro Pro Arg Pro Gly Ala Leu Thr Pro Thr Pro Ser 325	330	335
Leu Ser Ser Gln Ala Leu Pro Ser Pro Arg His Ala His Asp Arg Trp 340	345	350
Gly Pro Pro Ser Thr Asn Ile Pro His Pro Trp Trp Gly Phe Phe Leu 355	360	365
Trp Leu 370		

<210> 29  
 <211> 341  
 <212> PRT  
 <213> Mus musculus

<400> 29  
 Gln Leu Gln Leu His Leu Pro Ala Asn Arg Leu Gln Ala Val Glu Glu

1	5	10	15
Gly Glu Ser Gly Ala Ser Ala Trp Tyr Thr Leu His Arg Glu Val Ser	20	25	30
Ser Ser Gln Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe Lys Gln	35	40	45
Lys Glu Lys Glu Asp Gln Val Leu Ser Tyr Ile Asn Gly Val Thr Thr	50	55	60
Ser Lys Pro Gly Val Ser Leu Val Tyr Ser Met Pro Ser Arg Asn Leu	65	70	75
Ser Leu Arg Val Glu Gly Leu Gln Glu Lys Asp Ser Gly Pro Tyr Ser	85	90	95
Cys Ser Val Asn Val Gln Asp Lys Gln Gly Lys Ser Arg Gly His Ser	100	105	110
Ile Lys Thr Leu Glu Leu Asn Val Leu Val Pro Pro Ala Pro Pro Ser	115	120	125
Cys Arg Leu Gln Gly Val Pro His Val Gly Ala Asn Val Thr Leu Ser	130	135	140
Cys Gln Ser Pro Arg Ser Lys Pro Ala Val Gln Tyr Gln Trp Asp Arg	145	150	155
Gln Leu Pro Ser Phe Gln Thr Phe Phe Ala Pro Ala Leu Asp Val Ile	165	170	175
Arg Gly Ser Leu Ser Leu Thr Asn Leu Ser Ser Ser Met Ala Gly Val	180	185	190
Tyr Val Cys Lys Ala His Asn Glu Val Gly Thr Ala Gln Cys Asn Val	195	200	205
Thr Leu Glu Val Ser Thr Gly Pro Gly Ala Ala Val Val Ala Glu Ala	210	215	220
Val Val Gly Thr Leu Val Gly Leu Gly Leu Leu Ala Gly Leu Val Leu	225	230	235
Leu Tyr His Arg Arg Gly Lys Ala Leu Glu Glu Pro Ala Asn Asp Ile	245	250	255
Lys Glu Asp Ala Ile Ala Pro Arg Thr Leu Pro Trp Pro Lys Ser Ser	260	265	270
Asp Thr Ile Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg	275	280	285
Ala Leu Arg Pro Pro His Gly Pro Pro Arg Pro Gly Ala Leu Thr Pro	290	295	300
Thr Pro Ser Leu Ser Ser Gln Ala Leu Pro Ser Pro Arg His Ala His	305	310	315
			320

Asp Arg Trp Gly Pro Pro Ser Thr Asn Ile Pro His Pro Trp Trp Gly  
                   325                                  330                                  335

Phe Phe Leu Trp Leu  
                   340

<210> 30  
 <211> 29  
 <212> PRT  
 <213> Mus musculus

<220>  
 <221> SITE  
 <222> (13)  
 <223> Xaa=unknown amino acid  
 <400> 30

Met Ile Ser Leu Pro Gly Pro Leu Val Thr Asn Leu Xaa Arg Phe Leu  
   1                  5                                  10                                  15

Phe Leu Gly Leu Ser Ala Leu Ala Pro Pro Ser Arg Ala  
                   20                                  25

<210> 31  
 <211> 246  
 <212> PRT  
 <213> Mus musculus

<220>  
 <221> SITE  
 <222> (13)  
 <223> Xaa=unknown amino acid  
 <400> 31

Met Ile Ser Leu Pro Gly Pro Leu Val Thr Asn Leu Xaa Arg Phe Leu  
   1                  5                                  10                                  15

Phe Leu Gly Leu Ser Ala Leu Ala Pro Pro Ser Arg Ala Gln Leu Gln  
                   20                                  25                                  30

Leu His Leu Pro Ala Asn Arg Leu Gln Ala Val Glu Glu Gly Glu Ser  
                   35                                  40                                  45

Gly Ala Ser Ala Trp Tyr Thr Leu His Arg Glu Val Ser Ser Ser Gln  
                   50                                  55                                  60

Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe Lys Gln Lys Glu Lys  
   65                                  70                                  75                                  80

Glu Asp Gln Val Leu Ser Tyr Ile Asn Gly Val Thr Thr Ser Lys Pro  
                   85                                  90                                  95

Gly Val Ser Leu Val Tyr Ser Met Pro Ser Arg Asn Leu Ser Leu Arg  
                   100                                  105                                  110

Val Glu Gly Leu Gln Glu Lys Asp Ser Gly Pro Tyr Ser Cys Ser Val

115	120	125
Asn Val Gln Asp Lys Gln Gly Lys Ser Arg Gly His Ser Ile Lys Thr		
130	135	140
Leu Glu Leu Asn Val Leu Val Pro Pro Ala Pro Pro Ser Cys Arg Leu		
145	150	155
Gln Gly Val Pro His Val Gly Ala Asn Val Thr Leu Ser Cys Gln Ser		
	165	170
Pro Arg Ser Lys Pro Ala Val Gln Tyr Gln Trp Asp Arg Gln Leu Pro		
	180	185
Ser Phe Gln Thr Phe Phe Ala Pro Ala Leu Asp Val Ile Arg Gly Ser		
	195	200
Leu Ser Leu Thr Asn Leu Ser Ser Ser Met Ala Gly Val Tyr Val Cys		
	210	215
Lys Ala His Asn Glu Val Gly Thr Ala Gln Cys Asn Val Thr Leu Glu		
225	230	235
Val Ser Thr Gly Pro Gly		
	245	

<210> 32  
 <211> 653  
 <212> DNA  
 <213> Homo sapiens

<400> 32  
 ttttttgcac gtaacttttt tattgaggca caacaaggca ttgtaacttg cctggacttg 60  
 aggcagtcag ttttagtaagc tgaacgttaa tacagttaag gattaagtgc aaacaatata 120  
 cattcacagc ttgactagcg aggctacatc acaatttata aagtgccaga ttagtgctaa 180  
 ttgtcattca gcttgatttt tcacctcagg aaggaaaaca aaaaagtaag gacctcctcc 240  
 ctctaggaac aaaaaacatt ttcctaaacc aatcagtcac gagggcaaag actacttttc 300  
 cttcaatccc actaattaga acaccatcct tttattgtca atactgtact gactttcaat 360  
 cttgataaag aagatagcct gaaaacgtag aatatttcca gctacttcca taaattgctc 420  
 ccctgtgcag acgtaaccat atctgggtctc cctggaagag ctgaagaatt gcatgattgc 480  
 tagcagtttc atgggtctgga gcaccatcat tggcataggc tgataccaag acctcttcat 540  
 tcttcantga ggttgacata cagtggcaca ttcactgccg gcttttacat gtgaaaaatg 600  
 aaaaacgtag tgccattcac ttggcaatta aatctaccaa agctgagatc aaa 653

<210> 33  
 <211> 25  
 <212> PRT  
 <213> Mus musculus

<400> 33  
 Ala Ala Val Val Ala Glu Ala Val Val Gly Thr Leu Val Gly Leu Gly  
 1 5 10 15  
 Leu Leu Ala Gly Leu Val Leu Leu Tyr  
 20 25

<210> 34  
 <211> 99  
 <212> PRT  
 <213> Mus musculus

<400> 34  
 His Arg Arg Gly Lys Ala Leu Glu Glu Pro Ala Asn Asp Ile Lys Glu  
   1                  5                  10                  15  
 Asp Ala Ile Ala Pro Arg Thr Leu Pro Trp Pro Lys Ser Ser Asp Thr  
                   20                  25                  30  
 Ile Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg Ala Leu  
           35                  40                  45  
 Arg Pro Pro His Gly Pro Pro Arg Pro Gly Ala Leu Thr Pro Thr Pro  
   50                  55                  60  
 Ser Leu Ser Ser Gln Ala Leu Pro Ser Pro Arg His Ala His Asp Arg  
   65                  70                  75                  80  
 Trp Gly Pro Pro Ser Thr Asn Ile Pro His Pro Trp Trp Gly Phe Phe  
                   85                  90                  95  
 Leu Trp Leu

<210> 35  
 <211> 80  
 <212> PRT  
 <213> Mus musculus

<400> 35  
 Gly Ala Ser Ala Trp Tyr Thr Leu His Arg Glu Val Ser Ser Ser Gln  
   1                  5                  10                  15  
 Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe Lys Gln Lys Glu Lys  
           20                  25                  30  
 Glu Asp Gln Val Leu Ser Tyr Ile Asn Gly Val Thr Thr Ser Lys Pro  
   35                  40                  45  
 Gly Val Ser Leu Val Tyr Ser Met Pro Ser Arg Asn Leu Ser Leu Arg  
   50                  55                  60  
 Val Glu Gly Leu Gln Glu Lys Asp Ser Gly Pro Tyr Ser Cys Ser Val  
   65                  70                  75                  80

<210> 36  
 <211> 60  
 <212> PRT  
 <213> Mus musculus

&lt;400&gt; 36

Gly Ala Asn Val Thr Leu Ser Cys Gln Ser Pro Arg Ser Lys Pro Ala  
 1 5 10 15  
 Val Gln Tyr Gln Trp Asp Arg Gln Leu Pro Ser Phe Gln Thr Phe Phe  
 20 25 30  
 Ala Pro Ala Leu Asp Val Ile Arg Gly Ser Leu Ser Leu Thr Asn Leu  
 35 40 45  
 Ser Ser Ser Met Ala Gly Val Tyr Val Cys Lys Ala  
 50 55 60

&lt;210&gt; 37

&lt;211&gt; 1846

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 37

```

gtcgacccac gcggtccggtg cacattcggg ttgccgccgc tcaccacaa cacctgtaga 60
caccgtgtgt ccaactctcc ctgagtactc cgggccaaagg agggccatga ttcttcaggc 120
tggaaccccc gagaccagct tgctgcgggt tttgttcctg ggactgagta cccttgctgc 180
cttctccccg gctcagatgg agttgcacgt gccccgggc ctcaacaaat tggaagcggg 240
agagggagaa gaagtgggtg tccccgcctg gtacacgatg gcacgggagg agtcgtgggc 300
ccacccccgg gaggtgcca tcctgatctg gttcttgga caagaaggga aggaaccaa 360
ccaggtgttg tcttacatta atggagtcac gacaaataaa cctggaacag ccctgggtcca 420
ctctatctct tcacggaatg tgtccctgcg cctgggggca ctccaggagg gagactctgg 480
gacttaccgc tgttctgtca atgtgcagaa tgatgaaggc aaaagtatag gccacagcat 540
caaaagcata gagctcaaaag tgctggttcc tccagctcct ccacctgtga gtttacaggg 600
tgtaccctat gtcgggacca atgtgacct gaactgcaag tccccaagga gtaaacctac 660
tgctcagtac cagtgggaga ggctggcccc atcctcccag gtcttctttg gaccagcctt 720
agatgctgtt cgtggatctt taaagctcac taacctttcc attgccatgt ctggagtcta 780
tgtctgcaag gctcaaaaaca gagtgggctt tgccaagtgc aacgtgacct tggacgtgat 840
gacaggggtcc aaggctgcag tggctgctgg agcagttgtg ggcacttttg ttgggttggg 900
gctgatagct gggctgggtcc tgttgtagca gcgcgggagc aagaccttg aagagctggc 960
caatgatatac aaggaagatg ccattgctcc ccggaccttg ccttggaacca aaggctcaga 1020
cacaatctcc aagaatggga cactttcttc ggtaacctca gcacgagctc tgcggccacc 1080
caaggctgct cctccaagac ctggcacatt tactccaca ccagtgctc ctagccaggc 1140
cctgtcctca ccaagactgc ccagggtaga tgaaccccc cctcaggcag tgtccctgac 1200
cccagggtgg gtttcttctt ctgctctgag ccgcatgggt gctgtgcctg tgatgggtgc 1260
tgcacagagt caggctgggt ctcttggtg atagcccagg cactcattag ctacatctgg 1320
tatctgacct ttctgtaaag gtctccttgt ggcacagagg actcaatctt gggaggatgc 1380
ccacattcta gacctccagt cctttgctcc tacctccttc tattgttggg atactggggc 1440
tcagtaagac taaaatctgg gtcaaaggac aaaaggagga aatggacctg aggtaggggg 1500
ttgggagtga ggaggcttca ctctcctcct gcttctcct gaagccagat gaatgctgcg 1560
gaagatcggc taccctccaa gggctctgga ggagactgcc agtcagtgat gcccctggct 1620
ctgtgatctg tacaacaccc ttatctaata ctgtcctttg ccgttcgctc catctccctg 1680
tattaatata acctgtcctg ctggcttggc tgggttttgg ttagcaggg ggataggaaa 1740
gacattttaa aatctgactt gaaattgatg tttttgttt tttttgcaa atttcaataa 1800
agatacatcg catttgcatg gaaaaaaaaa aaaaaagggc ggccgc 1846

```

&lt;210&gt; 38

&lt;211&gt; 1182

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 38

```

atgattcttc aggctggaac ccccgagacc agcttgctgc gggttttgtt cctgggactg 60
agtacccttg ctgccttctc ccgagctcag atggagttgc acgtgcccc gggcctcaac 120
aaattggaag cggtagaggg agaagaagtg gtgctcccc cctggtacac gatggcacgg 180
gaggagtcgt ggtcccaccc ccgggaggtg cccatcctga tctggttctt ggaacaagaa 240
gggaaggaac caaaccaggt gttgtcttac attaatggag tcatgacaaa taaacctgga 300
acagccctgg tccactctat ctcttcacgg aatgtgtccc tgcgcctggg ggcactccag 360
gagggagact ctgggactta ccgctgttct gtcaatgtgc agaatgatga aggcaaaagt 420
ataggccaca gcatcaaaag catagagctc aaagtgtctg ttccctccagc tcctccatcc 480
tgtagtttac aggggtgtacc ctatgtcggg accaatgtga ccctgaactg caagtcccca 540
aggagtaaac ctactgtcga gtaccagtgg gagaggctgg ccccatcctc ccaggtcttc 600
tttgaccag ccttagatgc tggtcgtgga tctttaaac tcactaacct ttccattgcc 660
atgtctggag tctatgtctg caaggctcaa aacagagtgg gctttgcaa gtgcaacgtg 720
accttggaag tgatgacagg gtccaaggct gcagtggctg ctggagcagt tgtgggcact 780
tttggtgggt tgggtgtgat agctgggctg gtccctgtgt accagcgccg gagcaagacc 840
ttggaagagc tggccaatga tatcaaggaa gatgccattg ctcccggac cttgccttgg 900
accaaaggct cagacacaat ctccaagaat gggacacttt cttcggtcac ctgagcacga 960
gctctgcggc cacccaaggc tgctcctcca agacctggca catttactcc cacaccagt 1020
gtctctagcc aggccctgtc ctcaccaaga ctgcccaggg tagatgaacc cccacctcag 1080
gcagtgtccc tgaccccagg tggggtttct tcttctgctc tgagccgcat ggggtgctgtg 1140
cctgtgatgg tgctgcaca gagtcaggct gggctctctg tg 1182

```

&lt;210&gt; 39

&lt;211&gt; 394

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 39

```

Met Ile Leu Gln Ala Gly Thr Pro Glu Thr Ser Leu Leu Arg Val Leu
  1               5               10               15

```

```

Phe Leu Gly Leu Ser Thr Leu Ala Ala Phe Ser Arg Ala Gln Met Glu
      20               25               30

```

```

Leu His Val Pro Pro Gly Leu Asn Lys Leu Glu Ala Val Glu Gly Glu
      35               40               45

```

```

Glu Val Val Leu Pro Ala Trp Tyr Thr Met Ala Arg Glu Glu Ser Trp
      50               55               60

```

```

Ser His Pro Arg Glu Val Pro Ile Leu Ile Trp Phe Leu Glu Gln Glu
      65               70               75               80

```

```

Gly Lys Glu Pro Asn Gln Val Leu Ser Tyr Ile Asn Gly Val Met Thr
      85               90               95

```

```

Asn Lys Pro Gly Thr Ala Leu Val His Ser Ile Ser Ser Arg Asn Val
      100               105               110

```

```

Ser Leu Arg Leu Gly Ala Leu Gln Glu Gly Asp Ser Gly Thr Tyr Arg
      115               120               125

```

```

Cys Ser Val Asn Val Gln Asn Asp Glu Gly Lys Ser Ile Gly His Ser
      130               135               140

```

```

Ile Lys Ser Ile Glu Leu Lys Val Leu Val Pro Pro Ala Pro Pro Ser
      145               150               155               160

```

```

Cys Ser Leu Gln Gly Val Pro Tyr Val Gly Thr Asn Val Thr Leu Asn

```

	165		170		175
Cys Lys Ser Pro Arg Ser Lys Pro Thr Ala Gln Tyr Gln Trp Glu Arg					
	180		185		190
Leu Ala Pro Ser Ser Gln Val Phe Phe Gly Pro Ala Leu Asp Ala Val					
	195		200		205
Arg Gly Ser Leu Lys Leu Thr Asn Leu Ser Ile Ala Met Ser Gly Val					
	210		215		220
Tyr Val Cys Lys Ala Gln Asn Arg Val Gly Phe Ala Lys Cys Asn Val					
	225		230		240
Thr Leu Asp Val Met Thr Gly Ser Lys Ala Ala Val Val Ala Gly Ala					
		245		250	255
Val Val Gly Thr Phe Val Gly Leu Val Leu Ile Ala Gly Leu Val Leu					
		260		265	270
Leu Tyr Gln Arg Arg Ser Lys Thr Leu Glu Glu Leu Ala Asn Asp Ile					
		275		280	285
Lys Glu Asp Ala Ile Ala Pro Arg Thr Leu Pro Trp Thr Lys Gly Ser					
		290		295	300
Asp Thr Ile Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg					
		305		310	315
Ala Leu Arg Pro Pro Lys Ala Ala Pro Pro Arg Pro Gly Thr Phe Thr					
		325		330	335
Pro Thr Pro Ser Val Ser Ser Gln Ala Leu Ser Ser Pro Arg Leu Pro					
		340		345	350
Arg Val Asp Glu Pro Pro Pro Gln Ala Val Ser Leu Thr Pro Gly Gly					
		355		360	365
Val Ser Ser Ser Ala Leu Ser Arg Met Gly Ala Val Pro Val Met Val					
		370		375	380
Pro Ala Gln Ser Gln Ala Gly Ser Leu Val					
	385		390		

&lt;210&gt; 40

&lt;211&gt; 365

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 40

Gln Met Glu Leu His Val Pro Pro Gly Leu Asn Lys Leu Glu Ala Val
1 5 10 15

Glu Gly Glu Glu Val Val Leu Pro Ala Trp Tyr Thr Met Ala Arg Glu
20 25 30

Glu Ser Trp Ser His Pro Arg Glu Val Pro Ile Leu Ile Trp Phe Leu
---

35					40					45					
Glu	Gln	Glu	Gly	Lys	Glu	Pro	Asn	Gln	Val	Leu	Ser	Tyr	Ile	Asn	Gly
50					55					60					
Val	Met	Thr	Asn	Lys	Pro	Gly	Thr	Ala	Leu	Val	His	Ser	Ile	Ser	Ser
65					70					75					80
Arg	Asn	Val	Ser	Leu	Arg	Leu	Gly	Ala	Leu	Gln	Glu	Gly	Asp	Ser	Gly
				85					90					95	
Thr	Tyr	Arg	Cys	Ser	Val	Asn	Val	Gln	Asn	Asp	Glu	Gly	Lys	Ser	Ile
			100					105					110		
Gly	His	Ser	Ile	Lys	Ser	Ile	Glu	Leu	Lys	Val	Leu	Val	Pro	Pro	Ala
			115				120					125			
Pro	Pro	Ser	Cys	Ser	Leu	Gln	Gly	Val	Pro	Tyr	Val	Gly	Thr	Asn	Val
			130				135					140			
Thr	Leu	Asn	Cys	Lys	Ser	Pro	Arg	Ser	Lys	Pro	Thr	Ala	Gln	Tyr	Gln
145					150					155					160
Trp	Glu	Arg	Leu	Ala	Pro	Ser	Ser	Gln	Val	Phe	Phe	Gly	Pro	Ala	Leu
				165					170					175	
Asp	Ala	Val	Arg	Gly	Ser	Leu	Lys	Leu	Thr	Asn	Leu	Ser	Ile	Ala	Met
				180				185					190		
Ser	Gly	Val	Tyr	Val	Cys	Lys	Ala	Gln	Asn	Arg	Val	Gly	Phe	Ala	Lys
			195				200					205			
Cys	Asn	Val	Thr	Leu	Asp	Val	Met	Thr	Gly	Ser	Lys	Ala	Ala	Val	Val
			210				215					220			
Ala	Gly	Ala	Val	Val	Gly	Thr	Phe	Val	Gly	Leu	Val	Leu	Ile	Ala	Gly
225					230					235					240
Leu	Val	Leu	Leu	Tyr	Gln	Arg	Arg	Ser	Lys	Thr	Leu	Glu	Glu	Leu	Ala
				245					250					255	
Asn	Asp	Ile	Lys	Glu	Asp	Ala	Ile	Ala	Pro	Arg	Thr	Leu	Pro	Trp	Thr
			260					265					270		
Lys	Gly	Ser	Asp	Thr	Ile	Ser	Lys	Asn	Gly	Thr	Leu	Ser	Ser	Val	Thr
			275				280					285			
Ser	Ala	Arg	Ala	Leu	Arg	Pro	Pro	Lys	Ala	Ala	Pro	Pro	Arg	Pro	Gly
			290				295					300			
Thr	Phe	Thr	Pro	Thr	Pro	Ser	Val	Ser	Ser	Gln	Ala	Leu	Ser	Ser	Pro
305					310					315					320
Arg	Leu	Pro	Arg	Val	Asp	Glu	Pro	Pro	Pro	Gln	Ala	Val	Ser	Leu	Thr
				325					330					335	
Pro	Gly	Gly	Val	Ser	Ser	Ser	Ala	Leu	Ser	Arg	Met	Gly	Ala	Val	Pro
			340					345					350		

Val Met Val Pro Ala Gln Ser Gln Ala Gly Ser Leu Val  
 355 360 365

<210> 41  
 <211> 29  
 <212> PRT  
 <213> Mus musculus

<400> 41  
 Met Ile Leu Gln Ala Gly Thr Pro Glu Thr Ser Leu Leu Arg Val Leu  
 1 5 10 15

Phe Leu Gly Leu Ser Thr Leu Ala Ala Phe Ser Arg Ala  
 20 25

<210> 42  
 <211> 249  
 <212> PRT  
 <213> Mus musculus

<400> 42  
 Met Ile Leu Gln Ala Gly Thr Pro Glu Thr Ser Leu Leu Arg Val Leu  
 1 5 10 15

Phe Leu Gly Leu Ser Thr Leu Ala Ala Phe Ser Arg Ala Gln Met Glu  
 20 25 30

Leu His Val Pro Pro Gly Leu Asn Lys Leu Glu Ala Val Glu Gly Glu  
 35 40 45

Glu Val Val Leu Pro Ala Trp Tyr Thr Met Ala Arg Glu Glu Ser Trp  
 50 55 60

Ser His Pro Arg Glu Val Pro Ile Leu Ile Trp Phe Leu Glu Gln Glu  
 65 70 75 80

Gly Lys Glu Pro Asn Gln Val Leu Ser Tyr Ile Asn Gly Val Met Thr  
 85 90 95

Asn Lys Pro Gly Thr Ala Leu Val His Ser Ile Ser Ser Arg Asn Val  
 100 105 110

Ser Leu Arg Leu Gly Ala Leu Gln Glu Gly Asp Ser Gly Thr Tyr Arg  
 115 120 125

Cys Ser Val Asn Val Gln Asn Asp Glu Gly Lys Ser Ile Gly His Ser  
 130 135 140

Ile Lys Ser Ile Glu Leu Lys Val Leu Val Pro Pro Ala Pro Pro Ser  
 145 150 155 160

Cys Ser Leu Gln Gly Val Pro Tyr Val Gly Thr Asn Val Thr Leu Asn  
 165 170 175

Cys Lys Ser Pro Arg Ser Lys Pro Thr Ala Gln Tyr Gln Trp Glu Arg  
 180 185 190

Leu Ala Pro Ser Ser Gln Val Phe Phe Gly Pro Ala Leu Asp Ala Val  
 195 200 205

Arg Gly Ser Leu Lys Leu Thr Asn Leu Ser Ile Ala Met Ser Gly Val  
 210 215 220

Tyr Val Cys Lys Ala Gln Asn Arg Val Gly Phe Ala Lys Cys Asn Val  
 225 230 235 240

Thr Leu Asp Val Met Thr Gly Ser Lys  
 245

<210> 43  
 <211> 355  
 <212> PRT  
 <213> Mus musculus

<220>  
 <221> SITE  
 <222> (355)  
 <223> Xaa=unknown amino acid  
 <400> 43

Met Gly Pro Ser Thr Pro Leu Leu Ile Leu Phe Leu Leu Ser Trp Ser  
 1 5 10 15

Gly Pro Leu Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg  
 20 25 30

Arg Leu Ala Ala Leu Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser  
 35 40 45

Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro  
 50 55 60

Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Ala Leu Arg Thr Glu Ala  
 65 70 75 80

Asp Thr Ile Ser Gly Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr  
 85 90 95

Leu Glu Thr Gln Asn Pro Ala Leu Pro Cys Val Glu Phe Asp Glu Lys  
 100 105 110

Val Thr Gly Gly Pro Gly Thr Lys Gly Lys Gly Arg Arg Asn Glu Lys  
 115 120 125

Tyr Asp Met Val Thr Asp Cys Gly Tyr Thr Ile Ser Gln Val Arg Ser  
 130 135 140

Met Lys Ile Leu Lys Arg Phe Gly Gly Pro Ala Gly Leu Trp Thr Lys  
 145 150 155 160

Asp Pro Leu Gly Gln Thr Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln  
 165 170 175

Asn Asp Thr Ala Phe Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala

180                                      185                                      190  
 Met Ala Ala Arg Lys Ala Ser Arg Val Arg Val Pro Phe Pro Trp Val  
       195                                      200                                      205  
 Gly Thr Gly Gln Leu Val Tyr Gly Gly Phe Leu Tyr Phe Ala Arg Arg  
       210                                      215                                      220  
 Pro Pro Gly Arg Pro Gly Gly Gly Gly Glu Met Glu Asn Thr Leu Gln  
       225                                      230                                      235                                      240  
 Leu Ile Lys Phe His Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val  
                                     245                                      250                                      255  
 Phe Pro Ala Glu Gly Leu Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr  
                                     260                                      265                                      270  
 Tyr Ile Asp Leu Ala Ala Asp Glu Glu Gly Leu Trp Ala Val Tyr Ala  
                                     275                                      280                                      285  
 Thr Arg Glu Asp Asp Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln  
                                     290                                      295                                      300  
 Thr Leu Asp Thr Glu Gln Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn  
       305                                      310                                      315                                      320  
 Ala Glu Ala Ala Phe Val Ile Cys Gly Thr Leu Tyr Val Val Tyr Asn  
                                     325                                      330                                      335  
 Thr Arg Pro Ala Ser Arg Ala Arg Ile Gln Cys Ser Phe Asp Ala Ser  
                                     340                                      345                                      350  
 Gly Pro Xaa  
       355

<210> 44  
 <211> 25  
 <212> PRT  
 <213> Mus musculus

<400> 44  
 Ala Ala Val Val Ala Gly Ala Val Val Gly Thr Phe Val Gly Leu Val  
       1                                      5                                      10                                      15  
 Leu Ile Ala Gly Leu Val Leu Leu Tyr  
                                     20                                      25

<210> 45  
 <211> 120  
 <212> PRT  
 <213> Mus musculus

<400> 45  
 Gln Arg Arg Ser Lys Thr Leu Glu Glu Leu Ala Asn Asp Ile Lys Glu  
       1                                      5                                      10                                      15

Asp Ala Ile Ala Pro Arg Thr Leu Pro Trp Thr Lys Gly Ser Asp Thr  
                   20                                  25                                  30  
 Ile Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg Ala Leu  
                   35                                  40                                  45  
 Arg Pro Pro Lys Ala Ala Pro Pro Arg Pro Gly Thr Phe Thr Pro Thr  
                   50                                  55                                  60  
 Pro Ser Val Ser Ser Gln Ala Leu Ser Ser Pro Arg Leu Pro Arg Val  
                   65                                  70                                  75                                  80  
 Asp Glu Pro Pro Pro Gln Ala Val Ser Leu Thr Pro Gly Gly Val Ser  
                   85                                  90                                  95  
 Ser Ser Ala Leu Ser Arg Met Gly Ala Val Pro Val Met Val Pro Ala  
                   100                                  105                                  110  
 Gln Ser Gln Ala Gly Ser Leu Val  
                   115                                  120

&lt;210&gt; 46

&lt;211&gt; 1801

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 46

```

gtcgcacccac gcgtccggcg gaggttgtgg ctgcaccgtg gtccctgggct tggctcctggg 60
cttgatgcgt ctgtttgtcc gtccgtccgt ccgtcccgcc atggctgcgc cggcgccttc 120
tccgtggacc ctttcgctgc tgctgttgtt gctactgccg tctccgggtg cccatggcga 180
gctgtgcagg cccttcgggtg aagacaattc gatcccagag tccgtgcctg acttctgttg 240
tggctcctgt tccagccaat actgctgctc tgacgtgctg aagaaaatcc agtggaatga 300
ggaaatgtgc cctgagccag agtccagcag attttccgcc caccgggaga caccagaaca 360
gctggggttca gcgctgaagt atcagtcag tcttgacagt gacaacatgc cagggttcgg 420
agcgaccgtg gccatcggcc tgaccgtcct cgtggtgttt atcgctacca tcattgtgtg 480
ctttacctgc tctgtctgct gtctatataa gatgtgctgc cgcccacgac ctgtcgtgtc 540
caacaccaca actactaccg tggttcacac cgcttaccct cagcctcaac ctgtggcccc 600
cagctatcct ggaccaacat accagggtta ccatcccatg cccccccagc caggaatgcc 660
agcagcacc taccacacgc agtaccctcc accctacctg gccagccca caggggccacc 720
agcctatcat gagacgttgg ctggagccag ccagcctcca tacaaccggg cctacatgga 780
tcccccaaag gcagttccct gagcctgccc ccagcctctt tggctaacat ttgattatgt 840
catgtgtgtg tgagtgtat gcagagttct ttactgctgt ctgtggtgcg tgtgccttgt 900
ctagacatgt ggcttcctct gctgatgacc aggtaggcac aaatcttacc agtgcctggt 960
gggaccaatc tgttttcttc ctacttgaa attgtaattt ctgaaatttc aagtaaatta 1020
aaaacaatag ggtaggaggt atttcccgt tcaccccaag gtgaccagcc atagcctgcc 1080
acacatagga gagcaagctt tttgtgggtc catgtcctgc tttggggagt agccagctag 1140
ctgctgctat gggtttatcc ccagggttg gctgcattta gctggacaga gaacaagggg 1200
cctcagtggc agtgggtcag tgactgatgt cagagcacac taggcagaga gccccgtccg 1260
tctccatcag ctgtctgtct ggacgggtccc actgtctttc ctgggactat gtagagggcc 1320
acatgtattc actattcagg ctccagtggc ttccaggcca ggggcctctg tctactacac 1380
actctgggtt ctccctacag tgtcttttta cgattagcca aacatattgc ctgttttttg 1440
tatccagatg tgtgataatt ggtgaggttg aaatccttgg ttcctggaga acaggaaacc 1500
tgacctctga cagtccgttt cccttgacac cagcttcata gaatacctga ctctgtact 1560
acagtccagt ttgttccagt agcagggaca ccagggccag gggttatctg gaccaagggg 1620
gggggtggag agcctggatg gtagctctgg accagatgtg aatgcctcca tattccctgt 1680
tggttcctgt ttcactggct gttttagttt tgtgttaatt ggtgtttctg agcattcaaa 1740
ctccgcaccc tcgtttataa taaatgaata tttggaaaaa aaaaaaaaaa aaaaaaaaaa 1800

```

a

1801

&lt;210&gt; 47

&lt;211&gt; 735

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 47

```

atgctgtctgt ttgtccgtcc gtccgtccgt cccgccatgg ctgcgccggc gccctctccg 60
tggacccttt cgctgctgct gttgttgcta ctgccgtctc cgggtgcccc tggcgagctg 120
tgcaggccct tcggtgaaga caattcgatc ccagagtcct gtcctgactt ctgttgaggc 180
tcctgttcca gccaatactg ctgctctgac gtgctgaaga aaatccagtg gaatgaggaa 240
atgtgccctg agccagagtc cagcagattt tccgcccacc cggagacacc agaacagctg 300
ggttcagcgc tgaagtatca gtccagtctt gacagtgaaca acatgccagg gttcggagcg 360
accgtggcca tcggcctgac cgtcttcgtg gtgtttatcg ctaccatcat tgtgtgcttt 420
acctgtcct gctgctgtct atataagatg tgctgccgcc cacgacctgt cgtgtccaac 480
accacaacta ctaccgtggg tcacaccgct taccctcagc ctcaacctgt ggcccccagc 540
taccctggac caacatacca gggctaccat cccatgcccc cccagccagg aatgccagca 600
gcaccctacc caacgcagta ccctccaccc tacctggccc agccacagg gccaccagcc 660
tatcatgaga cgttggctgg agccagccag cctccataca acccggccta catggatccc 720
ccaaaggcag ttccc                                     735

```

&lt;210&gt; 48

&lt;211&gt; 245

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 48

```

Met Arg Leu Phe Val Arg Pro Ser Val Arg Pro Ala Met Ala Ala Pro
 1              5              10              15

Ala Pro Ser Pro Trp Thr Leu Ser Leu Leu Leu Leu Leu Leu Pro
      20              25              30

Ser Pro Gly Ala His Gly Glu Leu Cys Arg Pro Phe Gly Glu Asp Asn
      35              40              45

Ser Ile Pro Glu Ser Cys Pro Asp Phe Cys Cys Gly Ser Cys Ser Ser
      50              55              60

Gln Tyr Cys Cys Ser Asp Val Leu Lys Lys Ile Gln Trp Asn Glu Glu
      65              70              75              80

Met Cys Pro Glu Pro Glu Ser Ser Arg Phe Ser Ala His Pro Glu Thr
      85              90              95

Pro Glu Gln Leu Gly Ser Ala Leu Lys Tyr Gln Ser Ser Leu Asp Ser
      100              105              110

Asp Asn Met Pro Gly Phe Gly Ala Thr Val Ala Ile Gly Leu Thr Val
      115              120              125

Phe Val Val Phe Ile Ala Thr Ile Ile Val Cys Phe Thr Cys Ser Cys
      130              135              140

Cys Cys Leu Tyr Lys Met Cys Cys Arg Pro Arg Pro Val Val Ser Asn
      145              150              155              160

```

Thr Thr Thr Thr Thr Val Val His Thr Ala Tyr Pro Gln Pro Gln Pro  
 165 170 175  
 Val Ala Pro Ser Tyr Pro Gly Pro Thr Tyr Gln Gly Tyr His Pro Met  
 180 185 190  
 Pro Pro Gln Pro Gly Met Pro Ala Ala Pro Tyr Pro Thr Gln Tyr Pro  
 195 200 205  
 Pro Pro Tyr Leu Ala Gln Pro Thr Gly Pro Pro Ala Tyr His Glu Thr  
 210 215 220  
 Leu Ala Gly Ala Ser Gln Pro Pro Tyr Asn Pro Ala Tyr Met Asp Pro  
 225 230 235 240  
 Pro Lys Ala Val Pro  
 245

<210> 49  
 <211> 38  
 <212> PRT  
 <213> Homo sapiens

<400> 49  
 Met Arg Leu Phe Val Arg Pro Ser Val Arg Pro Ala Met Ala Ala Pro  
 1 5 10 15  
 Ala Pro Ser Pro Trp Thr Leu Ser Leu Leu Leu Leu Leu Leu Pro  
 20 25 30  
 Ser Pro Gly Ala His Gly  
 35

<210> 50  
 <211> 207  
 <212> PRT  
 <213> Homo sapiens

<400> 50  
 Glu Leu Cys Arg Pro Phe Gly Glu Asp Asn Ser Ile Pro Glu Ser Cys  
 1 5 10 15  
 Pro Asp Phe Cys Cys Gly Ser Cys Ser Ser Gln Tyr Cys Cys Ser Asp  
 20 25 30  
 Val Leu Lys Lys Ile Gln Trp Asn Glu Glu Met Cys Pro Glu Pro Glu  
 35 40 45  
 Ser Ser Arg Phe Ser Ala His Pro Glu Thr Pro Glu Gln Leu Gly Ser  
 50 55 60  
 Ala Leu Lys Tyr Gln Ser Ser Leu Asp Ser Asp Asn Met Pro Gly Phe  
 65 70 75 80  
 Gly Ala Thr Val Ala Ile Gly Leu Thr Val Phe Val Val Phe Ile Ala  
 85 90 95

Thr Ile Ile Val Cys Phe Thr Cys Ser Cys Cys Cys Leu Tyr Lys Met  
 100 105 110  
 Cys Cys Arg Pro Arg Pro Val Val Ser Asn Thr Thr Thr Thr Thr Val  
 115 120 125  
 Val His Thr Ala Tyr Pro Gln Pro Gln Pro Val Ala Pro Ser Tyr Pro  
 130 135 140  
 Gly Pro Thr Tyr Gln Gly Tyr His Pro Met Pro Pro Gln Pro Gly Met  
 145 150 155 160  
 Pro Ala Ala Pro Tyr Pro Thr Gln Tyr Pro Pro Pro Tyr Leu Ala Gln  
 165 170 175  
 Pro Thr Gly Pro Pro Ala Tyr His Glu Thr Leu Ala Gly Ala Ser Gln  
 180 185 190  
 Pro Pro Tyr Asn Pro Ala Tyr Met Asp Pro Pro Lys Ala Val Pro  
 195 200 205

<210> 51  
 <211> 85  
 <212> PRT  
 <213> Homo sapiens

<400> 51  
 Glu Leu Cys Arg Pro Phe Gly Glu Asp Asn Ser Ile Pro Glu Ser Cys  
 1 5 10 15  
 Pro Asp Phe Cys Cys Gly Ser Cys Ser Ser Gln Tyr Cys Cys Ser Asp  
 20 25 30  
 Val Leu Lys Lys Ile Gln Trp Asn Glu Glu Met Cys Pro Glu Pro Glu  
 35 40 45  
 Ser Ser Arg Phe Ser Ala His Pro Glu Thr Pro Glu Gln Leu Gly Ser  
 50 55 60  
 Ala Leu Lys Tyr Gln Ser Ser Leu Asp Ser Asp Asn Met Pro Gly Phe  
 65 70 75 80  
 Gly Ala Thr Val Ala  
 85

<210> 52  
 <211> 25  
 <212> PRT  
 <213> Homo sapiens

<400> 52  
 Ile Gly Leu Thr Val Phe Val Val Phe Ile Ala Thr Ile Ile Val Cys  
 1 5 10 15  
 Phe Thr Cys Ser Cys Cys Cys Leu Tyr  
 20 25

<210> 53  
 <211> 97  
 <212> PRT  
 <213> Homo sapiens

<400> 53

Lys Met Cys Cys Arg Pro Arg Pro Val Val Ser Asn Thr Thr Thr Thr  
 1 5 10 15  
 Thr Val Val His Thr Ala Tyr Pro Gln Pro Gln Pro Val Ala Pro Ser  
 20 25 30  
 Tyr Pro Gly Pro Thr Tyr Gln Gly Tyr His Pro Met Pro Pro Gln Pro  
 35 40 45  
 Gly Met Pro Ala Ala Pro Tyr Pro Thr Gln Tyr Pro Pro Pro Tyr Leu  
 50 55 60  
 Ala Gln Pro Thr Gly Pro Pro Ala Tyr His Glu Thr Leu Ala Gly Ala  
 65 70 75 80  
 Ser Gln Pro Pro Tyr Asn Pro Ala Tyr Met Asp Pro Pro Lys Ala Val  
 85 90 95  
 Pro

<210> 54  
 <211> 50  
 <212> PRT  
 <213> Homo sapiens

<400> 54

Cys Arg Pro Phe Gly Glu Asp Asn Ser Ile Pro Glu Ser Cys Pro Asp  
 1 5 10 15  
 Phe Cys Cys Gly Ser Cys Ser Ser Gln Tyr Cys Cys Ser Asp Val Leu  
 20 25 30  
 Lys Lys Ile Gln Trp Asn Glu Glu Met Cys Pro Glu Pro Glu Ser Ser  
 35 40 45  
 Arg Phe  
 50

<210> 55  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens

<400> 55

Thr Val Phe Val Val Phe Ile Ala Thr Ile Ile Val Cys Phe Thr Cys  
 1 5 10 15  
 Ser Cys Cys Cys Leu Tyr Lys Met Cys Cys Arg Pro Arg Pro Val Val

20

25

30

Ser Asn Thr Thr Thr Thr Thr Val Val His Thr Ala Tyr Pro Gln Pro  
 35 40 45

Gln Pro Val Ala Pro Ser Tyr Pro  
 50 55

&lt;210&gt; 56

&lt;211&gt; 1858

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 56

```

gtcgacccac gcgtccgcgc ggaggttgcg gcggcaccgt ggtcttgggc ttggtccgtc 60
tggtcgccg tccgttggtc tgtcccgcca tggctgcgcc ggccgacctc ctgtggaccc 120
tattgctgct gctgttgctg ctgccgcgc ctccgggtgc ccatggtgag ctgtgcaggc 180
cctttggtga agacaattcg atcccagtg tctgtcctga tttctgttgt ggttcctgtt 240
ccaaccaata ctgctgctcg gacgtgctga ggaaaatcca gtggaatgag gaaatgtgtc 300
ctgagccaga gtccagcaga ttttccacc ccgcggagga gacaccgaa catctgggtt 360
cagcgtcgaa atttcgatcc agttttgaca gtgacctat gtcaggggtc ggagcgaccg 420
tcgcattgg cgtgaccatc tttgtggtgt ttattgccac tatcatcatc tgcttcacct 480
gctcctgctg ctgtctgtat aagatgtgct gccccaacg ccctgtcgtg accaacacca 540
caactactac cgtggttcat gccccttacc ctccagctca acctcaacct gtggccccc 600
gctatcctgg accaacatac cagggtacc atcccatgcc ccccccagcc aggaatgcc 660
gcagcaccct acccaacgca gtaccacca ccctacctgg ccagccccc agggccgcca 720
ccctaccatg agtccttggc tggagccagc cagcctccat acaaccgac ctacatggat 780
tccctaaaga caattccctg aacctgcccc cagcctcttt ggctgccatt tatgtcgtgt 840
gtgagtgaat gatacgcaga gttctttact gctgtctgtg gtgtgtgtgc cttgtctaga 900
catgtggctt cctctgctgt tgaccaggta ggcgcaagtc ttaccagtgt gggtcgggac 960
caacctgttt tcttcctcac ttgaaattgt actttctgaa atttcaagca aattaaaaaac 1020
aataaggtag gaggtatttc ccacgtcacc ccaaggtag cagccatggc ctgtcatact 1080
taggagagca agctttttgc gggtagagag caggctttgg ggggtaacca gctagctgct 1140
gctaggcctt tattcccagg gtttggtgctc attggcagtg aggcagggtg ctgggggtga 1200
caccagggtg caaggggact cagtggcagg ggtcacacc aggcagaaca ccatacactc 1260
tccatcagct gtctgtctgg atgtcactgt cttcccggg gctgtataga gggccacatg 1320
tgttcactat tcaggctcca ctgggggaat tttcctacct ttgctggctt ggctcctgtc 1380
ccagggccag ggacctcggt ctgtctacta cacactctgg tttctccctg cactgtcttt 1440
ttactgttag ccaaactttt tgctgtttt ctgtctccag atgtgtgata attggtgtga 1500
ggttgaaatc cctggttcct ggaggacaga caacctgacc tccgactgtc agtttccctt 1560
gacaccatct tcatagaaat acctgactcc tgtaccacag tccagtttgt ccagtagca 1620
gggacaccaa ggccaatggg ttatctggac caaagggtgg gtggaggggc tagatgggat 1680
ctccggccca gatgtgaata cctccatatt ccctgttggg tcctgtttca ctggctgttt 1740
tagctttgtg ttgattgggtg tttctgagca ttcagactcc gcaccctcat ttctaataaa 1800
tgcaacattg gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaagg gcggccgc 1858

```

&lt;210&gt; 57

&lt;211&gt; 639

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 57

```

atggctgcgc cggcgccctc tctgtggacc ctattgctgc tgctgttget gctgccgccg 60
cctccgggtg cccatggtga gctgtgcagg ccctttggtg aagacaattc gatcccagtg 120
ttctgtcctg atttctgttg tggttcctgt tccaaccaat actgctgctc ggacgtgctg 180
aggaaaatcc agtggaaatga ggaaatgtgt cctgagccag agtccagcag attttccacc 240
cccgcggagg agacacccga acatctgggt tcagcgtga aatttcgatc cagttttgac 300

```

```

agtgacccta tgtcagggtt cggagcgcacc gtcgccattg gcgtgaccat ctttgtggtg 360
tttattgccca ctatcatcat ctgcttcacc tgctcctgct gctgtctgta taagatgtgc 420
tgcccccaac gccctgtcgt gaccaacacc acaactacta ccgtgggttca tgcccccttac 480
cctcagcctc aacctcaacc tgtggccccc agctatcctg gaccaacata ccagggctac 540
catcccatgc cccccccagc caggaatgcc agcagcaccc tacccaacgc agtaccacc 600
accctacctg gcccgccca cagggccgcc accctacca 639

```

&lt;210&gt; 58

&lt;211&gt; 213

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 58

```

Met Ala Ala Pro Ala Pro Ser Leu Trp Thr Leu Leu Leu Leu Leu Leu
  1              5              10              15

Leu Leu Pro Pro Pro Pro Gly Ala His Gly Glu Leu Cys Arg Pro Phe
      20              25              30

Gly Glu Asp Asn Ser Ile Pro Val Phe Cys Pro Asp Phe Cys Cys Gly
      35              40              45

Ser Cys Ser Asn Gln Tyr Cys Cys Ser Asp Val Leu Arg Lys Ile Gln
      50              55              60

Trp Asn Glu Glu Met Cys Pro Glu Pro Glu Ser Ser Arg Phe Ser Thr
      65              70              75              80

Pro Ala Glu Glu Thr Pro Glu His Leu Gly Ser Ala Leu Lys Phe Arg
      85              90              95

Ser Ser Phe Asp Ser Asp Pro Met Ser Gly Phe Gly Ala Thr Val Ala
      100              105              110

Ile Gly Val Thr Ile Phe Val Val Phe Ile Ala Thr Ile Ile Ile Cys
      115              120              125

Phe Thr Cys Ser Cys Cys Cys Leu Tyr Lys Met Cys Cys Pro Gln Arg
      130              135              140

Pro Val Val Thr Asn Thr Thr Thr Thr Thr Val Val His Ala Pro Tyr
      145              150              155              160

Pro Gln Pro Gln Pro Gln Pro Val Ala Pro Ser Tyr Pro Gly Pro Thr
      165              170              175

Tyr Gln Gly Tyr His Pro Met Pro Pro Pro Ala Arg Asn Ala Ser Ser
      180              185              190

Thr Leu Pro Asn Ala Val Pro Thr Thr Leu Pro Gly Pro Ala His Arg
      195              200              205

Ala Ala Thr Leu Pro
      210

```

&lt;210&gt; 59

&lt;211&gt; 26

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 59

Met Ala Ala Pro Ala Pro Ser Leu Trp Thr Leu Leu Leu Leu Leu Leu  
 1 5 10 15

Leu Leu Pro Pro Pro Pro Gly Ala His Gly  
 20 25

&lt;210&gt; 60

&lt;211&gt; 187

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 60

Glu Leu Cys Arg Pro Phe Gly Glu Asp Asn Ser Ile Pro Val Phe Cys  
 1 5 10 15

Pro Asp Phe Cys Cys Gly Ser Cys Ser Asn Gln Tyr Cys Cys Ser Asp  
 20 25 30

Val Leu Arg Lys Ile Gln Trp Asn Glu Glu Met Cys Pro Glu Pro Glu  
 35 40 45

Ser Ser Arg Phe Ser Thr Pro Ala Glu Glu Thr Pro Glu His Leu Gly  
 50 55 60

Ser Ala Leu Lys Phe Arg Ser Ser Phe Asp Ser Asp Pro Met Ser Gly  
 65 70 75 80

Phe Gly Ala Thr Val Ala Ile Gly Val Thr Ile Phe Val Val Phe Ile  
 85 90 95

Ala Thr Ile Ile Ile Cys Phe Thr Cys Ser Cys Cys Cys Leu Tyr Lys  
 100 105 110

Met Cys Cys Pro Gln Arg Pro Val Val Thr Asn Thr Thr Thr Thr Thr  
 115 120 125

Val Val His Ala Pro Tyr Pro Gln Pro Gln Pro Gln Pro Val Ala Pro  
 130 135 140

Ser Tyr Pro Gly Pro Thr Tyr Gln Gly Tyr His Pro Met Pro Pro Pro  
 145 150 155 160

Ala Arg Asn Ala Ser Ser Thr Leu Pro Asn Ala Val Pro Thr Thr Leu  
 165 170 175

Pro Gly Pro Ala His Arg Ala Ala Thr Leu Pro  
 180 185

&lt;210&gt; 61

&lt;211&gt; 86

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 61

Glu Leu Cys Arg Pro Phe Gly Glu Asp Asn Ser Ile Pro Val Phe Cys  
 1 5 10 15

Pro Asp Phe Cys Cys Gly Ser Cys Ser Asn Gln Tyr Cys Cys Ser Asp  
 20 25 30

Val Leu Arg Lys Ile Gln Trp Asn Glu Glu Met Cys Pro Glu Pro Glu  
 35 40 45

Ser Ser Arg Phe Ser Thr Pro Ala Glu Glu Thr Pro Glu His Leu Gly  
 50 55 60

Ser Ala Leu Lys Phe Arg Ser Ser Phe Asp Ser Asp Pro Met Ser Gly  
 65 70 75 80

Phe Gly Ala Thr Val Ala  
 85

&lt;210&gt; 62

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 62

Ile Gly Val Thr Ile Phe Val Val Phe Ile Ala Thr Ile Ile Ile Cys  
 1 5 10 15

Phe Thr Cys Ser Cys Cys Cys Leu Tyr  
 20 25

&lt;210&gt; 63

&lt;211&gt; 76

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 63

Lys Met Cys Cys Pro Gln Arg Pro Val Val Thr Asn Thr Thr Thr Thr  
 1 5 10 15

Thr Val Val His Ala Pro Tyr Pro Gln Pro Gln Pro Gln Pro Val Ala  
 20 25 30

Pro Ser Tyr Pro Gly Pro Thr Tyr Gln Gly Tyr His Pro Met Pro Pro  
 35 40 45

Pro Ala Arg Asn Ala Ser Ser Thr Leu Pro Asn Ala Val Pro Thr Thr  
 50 55 60

Leu Pro Gly Pro Ala His Arg Ala Ala Thr Leu Pro  
 65 70 75

&lt;210&gt; 64

&lt;211&gt; 50

&lt;212&gt; PRT

<213> Mus musculus

<400> 64

```

Cys Pro Asp Phe Cys Cys Gly Ser Cys Ser Asn Gln Tyr Cys Cys Ser
 1             5             10             15

Asp Val Leu Arg Lys Ile Gln Trp Asn Glu Glu Met Cys Pro Glu Pro
      20             25             30

Glu Ser Ser Arg Phe Ser Thr Pro Ala Glu Glu Thr Pro Glu His Leu
      35             40             45

Gly Ser
      50

```

<210> 65

<211> 56

<212> PRT

<213> Mus musculus

<400> 65

```

Cys Phe Thr Cys Ser Cys Cys Cys Leu Tyr Lys Met Cys Cys Pro Gln
 1             5             10             15

Arg Pro Val Val Thr Asn Thr Thr Thr Thr Thr Val Val His Ala Pro
      20             25             30

Tyr Pro Gln Pro Gln Pro Gln Pro Val Ala Pro Ser Tyr Pro Gly Pro
      35             40             45

Thr Tyr Gln Gly Tyr His Pro Met
      50             55

```

<210> 66

<211> 1927

<212> DNA

<213> Homo sapiens

<220>

<221> modified\_base

<222> all "n" positions

<223> n=a, c, g, or t

<400> 66

```

ccccgcctcc aaagctaacc ctcgggcttg aggggaagan gctgactgta cgttccttct 60
actctggcac cactctccag gctgccatgg ggcccagcac ccctctctctc atcttggtcc 120
ttttgtcatg gtcgggaccc ctccaaggac agcagcacca ccttgaggag tacatggaac 180
gccgactagc tgcttttagag gaacggctgg ccagtgcca ggaccagagt agtcggcatg 240
ctgctgagct gcgggacttc aagaacaaga tgctngccac tgctggaggt ggcagagaag 300
gagcgggagg cactcagaac tgaggccgac accatctccg ggagagtggg tctgtctggag 360
cgggaggttag actatctgga gaccagaac ccagctctgc cctgtgtaga gtttgatgag 420
aaggttgact ggaggccctg ggaccaaagg caagggaaga aggaatgaga agtacgatat 480
ggtgacagac tgtggctaca caatctctca agtgagatca atgaagattc tgaagcgatt 540
tggtggccca gctggtctat ggaccaagga tccactgggg caaacagaga agatctacgt 600
gttagatggg acacagaatg acacagcctt tgtcttccca aggctgcgtg acttcaccct 660
tgccatggct gcccggaaag cttcccagat ccgggtgccc tccccctggg taggcacagg 720

```

```

gcagctggta tatggtggct ttctttatct tgctcggagg cctcctggaa gacctgggtg 780
aggtgggtgag atggagaaca ctttgcagct aatcaaattc cacctggcaa accgaacagt 840
ggtggacagc tcagtattcc cagcagaggg gctgatcccc ccctacggct tgacagcaga 900
cacctacatc gacctggcag ctgatgagga aggtctttgg gctgtctatg ccacccggga 960
ggatgacagg cacttggtgc tggccaagtt agatccacag aactggaca cagagcagca 1020
gtgggacaca ccatgtccca gagagaatgc tgaggctgcc tttntcatct gtgggaccct 1080
ctatgtcgtc tataacaccc gtccctgccag tggggcccgc atccagtgtc cctttgatgc 1140
cagcggaccc tgacccctga acgggcagca ctcccttatt ttccccgcag atatggtgcc 1200
catgccagcc tccgctataa cccccgagaa cgccagctct atgcctggga tgatcgctac 1260
cagattgtct ataagctgga gatgaggaag aaagaggagg aggtttgagg agctagcctt 1320
gttttttgca tctttctcac tcccatacat ttatattata tccccactaa atttcttggt 1380
cctcattctt caaatgtggg ccagttgtgg ctcaaattct ctatattttt agccaatggc 1440
aatcaaattc tttcagctcc tttgtttcat acggaactcc agatcctgag taatcctttt 1500
agagcccga gagtcaaaac cctcaatggt cctcctgtct ctctgcccc atgtcaacaa 1560
atctcaggct aaggatgccc cagaccaggg gctctaacct tgtatgcggg caggcccagg 1620
gagcaggcag cagtgttctt cccctcagag tgacttgggg agggagaaat aggaggagac 1680
gtccagctct gtcctctctt cctcactcct cccttcagtg tcctcaggaa caggactttc 1740
tccacattgt tttgtattgc aacattttgc attaaaaagg aaaatccana aaaaaaaaaa 1800
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860
aaactgcggc cgctgtccct tctgtcgtct tctcgcagcc gtacccttct gtcgtcttct 1920
cgcagcc 1927

```

<210> 67

<211> 319

<212> PRT

<213> Homo sapiens

<400> 67

```

Met Val Gly Lys Met Trp Pro Val Leu Trp Thr Leu Cys Ala Val Arg
 1             5             10            15

Val Thr Val Asp Ala Ile Ser Val Glu Thr Pro Gln Asp Val Leu Arg
      20             25            30

Ala Ser Gln Gly Lys Ser Val Thr Leu Pro Cys Thr Tyr His Thr Ser
 35             40            45

Thr Ser Ser Arg Glu Gly Leu Ile Gln Trp Asp Lys Leu Leu Leu Thr
 50             55            60

His Thr Glu Arg Val Val Ile Trp Pro Phe Ser Asn Lys Asn Tyr Ile
 65             70            75            80

His Gly Glu Leu Tyr Lys Asn Arg Val Ser Ile Ser Asn Asn Ala Glu
      85             90            95

Gln Ser Asp Ala Ser Ile Thr Ile Asp Gln Leu Thr Met Ala Asp Asn
 100            105            110

Gly Thr Tyr Glu Cys Ser Val Ser Leu Met Ser Asp Leu Glu Gly Asn
 115            120            125

Thr Lys Ser Arg Val Arg Leu Leu Val Leu Val Pro Pro Ser Lys Pro
 130            135            140

Glu Cys Gly Ile Glu Gly Glu Thr Ile Ile Gly Asn Asn Ile Gln Leu
 145            150            155            160

```

Thr Cys Gln Ser Lys Glu Gly Ser Pro Thr Pro Gln Tyr Ser Trp Lys  
 165 170 175  
 Arg Tyr Asn Ile Leu Asn Gln Glu Gln Pro Leu Ala Gln Pro Ala Ser  
 180 185 190  
 Gly Gln Pro Val Ser Leu Lys Asn Ile Ser Thr Asp Thr Ser Gly Tyr  
 195 200 205  
 Tyr Ile Cys Thr Ser Ser Asn Glu Glu Gly Thr Gln Phe Cys Asn Ile  
 210 215 220  
 Thr Val Ala Val Arg Ser Pro Ser Met Asn Val Ala Leu Tyr Val Gly  
 225 230 235 240  
 Ile Ala Val Gly Val Val Ala Ala Leu Ile Ile Ile Gly Ile Ile Ile  
 245 250 255  
 Tyr Cys Cys Cys Cys Arg Gly Lys Asp Asp Asn Thr Glu Asp Lys Glu  
 260 265 270  
 Asp Ala Arg Pro Asn Arg Glu Ala Tyr Glu Glu Pro Pro Glu Gln Leu  
 275 280 285  
 Arg Glu Leu Ser Arg Glu Arg Glu Glu Glu Asp Asp Tyr Arg Gln Glu  
 290 295 300  
 Glu Gln Arg Ser Thr Gly Arg Glu Ser Pro Asp His Leu Asp Gln  
 305 310 315

<210> 68  
 <211> 2793  
 <212> DNA  
 <213> Homo sapiens

<400> 68  
 ctaccccttt gtgagcagtc taggactttg tacacctgtt aagtagggag aaggcagggg 60  
 aggtggctgg tttaagggga acttgaggga agtaggggaag actcctcttg ggaccttttg 120  
 agtaggtgac acatgagccc agccccagct cacctgcca tccagctgag gagctcacct 180  
 gccaatccag ctgaggctgg gcagaggtgg gtgagaagag ggaaaattgc agggacctcc 240  
 agttgggcca ggccagaagc tgctgtagct ttaaccagac agctcagacc tgtctggagg 300  
 ctgccagtga caggttaggt ttagggcaga gaagaagcaa gaccatggtg gggaagatgt 360  
 ggctgtgtt gtggacactc tgtgcagtca ggtgaccgt cgatgccatc tctgtggaaa 420  
 ctccgcagga cgttcttcgg gcttcgcagg gaaagagtgt caccctgccc tgcacctacc 480  
 acacttccac ctccagtcga gagggactta ttcaatggga taagctcctc ctcactcata 540  
 cggaaagggt ggtcatctgg ccgttttcaa acaaaaacta catccatggt gagctttata 600  
 agaatcgcg cagcatatcc aacaatgctg agcagtccga tgcctccatc accattgatc 660  
 agctgaccat ggctgacaac ggcacctacg agtggtctgt ctcgctgatg tcagacctgg 720  
 agggcaacac caagtcacgt gtccgcctgt tggtcctcgt gccaccctcc aaaccagaat 780  
 gcggcatcga gggagagacc ataattggga acaacatcca gctgacctgc caatcaaagg 840  
 agggctcacc aaccctcag tacagctgga agaggtaaca catcctgaat caggagcagc 900  
 ccctggccca gccagcctca ggtcagcctg tctccctgaa gaatatctcc acagacacat 960  
 cgggttacta catctgtacc tccagcaatg aggaggggac gcagttctgc aacatcacgg 1020  
 tggccgtcag atctccctcc atgaacgtgg ccctgtatgt gggcatcgcg gtgggctgtg 1080  
 ttgcagccct cattatcatt ggcacatca tctactgctg ctgctgccga gggaaggacg 1140  
 acaacactga agacaaggag gatgcaaggc cgaaccggga agcctatgag gagccaccag 1200  
 agcagctaag agaactttcc agagagaggg aggaggagga tgactacagg caagaagagc 1260

```

agaggagcac tgggcgtgaa tccccggacc acctcgacca gtgacaggcc agcagcagag 1320
ggcggcgagg gaagggttag gggttcattc tcccgttcc tggcctccct tctcctttct 1380
aagccctgtt ctcctgtccc tccatcccag acattgatgg ggacatttct tccccagtgt 1440
cagctgtggg gaacatggct ggcctggtaa ggggggtccct gtgctgatcc tgctgacctc 1500
actgtcctgt gaagtaaccc ctccctggctg tgacacctgg tgcgggcctg gccctcactc 1560
aagaccaggc tgcagcctcc acttccctcg tagttggcag gagctcctgg aagcacagcg 1620
ctgagcatgg ggcgctccca ctcagaactc tccagggagg cgatgccagc cttggggggg 1680
gggggctgtc ctgctcacct gtgtgccag cacctggagg ggcaccagggt ggaggggtttg 1740
cactccacac atctttcttg aatgaatgaa agaataagt agtatgcttg ggcctgcat 1800
tggcctggcc tccagctccc actcccttc caacctcact tcccgtagct gccagtatgt 1860
tccaaaccct cctgggaagg ccacctccca ctctgctgc acaggccctg gggagctttt 1920
gcccacacac tttccatctc tgcctgtcaa tatcgtacct gtccctccag gccatctca 1980
aatcacaagg atttctctaa ccctatccta attgtccaca tacgtggaaa caatcctgtt 2040
actctgtccc acgtccaatc atgggccaca aggcacagtc ttctgagcga gtgctctcac 2100
tgtattagag cgccagctcc ttggggcagg gctgggcct catggctttt gctttccctg 2160
aagccctagt agctggcgcc catcctagt ggcacttaag ctttaattggg gaaactgctt 2220
tgattggttg tgccttccct tctctggtct ccttgagatg atcgtagaca cagggatgat 2280
tcccacccaa acccacgtat tcattcagtg agttaaacac gaattgattt aaagtgaaca 2340
cacacaaggg agcttgcttg cagatggtct gagttcttgt gtccctggtaa ttcctctcca 2400
ggccagaata attggcatgt ctctcaacc cacatgggggt tcttggttgt tctgcatcc 2460
cgatacctca gccctggccc tgcccagccc atttgggctc tgggtttctg gtggggctgt 2520
cctgctgccc tcccacagcc tccttctgtt tgtcgagcat ttcttctact cttgagagct 2580
caggcagcgt tagggctgct taggtctcat ggaccagtgg ctggtctcac ccaactgcag 2640
tttactattg ctatcttttc tggatgatca gaaaaataat tccataaatc tattgtctac 2700
ttgcgatttt ttaaaaaatg tatattttta tatatattgt taaatccttt gcttcattcc 2760
aaatgctttc agtaataata aaattgtggg tgg 2793

```

&lt;210&gt; 69

&lt;211&gt; 52

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 69

```

Lys Thr Ala Leu Gly Glu Leu Leu Lys Pro Leu Asn Ser Glu Tyr Gly
  1                      5                      10                     15

```

```

Lys Val Ala Pro Gly Trp Gly Thr Thr Pro Leu Met Gly Val Phe Met
      20                      25                     30

```

```

Ala Leu Phe Ala Val Phe Leu Leu Ile Ile Leu Glu Ile Tyr Asn Ser
    35                      40                     45

```

```

Ser Val Leu Leu
    50

```

&lt;210&gt; 70

&lt;211&gt; 1832

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; all "n" positions

&lt;223&gt; n=a, c, g, or t

&lt;400&gt; 70

```

tgtggctgac gtcactctgga ggagatttgc tttctttttc tccaaaaggg gaggaaattg 60

```

```

aaactgcagt ggcccacgat ggggaagaggg gaaagcccag gggtagacagga ggccctctggg 120
tgaaggcaga ggctaacatg ggggttcggag cgaccttggc cgttggctga ccatctttgt 180
gctgtctgtc gtcactatca tcatctgctt cacctgtccc tgctgctgcc ttacaagac 240
gtgccgccga ccacgtccgg ttgtcaccac caccacatcc accactgtgg tgcattgcccc 300
ttatcctcag cctccaagtg tgccgcccag ctaccctgga ccaagctacc agggctacca 360
caccatgccg cctcagccag ggatgccagc agcaccctac ccaatgcagt acccaccacc 420
ttaccagacc cagcccattg gccaccggc ctaccacgag accctggctg gaggagcagc 480
cgcgccctam cccgscagcc agcctcctta caaccggcc tacatggatg cccgaagcgg 540
ccctctgagc attccctggc ctctytggct gccacttggg tatgttgtgt gtgtgctga 600
gtgggtgtgca ggcgcgggtt cttacgcccc atgtgtgtgt tggtgtgtcca ggcacgggtt 660
cttacgcccc atgtgtgtgt tggtgtgtct gcctgtatat gtggcttctt ctgatgtgta 720
caagtgggga acaatccttg ccagagtggg ctgggaccag actttgttct cttcctcacc 780
tgaaattatg cttcctaataa tctcaagcca aactcaaaga atgggggtgt ggggggcacc 840
ctgtgaggtg gcccctgaga ggtggggggc tctccagggc acatctggag ttcttctcca 900
gcttacccta gggtagccaa gtagggcctg tcacaccagg gtggcgcast ttctgtgtga 960
tgcagatgtg tcttggtttc ggcagcgtag ccagctgctg cttgaggcca tggctcgtcc 1020
cgggagttgg gggtagccgt tgcagagcca gggacatgat gcaggcgaag yttgggatct 1080
ggccaagtgg gactttgatc ctttgggcag atgtcccatt gctccctgga gcctgtcatg 1140
cctgttgggg atcaggcagc ctctgtatgc cagaacacct caggcagagc cctactcagc 1200
tgtacctgtc tgccctggact gtcccctgtc cccgcatctc ccctgggacc agctggaggg 1260
ccacatgcac acacagccta gctgccccca gggagctctg ctgccccttg tggccctgcc 1320
cttcccacag gtgagcaggg ctctgttcca ccagcacact cagttctctt ccctgcagt 1380
ttttcatttt atttttagcca aacattttgc ctgttttctg tttcaaaccat gatagtgtat 1440
atgagactga aacccttggg ttgtggaggg aaattggctc agagatggac aacctggcaa 1500
ctgtgagtcg ctgcttcccc acaccagcct catggaatat gcaacaactc ctgtacccca 1560
gtccacgggt ttctggcagc agggacacct gggccaatgg gccatctgga ccaaagggtg 1620
gggtgtgggg cctggatggc agctctggcc cagacatgaa tacctcgtgt tcctcctccc 1680
tctattactg ttccaccaga gctgtcttag ctcaaactctg ttgtgtttct gagtctaggg 1740
tctgtacact tgttttataat aaatgcaatc gtttnggaaa aaaaananaa aaaaaaaagg 1800
ggsggcgctc taaaaggatn cccnaaggg gg 1832

```

&lt;210&gt; 71

&lt;211&gt; 51

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 71

```

Ser Pro Arg Ser Lys Pro Thr Ala Gln Tyr Gln Trp Glu Arg Leu Ala
  1                      5                      10                      15

```

```

Pro Ser Ser Gln Val Phe Phe Gly Pro Ala Leu Asp Ala Val Arg Gly
      20                      25                      30

```

```

Ser Leu Lys Leu Thr Asn Leu Ser Ile Ala Met Ser Gly Val Tyr Val
      35                      40                      45

```

```

Cys Lys Ala
      50

```

&lt;210&gt; 72

&lt;211&gt; 2557

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 72

```

gaattccggg agaagtgacc agagcaattt ctgcttttca caggggcgggt ttctcaacgg 60
tgacttgtgg gcagtgcctt ctgctgagcg agtcatggcc cgaaggcaga actaactgtg 120

```

```

cctgcagtct tcactctcag gatgcagccg aggtggggccc aagggggccac gatgtggttt 180
ggagtcctgc tgacccttct gctctgttca agccttgagg gtcaagaaaa ctctttcaca 240
atcaacagtg ttgacatgaa gagcctgccg gactggacgg tgcaaaatgg gaagaacctg 300
accctgcagt gcttcgcgga tgtcagcacc acctctcacg tcaagcctca gcaccagatg 360
ctgtttctata aggatgacgt gctgttttac aacatctcct ccatgaagag cacagagagt 420
tattttattc ctgaagtccg gatctatgac tcagggacat ataaatgtac tgtgattgtg 480
aacaacaaag agaaaaccac tgcagagtac cagctgttgg tggaggaggt gccaggtccc 540
aggggtgacac tggacaagaa agaggccatc caaggtggga tcgtgagggg caactgttct 600
gtcccagagg aaaaggcccc aatacacttc acaattgaaa aacttgaact aaatgaaaaa 660
atggtcaagc tgaagagaga gaagaattct cgagaccaga attttgtgat actggaattc 720
ccggttgagg aacaggaccg cgttttatcc ttccgatgtc aagctaggat cttttctggg 780
atccatagtc agacctcaga atctaccaag agtgaactgg tcaccgtgac ggaatccttc 840
tctacacca agttccacat cagccccacc ggaatgatca tggaggagc tcagctccac 900
attaagtga ccattcaagt gactcacctg gccaggagt ttccagaaat cataattcag 960
aaggacaagg cgattgtggc ccacaacaga catggcaaca aggtgtgtg ctcagtcag 1020
gccatggtgg agcacagtgg caactacacg tgcaaaagtgg agtccagccg catatccaag 1080
gtcagcagca tcgtggtcaa cataacagaa ctattttcca agcccgaact ggaatcttcc 1140
ttcacacatc tggaccaagg tgaagactg aacctgtcct gctccatccc aggagcacct 1200
ccagccaact tcaccatcca gaaggaagat acgattgtgt cacagactca agatttcacc 1260
aagatagcct caaagtcgga cagtgggacg tatatctgca ctgcaggtat tgacaaagtg 1320
gtcaagaaaa gcaacacagt ccagatagtc gtatgtgaaa tgctctccca gccaggatt 1380
tcttatgatg cccagtttga ggtcataaaa ggacagacca tcgaagtccg ttgcgaatcg 1440
atcagtggaa ctttgcctat ttcttaccaa cttttaaaaa caagtaaagt tttggagaat 1500
agtaccaaga actcaaatga tcctgcggtt ttcaaagaca accccactga agacgtcgaa 1560
taccagtgtg ttgcagataa ttgccattcc catgccaaaa tgttaagtga ggttctgagg 1620
gtgaaggtga tagccccggt ggatgaggtc cagatttcta tcctgtcaag taaggtggtg 1680
gagtctggag aggacattgt gctgcaatgt gctgtgaatg aaggatctgg tcccatcacc 1740
tataagtttt acagagaaaa agagggcaaa cccttctatc aaatgacctc aaatgccacc 1800
caggcatttt ggaccaagca gaaggctagc aaggaacagg agggagagta ttactgcaca 1860
gccttcaaca gagccaacca cgctccagt gtcccagaa gcaaaatact gacagtcaga 1920
gtcattcttg ccccatggaa gaaaggactt attgcagtgg ttatcatcgg agtgatcatt 1980
gctctcttga tcattgcggc caaatgttat tttctgagga aagccaaggc caagcagatg 2040
ccagtggaaa tgtccaggcc agcagtacca cttctgaact ccaacaacga gaaaatgtca 2100
gatcccaata tggaagctaa cagtcattac ggtcacatg acgatgtcag aaaccatgca 2160
atgaaaccaaa taaatgataa taaagagcct ctgaactcag acgtgcagta cacggaagtt 2220
caagtgtcct cagctgagtc tcacaaagat ctaggaaaga aggacacaga gacagtgtag 2280
agtgaagtcc ggaaagctgt ccctgatgcc gtggaaagca gatactctag aacggaaggc 2340
tcccttgatg gaacttagac agcaaggcca gatgcacatc cctggaagga catccatgtt 2400
ccgagaagaa cagataatcc ctgtatttca agacctctgt gcacttattt atgaacctgc 2460
cctgctccca cagaacacag caattcctca ggctaagctg ccggttctta aatccatcct 2520
gctaagttaa tgttgggtag aaagagatac agagggg 2557

```

<210> 73  
 <211> 738  
 <212> PRT  
 <213> Homo sapiens

<400> 73  
 Met Gln Pro Arg Trp Ala Gln Gly Ala Thr Met Trp Leu Gly Val Leu  
 1 5 10 15  
 Leu Thr Leu Leu Leu Cys Ser Ser Leu Glu Gly Gln Glu Asn Ser Phe  
 20 25 30  
 Thr Ile Asn Ser Val Asp Met Lys Ser Leu Pro Asp Trp Thr Val Gln  
 35 40 45  
 Asn Gly Lys Asn Leu Thr Leu Gln Cys Phe Ala Asp Val Ser Thr Thr

50	55	60
Ser His Val Lys Pro Gln His Gln Met Leu Phe Tyr Lys Asp Asp Val 65 70 75 80		
Leu Phe Tyr Asn Ile Ser Ser Met Lys Ser Thr Glu Ser Tyr Phe Ile 85 90 95		
Pro Glu Val Arg Ile Tyr Asp Ser Gly Thr Tyr Lys Cys Thr Val Ile 100 105 110		
Val Asn Asn Lys Glu Lys Thr Thr Ala Glu Tyr Gln Leu Leu Val Glu 115 120 125		
Gly Val Pro Ser Pro Arg Val Thr Leu Asp Lys Lys Glu Ala Ile Gln 130 135 140		
Gly Gly Ile Val Arg Val Asn Cys Ser Val Pro Glu Glu Lys Ala Pro 145 150 155 160		
Ile His Phe Thr Ile Glu Lys Leu Glu Leu Asn Glu Lys Met Val Lys 165 170 175		
Leu Lys Arg Glu Lys Asn Ser Arg Asp Gln Asn Phe Val Ile Leu Glu 180 185 190		
Phe Pro Val Glu Glu Gln Asp Arg Val Leu Ser Phe Arg Cys Gln Ala 195 200 205		
Arg Ile Ile Ser Gly Ile His Met Gln Thr Ser Glu Ser Thr Lys Ser 210 215 220		
Glu Leu Val Thr Val Thr Glu Ser Phe Ser Thr Pro Lys Phe His Ile 225 230 235 240		
Ser Pro Thr Gly Met Ile Met Glu Gly Ala Gln Leu His Ile Lys Cys 245 250 255		
Thr Ile Gln Val Thr His Leu Ala Gln Glu Phe Pro Glu Ile Ile Ile 260 265 270		
Gln Lys Asp Lys Ala Ile Val Ala His Asn Arg His Gly Asn Lys Ala 275 280 285		
Val Tyr Ser Val Met Ala Met Val Glu His Ser Gly Asn Tyr Thr Cys 290 295 300		
Lys Val Glu Ser Ser Arg Ile Ser Lys Val Ser Ser Ile Val Val Asn 305 310 315 320		
Ile Thr Glu Leu Phe Ser Lys Pro Glu Leu Glu Ser Ser Phe Thr His 325 330 335		
Leu Asp Gln Gly Glu Arg Leu Asn Leu Ser Cys Ser Ile Pro Gly Ala 340 345 350		
Pro Pro Ala Asn Phe Thr Ile Gln Lys Glu Asp Thr Ile Val Ser Gln 355 360 365		

Thr Gln Asp Phe Thr Lys Ile Ala Ser Lys Ser Asp Ser Gly Thr Tyr  
 370 375 380  
 Ile Cys Thr Ala Gly Ile Asp Lys Val Val Lys Lys Ser Asn Thr Val  
 385 390 395 400  
 Gln Ile Val Val Cys Glu Met Leu Ser Gln Pro Arg Ile Ser Tyr Asp  
 405 410 415  
 Ala Gln Phe Glu Val Ile Lys Gly Gln Thr Ile Glu Val Arg Cys Glu  
 420 425 430  
 Ser Ile Ser Gly Thr Leu Pro Ile Ser Tyr Gln Leu Leu Lys Thr Ser  
 435 440 445  
 Lys Val Leu Glu Asn Ser Thr Lys Asn Ser Asn Asp Pro Ala Val Phe  
 450 455 460  
 Lys Asp Asn Pro Thr Glu Asp Val Glu Tyr Gln Cys Val Ala Asp Asn  
 465 470 475 480  
 Cys His Ser His Ala Lys Met Leu Ser Glu Val Leu Arg Val Lys Val  
 485 490 495  
 Ile Ala Pro Val Asp Glu Val Gln Ile Ser Ile Leu Ser Ser Lys Val  
 500 505 510  
 Val Glu Ser Gly Glu Asp Ile Val Leu Gln Cys Ala Val Asn Glu Gly  
 515 520 525  
 Ser Gly Pro Ile Thr Tyr Lys Phe Tyr Arg Glu Lys Glu Gly Lys Pro  
 530 535 540  
 Phe Tyr Gln Met Thr Ser Asn Ala Thr Gln Ala Phe Trp Thr Lys Gln  
 545 550 555 560  
 Lys Ala Ser Lys Glu Gln Glu Gly Glu Tyr Tyr Cys Thr Ala Phe Asn  
 565 570 575  
 Arg Ala Asn His Ala Ser Ser Val Pro Arg Ser Lys Ile Leu Thr Val  
 580 585 590  
 Arg Val Ile Leu Ala Pro Trp Lys Lys Gly Leu Ile Ala Val Val Ile  
 595 600 605  
 Ile Gly Val Ile Ile Ala Leu Leu Ile Ile Ala Ala Lys Cys Tyr Phe  
 610 615 620  
 Leu Arg Lys Ala Lys Ala Lys Gln Met Pro Val Glu Met Ser Arg Pro  
 625 630 635 640  
 Ala Val Pro Leu Leu Asn Ser Asn Asn Glu Lys Met Ser Asp Pro Asn  
 645 650 655  
 Met Glu Ala Asn Ser His Tyr Gly His Asn Asp Asp Val Arg Asn His  
 660 665 670  
 Ala Met Lys Pro Ile Asn Asp Asn Lys Glu Pro Leu Asn Ser Asp Val

675					680					685					
Gln.	Tyr	Thr	Glu	Val	Gln	Val	Ser	Ser	Ala	Glu	Ser	His	Lys	Asp	Leu
690					695					700					
Gly	Lys	Lys	Asp	Thr	Glu	Thr	Val	Tyr	Ser	Glu	Val	Arg	Lys	Ala	Val
705					710					715					720
Pro	Asp	Ala	Val	Glu	Ser	Arg	Tyr	Ser	Arg	Thr	Glu	Gly	Ser	Leu	Asp
725					730					735					
Gly Thr															

```
<210> 74
<211> 601
<212> DNA
<213> Rattus norvegicus
```

```
<220>
<221> modified_base
<222> all "n" positions
<223> n=a, c, g, or t
```

<400> 74						
gnnnnnnnnagg	tntanagncn	cctttacncc	gccgcggacg	cgtggggcggga	cgcgtggsgt	60
gctgtggagc	aagaagcaac	ccgaagctag	gagtcgtca	gcgagggcag	gggctgcctg	120
gttggggtag	gagtgggagc	agggccagca	ggaggggtctg	aggaagccat	tcaaagcgag	180
cagctgggag	agctggggag	ccgggaaggg	cctacagact	acaagagagg	atcctggcgt	240
ctgggcctcc	tgggtcatca	ccatgaggcc	acttcttgcc	ctgctgcttc	tgggtctggc	300
atcaggctct	cctcctctgg	acgacaacaa	gatccccagc	ctgtgtcccg	ggcagcccgg	360
cctcccaggc	acaccaggcc	accacggcag	ccaaggcctg	cctggccgtg	acggccgtga	420
tggccgcgac	ggtgcacccg	gagctccggg	agagaaaggc	gagggcgggga	gaccgggact	480
acctggggcca	cgtngggagc	ccgggcccgc	tggagaggca	ggacctgtgg	gggctatcgg	540
gcctggngggg	gaatgctcgg	tgccccacga	tcagcttcag	tgccaagcga	tcagaaaagcc	600
c						601

```
<210> 75
<211> 732
<212> DNA
<213> Rattus norvegicus
```

```
<220>  
<221> modified_base  
<222> all "n" positions  
<223> n=a, c, g, or t
```

<400> 75						
gngngttnnn	ttccnccctcc	gacttaaggc	tgccatgggg	cccagtgtctc	ctctgtctcct	60
cttcttccctt	ttgtcatggc	cgggaccct	tcagggaacag	cagcaccacc	ttgtggagta	120
catggaacgc	cgactagctg	ccttagagga	gcggctggca	cagtgccagg	atcagagcag	180
tcggcatgct	gctgagcttc	gggacttcaa	aaacaagatg	ctgcctctac	tggaggtggc	240
agagaaggag	cgggaaacac	tcagaaccga	ggcagacagc	atttcaggaa	gagtggaccg	300
tcttgaacgg	gaagtagact	acctggagac	acagaaccca	gctttgccct	gtgtagaact	360
ggatgagaag	gtgactggag	gccctggaac	caaaggcaag	ggccggagaa	atgagaaata	420
cgatatggtg	acagactgta	gctacacaat	ctctcaggtg	aggtcaatga	agatcctgaa	480
gcggttttgg	ggctcagctg	gcctatggac	caaggatcca	ctggggccag	canagaagat	540

ctacgtgtta gacggnacgc agaacgacac ggccttcgtt ttccganggt gcgtgactta 600  
 ccctcaccat ggctgccgca aagttccgaa tcgggtgccc ttncctgggt agnacaagaa 660  
 aactgggtgn tgtggcttcc tttttatctc aangcntctg gaggaacttg nanggggggn 720  
 nggtggnaaa at 732

<210> 76  
 <211> 177  
 <212> PRT  
 <213> Homo sapiens

<400> 76  
 Gln Leu Gln Leu His Leu Pro Ala Asn Arg Leu Gln Ala Val Glu Glu  
 1 5 10 15  
 Gly Glu Ser Gly Ala Ser Ala Trp Tyr Thr Leu His Arg Glu Val Ser  
 20 25 30  
 Ser Ser Gln Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe Lys Gln  
 35 40 45  
 Lys Glu Lys Glu Asp Gln Val Leu Ser Tyr Ile Asn Gly Val Thr Thr  
 50 55 60  
 Ser Lys Pro Gly Val Ser Leu Val Tyr Ser Met Pro Ser Arg Asn Leu  
 65 70 75 80  
 Ser Leu Arg Val Glu Gly Leu Gln Glu Lys Asp Ser Gly Pro Tyr Ser  
 85 90 95  
 Cys Ser Val Asn Val Gln Asp Lys Gln Gly Lys Ser Arg Gly His Ser  
 100 105 110  
 Ile Lys Thr Leu Glu Leu Asn Val Leu Val Pro Pro Ala Pro Pro Ser  
 115 120 125  
 Cys Arg Leu Gln Gly Val Pro His Val Gly Ala Asn Val Thr Leu Ser  
 130 135 140  
 Cys Gln Ser Pro Arg Ser Lys Pro Ala Val Gln Tyr Gln Trp Asp Arg  
 145 150 155 160  
 Gln Leu Pro Ser Phe Gln Thr Phe Phe Ala Pro Ala Leu Asp Val Ile  
 165 170 175  
 Arg

<210> 77  
 <211> 735  
 <212> DNA  
 <213> Homo sapiens

<400> 77  
 atgcgtctgt ttgtccgtcc gtccgtccgt cccgccatgg ctgcgccggc gccctctccg 60  
 tggacccttt cgctgctgct gttgttgcta ctgccgtctc cgggtgccc tggcgagctg 120  
 tgcaggccct tcgggtgaaga caattcgatc ccagagtcct gtcctgactt ctgttggtggc 180  
 tcctgttcca gccaataactg ctgctctgac gtgctgaaga aaatccagtg gaatgaggaa 240  
 atgtgccctg agccagagtc cagcagatct tccgccacc cggagacacc agaacagctg 300  
 ggttcagcgc tgaagtatca gtccagtctt gacagtgaaca acatgccagg gttcggagcg 360  
 accgtggcca tcggcctgac cgtcttcgtg gtgtttatcg ctaccatcat tgtgtgcttt 420  
 acctgctcct gctgctgtct atataagatg tgctgccgcc cagcaccgtg cgtgtccaac 480  
 accacaacta ctaccgtggg tcacaccgct taccctcagc ctcaacctgt ggccccagc 540  
 tatcctggac caacatacca gggctaccat cccatgcccc cccagccagg aatgccagca 600  
 gcaccctacc caacgcagta ccctccaccc tacctggccc agcccacagg gccaccagcc 660  
 tatcatgaga cgttggctgg agccagccag cctccatata acccggccta catggatccc 720  
 ccaaggtag ttccc 735

<210> 78

<211> 18  
 <212> PRT  
 <213> Homo sapiens

<400> 78  
 Gly Ser Leu Ser Leu Thr Asn Leu Ser Ser Ser Met Ala Gly Val Tyr  
 1 5 10 15  
 Val Cys

<210> 79  
 <211> 22  
 <212> PRT  
 <213> Homo sapiens

<400> 79  
 Lys Ala His Asn Glu Val Gly Thr Ala Gln Cys Asn Val Thr Leu Glu  
 1 5 10 15  
 Val Ser Thr Gly Pro Gly  
 20

<210> 80  
 <211> 728  
 <212> DNA  
 <213> Homo sapiens

<400> 80  
 atgaggccac tcctcgtcct gctgctcctg ggccctggcgg ccggctcgcc cccactggac 60  
 gacaacaaga tccccagcct ctgcccgggg caccgccggc ttccaggcac gccggggccac 120  
 catggcagcc agggccttgc gggccgcgat ggccgcgacg gccgcgacgg cgcgcccggg 180  
 gctccgggag agaaaggcga gggcgggagg cgggactgcc gggacctcga ggggaccccg 240  
 ggccgcgagg agaggcggga cccgcggggc ccaccggggc tgccggggag tgctcggtag 300  
 ctccgcgata cgctttcagc gccaaagcgt ccgagagccg ggtgcctccg ccgtctgacg 360  
 cacccttgcc cttcgaccgc gtgctggtga acgagcaggg acattacgac gccgtcaccg 420  
 gcaagttcac ctgccagggt cctgggggtct actacttcgc cgtccatgcc accgtctacc 480  
 gggccagcct gcagtttgat ctggtgaaga atggcgaatc ccttgccctct ttcttccagt 540  
 ttttcggggg gtggcccaag ccagcctcgc tctcgggggg ggccatggtg aggtcggagc 600  
 ctgaggacca agtgtgggtg cagggtgggtg tgggtgacta cattggcatc tatgccagca 660  
 tcaagacaga cagcaccttc tccggatttc tgggtgtact cgactggcac agctccccag 720  
 tctttgct 728

<210> 81  
 <211> 206  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (13)  
 <223> Xaa=unknown amino acid

<400> 81  
 Met Ile Ser Leu Pro Gly Pro Leu Val Thr Asn Leu Xaa Arg Phe Leu  
 1 5 10 15  
 Phe Leu Gly Leu Ser Ala Leu Ala Pro Pro Ser Arg Ala Gln Leu Gln  
 20 25 30  
 Leu His Leu Pro Ala Asn Arg Leu Gln Ala Val Glu Glu Gly Glu Ser  
 35 40 45

Gly Ala Ser Ala Trp Tyr Thr Leu His Arg Glu Val Ser Ser Ser Gln  
 50 55 60  
 Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe Lys Gln Lys Glu Lys  
 65 70 75 80  
 Glu Asp Gln Val Leu Ser Tyr Ile Asn Gly Val Thr Thr Ser Lys Pro  
 85 90 95  
 Gly Val Ser Leu Val Tyr Ser Met Pro Ser Arg Asn Leu Ser Leu Arg  
 100 105 110  
 Val Glu Gly Leu Gln Glu Lys Asp Ser Gly Pro Tyr Ser Cys Ser Val  
 115 120 125  
 Asn Val Gln Asp Lys Gln Gly Lys Ser Arg Gly His Ser Ile Lys Thr  
 130 135 140  
 Leu Glu Leu Asn Val Leu Val Pro Pro Ala Pro Pro Ser Cys Arg Leu  
 145 150 155 160  
 Gln Gly Val Pro His Val Gly Ala Asn Val Thr Leu Ser Cys Gln Ser  
 165 170 175  
 Pro Arg Ser Lys Pro Ala Val Gln Tyr Gln Trp Asp Arg Gln Leu Pro  
 180 185 190  
 Ser Phe Gln Thr Phe Phe Ala Pro Ala Leu Asp Val Ile Arg  
 195 200 205

&lt;210&gt; 82

&lt;211&gt; 217

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 82

Gln Leu Gln Leu His Leu Pro Ala Asn Arg Leu Gln Ala Val Glu Glu  
 1 5 10 15  
 Gly Glu Ser Gly Ala Ser Ala Trp Tyr Thr Leu His Arg Glu Val Ser  
 20 25 30  
 Ser Ser Gln Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe Lys Gln  
 35 40 45  
 Lys Glu Lys Glu Asp Gln Val Leu Ser Tyr Ile Asn Gly Val Thr Thr  
 50 55 60  
 Ser Lys Pro Gly Val Ser Leu Val Tyr Ser Met Pro Ser Arg Asn Leu  
 65 70 75 80  
 Ser Leu Arg Val Glu Gly Leu Gln Glu Lys Asp Ser Gly Pro Tyr Ser  
 85 90 95  
 Cys Ser Val Asn Val Gln Asp Lys Gln Gly Lys Ser Arg Gly His Ser  
 100 105 110  
 Ile Lys Thr Leu Glu Leu Asn Val Leu Val Pro Pro Ala Pro Pro Ser  
 115 120 125  
 Cys Arg Leu Gln Gly Val Pro His Val Gly Ala Asn Val Thr Leu Ser  
 130 135 140  
 Cys Gln Ser Pro Arg Ser Lys Pro Ala Val Gln Tyr Gln Trp Asp Arg  
 145 150 155 160  
 Gln Leu Pro Ser Phe Gln Thr Phe Phe Ala Pro Ala Leu Asp Val Ile  
 165 170 175  
 Arg Gly Ser Leu Ser Leu Thr Asn Leu Ser Ser Ser Met Ala Gly Val  
 180 185 190  
 Tyr Val Cys Lys Ala His Asn Glu Val Gly Thr Ala Gln Cys Asn Val  
 195 200 205  
 Thr Leu Glu Val Ser Thr Gly Pro Gly  
 210 215

&lt;210&gt; 83

&lt;211&gt; 220

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 83

Gln	Leu	Gln	Leu	His	Leu	Pro	Ala	Asn	Arg	Leu	Gln	Ala	Val	Glu	Glu
1				5					10					15	
Gly	Glu	Ser	Gly	Ala	Ser	Ala	Trp	Tyr	Thr	Leu	His	Arg	Glu	Val	Ser
			20					25					30		
Ser	Ser	Gln	Pro	Trp	Glu	Val	Pro	Phe	Val	Met	Trp	Phe	Phe	Lys	Gln
		35					40					45			
Lys	Glu	Lys	Glu	Asp	Gln	Val	Leu	Ser	Tyr	Ile	Asn	Gly	Val	Thr	Thr
	50					55					60				
Ser	Lys	Pro	Gly	Val	Ser	Leu	Val	Tyr	Ser	Met	Pro	Ser	Arg	Asn	Leu
65					70					75				80	
Ser	Leu	Arg	Val	Glu	Gly	Leu	Gln	Glu	Lys	Asp	Ser	Gly	Pro	Tyr	Ser
			85						90					95	
Cys	Ser	Val	Asn	Val	Gln	Asp	Lys	Gln	Gly	Lys	Ser	Arg	Gly	His	Ser
		100						105					110		
Ile	Lys	Thr	Leu	Glu	Leu	Asn	Val	Leu	Val	Pro	Pro	Ala	Pro	Pro	Ser
	115					120						125			
Cys	Arg	Leu	Gln	Gly	Val	Pro	His	Val	Gly	Ala	Asn	Val	Thr	Leu	Ser
130						135					140				
Cys	Gln	Ser	Pro	Arg	Ser	Lys	Pro	Ala	Val	Gln	Tyr	Gln	Trp	Asp	Arg
145					150					155				160	
Gln	Leu	Pro	Ser	Phe	Gln	Thr	Phe	Phe	Ala	Pro	Ala	Leu	Asp	Val	Ile
			165					170					175		
Arg	Gly	Ser	Leu	Ser	Leu	Thr	Asn	Leu	Ser	Ser	Ser	Met	Ala	Gly	Val
		180					185					190			
Tyr	Val	Cys	Lys	Ala	His	Asn	Glu	Val	Gly	Thr	Ala	Gln	Cys	Asn	Val
	195					200					205				
Thr	Leu	Glu	Val	Ser	Thr	Gly	Pro	Gly	Ala	Ala	Val				
	210					215					220				

&lt;210&gt; 84

&lt;211&gt; 202

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 84

Met	Gly	Pro	Ser	Thr	Pro	Leu	Leu	Ile	Leu	Phe	Leu	Leu	Ser	Trp	Ser
1				5					10					15	
Gly	Pro	Leu	Gln	Gly	Gln	Gln	His	His	Leu	Val	Glu	Tyr	Met	Glu	Arg
		20					25						30		
Arg	Leu	Ala	Ala	Leu	Glu	Glu	Arg	Leu	Ala	Gln	Cys	Gln	Asp	Gln	Ser
	35						40					45			
Ser	Arg	His	Ala	Ala	Glu	Leu	Arg	Asp	Phe	Lys	Asn	Lys	Met	Leu	Pro
	50					55					60				
Leu	Leu	Glu	Val	Ala	Glu	Lys	Glu	Arg	Glu	Ala	Leu	Arg	Thr	Glu	Ala
65					70				75					80	
Asp	Thr	Ile	Ser	Gly	Arg	Val	Asp	Arg	Leu	Glu	Arg	Glu	Val	Asp	Tyr
		85					90					95			
Leu	Glu	Thr	Gln	Asn	Pro	Ala	Leu	Pro	Cys	Val	Glu	Phe	Asp	Glu	Lys
	100						105					110			
Val	Thr	Gly	Pro	Gly	Thr	Lys	Gly	Lys	Gly	Arg	Arg	Asn	Glu	Lys	
	115					120					125				
Tyr	Asp	Met	Val	Thr	Asp	Cys	Gly	Tyr	Thr	Ile	Ser	Gln	Val	Arg	Ser
	130					135					140				
Met	Lys	Ile	Leu	Lys	Arg	Phe	Gly	Gly	Pro	Ala	Gly	Leu	Trp	Thr	Lys

```

145          150          155          160
Asp Pro Leu Gly Gln Thr Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln
          165          170          175
Asn Asp Thr Ala Phe Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala
          180          185          190
Met Ala Ala Arg Lys Ala Ser Arg Val Arg
          195          200

```

<210> 85  
 <211> 67  
 <212> PRT  
 <213> Homo sapiens

```

<400> 85
Ala Ser Arg Ala Arg Ile Gln Cys Ser Phe Asp Ala Ser Gly Thr Leu
 1          5          10          15
Thr Pro Glu Arg Ala Ala Leu Pro Tyr Phe Pro Arg Arg Tyr Gly Ala
          20          25          30
His Ala Ser Leu Arg Tyr Asn Pro Arg Glu Arg Gln Leu Tyr Ala Trp
          35          40          45
Asp Asp Gly Tyr Gln Ile Val Tyr Lys Leu Glu Met Arg Lys Lys Glu
          50          55          60
Glu Glu Val
65

```

<210> 86  
 <211> 19  
 <212> PRT  
 <213> Homo sapiens

```

<400> 86
Val Pro Phe Pro Trp Val Gly Thr Gly Gln Leu Val Tyr Gly Gly Phe
 1          5          10          15
Leu Tyr Phe

```

<210> 87  
 <211> 17  
 <212> PRT  
 <213> Homo sapiens

```

<400> 87
Ala Glu Ala Ala Phe Val Ile Cys Gly Thr Leu Tyr Val Val Tyr Asn
 1          5          10          15
Thr

```

<210> 88  
 <211> 99  
 <212> PRT  
 <213> Homo sapiens

```

<400> 88
Ala Arg Arg Pro Pro Gly Arg Pro Gly Gly Gly Glu Met Glu Asn
 1          5          10          15
Thr Leu Gln Leu Ile Lys Phe His Leu Ala Asn Arg Thr Val Val Asp
          20          25          30
Ser Ser Val Phe Pro Ala Glu Gly Leu Ile Pro Pro Tyr Gly Leu Thr

```

35	40	45
Ala Asp Thr Tyr Ile Asp Leu	Ala Ala Asp Glu Glu Gly Leu Trp Ala	
50	55	60
Val Tyr Ala Thr Arg Glu	Asp Asp Arg His Leu Cys Leu Ala Lys Leu	
65	70	75
Asp Pro Gln Thr Leu Asp	Thr Glu Gln Gln Trp Asp Thr Pro Cys Pro	
85	90	95
Arg Glu Asn		

&lt;210&gt; 89

&lt;211&gt; 320

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 89

Met Gly Pro Ser Thr Pro Leu Leu Ile Leu Phe Leu Leu Ser Trp Ser	
1	5
Gly Pro Leu Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg	
20	25
Arg Leu Ala Ala Leu Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser	
35	40
Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro	
50	55
Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Ala Leu Arg Thr Glu Ala	
65	70
Asp Thr Ile Ser Gly Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr	
85	90
Leu Glu Thr Gln Asn Pro Ala Leu Pro Cys Val Glu Phe Asp Glu Lys	
100	105
Val Thr Gly Gly Pro Gly Thr Lys Gly Lys Gly Arg Arg Asn Glu Lys	
115	120
Tyr Asp Met Val Thr Asp Cys Gly Tyr Thr Ile Ser Gln Val Arg Ser	
130	135
Met Lys Ile Leu Lys Arg Phe Gly Gly Pro Ala Gly Leu Trp Thr Lys	
145	150
Asp Pro Leu Gly Gln Thr Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln	
165	170
Asn Asp Thr Ala Phe Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala	
180	185
Met Ala Ala Arg Lys Ala Ser Arg Val Arg Val Pro Phe Pro Trp Val	
195	200
Gly Thr Gly Gln Leu Val Tyr Gly Gly Phe Leu Tyr Phe Ala Arg Arg	
210	215
Pro Pro Gly Arg Pro Gly Gly Gly Gly Glu Met Glu Asn Thr Leu Gln	
225	230
Leu Ile Lys Phe His Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val	
245	250
Phe Pro Ala Glu Gly Leu Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr	
260	265
Tyr Ile Asp Leu Ala Ala Asp Glu Glu Gly Leu Trp Ala Val Tyr Ala	
275	280
Thr Arg Glu Asp Asp Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln	
290	295
Thr Leu Asp Thr Glu Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn	
305	310
	315
	320

&lt;210&gt; 90

&lt;211&gt; 385

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 90

Gln Gln His His Leu Val Glu Tyr Met Glu Arg Arg Leu Ala Ala Leu  
 1 5 10 15  
 Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser Ser Arg His Ala Ala  
 20 25 30  
 Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro Leu Leu Glu Val Ala  
 35 40 45  
 Glu Lys Glu Arg Glu Ala Leu Arg Thr Glu Ala Asp Thr Ile Ser Gly  
 50 55 60  
 Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr Leu Glu Thr Gln Asn  
 65 70 75 80  
 Pro Ala Leu Pro Cys Val Glu Phe Asp Glu Lys Val Thr Gly Gly Pro  
 85 90 95  
 Gly Thr Lys Gly Lys Gly Arg Arg Asn Glu Lys Tyr Asp Met Val Thr  
 100 105 110  
 Asp Cys Gly Tyr Thr Ile Ser Gln Val Arg Ser Met Lys Ile Leu Lys  
 115 120 125  
 Arg Phe Gly Gly Pro Ala Gly Leu Trp Thr Lys Asp Pro Leu Gly Gln  
 130 135 140  
 Thr Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln Asn Asp Thr Ala Phe  
 145 150 155 160  
 Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala Met Ala Ala Arg Lys  
 165 170 175  
 Ala Ser Arg Val Arg Val Pro Phe Pro Trp Val Gly Thr Gly Gln Leu  
 180 185 190  
 Val Tyr Gly Gly Phe Leu Tyr Phe Ala Arg Arg Pro Pro Gly Arg Pro  
 195 200 205  
 Gly Gly Gly Gly Glu Met Glu Asn Thr Leu Gln Leu Ile Lys Phe His  
 210 215 220  
 Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val Phe Pro Ala Glu Gly  
 225 230 235 240  
 Leu Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr Tyr Ile Asp Leu Ala  
 245 250 255  
 Ala Asp Glu Glu Gly Leu Trp Ala Val Tyr Ala Thr Arg Glu Asp Asp  
 260 265 270  
 Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln Thr Leu Asp Thr Glu  
 275 280 285  
 Gln Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn Ala Glu Ala Ala Phe  
 290 295 300  
 Val Ile Cys Gly Thr Leu Tyr Val Val Tyr Asn Thr Arg Pro Ala Ser  
 305 310 315 320  
 Arg Ala Arg Ile Gln Cys Ser Phe Asp Ala Ser Gly Thr Leu Thr Pro  
 325 330 335  
 Glu Arg Ala Ala Leu Pro Tyr Phe Pro Arg Arg Tyr Gly Ala His Ala  
 340 345 350  
 Ser Leu Arg Tyr Asn Pro Arg Glu Arg Gln Leu Tyr Ala Trp Asp Asp  
 355 360 365  
 Gly Tyr Gln Ile Val Tyr Lys Leu Glu Met Arg Lys Lys Glu Glu Glu  
 370 375 380  
 Val  
 385

&lt;210&gt; 91

&lt;211&gt; 728

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 91

```

atgaggccac tctctgtcct gctgctcctg ggccctggcgg ccggtctgcc cccactggac      60
gacaacaaga tccccagcct ctgcccgggg caccctggcc ttccaggcac gccggggccac      120
catggcagcc agggcttgcc gggccgcgat ggccgcgacg gccgcgacgg tgcgcccggg      180
gctccgggag agaaaggcga gggcgggagg cgggactgcc gggacctcga ggggaccccg      240
ggccgcgagg agaggcggga cccgcggggc ccaccgggccc tgccggggag tgctcggtgc      300
ctccgcgata cgccttcagc gccaaagcgt ccgagagccg ggtgcctccg ccgtctgacg      360
cacccttgcc cttcgaccgc gtgctggtga acgagcaggg acattacgac gccgtcaccg      420
gcaagttcac ctgccagggtg cctgggggtct actacttcgc cgtccatgcc accgtctacc      480
gggccagcct gcagtttgat ctgggtgaaga atggcgaaac cattgcctct ttcttccagt      540
ttttcggggg gtggcccaag ccagcctcgc tctcgggggg ggccatgggtg aggctggagc      600
ctgaggacca agtgtgggtg caggtgggtg tgggtgacta cattggcatc tatgccagca      660
tcaagacaga cagcaccttc tccggatttc tgggtgtactc cgactggcac agctccccag      720
tctttgct                                     728

```

&lt;210&gt; 92

&lt;211&gt; 69

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 92

```

Arg Pro Ala Ser Arg Ala Arg Ile Gln Cys Ser Phe Asp Ala Ser Gly
 1           5           10           15
Thr Leu Thr Pro Glu Arg Ala Ala Leu Pro Tyr Phe Pro Arg Arg Tyr
          20           25           30
Gly Ala His Ala Ser Leu Arg Tyr Asn Pro Arg Glu Arg Gln Leu Tyr
          35           40           45
Ala Trp Asp Asp Gly Tyr Gln Ile Val Tyr Lys Leu Glu Met Arg Lys
          50           55           60
Lys Glu Glu Glu Val
65

```

&lt;210&gt; 93

&lt;211&gt; 202

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 93

```

Met Gly Pro Ser Ala Pro Leu Leu Leu Leu Phe Phe Leu Ser Trp Thr
 1           5           10           15
Gly Pro Leu Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg
          20           25           30
Arg Leu Ala Ala Leu Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser
          35           40           45
Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro
          50           55           60
Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Thr Leu Arg Thr Glu Ala
65           70           75           80
Asp Ser Ile Ser Gly Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr
          85           90           95
Leu Glu Thr Gln Asn Pro Ala Leu Pro Cys Val Glu Leu Asp Glu Lys
          100          105          110
Val Thr Gly Gly Pro Gly Ala Lys Gly Lys Gly Arg Arg Asn Glu Lys
          115          120          125
Tyr Asp Met Val Thr Asp Cys Ser Tyr Thr Val Ala Gln Val Arg Ser

```

130		135		140
Met Lys Ile Leu Lys Arg Phe Gly Gly Ser Val Gly Leu Trp Thr Lys				
145		150		155
Asp Pro Leu Gly Pro Ala Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln				
	165		170	175
Asn Asp Thr Ala Phe Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala				
	180		185	190
Met Ala Ala Arg Lys Ala Ser Arg Ile Arg				
	195		200	

&lt;210&gt; 94

&lt;211&gt; 69

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 94

Arg Pro Ala Ser Arg Ala Arg Ile Gln Cys Ser Phe Asp Ala Ser Gly				
1	5	10	15	
Thr Leu Ala Pro Glu Arg Ala Ala Leu Ser Tyr Phe Pro Arg Arg Tyr				
	20	25	30	
Gly Ala His Ala Ser Leu Arg Tyr Asn Pro Arg Glu Arg Gln Leu Tyr				
	35	40	45	
Ala Trp Asp Asp Gly Tyr Gln Ile Val Tyr Lys Leu Glu Met Lys Lys				
	50	55	60	
Lys Glu Glu Glu Val				
65				

&lt;210&gt; 95

&lt;211&gt; 19

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 95

Val Pro Phe Pro Trp Val Gly Thr Gly Gln Leu Val Tyr Gly Gly Phe				
1	5	10	15	
Leu Tyr Tyr				

&lt;210&gt; 96

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 96

Glu Ala Ala Phe Val Ile Cys Gly Thr Leu Tyr Val Val Tyr Asn Thr				
1	5	10	15	

&lt;210&gt; 97

&lt;211&gt; 99

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 97

Ala Arg Arg Pro Pro Gly Gly Pro Gly Gly Gly Glu Leu Glu Asn				
1	5	10	15	
Thr Leu Gln Leu Ile Lys Phe His Leu Ala Asn Arg Thr Val Val Asp				
	20	25	30	
Ser Ser Val Phe Pro Ala Glu Ser Leu Ile Pro Pro Tyr Gly Leu Thr				

```

      35              40              45
Ala Asp Thr Tyr Ile Asp Leu Ala Ala Asp Glu Glu Gly Leu Trp Ala
  50              55              60
Val Tyr Ala Thr Arg Asp Asp Arg His Leu Cys Leu Ala Lys Leu
  65              70              75              80
Asp Pro Gln Thr Leu Asp Thr Glu Gln Gln Trp Asp Thr Pro Cys Pro
      85              90              95
Arg Glu Asn

```

<210> 98  
 <211> 320  
 <212> PRT  
 <213> Mus musculus

```

<400> 98
Met Gly Pro Ser Ala Pro Leu Leu Leu Leu Phe Phe Leu Ser Trp Thr
  1              5              10              15
Gly Pro Leu Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg
      20              25              30
Arg Leu Ala Ala Leu Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser
      35              40              45
Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro
      50              55              60
Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Thr Leu Arg Thr Glu Ala
      65              70              75              80
Asp Ser Ile Ser Gly Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr
      85              90              95
Leu Glu Thr Gln Asn Pro Ala Leu Pro Cys Val Glu Leu Asp Glu Lys
      100              105              110
Val Thr Gly Gly Pro Gly Ala Lys Gly Lys Gly Arg Arg Asn Glu Lys
      115              120              125
Tyr Asp Met Val Thr Asp Cys Ser Tyr Thr Val Ala Gln Val Arg Ser
      130              135              140
Met Lys Ile Leu Lys Arg Phe Gly Gly Ser Val Gly Leu Trp Thr Lys
      145              150              155              160
Asp Pro Leu Gly Pro Ala Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln
      165              170              175
Asn Asp Thr Ala Phe Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala
      180              185              190
Met Ala Ala Arg Lys Ala Ser Arg Ile Arg Val Pro Phe Pro Trp Val
      195              200              205
Gly Thr Gly Gln Leu Val Tyr Gly Gly Phe Leu Tyr Tyr Ala Arg Arg
      210              215              220
Pro Pro Gly Gly Pro Gly Gly Gly Gly Glu Leu Glu Asn Thr Leu Gln
      225              230              235              240
Leu Ile Lys Phe His Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val
      245              250              255
Phe Pro Ala Glu Ser Leu Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr
      260              265              270
Tyr Ile Asp Leu Ala Ala Asp Glu Glu Gly Leu Trp Ala Val Tyr Ala
      275              280              285
Thr Arg Asp Asp Asp Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln
      290              295              300
Thr Leu Asp Thr Glu Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn
      305              310              315              320

```

<210> 99

&lt;211&gt; 299

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 99

```

Gln Gln His His Leu Val Glu Tyr Met Glu Arg Arg Leu Ala Ala Leu
 1           5           10           15
Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser Ser Arg His Ala Ala
 20           25           30
Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro Leu Leu Glu Val Ala
 35           40           45
Glu Lys Glu Arg Glu Thr Leu Arg Thr Glu Ala Asp Ser Ile Ser Gly
 50           55           60
Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr Leu Glu Thr Gln Asn
 65           70           75           80
Pro Ala Leu Pro Cys Val Glu Leu Asp Glu Lys Val Thr Gly Gly Pro
 85           90           95
Gly Ala Lys Gly Lys Gly Arg Arg Asn Glu Lys Tyr Asp Met Val Thr
100           105           110
Asp Cys Ser Tyr Thr Val Ala Gln Val Arg Ser Met Lys Ile Leu Lys
115           120           125
Arg Phe Gly Gly Ser Val Gly Leu Trp Thr Lys Asp Pro Leu Gly Pro
130           135           140
Ala Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln Asn Asp Thr Ala Phe
145           150           155           160
Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala Met Ala Ala Arg Lys
165           170           175
Ala Ser Arg Ile Arg Val Pro Phe Pro Trp Val Gly Thr Gly Gln Leu
180           185           190
Val Tyr Gly Gly Phe Leu Tyr Tyr Ala Arg Arg Pro Pro Gly Gly Pro
195           200           205
Gly Gly Gly Gly Glu Leu Glu Asn Thr Leu Gln Leu Ile Lys Phe His
210           215           220
Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val Phe Pro Ala Glu Ser
225           230           235           240
Leu Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr Tyr Ile Asp Leu Ala
245           250           255
Ala Asp Glu Glu Gly Leu Trp Ala Val Tyr Ala Thr Arg Asp Asp Asp
260           265           270
Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln Thr Leu Asp Thr Glu
275           280           285
Gln Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn
290           295

```

&lt;210&gt; 100

&lt;211&gt; 728

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 100

```

atgaggccac tcctcgtcct gctgctcctg ggcctggcgg ccggctcgcc cccactggac      60
gacaacaaga tccccagcct ctgcccgggg caccgcggcc ttccaggcac gccggggccac      120
catggcagcc agggcttgcc gggccgcgat ggccgcgacg gccgcgacgg cgcgcccggg      180
gctccgggag agaaaggcga gggcgggagg cgggactgcc gggacctcga ggggaccccg      240
ggccgcgagg agaggcggga cccgcggggc ccaccgggcc tgtcggggag tgctcggtgc      300
ctccgcgata cgcttcagc gccaaagcgt ccgagagccg ggtgcctccg ccgtctgacg      360
cacccttgcc cttcgaccgc gtgctggtga acgagcaggg acattacgac gccgtcaccg      420
gcaagttcac ctgccaggtg cctgggggtct actacttcgc cgtccatgcc accgtctacc      480

```

```

gggccagcct gcagtttgat ctggtgaaga atggcgaatc cattgcctct ttcttccagt 540
ttttcggggg gtggcccaag ccagcctcgc tctcgggggg ggccatggtg aggctggagc 600
ctgaggacca agtgtgggtg caggtgggtg tgggtgacta cattggcatc tatgccagca 660
tcaagacaga cagcaccttc tccggatttc tgggtgactc cgactggcac agtccccag 720
tctttgct 728

```

&lt;210&gt; 101

&lt;211&gt; 728

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 101

```

atgaggccac tcctcgtcct gctgctcctg ggccctggcgg ccggctcgcc cccactggac 60
gacaacaaga tccccagcct ctgcccgagg caccctggcc ttccaggcac gccggggccac 120
catggcagcc agggcttgcc gggccgcgat ggccgcgacg gccgcgacgg cgcgcccggg 180
gctccgggag agaaaggcga gggcgggagg cgggactgcc gggacctcga ggggaccccg 240
ggccgcgagg agaggcgga cccgcggggc ccaccgggac tgccggggag tgctcggtgc 300
ctccgcgacg cgccttcagc gccaagcgct ccgagagccg ggtgcctccg ccgtctgacg 360
cacccttgcc ctccgaccgc gtgctggtga acgagcaggg acattacgac gccgtcaccg 420
gcaagttcac ctgccagggt cctgggggtct actacttcgc cgtccatgcc accgtctacc 480
gggccagcct gcagtttgat ctggtgaaga atggcgaatc cattgcctct ttcttccagt 540
ttttcggggg gtggcccaag ccagcctcgc tctcgggggg ggccatggtg aggctggagc 600
ctgaggacca agtgtgggtg caggtgggtg tgggtgacta cattggcatc tatgccagca 660
tcaagacaga cagcaccttc tccggatttc tgggtgactc cgactggcac agtccccag 720
tctttgct 728

```

&lt;210&gt; 102

&lt;211&gt; 243

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 102

```

Met Arg Pro Leu Leu Val Leu Leu Leu Gly Leu Ala Ala Gly Ser
1          5          10          15
Pro Pro Leu Asp Asn Lys Ile Pro Ser Leu Cys Pro Gly His Pro
20          25          30
Gly Leu Pro Gly Thr Pro Gly His Gly Ser Gln Gly Leu Pro Gly
35          40          45
Arg Asp Gly Arg Asp Gly Arg Asp Gly Val Pro Gly Ala Pro Gly Glu
50          55          60
Lys Gly Glu Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Asp Pro
65          70          75          80
Gly Pro Arg Gly Glu Ala Gly Pro Ala Gly Pro Thr Gly Pro Ala Gly
85          90          95
Glu Cys Ser Val Pro Pro Arg Ser Ala Phe Ser Ala Lys Arg Ser Glu
100          105          110
Ser Arg Val Pro Pro Pro Ser Asp Ala Pro Leu Pro Phe Asp Arg Val
115          120          125
Leu Val Asn Glu Gln Gly His Tyr Asp Ala Val Thr Gly Lys Phe Thr
130          135          140
Cys Gln Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val Tyr
145          150          155          160
Arg Ala Ser Leu Gln Phe Asp Leu Val Lys Asn Gly Glu Ser Ile Ala
165          170          175
Ser Phe Phe Gln Phe Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu Ser
180          185          190
Gly Gly Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val Gln
195          200          205

```

Val Gly Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr Asp  
 210 215 220  
 Ser Thr Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser Pro  
 225 230 235 240  
 Val Phe Ala

<210> 103  
 <211> 1338  
 <212> DNA  
 <213> Homo sapiens

<400> 103  
 gtcgaccac gcgtccggga ctgggggtgac ggcagggcag gggggcgctg gccggggaga 60  
 agcgcggggg ctggagcacc accaactgga ggggtccggag tagcgagcgc cccgaaggag 120  
 gccatcgggg agccgggagg ggggactgag agaggacccc ggcgccggg cccccgggtgc 180  
 cagcgctatg aggccactcc tcgtcctgct gtcctggggc ctggcgggcg gctcgccccc 240  
 actggacgac aacaagatcc ccagcctctg cccggggcac cccggccttc caggcacgcc 300  
 gggccaccat ggcagccagg gcttgccggg ccgcgatggc cgcgacggcc gcgacggtgc 360  
 gcccggggct ccgggagaga aaggcgaggg cgggaggcgg gactgccggg acctcgaggg 420  
 gaccccgggc cgcgaggaga ggcgggaccc gcggggccca cccggcctgc cggggagtgc 480  
 tcggtgcctc cgcgatccgc cttcagcgcc aagcgctccg agagccgggt gcctccgccg 540  
 tctgacgcac ccttgccctt cgaccgcgtg ctgggtgaac agcagggaca ttacgacgcc 600  
 gtcaccggca agttcacctg ccaggtgcct ggggtctact acttcgccgt ccatgccacc 660  
 gtctaccggg ccagcctgca gtttgatctg gtgaagaatg gcgaatccat tgcctctttc 720  
 ttccagtttt tcgggggggtg gcccaagcca gcctcgctct cggggggggc catggtgagg 780  
 ctggagcctg aggaccaagt gtgggtgcag gtgggtgtgg gtgactacat tggcatctat 840  
 gccagcatca agacagacag caccttctcc ggatttctgg tgtactccga ctggcacagc 900  
 tccccagtct ttgcttagtg cccactgcaa agtgagctca tgctctcact cctagaagga 960  
 ggggtgtgagg ctgacaacct ggtcatccag gagggtctgg ccccttgaa tattgtgaat 1020  
 gactagggag gtggggtaga gcactctccg tcctgctgct ggcaaggaaat gggaacagt 1080  
 gctgtctgag atcagggtctg gcagcatggg gcagtggctg gatttctgcc caagaccaga 1140  
 ggagtgtgct gtgctggcaa gtgtaagtcc cccagttgct ctggtccagg agcccacggt 1200  
 ggggtgctct cttctggtc ctctgcttct ctggatcctc cccacccct cctgctcctg 1260  
 gggccggccc tttctcaga gatcactcaa taaacctaa aacctccaa aaaaaaaaaa 1320  
 aaaaaaagg gcggccgc 1338

<210> 104  
 <211> 243  
 <212> PRT  
 <213> Homo sapiens

<400> 104  
 Met Arg Pro Leu Leu Val Leu Leu Leu Leu Gly Leu Ala Ala Gly Ser  
 1 5 10 15  
 Pro Pro Leu Asp Asp Asn Lys Ile Pro Ser Leu Cys Pro Gly His Pro  
 20 25 30  
 Gly Leu Pro Gly Thr Pro Gly His His Gly Ser Gln Gly Leu Pro Gly  
 35 40 45  
 Arg Asp Gly Arg Asp Gly Arg Asp Gly Ala Pro Gly Ala Pro Gly Glu  
 50 55 60  
 Lys Gly Glu Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Asp Pro  
 65 70 75 80  
 Gly Pro Arg Gly Glu Ala Gly Pro Ala Gly Pro Thr Gly Pro Val Gly  
 85 90 95  
 Glu Cys Ser Val Pro Pro Arg Ser Ala Phe Ser Ala Lys Arg Ser Glu  
 100 105 110  
 Ser Arg Val Pro Pro Pro Ser Asp Ala Pro Leu Pro Phe Asp Arg Val

115	120	125
Leu Val Asn Glu Gln Gly His Tyr Asp Ala Val Thr Gly Lys Phe Thr		
130	135	140
Cys Gln Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val Tyr		
145	150	155
Arg Ala Ser Leu Gln Phe Asp Leu Val Lys Asn Gly Glu Ser Ile Ala		
165	170	175
Ser Phe Phe Gln Phe Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu Ser		
180	185	190
Gly Gly Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val Gln		
195	200	205
Val Gly Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr Asp		
210	215	220
Ser Thr Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser Pro		
225	230	235
Val Phe Ala		240

<210> 105  
 <211> 1338  
 <212> DNA  
 <213> Homo sapiens

<400> 105  
 gtcgacccac gcgtccggga ctgggggtgac ggcagggcag ggggcgcctg gccggggaga 60  
 agcgcggggg ctggagcacc accaactgga ggggtccggag tagcgagcgc cccgaaggag 120  
 gccatcgggg agccgggagg ggggactgcg agaggacccc ggcgtccggg ctcccggtgc 180  
 cagcgctatg aggccactcc tcgtcctgct gctcctgggc ctggcgggccg gctcgcctcc 240  
 actggacgac aacaagatcc ccagcctctg ccgggggcac cccggccttc caggcacgcc 300  
 gggccaccat ggcagccagg gcttgccggg ccgcgatggc cgcgacggcc gcgacggcgc 360  
 gcccgggggt ccgggagaga aaggcgaggg cgggagggcg gactgccggg acctcgaggg 420  
 gaccccgggc cgcgaggaga ggcgggaccc gcggggccca ccgggcctgt cggggagtgc 480  
 tcgggtgctc cgcgatccgc ctccagcgcc aagcgctccg agagccgggt gcctccgccc 540  
 tctgacgcac ccttgccctt cgaccgctg ctggtgaacg agcagggaca ttacgacgcc 600  
 gtcaccggca agttcacctg ccagggtgct ggggtctact acttcgccgt ccattgccacc 660  
 gtctaccggg ccagcctgca gtttgatctg gtgaagaatg gcgaatccat tgctctttc 720  
 ttccagtttt tcgggggggtg gcccagcca gcctcgctct cggggggggc catggtgagg 780  
 ctggagcctg aggaccaagt gtgggtgagc gtgggtgtgg gtgactacat tggcatctat 840  
 gccagcatca agacagacag caccttctcc ggatttctgg tgtactccga ctggcacagc 900  
 tccccagtct ttgcttagtg cccactgcaa agtgagctca tgctctcact cctagaaggga 960  
 ggggtgtgagg ctgacaacct ggatcatccag gagggtctgg cccctggaa tattgtgaat 1020  
 gactagggag gtggggtaga gcaactctcg tcctgctgct ggcaaggaaat gggaacagtg 1080  
 gctgtctgcg atcaggtctg gcagcatggg gcagtggtcg gatttctgcc caagaccaga 1140  
 ggagtgtgct gtgctggcaa gtgtaagtcc cccagttgct ctggtccagg agccacgggt 1200  
 ggggtgctct ctctctggtc ctctgcttct ctggatctc cccacccct cctgctcctg 1260  
 gggccggccc ttttctcaga gatcactcaa taaacctaa aaccctcaa aaaaaaaaaa 1320  
 aaaaaaagg gcggccgc 1338

<210> 106  
 <211> 243  
 <212> PRT  
 <213> Homo sapiens

<400> 106  
 Met Arg Pro Leu Leu Val Leu Leu Leu Leu Gly Leu Ala Ala Gly Ser  
 1 5 10 15  
 Pro Pro Leu Asp Asp Asn Lys Ile Pro Ser Leu Cys Pro Gly His Pro  
 20 25 30

Gly Leu Pro Gly Thr Pro Gly His His Gly Ser Gln Gly Leu Pro Gly  
 35 40 45  
 Arg Asp Gly Arg Asp Gly Arg Asp Gly Ala Pro Gly Ala Pro Gly Glu  
 50 55 60  
 Lys Gly Glu Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Asp Pro  
 65 70 75 80  
 Gly Pro Arg Gly Glu Ala Gly Pro Ala Gly Pro Thr Gly Pro Ala Gly  
 85 90 95  
 Glu Cys Ser Val Pro Pro Arg Ser Ala Phe Ser Ala Lys Arg Ser Glu  
 100 105 110  
 Ser Arg Val Pro Pro Pro Ser Asp Ala Pro Leu Pro Phe Asp Arg Val  
 115 120 125  
 Leu Ala Asn Glu Gln Gly His Tyr Asp Ala Val Thr Gly Lys Phe Thr  
 130 135 140  
 Cys Gln Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val Tyr  
 145 150 155 160  
 Arg Ala Ser Leu Gln Phe Asp Leu Val Lys Asn Gly Glu Ser Ile Ala  
 165 170 175  
 Ser Phe Phe Gln Phe Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu Ser  
 180 185 190  
 Gly Gly Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val Gln  
 195 200 205  
 Val Gly Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr Asp  
 210 215 220  
 Ser Thr Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser Pro  
 225 230 235 240  
 Val Phe Ala

&lt;210&gt; 107

&lt;211&gt; 1338

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 107

gtcgacccac gcgtccggga ctgggggtgac ggcaggggcag ggggcgcctg gccggggaga 60  
 agcgcggggg ctggagcacc accaactgga ggggtccggag tagcgagcgc cccgaaggag 120  
 gccatcgggg agccgggagg ggggactgag agaggacccc ggcgtccggg ctcccgtgac 180  
 cagcgctatg aggccactcc tcgtcctgct gctcctgggc ctggcgggccg gctcgcccc 240  
 actggacgac aacaagatcc ccagcctctg cccggggcac cccggccttc caggcacgcc 300  
 gggccaccat ggcagccagg gcttgccggg ccgcgatggc cgcgacggcc gcgacggcgc 360  
 gcccggggct ccgggagaga aaggcgaggg cgggaggcgg gactgccggg acctcgaggg 420  
 gaccccgggc cgcgaggaga ggcgggaccc gcggggccca ccgggcctgc cggggagtgc 480  
 tcggtgcctc cgcgatccgc cttcagcgcc aagcgctccg agagccgggt gcctccgccg 540  
 tctgacgcac ccttgccctt cgaccgcgtg ctggcgaaac agcagggaca ttacgacgcc 600  
 gtcaccggca agttcacctg ccaggtgcct ggggtctact acttcgccgt ccatgccacc 660  
 gtctaccggg ccagcctgca gtttgatctg gtgaagaatg gcgaatccat tgcctcttc 720  
 ttccagtttt tcgggggggtg gcccaagcca gcctcgctct cggggggggc catggtgagg 780  
 ctggagcctg aggaccaagt gtgggtgcag gtgggtgtgg gtgactacat tggcatctat 840  
 gccagcatca agacagacag caccttctcc ggatttctgg tgtactccga ctggcacagc 900  
 tccccagtct ttgcttagtg cccactgcaa agtgagctca tgctctcact cctagaagga 960  
 ggggtgtgagg ctgacaacct ggtcatccag gagggtggc cccctggaa tattgtgaat 1020  
 gactagggag gtggggtaga gcactctccg tcctgctgct ggcaaggaat gggaacagtg 1080  
 gctgtctgag atcaggtctg gcagcatggg gcagtggctg gatttctgcc caagaccaga 1140  
 ggagtgtgct gtgctggcaa gtgtaagtcc cccagttgct ctgggtccag agcccacggg 1200  
 ggggtgctct cttcctggtc ctctgcttct ctggatcctc cccacccct cctgctcctg 1260  
 gggccggccc ttttctcaga gatcaactcaa taaacctaa aacctccaa aaaaaaaaaa 1320  
 aaaaaaagg gcggccgc 1338

&lt;210&gt; 108

&lt;211&gt; 243

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 108

```

Met Arg Pro Leu Leu Val Leu Leu Leu Leu Gly Leu Ala Ala Gly Ser
 1           5           10           15
Pro Pro Leu Asp Asp Asn Lys Ile Pro Ser Leu Cys Pro Gly His Pro
 20           25           30
Gly Leu Pro Gly Thr Pro Gly His His Gly Ser Gln Gly Leu Pro Gly
 35           40           45
Arg Asp Gly Arg Asp Gly Arg Asp Gly Ala Pro Gly Ala Pro Gly Glu
 50           55           60
Lys Gly Glu Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Asp Pro
 65           70           75           80
Gly Pro Arg Gly Glu Ala Gly Pro Ala Gly Pro Thr Gly Pro Ala Gly
 85           90           95
Glu Cys Ser Val Pro Pro Arg Ser Ala Phe Ser Ala Lys Arg Ser Glu
100           105           110
Ser Arg Val Pro Pro Pro Ser Asp Ala Pro Leu Pro Phe Asp Arg Val
115           120           125
Leu Val Asn Glu Gln Gly His Tyr Asp Ala Val Thr Gly Lys Phe Thr
130           135           140
Cys Gln Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val Tyr
145           150           155           160
Arg Ala Ser Leu Gln Phe Asp Leu Val Lys Asn Gly Glu Ser Leu Ala
165           170           175
Ser Phe Phe Gln Phe Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu Ser
180           185           190
Gly Gly Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val Gln
195           200           205
Val Gly Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr Asp
210           215           220
Ser Thr Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser Pro
225           230           235           240
Val Phe Ala

```

&lt;210&gt; 109

&lt;211&gt; 1338

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 109

```

gtcgacccac gcgtccggga ctgggggtgac ggcagggcag ggggcgcctg gccggggaga      60
agcgcggggg ctggagcacc accaactgga ggggtccggag tagcgagcgc cccgaaggag      120
gccatcgggg agccgggagg ggggactgcg agaggacccc ggcgtccggg ctcccgggtgc      180
cagcgctatg aggccactcc tcgtcctgct gtcctctgggc ctggcgggccg gctcgcccccc      240
actggacgac aacaagatcc ccagcctctg cccgggggcac cccggccttc caggcacgcc      300
gggccaccat ggcagccagg gcttgccggg ccgcgatggc cgcgacggcc gcgacggcgc      360
gcccggggct ccgggagaga aaggcgaggg cgggaggcgg gactgccggg acctcgaggg      420
gaccccgggc cgcgaggaga ggcgggaccc gcggggccca ccgggcctgc cggggagtgc      480
tcggtgccct cgcgatccgc cttcagcgcc aagcgctccg agagccgggt gcctccgccg      540
tctgacgcac ccttgccctt cgaccgcgtg ctggtgaacg agcagggaca ttacgacgcc      600
gtcaccggga agttcacctg ccagggtgct ggggtctact acttcgccgt ccattgccacc      660
gtctaccggg ccagcctgca gtttgatctg gtgaagaatg gcgaatccct tgcctctttc      720
ttccagtttt tcgggggggtg gcccaagcca gcctcgctct cgggggggggc catggtgagg      780

```

```

ctggagcctg aggaccaagt gtgggtgcag gtgggtgtgg gtgactacat tggcatctat      840
gccagcatca agacagacag caccttctcc ggatttctgg tgtactccga ctggcacagc      900
tccccagtct ttgcttagtg cccactgcaa agtgagctca tgctctcact cctagaagga      960
gggtgtgagg ctgacaacct ggtcatccag gagggctggc cccctggaa tattgtgaat     1020
gactagggag gtggggtaga gcactctccg tctgtctgct ggcaaggaat gggaacagtg     1080
gctgtctgcg atcaggtctg gcagcatggg gcagtggctg gatttctgcc caagaccaga     1140
ggagtgtgct gtgctggcaa gtgtaagtcc cccagttgct ctgggtccagg agcccacggt     1200
gggtgtctct cttcctggtc ctctgcttct ctggatcctc cccacccct cctgctcctg     1260
gggccggccc ttttctcaga gatcactcaa taaacctaag aaccctccaa aaaaaaaaaa     1320
aaaaaaaaag gcggccgc                                     1338

```

&lt;210&gt; 110

&lt;211&gt; 406

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 110

```

Met Gly Pro Ser Thr Pro Leu Leu Ile Leu Phe Leu Leu Ser Trp Ser
  1           5           10           15
Gly Pro Leu Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg
          20           25           30
Arg Leu Ala Ala Leu Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser
          35           40           45
Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro
          50           55           60
Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Ala Leu Arg Thr Glu Ala
        65           70           75           80
Asp Thr Ile Ser Gly Arg Val Asp Arg Leu Glu Arg Glu Ala Asp Tyr
          85           90           95
Leu Glu Thr Gln Asn Pro Ala Leu Pro Cys Val Glu Phe Asp Glu Lys
          100          105          110
Val Thr Gly Gly Pro Gly Thr Lys Gly Lys Gly Arg Arg Asn Glu Lys
          115          120          125
Tyr Asp Met Val Thr Asp Cys Gly Tyr Thr Ile Ser Gln Val Arg Ser
          130          135          140
Met Lys Ile Leu Lys Arg Phe Gly Gly Pro Ala Gly Leu Trp Thr Lys
          145          150          155          160
Asp Pro Leu Gly Gln Thr Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln
          165          170          175
Asn Asp Thr Ala Phe Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala
          180          185          190
Met Ala Ala Arg Lys Ala Ser Arg Val Arg Val Pro Phe Pro Trp Val
          195          200          205
Gly Thr Gly Gln Leu Val Tyr Gly Gly Phe Leu Tyr Phe Ala Arg Arg
          210          215          220
Pro Pro Gly Arg Pro Gly Gly Gly Gly Glu Met Glu Asn Thr Leu Gln
          225          230          235          240
Leu Ile Lys Phe His Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val
          245          250          255
Phe Pro Ala Glu Gly Leu Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr
          260          265          270
Tyr Ile Asp Leu Ala Ala Asp Glu Gly Leu Trp Ala Val Tyr Ala
          275          280          285
Thr Arg Glu Asp Asp Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln
          290          295          300
Thr Leu Asp Thr Glu Gln Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn
          305          310          315          320
Ala Glu Ala Ala Phe Val Ile Cys Gly Thr Leu Tyr Val Val Tyr Asn

```

```

          325          330          335
Thr Arg Pro Ala Ser Arg Ala Arg Ile Gln Cys Ser Phe Asp Ala Ser
          340          345          350
Gly Thr Leu Thr Pro Glu Arg Ala Ala Leu Pro Tyr Phe Pro Arg Arg
          355          360          365
Tyr Gly Ala His Ala Ser Leu Arg Tyr Asn Pro Arg Glu Arg Gln Leu
          370          375          380
Tyr Ala Trp Asp Asp Gly Tyr Gln Ile Val Tyr Lys Leu Glu Met Arg
          385          390          395          400
Lys Lys Glu Glu Glu Val
          405

```

&lt;210&gt; 111

&lt;211&gt; 1831

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 111

```

gtcgacccac gcgtccgcgg acgcgtgggt gaggggaaga ggctgactgt acgttccttc      60
tactctggca ccaactctcca ggctgccatg gggcccagca cccctctcct catcttgttc      120
cttttgtcat ggtcgggacc cctccaagga cagcagcacc accttggtgga gtacatggaa      180
cgccgactag ctgctttaga ggaacggctg gcccagtgcc aggaccagag tagtcggcat      240
gctgctgagc tgcgggactt caagaacaag atgctgccac tgctggaggt ggcagagaag      300
gagcgggagg cactcagaac tgaggccgac accatctccg ggagagtgga tcgtctggag      360
cgggaggcag actatctgga gaccagaac ccagctctgc cctgtgtaga gtttgatgag      420
aaggtgactg gaggccctgg gaccaaaggc aaggggaaga ggaatgagaa gtacgatatg      480
gtgacagact gtggctacac aatctctcaa gtgagatcaa tgaagattct gaagcgattt      540
gggtggcccag ctggtctatg gaccaaggat ccactggggc aaacagagaa gatctacgtg      600
ttagatggga cacagaatga cacagccttt gtcttcccaa ggctgcgtga cttcaccctt      660
gccatggctg cccggaaaagc ttcccagagc cgggtgccct tcccctgggt aggcacaggg      720
cagctgggat atggtggctt tctttatttt gctcggaggc ctccctggaag acctggtgga      780
gggtggtgaga tggagaacac tttgcagcta atcaaattcc acctggcaaa ccgaacagtg      840
gtggacagct cagtattccc agcagagggg ctgatcccc cctacggctt gacagcagac      900
acctacatcg acctggcagc tgatgaggaa ggtctttggg ctgtctatgc caccggggag      960
gatgacaggc acttggtgtc ggccaagtta gatccacaga cactggacac agagcagcag      1020
tgggacacac catgtcccag agagaatgct gaggtgcct ttgtcatctg tgggaccctc      1080
tatgtcgtct ataacaccg tccctgccagt cgggcccgcg tccagtgtct ctttgatgcc      1140
agcggcaccc tgaccctga acgggcagca ctcccttatt ttcccgcag atatggtgcc      1200
catgccagcc tccgctataa ccccgcagaa cgccagctct atgcctggga tgatggctac      1260
cagattgtct ataagctgga gatgaggaag aaagaggagg aggtttgagg agctagcctt      1320
gttttttgca tctttctcac tccatacat ttatattata tcccactaa atttcttgtt      1380
cctcattctt caaatgtggg ccagttgtgg ctcaaactct ctatatTTTT agccaatggc      1440
aatcaaatc tttcagctcc tttgtttcat acggaactcc agatcctgag taatcctttt      1500
agagcccga gagtcaaaac cctcaatggt ccctcctgct ctctgcccc atgtcaacaa      1560
atttcaggct aaggatgccc cagacccagg gctctaacct tgtatgcggg caggcccagg      1620
gagcaggcag cagtgttctt cccctcagag tgacttgggg agggagaaat agggaggagc      1680
gtccagctct gtctctctt cctcactcct cccttcagtg tccagaggaa caggactttc      1740
tccacattgt tttgtattgc aacattttgc attaaaagga aaatccactg ctaaaaaaaa      1800
aaaaaaaaaa aaaaaaaaaa agggcgggccg c                                     1831

```

&lt;210&gt; 112

&lt;211&gt; 406

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 112

```

Met Gly Pro Ser Thr Pro Leu Leu Ile Leu Phe Leu Leu Ser Trp Ser
  1              5              10              15

```

Gly Pro Leu Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg  
 20 25 30  
 Arg Leu Ala Ala Leu Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser  
 35 40 45  
 Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro  
 50 55 60  
 Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Ala Leu Arg Thr Glu Ala  
 65 70 75 80  
 Asp Thr Ile Ser Gly Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr  
 85 90 95  
 Leu Glu Thr Gln Asn Pro Ala Leu Pro Cys Val Glu Phe Asp Glu Lys  
 100 105 110  
 Val Thr Gly Gly Pro Gly Thr Lys Gly Lys Gly Arg Arg Asn Glu Lys  
 115 120 125  
 Tyr Asp Ile Val Thr Asp Cys Gly Tyr Thr Ile Ser Gln Val Arg Ser  
 130 135 140  
 Met Lys Ile Leu Lys Arg Phe Gly Gly Pro Ala Gly Leu Trp Thr Lys  
 145 150 155 160  
 Asp Pro Leu Gly Gln Thr Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln  
 165 170 175  
 Asn Asp Thr Ala Phe Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala  
 180 185 190  
 Met Ala Ala Arg Lys Ala Ser Arg Val Arg Val Pro Phe Pro Trp Val  
 195 200 205  
 Gly Thr Gly Gln Leu Val Tyr Gly Gly Phe Leu Tyr Phe Ala Arg Arg  
 210 215 220  
 Pro Pro Gly Arg Pro Gly Gly Gly Glu Met Glu Asn Thr Leu Gln  
 225 230 235 240  
 Leu Ile Lys Phe His Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val  
 245 250 255  
 Phe Pro Ala Glu Gly Leu Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr  
 260 265 270  
 Tyr Ile Asp Leu Ala Ala Asp Glu Gly Leu Trp Ala Val Tyr Ala  
 275 280 285  
 Thr Arg Glu Asp Asp Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln  
 290 295 300  
 Thr Leu Asp Thr Glu Gln Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn  
 305 310 315 320  
 Ala Glu Ala Ala Phe Val Ile Cys Gly Thr Leu Tyr Val Val Tyr Asn  
 325 330 335  
 Thr Arg Pro Ala Ser Arg Ala Arg Ile Gln Cys Ser Phe Asp Ala Ser  
 340 345 350  
 Gly Thr Leu Thr Pro Glu Arg Ala Ala Leu Pro Tyr Phe Pro Arg Arg  
 355 360 365  
 Tyr Gly Ala His Ala Ser Leu Arg Tyr Asn Pro Arg Glu Arg Gln Leu  
 370 375 380  
 Tyr Ala Trp Asp Asp Gly Tyr Gln Ile Val Tyr Lys Leu Glu Met Arg  
 385 390 395 400  
 Lys Lys Glu Glu Val  
 405

&lt;210&gt; 113

&lt;211&gt; 1831

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 113

gtcgacccac gcgtccgcgg acgcgtgggt gaggggaaga ggctgactgt acgttccttc

60

```

tactctggca ccactctcca ggctgccatg gggcccagca cccctctcct catcttggtc 120
cttttgtcat ggtcgggacc cctccaagga cagcagcacc accttggtga gtacatggaa 180
cgccgactag ctgcttttaga ggaacggctg gccagtgcc aggaccagag tagtcggcat 240
gctgctgagc tgcgggactt caagaacaag atgctgccac tgctggagggt ggcagagaag 300
gagcgggagg cactcagaac tgaggccgac accatctccg ggagagtggg tctgtctggag 360
cgggaggtag actatctgga gacccagaac ccagctctgc cctgtgtaga gtttcatgag 420
aagggtgact gaggccctgg gaccaaaggc aagggaagaa ggaatgagaa gtacgatata 480
gtgacagact gtggctacac aatctctcaa gtgagatcaa tgaagattct gaagcgattt 540
gggtggcccag ctggtctatg gaccaaggat ccactggggc aaacagagaa gatctacgtg 600
ttagatggga cacagaatga cacagccttt gtcttcccaa ggctgcgtga cttcaccctt 660
gccatggctg cccggaaagc tctccgagtc cgggtgccct tcccctgggt aggcacaggg 720
cagctgggat atggtggctt tctttatttt gctcggaggc ctcttggaag acctggtgga 780
gggtggtgaga tggagaacac tttgcagcta atcaaattcc acctggcaaa ccgaacagtg 840
gtggacagct cagtattccc agcagagggg ctgatcccc cctacggctt gacagcagac 900
acctacatcg acctggcagc tgatgaggaa ggtctttggg ctgtctatgc caccggggag 960
gatgacaggc acttggtgtc ggccaagtta gatccacaga cactggacac agagcagcag 1020
tgggacacac catgtcccag agagaatgct gaggtgcct ttgtcatctg tgggaccctc 1080
tatgtcgtct ataacacccg tcttgccagt cggggccgca tccagtgtc ctttcatgcc 1140
agcggcacc cagcccctga acgggcagca ctcccttatt tccccgcag atatggtgac 1200
catgccagcc tccgctataa cccccgagaa gccagctct atgcttgga tgatggctac 1260
cagattgtct ataagctgga gatgaggaag aaagaggagg aggtttgagg agctagcctt 1320
gttttttgca tctttctcac tccatatac ttatattata tccccactaa atttctgtt 1380
cctcattctt caaatgtggg ccagtgtgg ctcaaatcct ctatattttt agccaatggc 1440
aatcaaatc tttcagctcc tttgtttcat acggaactcc agatcctgag taatcctttt 1500
agagcccga gagtcaaaac cctcaatggt cctcctgct ctctgcccc atgtcaacaa 1560
atttcaggct aaggatgccc cagaccaggg gctctaacct tgtatgcggg caggcccagg 1620
gagcaggcag cagtgttctt cccctcagag tgacttgggg agggagaaat agggaggagac 1680
gtccagctct gtcctctctt cctcactcct cccttcagtg tctgaggaa caggactttc 1740
tccacattgt tttgtattgc aacattttgc attaaaagga aaatccactg ctaaaaaaaa 1800
aaaaaaaaa aaaaaaaaaa agggcggccg c 1831

```

&lt;210&gt; 114

&lt;211&gt; 406

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 114

```

Met Gly Pro Ser Thr Pro Leu Leu Ile Leu Phe Leu Leu Ser Trp Ser
1          5          10          15
Gly Pro Leu Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg
20          25          30
Arg Leu Ala Ala Leu Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser
35          40          45
Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro
50          55          60
Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Ala Leu Arg Thr Glu Ala
65          70          75          80
Asp Thr Ile Ser Gly Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr
85          90          95
Leu Glu Thr Gln Asn Pro Ala Leu Pro Cys Val Glu Phe Asp Glu Lys
100         105         110
Val Thr Gly Gly Pro Gly Thr Lys Gly Lys Gly Arg Arg Asn Glu Lys
115         120         125
Tyr Asp Met Val Thr Asp Cys Gly Tyr Thr Ile Ser Gln Val Arg Ser
130         135         140
Met Lys Ile Leu Lys Arg Phe Gly Gly Pro Ala Gly Ile Trp Thr Lys
145         150         155         160
Asp Pro Leu Gly Gln Thr Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln

```

```
<210> 115
<211> 1831
<212> DNA
<213> Homo sapiens
```

<400>	115						
gtcgacccac	gcgtccgcgg	acgcgtgggt	gaggggaaga	ggctgactgt	acgttccttc		60
tactctggca	ccactctcca	ggctgccatg	gggccagca	cccctctcct	catcttggtc		120
cttttgtcat	ggtcgggacc	cctccaagga	cagcagcacc	accttgaggga	gtacatggaa		180
cgccgactag	ctgctttaga	ggaacggctg	gcccagtgcc	aggaccagag	tagtcggcat		240
gctgctgagc	tgccgggactt	caagaacaag	atgctgccac	tgctggaggt	ggcagagaag		300
gagcgggagg	cactcagaac	tgaggccgac	accatctccg	ggagagtggga	tcgtctggag		360
cgggaggtag	actatctgga	gacccagaac	ccagctctgc	cctgtgtaga	gtttgatgag		420
aagggtgactg	gagggccctgg	gaccaaaggc	aagggaagaa	ggaatgagaa	gtacgatatg		480
gtgacagact	gtggctacac	aatctctcaa	gtgagatcaa	tgaagattct	gaagcgattt		540
ggtggccacag	ctggtatatg	gaccaaggat	ccactggggc	aaacagagaa	gatctacgtg		600
ttagatggga	cacagaatga	cacagccttt	gtcttcccaa	ggctgcgtga	cttcaccctt		660
gccatggctg	cccggaaaagc	ttcccagctc	cgggtgccct	tcccctgggt	aggcacaggg		720
cagctggtat	atggtggctt	tctttatttt	gctcggaggc	ctcctggaag	acctggtgga		780
ggtggtgaga	tggagaacac	tttgacagta	atcaaattcc	acctggcaaa	ccgaacagtg		840
gtggacagct	cagtattccc	agcagagggg	ctgatcccc	cctacggctt	gacagcagac		900
acctacatcg	acctggcagc	tgatgaggaa	ggtctttggg	ctgtctatgc	caccggggag		960
gatgacaggc	acttgtgtct	ggcaaagtta	gatccacaga	cactgcagac	agagcagcag		1020
tgggacacac	catgtgccag	agcagaatgct	gaggtgcct	ttgtcatctg	tggggacctc		1080
tatgtcgtct	ataacacccg	tcctgccagt	cgggccgcga	tccagtgtct	ctttgatgcc		1140
agcggcaccc	tgacccctga	acgggcagca	ctcccttatt	ttcccgcgag	atatgggtgcc		1200

```

catgccagcc tccgctataa cccccgagaa cgccagctct atgcctggga tgatggctac 1260
cagattgtct ataagctgga gatgaggaag aaagaggagg aggtttgagg agctagcctt 1320
gttttttgca tctttctcac tcccatacat ttatattata tccccactaa atttcttggt 1380
cctcattctt caaatgtggg ccagttgtgg ctcaaatacct ctatatTTTT agccaatggc 1440
aatcaaatc tttcagctcc tttgtttcat acggaactcc agatcctgag taatcctttt 1500
agagcccga gagtcaaaac cctcaatggt cctcctgct ctcctgcccc atgtcaacaa 1560
atttcaggct aaggatgccc cagacccagg gctctaacct tgtatgcggg caggcccagg 1620
gagcaggcag cagtgttctt cccctcagag tgacttgggg agggagaaat aggaggagac 1680
gtccagctct gtctctctt cctcactcct cccttcagtg tcttgaggaa caggactttc 1740
tccacattgt tttgtattgc aacattttgc attaaaagga aaatccactg ctaaaaaaaaa 1800
aaaaaaaaa aaaaaaaaaa agggcgggccg c 1831

```

&lt;210&gt; 116

&lt;211&gt; 406

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 116

```

Met Gly Pro Ser Thr Pro Leu Leu Ile Leu Phe Leu Leu Ser Trp Ser
1          5          10          15
Gly Pro Leu Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg
20          25          30
Arg Leu Ala Ala Leu Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser
35          40          45
Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro
50          55          60
Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Ala Leu Arg Thr Glu Ala
65          70          75          80
Asp Thr Ile Ser Gly Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr
85          90          95
Leu Glu Thr Gln Asn Pro Ala Leu Pro Cys Val Glu Phe Asp Glu Lys
100         105         110
Val Thr Gly Gly Pro Gly Thr Lys Gly Lys Gly Arg Arg Asn Glu Lys
115         120         125
Tyr Asp Met Val Thr Asp Cys Gly Tyr Thr Ile Ser Gln Val Arg Ser
130         135         140
Met Lys Ile Leu Lys Arg Phe Gly Gly Pro Ala Gly Leu Trp Thr Lys
145         150         155         160
Asp Pro Leu Gly Gln Thr Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln
165         170         175
Asn Asp Thr Val Phe Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Ala
180         185         190
Met Ala Ala Arg Lys Ala Ser Arg Val Arg Val Pro Phe Pro Trp Val
195         200         205
Gly Thr Gly Gln Leu Val Tyr Gly Gly Phe Leu Tyr Phe Ala Arg Arg
210         215         220
Pro Pro Gly Arg Pro Gly Gly Gly Gly Glu Met Glu Asn Thr Leu Gln
225         230         235         240
Leu Ile Lys Phe His Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val
245         250         255
Phe Pro Ala Glu Gly Leu Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr
260         265         270
Tyr Ile Asp Leu Ala Ala Asp Glu Glu Gly Leu Trp Ala Val Tyr Ala
275         280         285
Thr Arg Glu Asp Asp Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln
290         295         300
Thr Leu Asp Thr Glu Gln Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn
305         310         315         320

```

[illegible]

```
<210> 117
<211> 1831
<212> DNA
<213> Homo sapiens
```

<400>	117						
gtcgacccac	gcgtccgctg	acgcgtgggt	gaggggaaga	ggctgactgt	acgttccttc		60
tactctggca	ccactctcca	ggctgccatg	ggcccagca	ccccctcct	catcttgttc		120
cttttgtcat	ggtcgggacc	cctccaagga	cagcagcacc	accttgtgga	gtacatggaa		180
cgcgactag	ctgctttaga	ggaacggctg	gccagtgcc	aggaccagag	tagtcggcat		240
gctgctgagc	tgcgggactt	caagaacaag	atgctgccac	tgctggaggt	ggcagagaag		300
gagcgggagg	cactcagaac	tgaggccgac	accatctccg	ggagagtgga	tcgtctggag		360
cgggaggtag	actatctgga	gaccagaac	ccagctctgc	cctgtgtaga	gtttgatgag		420
aagggtgactg	gaggccctgg	gaccaaaggc	aagggaagaa	ggaatgagaa	gtacgatatg		480
gtgacagact	gtggctacac	aatctctcaa	gtgagatcaa	tgaagattct	gaagcgattt		540
ggtggcccag	ctggtctatg	gaccaaggat	ccactggggc	aaacagagaa	gatctacgtg		600
ttagatggga	cacagaatga	cacagtcttt	gtcttcccaa	ggctgctgta	cttcaccctt		660
gccatggctg	cccggaaagc	ttcccagatc	cgggtgccct	tcccctgggt	aggcacaggg		720
cagctggtat	atggtggctt	tctttatfff	gctcggaggc	ctcctggaag	acctggtgga		780
ggtggtgaga	tggagaacac	tttgagcta	atcaaattcc	acctggcaaa	ccgaacagtg		840
gtggacagct	cagtattccc	agcagagggg	ctgatcccc	cctacggctt	gacagcagac		900
acctacatcg	acctggcagc	tgatgaggaa	ggtctttggg	ctgtctatgc	caccggggag		960
gatgacaggc	acttgtgtct	ggccaagtta	gatccacaga	cactggacac	agagcagcag		1020
tgggacacac	catgtcccag	agagaatgct	gaggctgcct	ttgtcatctg	tgggaccctc		1080
tatgtcgtct	ataacacccg	tcttgccagt	cgggcccgca	tccagtgtct	ctttgatgcc		1140
agcggcaccc	tgacccttga	acgggcagca	ctcccttatt	ttccccgcag	atatggtgcc		1200
catgccagcc	tccgctataa	cccccgagaa	cgccagctct	atgcctggga	tgatggctac		1260
cagattgtct	ataagctgga	gatgaggaag	aaagaggagg	aggtttgagg	agctagcctt		1320
gttttttgca	tctttctcac	tcccatacat	ttatattata	tccccactaa	atftcttggt		1380
cctcattctt	caaattgtgg	ccagttgtgg	ctcaaactct	ctatattfff	agccaatggc		1440
aatcaaattc	tttcagctcc	tttgtttcat	acggaactcc	agatcctgag	taatcctfff		1500
agagcccga	gagtcaaaa	cctcaatggt	ccctcctgct	ctcctgcccc	atgtcaaaaa		1560
atftcaggct	aaggatggcc	cagaccagg	gctctaacct	tgtatgcggg	caggcccagg		1620
gagcaggcag	cagtgttctt	ccctcagag	tgacttgggg	agggagaaa	aggaggagac		1680
gtccagctct	gtcctctctt	cctcactcct	cccttcagtg	tcttgaggaa	caggactttc		1740
tccacattgt	tttgtattgc	aacattttgc	attaaaagga	aatccactg	ctaaaaaaaa		1800
aaaaaaaaaa	aaaaaaaaaa	agggcggccg	c				1831

```
<210> 118
<211> 242
<212> PRT
<213> Mus musculus
```

<400> 118  
Met Arg Pro Leu Leu Ala Leu Leu Leu Leu Gly Leu Val Ser Gly Ser

1	5	10	15
Pro Pro Leu Asp Asp Asn Lys Ile Pro Ser Leu Cys Pro Gly Gln Pro			
	20	25	30
Gly Leu Pro Gly Thr Pro Gly His His Gly Ser Gln Gly Leu Pro Gly			
	35	40	45
Arg Asp Gly Arg Asp Gly Arg Asp Gly Ala Pro Gly Ala Pro Gly Glu			
	50	55	60
Lys Gly Glu Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Glu Pro			
	65	70	75
Gly Pro Arg Gly Glu Gly Pro Met Gly Ala Ile Gly Pro Ala Gly Glu			
	85	90	95
Cys Ser Val Pro Pro Arg Ser Ala Phe Ser Ala Lys Arg Ser Glu Ser			
	100	105	110
Arg Val Pro Pro Pro Ala Asp Thr Pro Leu Pro Phe Asp Arg Val Leu			
	115	120	125
Leu Asn Glu Gln Gly His Tyr Asp Pro Thr Thr Gly Lys Phe Thr Cys			
	130	135	140
Gln Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val Tyr Arg			
	145	150	155
Ala Ser Leu Gln Phe Asp Leu Val Lys Asn Gly Gln Ser Ile Ala Ser			
	165	170	175
Phe Phe Gln Tyr Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu Ser Gly			
	180	185	190
Gly Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val Gln Val			
	195	200	205
Gly Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr Asp Ser			
	210	215	220
Thr Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser Pro Val			
	225	230	235
Phe Ala			240

&lt;210&gt; 119

&lt;211&gt; 1263

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 119

gtcgacccac	gcgtccgcgc	tgtgaagcca	gcaaggagca	accagaagct	aggagtcagt	60
cagcaaggac	aggggctgcc	tgccctacaga	ctacaagaga	ggttcctgga	gtctgagcct	120
ccgggggtcac	caccatgagg	ccacttcttg	cccttctgct	tctgggtctg	gtgtcaggct	180
ctcctcctct	ggacgacaac	aagatcccca	gcctgtgtcc	cgggcagccc	ggccttccag	240
gcacaccagg	tcaccatggc	agccaaggcc	tgccctggccg	tgacggccgt	gatggccgcg	300
acgggtgcacc	cggagctccg	ggagagaaag	gcgagggcgg	gagaccggga	ctacctggcc	360
cacgtgggga	gcccgggccc	cgtggagagg	tagggcccat	gggggctatc	gggcctgcgg	420
gggagtgtc	ggtacccccca	cgatcagcct	tcagtgccaa	gcgatccgag	agccgggtac	480
ctccgcccagc	cgacacaccc	ctacctttcg	accgtgtgct	gctaaatgag	cagggccatt	540
acgacccac	tactggcaag	ttcacctgcc	aagtgcctgg	cgtctactac	tttgctgtgc	600
acgccactgt	ctaccggggcc	agcttgacagt	ttgatcttgt	caaaaacggg	cagtccatcg	660
cctctttctt	ccagtatttt	gggggggtggc	ccaagccagc	ctcgtctctca	gggggtgcga	720
tggttaaggct	agaacctgag	gaccaggtgt	gggtgcagg	gggcgtgggt	gattacattg	780
gcattctatgc	cagcatcaag	acagacagta	ccttctctgg	atttctcgtc	tattctgact	840
ggcacagctc	cccagtcttc	gcttaaaaca	cagtgaaccc	ggagctggca	cttgctcttc	900
agtggagggt	gtgacactaa	cccgcgcagc	gcataccagg	agggctggcc	ccctggaata	960
ttgtgaatga	cttaggaaga	gagggagcca	cttccagtcc	cactgctggc	aatgaatgga	1020
gacaggctgt	ctgaggtcaa	gacagcgtgg	agcagtggtg	gggtttctgc	ccaggacttt	1080
agaatgcagt	aggctggcag	ctgtgggtcc	tggcccagga	ctccaagggtg	ggatgctcca	1140
ttcctagtc	tgtgtccct	ctaggtccct	gactccatct	ctgctgctcc	cagggcaggc	1200

ctttttctca gaggtcactt aataaaccta aaatcctcaa aaaaaaaaaa aaagggcggc 1260  
cgc 1263

<210> 120  
<211> 243  
<212> PRT  
<213> Mus musculus

<400> 120  
Met Arg Pro Leu Leu Ala Leu Leu Leu Leu Gly Leu Val Ser Gly Ser  
1 5 10 15  
Pro Pro Leu Asp Asp Asn Lys Ile Pro Ser Leu Cys Pro Gly Gln Pro  
20 25 30  
Gly Leu Pro Gly Thr Pro Gly His His Gly Ser Gln Gly Leu Pro Gly  
35 40 45  
Arg Asp Gly Arg Asp Gly Arg Asp Gly Ala Pro Gly Ala Pro Gly Glu  
50 55 60  
Lys Gly Glu Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Glu Pro  
65 70 75 80  
Gly Pro Arg Gly Glu Ala Gly Pro Met Gly Ala Ile Gly Pro Ala Gly  
85 90 95  
Glu Cys Ser Val Pro Pro Arg Ser Ala Phe Ser Val Lys Arg Ser Glu  
100 105 110  
Ser Arg Val Pro Pro Pro Ala Asp Thr Pro Leu Pro Phe Asp Arg Val  
115 120 125  
Leu Leu Asn Glu Gln Gly His Tyr Asp Pro Thr Thr Gly Lys Phe Thr  
130 135 140  
Cys Gln Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val Tyr  
145 150 155 160  
Arg Ala Ser Leu Gln Phe Asp Leu Val Lys Asn Gly Gln Ser Ile Ala  
165 170 175  
Ser Phe Phe Gln Tyr Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu Ser  
180 185 190  
Gly Gly Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val Gln  
195 200 205  
Val Gly Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr Asp  
210 215 220  
Ser Thr Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser Pro  
225 230 235 240  
Val Phe Ala

<210> 121  
<211> 1263  
<212> DNA  
<213> Mus musculus

<400> 121  
gtcgacccac gcgtccgcgc tgtgaagcca gcaaggagca accagaagct aggagtcagt 60  
cagcaaggac aggggctgcc tgcctacaga ctacaagaga gggttcctgga gtctgagcct 120  
ccgggggtcac caccatgagg ccacttcttg cccttctgct tctgggtctg gtgtcaggct 180  
ctcctcctct ggacgacaac aagatcccca gcctgtgtcc cgggcagccc ggccttccag 240  
gcacaccagg tcaccatggc agccaaggcc tgctggccg tgacggccgt gatggcccg 300  
acggtgcacc cggagctccg ggagagaaag gcgaggggcg gagaccggga ctacctggcc 360  
cacgtgggga gcccgggccc cgtggagagg caggggccat gggggctatc gggcctgcgg 420  
gggagtgtct ggtacccccca cgatcagtct tcagtgccaa gcgatccgag agccgggtac 480  
ctccgccagc cgacacaccc ctacctttcg accgtgtgct gctaaatgag caggggccatt 540  
acgacccccc tactggcaag ttcacctgcc aagtgcctgg cgtctactac tttgctgtgc 600

```

acgccactgt ctaccgggcc agcttgccagt ttgatcttgt caaaaacggg cagtccatcg      660
cctcttttctt ccagtatattt ggggggtggc ccaagccagc ctcgctctca ggggggtgcga      720
tggtgaaggct agaacctgag gaccagggtgt ggggtgcagggt gggcgtgggt gattacattg      780
gcatctatgc cagcatcaag acagacagta ccttctcttg atttctcgtc tattctgact      840
ggcacagctc cccagtcttc gcttaaaaca cagtgaaccc ggagctggca cttgctcctc      900
agtggagggt gtgacactaa cccgcgcagc gcataccagg agggctggcc ccctggaata      960
ttgtgaatga cttaggaaga gagggagcca cttccagtcc cactgctggc aatgaatgga     1020
gacaggctgt ctgagggtcaa gacagcgtgg agcagtggct gggtttctgc ccaggacttt     1080
agaatgcagt aggctggcag ctgtgggtcc tggcccagga ctccaagggt ggatgctcca     1140
ttcctagtc tgtgtccct ctaggtccct gactccatct ctgctgctcc cagggcaggc     1200
ctttttctca gaggtcactt aataaaccta aaatcctcaa aaaaaaaaaa aaagggcggc     1260
cgc                                                                    1263

```

<210> 122  
 <211> 243  
 <212> PRT  
 <213> Mus musculus

```

<400> 122
Met Arg Pro Leu Leu Ala Leu Leu Leu Leu Gly Leu Val Ser Gly Ser
  1             5             10             15
Pro Pro Leu Asp Asp Asn Lys Ile Pro Ser Leu Cys Pro Gly Gln Pro
  20             25             30
Gly Leu Pro Gly Thr Pro Gly His His Gly Ser Gln Gly Leu Pro Gly
  35             40             45
Arg Asp Gly Arg Asp Gly Arg Asp Gly Ala Pro Gly Ala Pro Gly Glu
  50             55             60
Lys Gly Glu Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Glu Pro
  65             70             75             80
Gly Pro Arg Gly Glu Ala Gly Pro Met Gly Ala Ile Gly Pro Ala Gly
  85             90             95
Glu Cys Ser Val Pro Pro Arg Ser Ala Phe Ser Ala Lys Arg Ser Glu
  100            105            110
Ser Arg Val Pro Pro Pro Ala Asp Thr Pro Leu Pro Phe Asp Arg Ala
  115            120            125
Leu Leu Asn Glu Gln Gly His Tyr Asp Pro Thr Thr Gly Lys Phe Thr
  130            135            140
Cys Gln Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val Tyr
  145            150            155            160
Arg Ala Ser Leu Gln Phe Asp Leu Val Lys Asn Gly Gln Ser Ile Ala
  165            170            175
Ser Phe Phe Gln Tyr Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu Ser
  180            185            190
Gly Gly Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val Gln
  195            200            205
Val Gly Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr Asp
  210            215            220
Ser Thr Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser Pro
  225            230            235            240
Val Phe Ala

```

<210> 123  
 <211> 1263  
 <212> DNA  
 <213> Mus musculus

<400> 123

```

gtcgacccac gcgtccgcgc tgtgaagcca gcaaggagca accagaagct aggagtcagt      60
cagcaaggac aggggctgcc tgcctacaga' ctacaagaga ggttcctgga gtctgagcct      120
ccgggggtcac caccatgagg ccacttcttg cccttctgct tctgggtctg gtgtcaggct      180
ctcctcctct ggacgacaac aagatcccca gcctgtgtcc cgggcagccc ggccttccag      240
gcacaccagg tcaccatggc agccaaggcc tgcctggccg tgacggccgt gatggccgcg      300
acggtgcacc cggagctccg ggagagaaag gcgagggcgg gagaccggga ctacctggcc      360
cacgtgggga gcccggggcc cgtggagagg cagggcccat gggggctatc gggcctgcgg      420
gggagtgtct ggtaccccca cgatcagcct tcagtgccaa gcgatccgag agccgggtac      480
ctccgccagc cgacacaccc ctacctttcg accgtgcgt gctaaatgag cagggccatt      540
acgaccccac tactggcaag ttcacctgcc aagtgcctgg cgtctactac tttgtctgtc      600
acgccactgt ctaccgggcc agcttgaggt ttgatcttgt caaaaacggg cagtccatcg      660
cctctttctt ccagtatttt ggggggtggc ccaagccagc ctgcgtctca gggggtgcga      720
tggttaaggct agaacctgag gaccaggtgt ggggtgcaggt gggcgtgggt gattacattg      780
gcatctatgc cagcatcaag acagacagta ccttctctgg atttctcgtc tattctgact      840
ggcacagctc cccagtcttc gcttaaaaca cagtgaacce ggagctggca cttgctctc      900
agtggagggt gtgacactaa cccgcgcagc gcataccagg agggctggcc cctggaata      960
ttgtgaatga cttaggaaga gaggagacca cttccagtcc cactgctggc aatgaatgga     1020
gacaggctgt ctgaggtcaa gacagcgtgg agcagtggct gggtttctgc ccaggacttt     1080
agaatgcagt aggctggcag ctgtgggtcc tggcccagga ctccaaggtg ggatgctcca     1140
ttcctagtcc tgtgtccct ctaggtccct gactccatct ctgctgctcc cagggcaggc     1200
ctttttctca gaggtcactt aataaaccta aaatcctcaa aaaaaaaaaa aaagggcggc     1260
cgc                                                                    1263

```

&lt;210&gt; 124

&lt;211&gt; 243

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 124

```

Met Arg Pro Leu Leu Ala Leu Leu Leu Gly Leu Val Ser Gly Ser
 1          5          10          15
Pro Pro Leu Asp Asn Lys Ile Pro Ser Leu Cys Pro Gly Gln Pro
 20          25          30
Gly Leu Pro Gly Thr Pro Gly His His Gly Ser Gln Gly Leu Pro Gly
 35          40          45
Arg Asp Gly Arg Asp Gly Arg Asp Gly Ala Pro Gly Ala Pro Gly Glu
 50          55          60
Lys Gly Glu Gly Gly Arg Pro Gly Leu Pro Gly Pro Arg Gly Glu Pro
 65          70          75          80
Gly Pro Arg Gly Glu Ala Gly Pro Met Gly Ala Ile Gly Pro Ala Gly
 85          90          95
Glu Cys Ser Val Pro Pro Arg Ser Ala Phe Ser Ala Lys Arg Ser Glu
 100         105         110
Ser Arg Val Pro Pro Pro Ala Asp Thr Pro Leu Pro Phe Asp Arg Val
 115         120         125
Leu Leu Asn Glu Gln Gly His Tyr Asp Pro Thr Thr Gly Lys Phe Thr
 130         135         140
Cys Gln Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val Tyr
 145         150         155         160
Arg Ala Ser Leu Gln Phe Asp Ile Val Lys Asn Gly Gln Ser Ile Ala
 165         170         175
Ser Phe Phe Gln Tyr Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu Ser
 180         185         190
Gly Gly Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val Gln
 195         200         205
Val Gly Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr Asp
 210         215         220
Ser Thr Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser Pro

```

225  
Val Phe Ala

230

235

240

<210> 125  
<211> 1263  
<212> DNA  
<213> Mus musculus

<400> 125  
gtcgacccac gcgtccgcgc tgtgaagcca gcaaggagca accagaagct aggagtcagt 60  
cagcaaggac aggggctgcc tgcctacaga ctacaagaga ggttcctgga gtctgagcct 120  
ccgggggtcac caccatgagg ccacttcttg cccttctgct tctgggtctg gtgtcaggct 180  
ctcctcctct ggacgacaac aagatcccca gcctgtgtcc cgggcagccc ggccttccag 240  
gcacaccagg tcaccatggc agccaaggcc tgcctggccg tgacggccgt gatggccgcg 300  
acggtgcacc cggagctccg ggagagaaag gcgagggcgg gagaccgga ctacctggcc 360  
cacgtgggga gcccgggccc cgtggagagg cagggcccat gggggctatc gggcctgcgg 420  
gggagtgtc ggtaccccca cgatcagcct tcagtgccaa gcgatccgag agccgggtac 480  
ctccgccagc cgacacaccc ctacctttcg accgtgtgct gctaaatgag cagggccatt 540  
acgacccac tactggcaag ttcacctgcc aagtgcctgg cgtctactac tttgctgtgc 600  
acgccactgt ctaccgggcc agcttgagc ttgatattgt caaaaacggg cagtccatcg 660  
cctctttctt ccagtatttt ggggggtggc ccaagccagc ctcgctctca ggggggtgcga 720  
tggttaaggct agaacctgag gaccagggtg ggggtgcagg gggcgtgggt gattacattg 780  
gcatctatgc cagcatcaag acagacagta ccttctctgg atttctcgtc tattctgact 840  
ggcacagctc cccagtcttc gcttaaaaca cagtgaacc ggagctggca cttgctcctc 900  
agtggagggt gtgacactaa cccgcgcagc gcataccagg agggctggcc ccctggaata 960  
ttgtgaatga cttaggaaga gagggagcca cttccagtc cactgctggc aatgaatgga 1020  
gacaggctgt ctgaggtcaa gacagcgtgg agcagtggct gggtttctgc ccaggacttt 1080  
agaatgcagt aggtctggcag ctgtgggtcc tggcccagga ctccaagggt ggatgctcca 1140  
ttcctagtcc tgtgtccct ctaggccct gactccatct ctgctgctcc cagggcagggc 1200  
ctttttctca gaggtcactt aataaaccta aaatcctcaa aaaaaaaaaa aaagggcggc 1260  
cgc 1263

<210> 126  
<211> 406  
<212> PRT  
<213> Mus musculus

<400> 126  
Met Gly Pro Ser Ala Pro Leu Leu Leu Leu Phe Phe Leu Ser Trp Thr  
1 5 10 15  
Gly Pro Leu Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg  
20 25 30  
Arg Leu Ala Ala Leu Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser  
35 40 45  
Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro  
50 55 60  
Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Thr Leu Arg Thr Glu Ala  
65 70 75 80  
Asp Ser Ile Ser Gly Arg Val Asp Arg Ile Glu Arg Glu Val Asp Tyr  
85 90 95  
Leu Glu Thr Gln Asn Pro Ala Leu Pro Cys Val Glu Leu Asp Glu Lys  
100 105 110  
Val Thr Gly Gly Pro Gly Ala Lys Gly Lys Gly Arg Arg Asn Glu Lys  
115 120 125  
Tyr Asp Met Val Thr Asp Cys Ser Tyr Thr Val Ala Gln Val Arg Ser  
130 135 140  
Met Lys Ile Leu Lys Arg Phe Gly Gly Ser Val Gly Leu Trp Thr Lys

145	150	155	160
Asp Pro Leu Gly	Pro Ala Glu Lys Ile Tyr Val	Leu Asp Gly Thr	Gln
	165	170	175
Asn Asp Thr Ala	Phe Val Phe Pro Arg Leu Arg	Asp Phe Thr Leu	Ala
	180	185	190
Met Ala Ala Arg	Lys Ala Ser Arg Ile Arg Val	Pro Phe Pro Trp	Val
	195	200	205
Gly Thr Gly Gln	Leu Val Tyr Gly Gly Phe Leu Tyr	Tyr Ala Arg	Arg
	210	215	220
Pro Pro Gly Gly	Pro Gly Gly Gly Glu Leu Glu	Asn Thr Leu	Gln
	225	230	235
Leu Ile Lys Phe	His Leu Ala Asn Arg Thr Val Val	Asp Ser Ser	Val
	245	250	255
Phe Pro Ala Glu	Ser Leu Ile Pro Pro Tyr Gly	Leu Thr Ala	Asp Thr
	260	265	270
Tyr Ile Asp Leu	Ala Ala Asp Glu Glu Gly Leu Trp	Ala Val Tyr	Ala
	275	280	285
Thr Arg Asp Asp	Asp Arg His Leu Cys Leu Ala Lys	Leu Asp Pro	Gln
	290	295	300
Thr Leu Asp Thr	Glu Gln Gln Trp Asp Thr Pro Cys	Pro Arg Glu	Asn
	305	310	315
Ala Glu Ala Ala	Phe Val Ile Cys Gly Thr Leu Tyr	Val Val Tyr	Asn
	325	330	335
Thr Arg Pro Ala	Ser Arg Ala Arg Ile Gln Cys Ser	Phe Asp Ala	Ser
	340	345	350
Gly Thr Leu Ala	Pro Glu Arg Ala Ala Leu Ser Tyr	Phe Pro Arg	Arg
	355	360	365
Tyr Gly Ala His	Ala Ser Leu Arg Tyr Asn Pro Arg	Glu Arg Gln	Leu
	370	375	380
Tyr Ala Trp Asp	Asp Gly Tyr Gln Ile Val Tyr Lys	Leu Glu Met	Lys
	385	395	400
Lys Lys Glu Glu	Glu Val		
	405		

&lt;210&gt; 127

&lt;211&gt; 1721

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 127

gtcgaccac	gcgtccgact	taaggctgcc	atggggccca	gtgctcctct	gctgctcctc	60
ttctttttgt	catggacggg	accccttcag	ggacagcagc	accaccttgt	ggagtacatg	120
gaacgccgac	tagctgcctt	agaggaacgg	ctggcccaat	gccaggatca	gagtagtcgg	180
catgctgccg	agcttcggga	cttcaaaaac	aagatgttgc	ctctcctgga	ggtggcagag	240
aaggagcggg	agaccctcag	aactgaagca	gactccatct	caggaagagt	ggaccgtatt	300
gaaagggagg	tagactatct	ggagacacag	aaccagctt	tgccctgtgt	agagctggat	360
gagaaggtga	ctggaggtcc	tggagccaaa	ggcaagggcc	gaagaaatga	gaaatacgat	420
atggtgacgg	actgtagcta	cacagtcgct	caggtgaggt	caatgaagat	cctgaagcgg	480
tttggtgggt	cagttggcct	atggaccaag	gatccgctgg	ggccagcaga	gaagatctac	540
gtgttagacg	gcaccagaaa	cgacacggct	tttgtcttcc	caaggctgcg	tgacttcacc	600
cttgccatgg	ctgcccggaa	agcttcccga	attcgggtgc	ccttcccctg	ggtaggcacg	660
gggcagctgg	tgtacggtgg	cttcctttat	tatgctcgaa	ggcctcctgg	aggacctgga	720
gggggtgggtg	aattggagaa	cactctgcag	ctgatcaaat	ttcacttggc	aaaccgaaca	780
gtggtggata	gctcagtgtt	ccctgcagag	agcctgatac	ccccctacgg	cctgacagca	840
gatacatata	tcgacctggc	agctgatgag	gagggcctgt	gggctgtcta	tgccactcga	900
gatgatgaca	ggcatttgtg	tctagccaag	ttagaccac	agacacttga	cacagagcag	960
cagtgggaca	caccatgtcc	cagagagaac	gcagaggctg	cgtttgtcat	ctgtgggacc	1020
ctgtacgttg	tctataacac	ccgccctgcc	agtagggctc	gtattcagtg	ttccttcgat	1080

```

gccagtggta ctctcgcccc tgaaagggca gcactctcct attttccacg ccgatatggt 1140
gcccatgcca gccttcgcta taacccccgt gagcgccagc tgtatgcctg ggatgatggc 1200
taccagattg tctacaaatt ggagatgaag aagaaggagg aggaagttaa agcagctagc 1260
cttgtgctct tgattcttat gccagacat ttatattcct gtgagctctc ctgcagttca 1320
tccttcaaaa cgaaggccag tggtagtagc tcatataccc taatttctaa aggacaacca 1380
aattctcaag cccctctgtt ttatgcagaa ctccagatcc tgggtagcat tttagaactg 1440
aacagcaaac aaacacccta aatcttcact cctgccttat gtccacaaag tttagtcca 1500
aactcagagc cctgtccttt ggagaggggc aacccagac agcaggcgac agcattcttg 1560
ccctcagtat gaccgaaggg agagaactca gagacaaagc tgccctccct cccttcccc 1620
tccagtgtag gggagaatgg ggctttcccc acatcacttt gtatggtaac agtttgcatt 1680
aaaaggaaaa cccacaaaaa aaaaaaaaaa agggcgggccg c 1721

```

<210> 128  
 <211> 406  
 <212> PRT  
 <213> Mus musculus

<400> 128

Met	Gly	Pro	Ser	Ala	Pro	Leu	Leu	Leu	Leu	Phe	Phe	Leu	Ser	Trp	Thr
1				5					10					15	
Gly	Pro	Leu	Gln	Gly	Gln	Gln	His	His	Leu	Val	Glu	Tyr	Met	Glu	Arg
			20					25					30		
Arg	Leu	Ala	Ala	Leu	Glu	Glu	Arg	Leu	Ala	Gln	Cys	Gln	Asp	Gln	Ser
		35					40					45			
Ser	Arg	His	Ala	Ala	Glu	Leu	Arg	Asp	Phe	Lys	Asn	Lys	Met	Leu	Pro
	50					55					60				
Leu	Leu	Glu	Val	Ala	Glu	Lys	Glu	Arg	Glu	Thr	Leu	Arg	Thr	Glu	Ala
65					70				75					80	
Asp	Ser	Ile	Ser	Gly	Arg	Val	Asp	Arg	Leu	Glu	Arg	Glu	Val	Asp	Tyr
				85					90				95		
Leu	Glu	Thr	Gln	Asn	Pro	Ala	Leu	Pro	Cys	Val	Glu	Leu	Asp	Glu	Lys
			100					105					110		
Val	Thr	Gly	Gly	Pro	Gly	Ala	Lys	Gly	Lys	Gly	Arg	Arg	Asn	Glu	Lys
		115					120					125			
Tyr	Asp	Ile	Val	Thr	Asp	Cys	Ser	Tyr	Thr	Val	Ala	Gln	Val	Arg	Ser
	130					135					140				
Met	Lys	Ile	Leu	Lys	Arg	Phe	Gly	Gly	Ser	Val	Gly	Leu	Trp	Thr	Lys
145				150					155					160	
Asp	Pro	Leu	Gly	Pro	Ala	Glu	Lys	Ile	Tyr	Val	Leu	Asp	Gly	Thr	Gln
			165						170					175	
Asn	Asp	Thr	Ala	Phe	Val	Phe	Pro	Arg	Leu	Arg	Asp	Phe	Thr	Leu	Ala
		180					185						190		
Met	Ala	Ala	Arg	Lys	Ala	Ser	Arg	Ile	Arg	Val	Pro	Phe	Pro	Trp	Val
	195					200						205			
Gly	Thr	Gly	Gln	Leu	Val	Tyr	Gly	Gly	Phe	Leu	Tyr	Tyr	Ala	Arg	Arg
	210					215					220				
Pro	Pro	Gly	Gly	Pro	Gly	Gly	Gly	Gly	Glu	Leu	Glu	Asn	Thr	Leu	Gln
225				230					235					240	
Leu	Ile	Lys	Phe	His	Leu	Ala	Asn	Arg	Thr	Val	Val	Asp	Ser	Ser	Val
			245						250					255	
Phe	Pro	Ala	Glu	Ser	Leu	Ile	Pro	Pro	Tyr	Gly	Leu	Thr	Ala	Asp	Thr
	260						265						270		
Tyr	Ile	Asp	Leu	Ala	Ala	Asp	Glu	Gly	Leu	Trp	Ala	Val	Tyr	Ala	
	275					280					285				
Thr	Arg	Asp	Asp	Asp	Arg	His	Leu	Cys	Leu	Ala	Lys	Leu	Asp	Pro	Gln
	290				295						300				
Thr	Leu	Asp	Thr	Glu	Gln	Gln	Trp	Asp	Thr	Pro	Cys	Pro	Arg	Glu	Asn
305				310					315					320	

[illegible]

<210> 129

<211> 1721

<212> DNA

<213> Mus musculus

<400> 129

gtcagccac	gcgctcgact	taaggctgcc	atggggccca	gtgtctctct	gctgtctctc	60
ttctttttgt	catggacggg	accccttcag	ggacagcagc	accaccttgt	ggagtacatg	120
gaacgccgac	tagctgcctt	agaggaacgg	ctggcccaat	gccaggatca	gagtagtcgg	180
catgtgccc	agcttcggga	cttcaaaaac	aagatgttgc	ctctcctgga	ggtggcagag	240
aaggagcggg	agaccctcag	aactgaagca	gactccatct	caggaagagt	ggaccgtctt	300
gaaagggagg	tagactatct	ggagacacag	aaccagctt	tgccctgtgt	agagctggat	360
gagaaggtga	ctggaggtcc	tggagccaaa	ggcaagggcc	gaagaaatga	gaaatacgat	420
atagtacgg	actgtagcta	cacagtcgct	caggtgaggt	caatgaagat	cctgaagcgg	480
tttggtggtt	cagttggcct	atggaccaag	gatccgctgg	ggccagcaga	gaagatctac	540
gtgttagacg	gcaccacagaa	cgacacggct	tttgtcttcc	caaggctgcg	tgacttcacc	600
cttgccatgg	ctgcccggaa	agcttcccga	attcgggtgc	ccttcccctg	ggtaggcacg	660
gggcagctgg	tgtacgttgg	cttctcttat	tatgtctcaa	ggcctcctgg	aggacctgga	720
gggggtggtg	aattggagaa	cactctgcag	ctgatcaaat	ttcacttggc	aaaccgaaca	780
gtggtggata	gctcagtggt	ccctgcagag	agcctgatac	ccccctacgg	cctgcagcga	840
gatacatata	tgcacctggc	agctgatgag	gagggcctgt	gggctgtcta	tgccactcga	900
gatgatgaca	ggcatttggt	tctagccaag	ttagaccac	agacacttga	cacagagcag	960
cagtgggaca	caccatgtcc	cagagagAAC	gcagaggctg	cgtttgtcat	ctgtgggacc	1020
ctgtacgttg	tctataaac	ccgccctgcc	agtagggctc	gtattcagtg	ttccttcgat	1080
gccagtggta	ctctcgcccc	tgaaggggca	gcactctcct	attttccacg	ccgatatggt	1140
gcccattgcca	gccttcgcta	taacccccgt	gagcgccagc	tgtatgcctg	ggatgatggc	1200
taccagattg	tctacaaatt	ggagatgaag	aagaaggagg	aggaagttta	agcagctagc	1260
cttgtgctct	tgattcttat	gccagacat	ttatatcct	gtgagctctc	ctgcagttca	1320
tccttcaaaa	cgaaggccag	tggtagtagc	tcatataccc	taatttctaa	aggacaacca	1380
aattctcaag	cccctctggt	ttatgcagaa	ctccagatcc	tgggtagcat	tttagaactg	1440
aacagcaaac	aaacacccta	aatcttcact	cctgccttat	gtccacaaag	tttagttcca	1500
aactcagagc	cctgtccttt	ggagagggtc	aacccagagc	agcaggcgac	agcattcttg	1560
ccctcagtat	gaccgaaggg	agagaactca	gagacaaagc	tgccctccct	cccttcccc	1620
tccagtgtag	gggagaatgg	ggctttcccc	acatcacttt	gtatggtaac	agtttgcatt	1680
aaaaggaaaa	cccacaaaaa	aaaaaaaaaa	agggcgggccg	c		1721

<210> 130

<211> 406

<212> PRT

<213> Mus musculus

<400> 130

Met	Gly	Pro	Ser	Ala	Pro	Leu	Leu	Leu	Leu	Phe	Phe	Leu	Ser	Trp	Thr
1				5					10					15	
Gly	Pro	Leu	Gln	Gly	Gln	Gln	His	His	Leu	Val	Glu	Tyr	Met	Glu	Arg

	20		25		30										
Arg	Leu	Ala	Leu	Glu	Glu	Arg	Leu	Ala	Gln	Cys	Gln	Asp	Gln	Ser	
	35		40		45										
Ser	Arg	His	Ala	Ala	Glu	Leu	Arg	Asp	Phe	Lys	Asn	Lys	Met	Leu	Pro
	50		55		60										
Leu	Leu	Glu	Val	Ala	Glu	Lys	Glu	Arg	Glu	Thr	Leu	Arg	Thr	Glu	Ala
65			70		75				80						
Asp	Ser	Ile	Ser	Gly	Arg	Val	Asp	Arg	Leu	Glu	Arg	Glu	Val	Asp	Tyr
	85		90		95										
Leu	Glu	Thr	Gln	Asn	Pro	Ala	Leu	Pro	Cys	Val	Glu	Leu	Asp	Glu	Lys
	100		105		110										
Val	Thr	Gly	Gly	Pro	Gly	Ala	Lys	Gly	Lys	Gly	Arg	Arg	Asn	Glu	Lys
	115		120		125										
Tyr	Asp	Met	Val	Thr	Asp	Cys	Ser	Tyr	Thr	Val	Ala	Gln	Val	Arg	Ser
	130		135		140										
Met	Lys	Ile	Leu	Lys	Arg	Phe	Gly	Gly	Ser	Val	Gly	Leu	Trp	Thr	Lys
145			150		155				160						
Asp	Pro	Leu	Gly	Pro	Ala	Glu	Lys	Ile	Tyr	Ala	Leu	Asp	Gly	Thr	Gln
	165		170		175										
Asn	Asp	Thr	Ala	Phe	Val	Phe	Pro	Arg	Leu	Arg	Asp	Phe	Thr	Leu	Ala
	180		185		190										
Met	Ala	Ala	Arg	Lys	Ala	Ser	Arg	Ile	Arg	Val	Pro	Phe	Pro	Trp	Val
	195		200		205										
Gly	Thr	Gly	Gln	Leu	Val	Tyr	Gly	Gly	Phe	Leu	Tyr	Tyr	Ala	Arg	Arg
	210		215		220										
Pro	Pro	Gly	Gly	Pro	Gly	Gly	Gly	Gly	Glu	Leu	Glu	Asn	Thr	Leu	Gln
225			230		235				240						
Leu	Ile	Lys	Phe	His	Leu	Ala	Asn	Arg	Thr	Val	Val	Asp	Ser	Ser	Val
	245		250		255										
Phe	Pro	Ala	Glu	Ser	Leu	Ile	Pro	Pro	Tyr	Gly	Leu	Thr	Ala	Asp	Thr
	260		265		270										
Tyr	Ile	Asp	Leu	Ala	Ala	Asp	Glu	Glu	Gly	Leu	Trp	Ala	Val	Tyr	Ala
	275		280		285										
Thr	Arg	Asp	Asp	Asp	Arg	His	Leu	Cys	Leu	Ala	Lys	Leu	Asp	Pro	Gln
	290		295		300										
Thr	Leu	Asp	Thr	Glu	Gln	Trp	Asp	Thr	Pro	Cys	Pro	Arg	Glu	Asn	
305			310		315				320						
Ala	Glu	Ala	Ala	Phe	Val	Ile	Cys	Gly	Thr	Leu	Tyr	Val	Val	Tyr	Asn
	325		330		335										
Thr	Arg	Pro	Ala	Ser	Arg	Ala	Arg	Ile	Gln	Cys	Ser	Phe	Asp	Ala	Ser
	340		345		350										
Gly	Thr	Leu	Ala	Pro	Glu	Arg	Ala	Ala	Leu	Ser	Tyr	Phe	Pro	Arg	Arg
	355		360		365										
Tyr	Gly	Ala	His	Ala	Ser	Leu	Arg	Tyr	Asn	Pro	Arg	Glu	Arg	Gln	Leu
	370		375		380										
Tyr	Ala	Trp	Asp	Asp	Gly	Tyr	Gln	Ile	Val	Tyr	Lys	Leu	Glu	Met	Lys
385			390		395				400						
Lys	Lys	Glu	Glu	Glu	Val										
	405														

&lt;210&gt; 131

&lt;211&gt; 1721

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 131

gtcgacccac	gcgtccgact	taaggctgcc	atggggccca	gtgctcctct	gctgctcctc	60
ttctttttgt	catggacggg	accccttcag	ggacagcagc	accaccttgt	ggagtacatg	120

```

gaacgccgac tagctgcctt agaggaacgg ctggcccaat gccaggatca gagtagtcgg 180
catgtctgccg agcttcggga cttcaaaaac aagatgttgc ctctcctgga ggtggcagag 240
aaggagcggg agaccctcag aactgaagca gactccatct caggaagagt ggaccgtctt 300
gaaagggagg tagactatct ggagacaacag aaccagctt tgcctgtgt agagctggat 360
gagaaggtga ctggaggtcc tggagccaaa ggcaagggcc gaagaaatga gaaatacgat 420
atggtgacgg actgtagcta cacagtcgct caggtgaggt caatgaagat cctgaagcgg 480
tttggtggtt cagttggcct atggaccaag gatccgctgg gccagcaga gaagatctac 540
gcgttagacg gcaccagaa cgacacggct tttgtcttcc caaggctgcg tgacttcacc 600
cttgccatgg ctgcccggaa agcttcccga attcgggtgc ccttcccctg ggtaggcacg 660
gggcagctgg tgtacggtgg cttcctttat tatgctcgaa ggcctcctgg aggacctgga 720
gggggtggtg aattggagaa cactctgcag ctgatcaaat ttcacttggc aaaccgaaca 780
gtggtggata gctcagtggt ccctgcagag agcctgatac cccctacgg cctgacagca 840
gatacatata tcgacctggc agctgatgag gagggcctgt gggctgtcta tgccactcga 900
gatgatgaca ggcatttgtg tctagccaag ttagaccac agacacttga cacagagcag 960
cagtgggaca caccatgtcc cagagagaac gcagaggctg cgtttgcct ctgtgggacc 1020
ctgtacgttg tctataaacac ccgccctgcc agtagggctc gtattcagtg ttccttcgat 1080
gccagtggta ctctcgcccc tgaaagggca gcactctcct attttccacg ccgatatggt 1140
gcccatgcca gccttcgcta taacccccgt gagcgccagc tgtatgcctg ggatgatggc 1200
taccagattg tctacaaatt ggagatgaag aagaaggagg aggaagtta agcagctagc 1260
cttgtgctct tgattcttat gccagacat ttatatcct gtgagctctc ctgcagttca 1320
tccttcaaaa cgaaggccag tgggtgtagc tcatataccc taatttctaa aggacaacca 1380
aattctcaag cccctctggt ttatgcagaa ctccagatcc tgggtagcat tttagaactg 1440
aacagcaaac aaacacccta aatcttcact cctgccttat gtccacaaag tttagttcca 1500
aactcagagc cctgtccttt ggagagggtc aaccacagac agcaggcgac agcattcttg 1560
ccctcagtat gaccgaaggg agagaactca gagacaaagc tgccctccct cccttcccc 1620
tccagtgtag gggagaatgg ggctttcccc acatcacttt gtatggtaac agtttgcatt 1680
aaaaggaaaaa cccaccaaaaa aaaaaaaaaa agggcggccg c 1721

```

&lt;210&gt; 132

&lt;211&gt; 406

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 132

```

Met Gly Pro Ser Ala Pro Leu Leu Leu Leu Phe Phe Leu Ser Trp Thr
 1           5           10           15
Gly Pro Leu Gln Gly Gln Gln His His Leu Val Glu Tyr Met Glu Arg
 20           25           30
Arg Leu Ala Ala Leu Glu Glu Arg Leu Ala Gln Cys Gln Asp Gln Ser
 35           40           45
Ser Arg His Ala Ala Glu Leu Arg Asp Phe Lys Asn Lys Met Leu Pro
 50           55           60
Leu Leu Glu Val Ala Glu Lys Glu Arg Glu Thr Leu Arg Thr Glu Ala
 65           70           75           80
Asp Ser Ile Ser Gly Arg Val Asp Arg Leu Glu Arg Glu Val Asp Tyr
 85           90           95
Leu Glu Thr Gln Asn Pro Ala Leu Pro Cys Val Glu Leu Asp Glu Lys
100          105          110
Val Thr Gly Gly Pro Gly Ala Lys Gly Lys Gly Arg Arg Asn Glu Lys
115          120          125
Tyr Asp Met Val Thr Asp Cys Ser Tyr Thr Val Ala Gln Val Arg Ser
130          135          140
Met Lys Ile Leu Lys Arg Phe Gly Gly Ser Val Gly Leu Trp Thr Lys
145          150          155          160
Asp Pro Leu Gly Pro Ala Glu Lys Ile Tyr Val Leu Asp Gly Thr Gln
165          170          175
Asn Asp Thr Ala Phe Val Phe Pro Arg Leu Arg Asp Phe Thr Leu Val
180          185          190

```

Met Ala Ala Arg Lys Ala Ser Arg Ile Arg Val Pro Phe Pro Trp Val  
 195 200 205  
 Gly Thr Gly Gln Leu Val Tyr Gly Gly Phe Leu Tyr Tyr Ala Arg Arg  
 210 215 220  
 Pro Pro Gly Gly Pro Gly Gly Gly Gly Glu Leu Glu Asn Thr Leu Gln  
 225 230 235 240  
 Leu Ile Lys Phe His Leu Ala Asn Arg Thr Val Val Asp Ser Ser Val  
 245 250 255  
 Phe Pro Ala Glu Ser Leu Ile Pro Pro Tyr Gly Leu Thr Ala Asp Thr  
 260 265 270  
 Tyr Ile Asp Leu Ala Ala Asp Glu Glu Gly Leu Trp Ala Val Tyr Ala  
 275 280 285  
 Thr Arg Asp Asp Asp Arg His Leu Cys Leu Ala Lys Leu Asp Pro Gln  
 290 295 300  
 Thr Leu Asp Thr Glu Gln Gln Trp Asp Thr Pro Cys Pro Arg Glu Asn  
 305 310 315 320  
 Ala Glu Ala Ala Phe Val Ile Cys Gly Thr Leu Tyr Val Val Tyr Asn  
 325 330 335  
 Thr Arg Pro Ala Ser Arg Ala Arg Ile Gln Cys Ser Phe Asp Ala Ser  
 340 345 350  
 Gly Thr Leu Ala Pro Glu Arg Ala Ala Leu Ser Tyr Phe Pro Arg Arg  
 355 360 365  
 Tyr Gly Ala His Ala Ser Leu Arg Tyr Asn Pro Arg Glu Arg Gln Leu  
 370 375 380  
 Tyr Ala Trp Asp Asp Gly Tyr Gln Ile Val Tyr Lys Leu Glu Met Lys  
 385 390 395 400  
 Lys Lys Glu Glu Glu Val  
 405

<210> 133  
 <211> 1721  
 <212> DNA  
 <213> Mus musculus

<400> 133  
 gtcgaccac gcgctccgact taaggctgcc atggggccca gtgctcctct gctgctcctc 60  
 ttctttttgt catggacggg accccttcag ggacagcagc accaccttgt ggagtacatg 120  
 gaacgcccag tagctgcctt agaggaacgg ctggcccaat gccaggatca gagtagtcgg 180  
 catgctgccg agcttcggga cttcaaaaac aagatgttgc ctctcctgga ggtggcagag 240  
 aaggagcggg agaccctcag aactgaagca gactccatct caggaagagt ggaccgtctt 300  
 gaaagggagg tagactatct ggagacacag aaccagctt tgccctgtgt agagctggat 360  
 gagaaggtga ctggaggtcc tggagccaaa ggcaagggcc gaagaaatga gaaatacgat 420  
 atggtgacgg actgtagcta cacagtcgct cagggtgaggt caatgaagat cctgaagcgg 480  
 tttggtggtt cagttggcct atggaccaag gatccgctgg ggccagcaga gaagatctac 540  
 gtgttagacg gcacccagaa cgacacggct tttgtcttcc caaggctgcg tgacttcacc 600  
 cttgtcatgg ctgcccgga agcttcccga attcgggtgc ccttcccctg ggtaggcagc 660  
 gggcagctgg tgtacgggtg cttcctttat tatgctcgaa ggccctcctg aggacctgga 720  
 gggggtggtg aattggagaa cactctgcag ctgatcaaatt ttcacttggc aaaccgaaca 780  
 gtggtggata gctcagtggt ccctgcagag agcctgatac cccctacgg cctgacagca 840  
 gatacatata tcgacctggc agctgatgag gagggcctgt gggctgtcta tgccactcga 900  
 gatgatgaca ggcattttgtg tctagccaag ttagaccac agacacttga cacagagcag 960  
 cagtgggaca caccatgtcc cagagagaac gcagaggctg cgtttgtcat ctgtgggacc 1020  
 ctgtacgttg tctataacac ccgccctgcc agtagggctc gtattcagtg ttccttcgat 1080  
 gccagtggta ctctgcctcc tgaaagggca gcactctcct attttccacg ccgatatggg 1140  
 gcccatgcca gccttcgcta taacccccgt gaggcgccagc tgtatgcctg ggatgatggc 1200  
 taccagattg tctacaaatt ggagatgaag aagaaggagg aggaagtta agcagctagc 1260  
 cttgtgctct tgattcttat gccagacat ttatatctct gtgagctctc ctgcagttca 1320  
 tccttcaaaa cgaaggccag tgggtggtagc tcatataccc taatttctaa aggacaacca 1380

```

aattctcaag cccctctgtt ttatgcagaa ctccagatcc tgggtagcat tttagaactg      1440
aacagcaaac aaacacccta aatcttcact cctgccttat gtccacaaag tttagttcca      1500
aactcagagc cctgtccttt ggagagggtc aacccagac agcaggcgac agcattcttg      1560
ccctcagtat gaccgaaggg agagaactca gagacaaagc tgccttcctt cccttccccc      1620
tccagtgtag gggagaatgg ggctttcccc acatcacttt gtatggtaac agtttgcatt      1680
aaaaggaaaa cccacaaaaa aaaaaaaaaa agggcggccg c                        1721

```

&lt;210&gt; 134

&lt;211&gt; 370

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (13)

&lt;223&gt; Xaa=unknown amino acid

&lt;400&gt; 134

```

Met Ile Ser Leu Pro Gly Pro Leu Val Thr Asn Leu Xaa Arg Phe Leu
 1           5           10           15
Phe Leu Gly Leu Ser Ala Leu Ala Pro Pro Ser Arg Ala Gln Leu Gln
          20           25           30
Leu His Leu Pro Ala Asn Arg Leu Gln Ala Val Glu Glu Gly Glu Ser
          35           40           45
Gly Ala Ser Ala Trp Tyr Thr Leu His Arg Glu Ala Ser Ser Ser Gln
          50           55           60
Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe Lys Gln Lys Glu Lys
65           70           75           80
Glu Asp Gln Val Leu Ser Tyr Ile Asn Gly Val Thr Thr Ser Lys Pro
          85           90           95
Gly Val Ser Leu Val Tyr Ser Met Pro Ser Arg Asn Leu Ser Leu Arg
          100          105          110
Val Glu Gly Leu Gln Glu Lys Asp Ser Gly Pro Tyr Ser Cys Ser Val
          115          120          125
Asn Val Gln Asp Lys Gln Gly Lys Ser Arg Gly His Ser Ile Lys Thr
          130          135          140
Leu Glu Leu Asn Val Leu Val Pro Pro Ala Pro Pro Ser Cys Arg Leu
145          150          155          160
Gln Gly Val Pro His Val Gly Ala Asn Val Thr Leu Ser Cys Gln Ser
          165          170          175
Pro Arg Ser Lys Pro Ala Val Gln Tyr Gln Trp Asp Arg Gln Leu Pro
          180          185          190
Ser Phe Gln Thr Phe Phe Ala Pro Ala Leu Asp Val Ile Arg Gly Ser
          195          200          205
Leu Ser Leu Thr Asn Leu Ser Ser Ser Met Ala Gly Val Tyr Val Cys
          210          215          220
Lys Ala His Asn Glu Val Gly Thr Ala Gln Cys Asn Val Thr Leu Glu
225          230          235          240
Val Ser Thr Gly Pro Gly Ala Ala Val Val Ala Glu Ala Val Val Gly
          245          250          255
Thr Leu Val Gly Leu Gly Leu Leu Ala Gly Leu Val Leu Leu Tyr His
          260          265          270
Arg Arg Gly Lys Ala Leu Glu Glu Pro Ala Asn Asp Ile Lys Glu Asp
          275          280          285
Ala Ile Ala Pro Arg Thr Leu Pro Trp Pro Lys Ser Ser Asp Thr Ile
          290          295          300
Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg Ala Leu Arg
305          310          315          320

```

Pro Pro His Gly Pro Pro Arg Pro Gly Ala Leu Thr Pro Thr Pro Ser  
                   325                  330                  335  
 Leu Ser Ser Gln Ala Leu Pro Ser Pro Arg His Ala His Asp Arg Trp  
                   340                  345                  350  
 Gly Pro Pro Ser Thr Asn Ile Pro His Pro Trp Trp Gly Phe Phe Leu  
                   355                  360                  365  
 Trp Leu  
       370

&lt;210&gt; 135

&lt;211&gt; 1869

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; all "n" positions

&lt;223&gt; n=a, c, g, or t

&lt;400&gt; 135

```

gtcgaccac gcgtnctcc agcgtnccga gccgccctgg gtgtcagcgg ctcggtctccc      60
gcgcacgctc cggcgctgc gcagcctcgg cacctgcagg tccgtgcgtc ccgcggctgg      120
cgccctgac tccgtcccg ccaggagggg ccatgatttc cctcccgggg cccctggtga      180
ccaacttgnt gcggtttttg ttcttggggc tgagtgcctt cgcgcccccc tcgcggggccc      240
agctgcaact gcacttgccc gccaacccgt tgcaggcggg ggaggagggg gaaagtgggtg      300
cttcagcatg gtacaccttg cacaggagg cgtcttcata ccagccatgg gaggtgccct      360
ttgtgatgtg gttcttcaaa cagaaagaaa aggaggatca ggtgttgtcc tacatcaatg      420
gggtcacaa aagcaaacct ggagtacct tgggtacttc catgccctcc cggaacctgt      480
ccctgcgggt ggagggtctc caggagaaa actctggccc ctacagctgc tccgtgaatg      540
tgcaagacaa acaaggcaaa tctagggggc acagcatcaa aaccttagaa ctcaatgtac      600
tggttctctc agtctctcca tctgccgtc tccagggtgt gcccctatgt ggggcaaacg      660
tgacctgag ctgccagtct ccaaggagta agcccgctgt ccaataccag tgggatcggc      720
agcttccatc cttccagact ttctttgcac cagcattaga tgtcatccgt gggctcttaa      780
gcctcaccaa ccttttgtct tccatggctg gagtctatgt ctgcaaggcc cacaatgagg      840
tgggcaactg ccaatgtaat gtgacgctgg aagtgagcac agggcctgga gctgcagtgg      900
ttgctgaagc tgttgtgggt accctgggtg gactgggggt gctggctggg ctggctctct      960
tgtaccaccg ccggggcaag gccctggagg agccagccaa tgatatcaag gaggatgcca      1020
ttgctccccg gacctgccc tggcccaaga gctcagacac aatctccaag aatgggacct      1080
tttctctgt cacctccgca cgagccctcc ggccacccca tggccctccc aggcctgggtg      1140
cattgacccc cagccccagt ctatccagcc aggcctgcc ctcaccaaga catgcccacg      1200
acagatgggg cccacctca accaatatcc cccatccctg gtggggtttt ttcttttggc      1260
tttgagccgc atgggtgtcg ngcctgtgat ggngcctgcc cagagtcaag ctggctctct      1320
ggtatgatga cccaccact cattggctaa aggatttggg gtctctcctt cctataaggg      1380
tcacctctag cacagaggcc tgagtcattg gaaagagtca cactcctgac ccttagtact      1440
ctgccccac ctctctttac tgtgggaaaa ccatctcagt aagacctaa tgtccaggag      1500
acagaaggag aagaggaagt ggatctggaa ttgggaggag cctccaccca cccctgactc      1560
ctccttatga agccagctgc tgaaattagc tactaccaa gagtgagggg cagagacttc      1620
cagtcactga gtctcccagg ccccttgat ctgtacccca cccctatcta acaccacct      1680
tggtcccccac tccagctccc tgtattgata taacctgtca ggctggcttg gttagggttt      1740
actggggcag aggataggga atctcttatt aaaactaaca tgaaatatgt gttgttttca      1800
tttgcaaatt taaataaaga tacataatgt ttgtatgaga taagaaaaaa aaaaaaaaaa      1860
ggcgccgcg

```

&lt;210&gt; 136

&lt;211&gt; 370

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (13)

&lt;223&gt; Xaa=unknown amino acid

&lt;400&gt; 136

```

Met Ile Ser Leu Pro Gly Pro Leu Val Thr Asn Leu Xaa Arg Phe Leu
 1           5           10           15
Phe Leu Gly Leu Ser Ala Leu Ala Pro Ser Arg Ala Gln Leu Gln
           20           25           30
Leu His Leu Pro Ala Asn Arg Leu Gln Ala Val Glu Glu Gly Glu Ser
           35           40           45
Gly Ala Ser Ala Trp Tyr Thr Leu His Arg Glu Val Ser Ser Ser Gln
           50           55           60
Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe Lys Gln Lys Glu Lys
           65           70           75           80
Glu Asp Gln Val Leu Ser Tyr Ile Asn Gly Val Thr Thr Ser Lys Pro
           85           90           95
Gly Val Ser Leu Ala Tyr Ser Met Pro Ser Arg Asn Leu Ser Leu Arg
           100          105          110
Val Glu Gly Leu Gln Glu Lys Asp Ser Gly Pro Tyr Ser Cys Ser Val
           115          120          125
Asn Val Gln Asp Lys Gln Gly Lys Ser Arg Gly His Ser Ile Lys Thr
           130          135          140
Leu Glu Leu Asn Val Leu Val Pro Pro Ala Pro Pro Ser Cys Arg Leu
           145          150          155          160
Gln Gly Val Pro His Val Gly Ala Asn Val Thr Leu Ser Cys Gln Ser
           165          170          175
Pro Arg Ser Lys Pro Ala Val Gln Tyr Gln Trp Asp Arg Gln Leu Pro
           180          185          190
Ser Phe Gln Thr Phe Phe Ala Pro Ala Leu Asp Val Ile Arg Gly Ser
           195          200          205
Leu Ser Leu Thr Asn Leu Ser Ser Ser Met Ala Gly Val Tyr Val Cys
           210          215          220
Lys Ala His Asn Glu Val Gly Thr Ala Gln Cys Asn Val Thr Leu Glu
           225          230          235          240
Val Ser Thr Gly Pro Gly Ala Ala Val Val Ala Glu Ala Val Val Gly
           245          250          255
Thr Leu Val Gly Leu Gly Leu Leu Ala Gly Leu Val Leu Leu Tyr His
           260          265          270
Arg Arg Gly Lys Ala Leu Glu Glu Pro Ala Asn Asp Ile Lys Glu Asp
           275          280          285
Ala Ile Ala Pro Arg Thr Leu Pro Trp Pro Lys Ser Ser Asp Thr Ile
           290          295          300
Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg Ala Leu Arg
           305          310          315          320
Pro Pro His Gly Pro Pro Arg Pro Gly Ala Leu Thr Pro Thr Pro Ser
           325          330          335
Leu Ser Ser Gln Ala Leu Pro Ser Pro Arg His Ala His Asp Arg Trp
           340          345          350
Gly Pro Pro Ser Thr Asn Ile Pro His Pro Trp Trp Gly Phe Phe Leu
           355          360          365
Trp Leu
           370

```

&lt;210&gt; 137

&lt;211&gt; 1869

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; all "n" positions

&lt;223&gt; n=a, c, g, or t

&lt;400&gt; 137

```

gtcgacccac gcgtncttcc agcgtnccga gccgcccctgg gtgtcagcgg ctcgggtccc      60
gcgcacgctc cggccgctgc gcagcctcgg cacctgcagg tccgtgcgtc ccgcggctgg      120
cgccccctgac tccgtccccg ccagggagggg ccatgatttc cctccccggg cccctgggtga      180
ccaacttgnt gcggtttttt ttcttggggc tgagtgcctt cgcgcccccc tcgcggggccc      240
agctgcaact gcacttgccc gccaacccgt tgcaggcggg ggaggagggg gaaagtgggtg      300
cttcagcatg gtacaccttg cacaggaggg tgtcttcac ccagccatgg gaggtgcctt      360
ttgtgatgtg gttcttcaaa cagaaagaaa aggaggatca ggtgttgtcc tacatcaatg      420
gggtcacaa cagcaaacct ggagtatcct tggcctactc catgcctccc cggaaacctgt      480
ccctgcgggt ggagggtctc caggagaaa agctctggcc ctacagctgc tccgtgaatg      540
tgcaagacaa acaaggcaaa tctagggggc acagcatcaa aaccttagaa ctcaatgtac      600
tggttccctc agctcctcca tccgtccgtc tccagggtgt gccccatgtg ggggcaaacg      660
tgaccctgag ctgccagtct ccaaggagta agcccgtgt ccaataccag tgggatcggc      720
agcttccatc cttccagact ttctttgcac cagcattaga tgtcatccgt ggggtcttta      780
gcctcaccaa cctttcgtct tccatggctg gagtctatgt ctgcaaggcc cacaatgagg      840
tgggcactgc ccaatgtaat gtgacgtctg aagtgcagc agggcctgga gctgcagtgg      900
ttgctgaagc tgttgtgggt accctgggtg gactgggggt gctggctggg ctggctcctt      960
tgtaccaccg ccggggcaag gccctggagg agccagccaa tgatatcaag gaggatgcc      1020
ttgctccccg gaccctgccc tggcccaaga gctcagacac aatctccaag aatgggaccc      1080
tttctctgt caccctccga cgagccctcc ggccacccca tggccctccc aggcctgggtg      1140
cattgacccc cagcctcagt ctatccagcc aggcctgcc ctcaccaaga catgcccacg      1200
acagatgggg cccaccctca accaatatcc cccatccctg gtgggggttt ttcttttggc      1260
tttgagccgc atgggtgctg ngcctgtgat ggngcctgcc cagagtcaag ctggctctct      1320
ggtatgatga ccccaccact cattggctaa aggatttggg gtctctcctt cctataaggg      1380
tcacctctag cacagaggcc tgagtcatgg gaaagagtca cactcctgac ccttagtact      1440
ctgcccccac ctctctttac tgtgggaaaa ccatctcagt aagacctaa tgtccaggag      1500
acagaaggag aagaggaagt ggatctggaa ttgggaggag cctccaccca cccctgactc      1560
ctccttatga agccagctgc tgaaattagc tactcaccaa gagtgaaggg cagagacttc      1620
cagtcactga gtctcccagg ccccttgat ctgtacccca cccctatcta acaccacct      1680
tggctcccac tccagctccc tgtattgata taacctgtca ggctggcttg gttagggttt      1740
actggggcag aggataggga atctcttatt aaaactaaca tgaaatatgt gttgttttca      1800
tttgcaaatt taaataaaga tacataatgt ttgtatgaga taagaaaaaa aaaaaaaaag      1860
ggcgccgc

```

&lt;210&gt; 138

&lt;211&gt; 370

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (13)

&lt;223&gt; Xaa=unknown amino acid

&lt;400&gt; 138

```

Met Ile Ser Leu Pro Gly Pro Leu Val Thr Asn Leu Xaa Arg Phe Leu
 1             5             10             15
Phe Leu Gly Leu Ser Ala Leu Ala Pro Pro Ser Arg Ala Gln Leu Gln
      20             25             30

```

```
<210> 139
<211> 1869
<212> DNA
<213> Homo sapiens
```

```
<220>  
<221> modified_base  
<222> all "n" positions  
<223> n=a, c, q, or t
```

<400> 139  
gtcgacccac gcgtncttcc agcgtncgga gccgccctgg gtgtcagcgg ctcggtctcc 60  
gcgcacgctc cggccgtcgc gcagcctcgg cacctgcagg tccgtgcgtc ccgcggctgg 120

```

cgccccctgac tccgtccccg ccagggaggg ccatgatttc cctccccggg cccctggtga 180
ccaacttgnt gcggtttttg ttctggggc tgagtgcctt cgcgcccccc tcgcggggccc 240
agctgcaact gcacttgccc gccaaaccgt tgagggcggg ggaggagggg gaaagtgggtg 300
cttcagcatg gtacaccttg cacaggaggg tgtcttcac cagccatgg gaggtgccct 360
ttgtgatgtg gttcttcaaa cagaaagaaa agggaggatca ggtgttgtcc tacatcaatg 420
gggtcacaac aagcaaacct ggagtacctt tgggtctact catgccctcc cggaacctgt 480
ccctgcgggt ggagggtctc caggagaaag actctggccc ctacagctgc tccgtgaatg 540
tgcaagacaa acaaggcaaa tctaggggcc acagcatcaa aaccttagaa ctcaatgtac 600
tggttctctc agctcctcca tctgcccgt tccagggtgt gccccatgtg ggggcaaacg 660
tgaccctgag ctgccagtct ccaaggagta agcccgtgt ccaataccag tgggatcggc 720
agcttccatc cttccagact ttctttgcac cagcattaga tgtcatccgt ggggtctttaa 780
gcctcaccaa cctttcgtct tccatggctg gagtctatgt ctgcaaggcc cacaatgagg 840
tgggcactgc ccaatgtaat gtgacgctgg aagtgagcac agggcctgga gctgcagtgg 900
ttgctgaagc tgttgtgggt accctgggtt gactgggggt gctggctggg ctggtcctct 960
tgtaccaccg ccggggcaag gccctggagg agccagccaa tgatatcaag gaggatgccca 1020
ttgctccccg gacctgccc tggcccaaga gctcagacac aatctccaag aatgggaccc 1080
tttctctgt cactccgca cgagccctcc ggccacccca tggccctccc aggcctggtg 1140
cattgacccc cagccccagt ctatccagcc aggcctgcc ctcaccaaga catgcccacg 1200
acagatgggg cccaccctca accaatatcc cccatccctg gtgggggtttt ttcctttggc 1260
tttgagcgc atgggtgctg ngcctgtgat ggngcctgcc cagagtcaag ctggctctct 1320
gggtatgatg ccccaccact cattggctaa aggatttggg gtctctcctt cctataaggg 1380
tcacctctag cacagaggcc tgagtcattg gaaagagtca cactcctgac ccttagtact 1440
ctgccccac ctctctttac tgtgggaaaa ccatctcagt aagacctaa tgtccaggag 1500
acagaaggag aagaggaagt ggatctggaa ttgggaggag cctccaccca cccctgactc 1560
ctccttatga agccagctgc tgaaattagc tactcaccaa gagtgagggg cagagacttc 1620
cagtcactga gtctcccagg ccccttgat ctgtacccca cccctatcta acaccaccct 1680
tggtccccc tccagctccc tgtattgata taacctgtca ggctggcttg gttagggttt 1740
actggggcag aggataggga atctcttatt aaaactaaca tgaaatatgt gttgttttca 1800
tttgcaaatt taaataaaga tacataatgt ttgtatgaga taagaaaaaa aaaaaaaaag 1860
ggcgccgc

```

&lt;210&gt; 140

&lt;211&gt; 370

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (13)

&lt;223&gt; Xaa=unknown amino acid

&lt;400&gt; 140

```

Met Ile Ser Leu Pro Gly Pro Leu Val Thr Asn Leu Xaa Arg Phe Leu
 1           5           10          15
Phe Leu Gly Leu Ser Ala Leu Ala Pro Pro Ser Arg Ala Gln Leu Gln
 20          25          30
Leu His Leu Pro Ala Asn Arg Leu Gln Ala Val Glu Glu Gly Glu Ser
 35          40          45
Gly Ala Ser Ala Trp Tyr Thr Leu His Arg Glu Val Ser Ser Ser Gln
 50          55          60
Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe Lys Gln Lys Glu Lys
 65          70          75          80
Glu Asp Gln Val Leu Ser Tyr Ile Asn Gly Val Thr Thr Ser Lys Pro
 85          90          95
Gly Val Ser Leu Val Tyr Ser Met Pro Ser Arg Asn Leu Ser Leu Arg
100         105         110
Val Glu Gly Leu Gln Glu Lys Asp Ser Gly Pro Tyr Ser Cys Ser Val
115         120         125

```

Asn Val Gln Asp Lys Gln Gly Lys Ser Arg Gly His Ser Ile Lys Thr  
 130 135 140  
 Leu Glu Leu Asn Val Leu Val Pro Pro Ala Pro Pro Ser Cys Arg Leu  
 145 150 155 160  
 Gln Gly Val Pro His Val Gly Ala Asn Val Thr Leu Ser Cys Gln Ser  
 165 170 175  
 Pro Arg Ser Lys Pro Val Val Gln Tyr Gln Trp Asp Arg Gln Leu Pro  
 180 185 190  
 Ser Phe Gln Thr Phe Phe Ala Pro Ala Leu Asp Val Ile Arg Gly Ser  
 195 200 205  
 Leu Ser Leu Thr Asn Leu Ser Ser Met Ala Gly Val Tyr Val Cys  
 210 215 220  
 Lys Ala His Asn Glu Val Gly Thr Ala Gln Cys Asn Val Thr Leu Glu  
 225 230 235 240  
 Val Ser Thr Gly Pro Gly Ala Ala Val Val Ala Glu Ala Val Val Gly  
 245 250 255  
 Thr Leu Val Gly Leu Gly Leu Leu Ala Gly Leu Val Leu Leu Tyr His  
 260 265 270  
 Arg Arg Gly Lys Ala Leu Glu Glu Pro Ala Asn Asp Ile Lys Glu Asp  
 275 280 285  
 Ala Ile Ala Pro Arg Thr Leu Pro Trp Pro Lys Ser Ser Asp Thr Ile  
 290 295 300  
 Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg Ala Leu Arg  
 305 310 315 320  
 Pro Pro His Gly Pro Pro Arg Pro Gly Ala Leu Thr Pro Thr Pro Ser  
 325 330 335  
 Leu Ser Ser Gln Ala Leu Pro Ser Pro Arg His Ala His Asp Arg Trp  
 340 345 350  
 Gly Pro Pro Ser Thr Asn Ile Pro His Pro Trp Trp Gly Phe Phe Leu  
 355 360 365  
 Trp Leu  
 370

&lt;210&gt; 141

&lt;211&gt; 1869

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; all "n" positions

&lt;223&gt; n=a, c, g, or t

&lt;400&gt; 141

gtcgacccac	gcgtncntcc	agcgtncgga	gccgccctgg	gtgtcagcgg	ctcggctccc	60
gcgcacgctc	cggccgtcgc	gcagcctcgg	cacctgcagg	tccgtgcgtc	ccgcggctgg	120
cgcccttgac	tccgtcccgg	ccagggaggg	ccatgatttc	cctccccggg	cccctgggtga	180
ccaacttgnt	gcggtttttg	ttcctggggc	tgagtgcctt	cgcgcccccc	tcgcggggccc	240
agctgcaact	gcacttgccc	gccaaaccgt	tgaggcggt	ggaggagggg	gaaagtgggtg	300
cttcagcatg	gtacaccttg	cacagggagg	tgtcttcatt	ccagccatgg	gaggtgccct	360
ttgtgatgtg	gttcttcaaa	cagaaagaaa	aggaggatca	ggtgttgtcc	tacatcaatg	420
gggtcacaa	aagcaaacct	ggagtatcct	tggtctactc	catgccctcc	cggaaacctgt	480
ccctgcgggt	ggagggtctc	caggagaaag	actctggccc	ctacagctgc	tccgtgaatg	540
tgcaagacaa	acaaggcaaa	tctagggggc	acagcatcaa	aaccttagaa	ctcaatgtac	600
tggttctctc	agctcctcca	tcctgccgtc	tccagggtgt	gccccatgtg	ggggcaaacg	660
tgaccctgag	ctgccagtct	ccaaggagta	agcccgttgt	ccaataccag	tgggatcggc	720
agcttccatc	cttcagact	ttctttgcac	cagcattaga	tgatcatccg	gggtctttaa	780
gcctcaccaa	cctttcgtct	tccatggctg	gagttctatg	ctgcaaggcc	cacaatgagg	840

```

tgggcactgc ccaatgtaat gtgacgctgg aagtgagcac agggcctgga gctgcagtgg      900
ttgctgaagc tggttggtgt accctgggtg gactggggtt gctggctggg ctggtcctct      960
tgtaccaccg ccggggcaag gccctggagg agccagccaa tgatatcaag gaggatgcca     1020
ttgctccccg gacctgccc tggcccaaga gctcagacac aatctccaag aatgggaccc     1080
tttctctgtg cacctccgca cgagccctcc ggccacccca tggccctccc aggcctgggtg     1140
cattgacccc cacgcccagt ctatccagcc aggccttgcc ctcaccaaga catgcccacg     1200
acagatgggg cccaccctca accaatatcc cccatccctg gtgggggtttt ttcctttggc     1260
tttgagccgc atgggtgctg ngcctgtgat ggngcctgcc cagagtcaag ctggctctct     1320
ggtatgatga cccaccact cattggctaa aggatttggg gtctctcctt cctataaggg     1380
tcacctctag cacagaggcc tgagtcatgg gaaagagtca cactcctgac ccttagtact     1440
ctgcccccac ctctctttac tgtgggaaaa ccatctcagt aagacctaag tgtccaggag     1500
acagaaggag aagaggaagt ggatctggaa ttgggaggag cctccaccca cccctgactc     1560
ctccttatga agccagctgc tgaaattagc tactcaccaa gagtgagggg cagagacttc     1620
cagtcactga gtctcccagg ccccttgat ctgtacccca cccctatcta acaccaccct     1680
tggctccac tccagctccc tgtattgata taacctgtca ggctggcttg gttagggtttt     1740
actggggcag aggataggga atctcttatt aaaactaaca tgaaatatgt gttgttttca     1800
tttgcaaatt taaataaaga tacataatgt ttgtatgaga taagaaaaaa aaaaaaaaaag     1860
ggcgccgc                                     1869

```

&lt;210&gt; 142

&lt;211&gt; 394

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 142

```

Met Ile Leu Gln Ala Gly Thr Pro Glu Thr Ser Leu Leu Arg Val Leu
 1             5             10             15
Phe Leu Gly Leu Ser Thr Leu Ala Ala Phe Ser Arg Ala Gln Met Glu
 20             25             30
Leu His Val Pro Pro Gly Leu Asn Lys Leu Glu Ala Val Glu Gly Glu
 35             40             45
Glu Val Val Leu Pro Ala Trp Tyr Thr Met Ala Arg Glu Glu Ser Trp
 50             55             60
Ser His Pro Arg Glu Val Pro Ile Met Ile Trp Phe Leu Glu Gln Glu
 65             70             75             80
Gly Lys Glu Pro Asn Gln Val Leu Ser Tyr Ile Asn Gly Val Met Thr
 85             90             95
Asn Lys Pro Gly Thr Ala Leu Val His Ser Ile Ser Ser Arg Asn Val
100            105            110
Ser Leu Arg Leu Gly Ala Leu Gln Glu Gly Asp Ser Gly Thr Tyr Arg
115            120            125
Cys Ser Val Asn Val Gln Asn Asp Glu Gly Lys Ser Ile Gly His Ser
130            135            140
Ile Lys Ser Ile Glu Leu Lys Val Leu Val Pro Pro Ala Pro Pro Ser
145            150            155            160
Cys Ser Leu Gln Gly Val Pro Tyr Val Gly Thr Asn Val Thr Leu Asn
165            170            175
Cys Lys Ser Pro Arg Ser Lys Pro Thr Ala Gln Tyr Gln Trp Glu Arg
180            185            190
Leu Ala Pro Ser Ser Gln Val Phe Phe Gly Pro Ala Leu Asp Ala Val
195            200            205
Arg Gly Ser Leu Lys Leu Thr Asn Leu Ser Ile Ala Met Ser Gly Val
210            215            220
Tyr Val Cys Lys Ala Gln Asn Arg Val Gly Phe Ala Lys Cys Asn Val
225            230            235            240
Thr Leu Asp Val Met Thr Gly Ser Lys Ala Ala Val Val Ala Gly Ala
245            250            255
Val Val Gly Thr Phe Val Gly Leu Val Leu Ile Ala Gly Leu Val Leu

```

	260		265		270
Leu Tyr Gln Arg Arg Ser Lys Thr	Leu Glu Glu Leu Ala Asn Asp Ile				
275	280	285			
Lys Glu Asp Ala Ile Ala Pro Arg Thr Leu Pro Trp Thr Lys Gly Ser					
290	295	300			
Asp Thr Ile Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg					
305	310	315			320
Ala Leu Arg Pro Pro Lys Ala Ala Pro Pro Arg Pro Gly Thr Phe Thr					
325	330	335			
Pro Thr Pro Ser Val Ser Ser Gln Ala Leu Ser Ser Pro Arg Leu Pro					
340	345	350			
Arg Val Asp Glu Pro Pro Pro Gln Ala Val Ser Leu Thr Pro Gly Gly					
355	360	365			
Val Ser Ser Ser Ala Leu Ser Arg Met Gly Ala Val Pro Val Met Val					
370	375	380			
Pro Ala Gln Ser Gln Ala Gly Ser Leu Val					
385	390				

&lt;210&gt; 143

&lt;211&gt; 1846

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 143

gtcgacccac	gcgtccggtg	cacattcggg	ttgccgccgc	tcaccacaaa	cacctgtaga	60
caccgtgtgt	ccaactctcc	ctgagtactc	cgggccaagg	agggccatga	ttcttcaggc	120
tggaaccccc	gagaccagct	tgctgcgggt	tttgttctctg	ggactgagta	cccttgctgc	180
cttctccoga	gctcagatgg	agttgcacgt	gcccccgggc	ctcaacaaat	tggaagcggt	240
agagggagaa	gaagtgggtc	tccccgcctg	gtacacgatg	gcacgggagg	agtcgtggtc	300
ccacccccgg	gaggtgcca	tcattgatctg	gttcttgga	caagaaggga	aggaacaaaa	360
ccaggtgttg	tcttacatta	atggagtcac	gacaaataaa	cctggaacag	ccctgggtcca	420
ctctatctct	tcacggaatg	tgctccctgcg	cctggggggca	ctccaggagg	gagactctgg	480
gacttaccgc	tggtctgtca	atgtgcagaa	tgatgaaggc	aaaagtatag	gccacagcat	540
caaaagcata	gagctcaaaag	tgctggttcc	tccagctcct	ccatcctgta	gtttacaggg	600
tgtaccctat	gtcggggacca	atgtgaccct	gaactgcaag	tccccaaggga	gtaaacctac	660
tgtcagtag	cagtgggaga	ggctggcccc	atcctcccag	gtcttctttg	gaccagcctt	720
agatgctgtt	cgtggatctt	taaagctcac	taacctttcc	attgccatgt	ctggagtcta	780
tgtctgcaag	gctcaaaaaca	gagtgggctt	tgccaagtgc	aacgtgacct	tggacgtgat	840
gacaggggtcc	aaggctgcag	tggtcgctgg	agcagttgtg	ggcacttttg	ttgggttggt	900
gctgatagct	gggctgggtcc	tggtgtacca	gcgccggagc	aagaccttgg	aagagctggc	960
caatgatatc	aaggaagatg	ccattgctcc	ccggaccttg	ccttggaacca	aaggctcaga	1020
cacaatctcc	aagaatggga	cactttcttc	ggtcacctca	gcacgagctc	tgccggccacc	1080
caaggctgct	cctccaagac	ctggcacatt	tactcccaca	cccagtgctc	ctagccaggc	1140
cctgtcctca	ccaagactgc	ccagggtaga	tgaacccccca	cctcaggcag	tgtccctgac	1200
cccagggtggg	gtttcttctt	ctgctctgag	ccgcatgggt	gctgtgcctg	tgatgggtgcc	1260
tgcacagagt	caggctgggt	ctcttggtgtg	atagcccagg	cactcattag	ctacatctgg	1320
tatctgacct	ttctgtaaag	gtctccttgt	ggcacagagg	actcaatctt	gggaggatgc	1380
ccacattcta	gacctccagt	cctttgctcc	tacctccttc	tattgttgga	atactgggcc	1440
tcagtaagac	taaaatctgg	gtcaaaggac	aaaaggagga	aatggacctg	aggtaggggg	1500
ttgggagtga	ggaggcttca	cttcctccct	gcttctccct	gaagccagat	gaatgctgcg	1560
gaagatcggc	taccctccaa	gggctctgga	ggagactgcc	agtcagtgat	gcccctggct	1620
ctgtgatctg	tacaacaccc	ttatctaattg	ctgtcctttg	ccgttcgctc	catctccctg	1680
tattaatata	acctgtcctg	ctggccttggc	tgggttttgt	tgtagcaggg	ggataggaaa	1740
gacattttta	aatctgactt	gaaattgatg	tttttgtttt	tattttgcaa	atttcaataa	1800
agatacatcg	catttgcatg	gaaaaaaaaa	aaaaaagggc	ggccgc		1846

&lt;210&gt; 144

&lt;211&gt; 394

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 144

```

Met Ile Leu Gln Ala Gly Thr Pro Glu Thr Ser Leu Leu Arg Val Leu
 1           5           10           15
Phe Leu Gly Leu Ser Thr Leu Ala Ala Phe Ser Arg Ala Gln Met Glu
      20           25           30
Leu His Val Pro Pro Gly Leu Asn Lys Leu Glu Ala Val Glu Gly Glu
      35           40           45
Glu Val Val Leu Pro Ala Trp Tyr Thr Met Ala Arg Glu Glu Ser Trp
      50           55           60
Ser His Pro Arg Glu Val Pro Ile Leu Ile Trp Phe Leu Glu Gln Glu
      65           70           75           80
Gly Lys Glu Pro Asn Gln Val Leu Ser Tyr Ile Asn Gly Val Met Thr
      85           90           95
Asn Lys Pro Gly Thr Ala Leu Val His Ser Ile Ser Ser Arg Asn Val
      100           105           110
Ser Leu Arg Leu Gly Ala Leu Gln Glu Gly Asp Ser Gly Thr Tyr Arg
      115           120           125
Cys Ser Val Asn Val Gln Asn Asp Glu Gly Lys Ser Ile Gly His Ser
      130           135           140
Ile Lys Ser Ile Glu Leu Lys Ala Leu Val Pro Pro Ala Pro Pro Ser
      145           150           155           160
Cys Ser Leu Gln Gly Val Pro Tyr Val Gly Thr Asn Val Thr Leu Asn
      165           170           175
Cys Lys Ser Pro Arg Ser Lys Pro Thr Ala Gln Tyr Gln Trp Glu Arg
      180           185           190
Leu Ala Pro Ser Ser Gln Val Phe Phe Gly Pro Ala Leu Asp Ala Val
      195           200           205
Arg Gly Ser Leu Lys Leu Thr Asn Leu Ser Ile Ala Met Ser Gly Val
      210           215           220
Tyr Val Cys Lys Ala Gln Asn Arg Val Gly Phe Ala Lys Cys Asn Val
      225           230           235           240
Thr Leu Asp Val Met Thr Gly Ser Lys Ala Ala Val Val Ala Gly Ala
      245           250           255
Val Val Gly Thr Phe Val Gly Leu Val Leu Ile Ala Gly Leu Val Leu
      260           265           270
Leu Tyr Gln Arg Arg Ser Lys Thr Leu Glu Glu Leu Ala Asn Asp Ile
      275           280           285
Lys Glu Asp Ala Ile Ala Pro Arg Thr Leu Pro Trp Thr Lys Gly Ser
      290           295           300
Asp Thr Ile Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg
      305           310           315           320
Ala Leu Arg Pro Pro Lys Ala Ala Pro Pro Arg Pro Gly Thr Phe Thr
      325           330           335
Pro Thr Pro Ser Val Ser Ser Gln Ala Leu Ser Ser Pro Arg Leu Pro
      340           345           350
Arg Val Asp Glu Pro Pro Pro Gln Ala Val Ser Leu Thr Pro Gly Gly
      355           360           365
Val Ser Ser Ser Ala Leu Ser Arg Met Gly Ala Val Pro Val Met Val
      370           375           380
Pro Ala Gln Ser Gln Ala Gly Ser Leu Val
      385           390

```

&lt;210&gt; 145

&lt;211&gt; 1846

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 145

```

gtcgaccac gcgctccggtg cacattcggg ttgccgccgc tcaccacaa cacctgtaga      60
caccgtgtgt ccaactctcc ctgagtactc cgggccaaagg agggccatga ttcttcaggc      120
tggaaccccc gagaccagct tgctgcgggt tttgttcctg ggactgagta cccttgcctgc      180
cttctccccg gctcagatgg agttgcacgt gcccccgggc ctcaacaaat tggaagcggt      240
agagggagaa gaagtgggtg tccccgcctg gtacacgatg gcacgggagg agtcgtggtc      300
ccacccccgg gaggtgcccc tcttgatctg gttcttgaa caagaaggga aggaacaaaa      360
ccagggtgtg tcttacatta atggagtcac gacaaataaa cctggaacag ccctgggtcca      420
ctctatctct tcacggaatg tgcctctgcg cctgggggca ctccaggagg gagactctgg      480
gacttaccgc tgttctgtca atgtgcagaa tgatgaaggc aaaagtatag gccacagcat      540
caaaagcata gagctcaaag cgctgggtcc tccagctcct ccattcctgta gtttacaggg      600
tgtaccctat gtcgggacca atgtgacctt gaactgcaag tcccaagga gtaaaccctac      660
tgctcagtag cagtgggaga ggctggcccc atcctcccag gtcttctttg gaccagcctt      720
agatgctgtt cgtggatctt taaagctcac taacctttcc attgccatgt ctggagctcta      780
tgtctgcaag gctcaaaaaca gagtgggctt tgccaagtgc aacgtgacct tggagctgat      840
gacaggggtcc aaggctgcag tggctcgtgg agcagttgtg ggcacttttg ttgggttggg      900
gctgatagct gggctgggtcc tgttgtagca gcgccggagc aagaccttgg aagagctggc      960
caatgatata aaggaagatg ccattgctcc ccggaccttg ccttgagcca aaggctcaga     1020
cacaatctcc aagaatggga cactttcttc ggtcacctca gcacgagctc tgcggccacc     1080
caaggctgct cctccaagac ctggcacatt tactcccaca cccagtgtct ctagccaggc     1140
cctgtcctca ccaagactgc ccagggtaga tgaaccccc cctcaggcag tgcctctgac     1200
cccagggtgg gtttcttctt ctgctctgag ccgcatgggt gctgtgcctg tgatgggtgcc     1260
tgcacagagt caggctgggt ctcttctgtg atagcccagg cactcattag ctacatctgg     1320
tatctgacct ttctgtaaag gtctccttgt ggcacagagg actcaatctt gggaggatgc     1380
ccacattcta gacctccagt cctttgctcc tacctccttc tattgttggg atactggggc     1440
tcagtaagac taaaatctgg gtcaaaggac aaaaggagga aatggacctg aggtaggggg     1500
ttgggagtgga ggaggttcca cttcctccct gcttctccct gaagccagat gaatgctgcg     1560
gaagatcggc taccctccaa gggctctgga ggagactgcc agtcagtgat gcccctggct     1620
ctgtgatctg tacaacaccc ttatctaata ctgtcctttg ccgttcgctc catctccctg     1680
tattaatata acctgtcctg ctggcttggc tgggttttgt tgtagcaggg ggatagggaa     1740
gacattttaa aatctgactt gaaattgatg tttttgtttt tattttgcaa atttcaataa     1800
agatacatcg catttgcatg gaaaaaaaaa aaaaaagggc ggccgc                        1846

```

&lt;210&gt; 146

&lt;211&gt; 394

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 146

```

Met Ile Leu Gln Ala Gly Thr Pro Glu Thr Ser Leu Leu Arg Val Leu
 1             5             10             15
Phe Leu Gly Leu Ser Thr Leu Ala Ala Phe Ser Arg Ala Gln Met Glu
 20             25             30
Leu His Val Pro Pro Gly Leu Asn Lys Leu Glu Ala Val Glu Gly Glu
 35             40             45
Glu Val Val Leu Pro Ala Trp Tyr Thr Met Ala Arg Glu Glu Ser Trp
 50             55             60
Ser His Pro Arg Glu Val Pro Ile Leu Ile Trp Phe Leu Glu Gln Glu
 65             70             75             80
Gly Lys Glu Pro Asn Gln Val Leu Ser Tyr Ile Asn Gly Val Met Thr
 85             90             95
Asn Lys Pro Gly Thr Ala Leu Val His Ser Ile Ser Ser Arg Asn Val
100             105             110
Ser Leu Arg Leu Gly Ala Leu Gln Glu Gly Asp Ser Gly Thr Tyr Arg
115             120             125
Cys Ser Val Asn Val Gln Asn Asp Glu Gly Lys Ser Ile Gly His Ser

```

130	135	140
Ile Lys Ser Ile Glu Leu Lys Val Leu Val Pro Pro Ala Pro Pro Ser		
145	150	155
Cys Ser Leu Gln Gly Val Pro Tyr Val Gly Thr Asn Val Thr Leu Asn		160
	165	170
Cys Lys Ser Pro Arg Ser Lys Pro Thr Ala Gln Tyr Gln Trp Glu Arg		175
	180	185
Leu Val Pro Ser Ser Gln Val Phe Phe Gly Pro Ala Leu Asp Ala Val		190
	195	200
Arg Gly Ser Leu Lys Leu Thr Asn Leu Ser Ile Ala Met Ser Gly Val		205
	210	215
Tyr Val Cys Lys Ala Gln Asn Arg Val Gly Phe Ala Lys Cys Asn Val		220
225	230	235
Thr Leu Asp Val Met Thr Gly Ser Lys Ala Ala Val Val Ala Gly Ala		240
	245	250
Val Val Gly Thr Phe Val Gly Leu Val Leu Ile Ala Gly Leu Val Leu		255
	260	265
Leu Tyr Gln Arg Arg Ser Lys Thr Leu Glu Glu Leu Ala Asn Asp Ile		270
	275	280
Lys Glu Asp Ala Ile Ala Pro Arg Thr Leu Pro Trp Thr Lys Gly Ser		285
	290	295
Asp Thr Ile Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg		300
305	310	315
Ala Leu Arg Pro Pro Lys Ala Ala Pro Pro Arg Pro Gly Thr Phe Thr		320
	325	330
Pro Thr Pro Ser Val Ser Ser Gln Ala Leu Ser Ser Pro Arg Leu Pro		335
	340	345
Arg Val Asp Glu Pro Pro Pro Gln Ala Val Ser Leu Thr Pro Gly Gly		350
	355	360
Val Ser Ser Ser Ala Leu Ser Arg Met Gly Ala Val Pro Val Met Val		365
	370	375
Pro Ala Gln Ser Gln Ala Gly Ser Leu Val		380
385	390	

&lt;210&gt; 147

&lt;211&gt; 1846

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 147

gtcgacccac	gcgtccggtg	cacattcggg	ttgccgcgcg	tcacccacaa	cacctgtaga	60
caccgtgtgt	ccaactctcc	ctgagtactc	cgggccaaag	agggccatga	ttcttcaggc	120
tggaaccccc	gagaccagct	tgctgcgggt	tttgttctctg	ggactgagta	cccttgctgc	180
cttctcccga	gctcagatgg	agttgcacgt	gcccccgggc	ctcaacaaat	tggaagcggt	240
agagggagaa	gaagtgggtg	tccccgcctg	gtacacgatg	gcacgggagg	agtcgtgggtc	300
ccacccccgg	gaggtgcccc	tcttgatctg	gttcttgga	caagaaggga	aggaaccaa	360
ccaggtgttg	tcttacatta	atggagtcac	gacaaataaa	cctggaacag	ccctggtcca	420
ctctatctct	tcacggaatg	tgtccctgcg	cctggggggc	ctccaggagg	gagactctgg	480
gacttaccgc	tggtctgtca	atgtgcagaa	tgatgaaggc	aaaagtatat	gccacagcat	540
caaaagcata	gagctcaaag	tgctggttcc	tccagctcct	ccatcctgta	gtttacaggg	600
tgtaccctat	gtcgggacca	atgtgacct	gaactgcaag	tcaccaagga	gtaaacctac	660
tgctcagtac	cagtgggaga	ggctgggtccc	atcctcccag	gtcttctttg	gaccagcctt	720
agatgctggt	cgtggatctt	taaagctcac	taacctttcc	attgccatgt	ctggagtcta	780
tgtctgcaag	gctcaaaaca	gagtgggctt	tgccaagtgc	aacgtgacct	tggacgtgat	840
gacagggtcc	aaggctgcag	tggtcgctgg	agcagttgtg	ggcacttttg	ttgggttggt	900
gctgatagct	gggctgggtc	tggtgtacca	gcgcggagc	aagaccttgg	aagactggc	960
caatgatata	aaggaagatg	ccattgctcc	ccggaccttg	ccttggaaca	aaggtcaga	1020
cacaatctcc	aagaatggga	cactttcttc	ggtcacctca	gcacgagctc	tgcgccacc	1080

```

caaggctgct cctccaagac ctggcacatt tactcccaca cccagtgtct ctagccaggc 1140
cctgtcctca ccaagactgc ccagggtaga tgaaccccca cctcaggcag tgtccctgac 1200
cccagggtggg gtttcttctt ctgctctgag cgcgatgggt gctgtgcctg tgatgggtgcc 1260
tgcacagagt caggctgggt ctcttgtgtg atagcccagg cactcattag ctacatctgg 1320
tatctgacct ttctgtaaag gtctccttgt ggcacagagg actcaatctt gggaggatgc 1380
ccacattcta gacctccagt cctttgctcc tacctccttc tattgttggg atactggggc 1440
tcagtaagac taaaatctgg gtcaaaggac aaaaggagga aatggacctg aggtaggggg 1500
ttgggagtga ggaggcttca ctctctccct gcttctccct gaagccagat gaatgctgcg 1560
gaagatcggc taccttccaa gggctctgga ggagactgcc agtcagtgat gcccctggct 1620
ctgtgatctg tacaacaccc ttatctaata ctgtcctttg ccgttcgctc catctccctg 1680
tattaatata acctgtcctg ctggcttggc tgggttttgt tgtagcaggg ggataggaaa 1740
gacattttaa aatctgactt gaaattgatg tttttgtttt tattttgcaa atttcaataa 1800
agatacatcg catttgcacg gaaaaaaaaa aaaaaagggc ggccgc 1846

```

&lt;210&gt; 148

&lt;211&gt; 394

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 148

```

Met Ile Leu Gln Ala Gly Thr Pro Glu Thr Ser Leu Leu Arg Val Leu
  1           5           10           15
Phe Leu Gly Leu Ser Thr Leu Ala Ala Phe Ser Arg Ala Gln Met Glu
          20           25           30
Leu His Val Pro Pro Gly Leu Asn Lys Leu Glu Ala Val Glu Gly Glu
          35           40           45
Glu Val Val Leu Pro Ala Trp Tyr Thr Met Ala Arg Glu Glu Ser Trp
          50           55           60
Ser His Pro Arg Glu Val Pro Ile Leu Ile Trp Phe Leu Glu Gln Glu
          65           70           75           80
Gly Lys Glu Pro Asn Gln Val Leu Ser Tyr Ile Asn Gly Val Met Thr
          85           90           95
Asn Lys Pro Gly Thr Ala Leu Val His Ser Ile Ser Ser Arg Asn Val
          100          105          110
Ser Leu Arg Leu Gly Ala Leu Gln Glu Gly Asp Ser Gly Thr Tyr Arg
          115          120          125
Cys Ser Val Asn Val Gln Asn Asp Glu Gly Lys Ser Ile Gly His Ser
          130          135          140
Ile Lys Ser Ile Glu Leu Lys Val Leu Val Pro Pro Ala Pro Pro Ser
          145          150          155          160
Cys Ser Leu Gln Gly Val Pro Tyr Val Gly Thr Asn Val Thr Leu Asn
          165          170          175
Cys Lys Ser Pro Arg Ser Lys Pro Thr Ala Gln Tyr Gln Trp Glu Arg
          180          185          190
Leu Ala Pro Ser Ser Gln Val Phe Phe Gly Pro Ala Leu Asp Ala Val
          195          200          205
Arg Gly Ser Leu Lys Leu Thr Asn Leu Ser Ile Ala Met Ser Gly Val
          210          215          220
Tyr Val Cys Lys Ala Gln Asn Arg Val Gly Phe Ala Lys Cys Asn Val
          225          230          235          240
Thr Leu Asp Val Met Thr Gly Ser Lys Ala Ala Val Val Ala Gly Ala
          245          250          255
Val Val Gly Thr Phe Val Gly Leu Val Leu Ile Ala Gly Leu Val Leu
          260          265          270
Leu Tyr Gln Arg Arg Ser Lys Thr Leu Glu Glu Leu Ala Asn Asp Ile
          275          280          285
Lys Glu Asp Ala Ile Ala Pro Arg Thr Leu Pro Trp Thr Lys Gly Ser
          290          295          300

```

Asp Thr Ile Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg  
 305 310 315 320  
 Ala Leu Arg Pro Pro Lys Ala Ala Pro Pro Arg Pro Gly Thr Phe Thr  
 325 330 335  
 Pro Thr Pro Ser Val Ser Ser Gln Ala Leu Ser Ser Pro Arg Leu Pro  
 340 345 350  
 Arg Val Asp Glu Pro Pro Pro Gln Ala Val Ser Leu Thr Pro Gly Gly  
 355 360 365  
 Val Ser Ser Ser Val Leu Ser Arg Met Gly Ala Val Pro Val Met Val  
 370 375 380  
 Pro Ala Gln Ser Gln Ala Gly Ser Leu Val  
 385 390

&lt;210&gt; 149

&lt;211&gt; 1846

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 149

```

gtcgaccac gcgctccggtg cacattcggg ttgccgcgcg tcaccacaaa cacctgtaga      60
caccgtgtgt ccaactctcc ctgagtactc cgggccaaagg agggccatga ttcttcaggc      120
tggaaccccc gagaccagct tgctgcgggt tttgttcctg ggactgagta cccttgctgc      180
cttctcccgga gctcagatgg agttgcacgt gccccggggc ctcaacaaat tggaagcggg      240
agagggagaaa gaagtgggtgc tccccgcctg gtacacgatg gcacgggagg agtcgtgggc      300
ccacccccggg gaggtgcccc tcttgatctg gttcttgga caagaaggga aggaacaaaa      360
ccagggtgttg tcttacatta atggagtcac gacaaataaa cctggaacag ccctgggtcca      420
ctctatctct tcacggaatg tgcctctgcg cctgggggca ctccaggagg gagactctgg      480
gacttaccgc tgttctgtca atgtgcagaa tgatgaaggc aaaagtatag gccacagcat      540
caaaagcata gagctcaaag tgctgggtcc tccagctcct ccatcctgta gtttacaggg      600
tgtaccctat gtcggggacca atgtgacctt gaactgcaag tccccaaagg gtaaacctac      660
tgctcagtag cagtgggaga ggctggcccc atcctcccag gtcttctttg gaccagcctt      720
agatgctggt cgtggatctt taaagctcac taacctttcc attgccatgt ctggagtcta      780
tgtctgcaag gctcaaaaca gagtgggctt tgccaagtgc aacgtgacct tggacgtgat      840
gacagggtcc aaggctgcag tggctcgtgg agcagttgtg ggcacttttg ttgggttggt      900
gctgatagct gggctgggtcc tgttgtagca gcgcgggagc aagaccttgg aagagctggc      960
caatgatatac aaggaagatg ccattgctcc ccggaccttg ccttggaaca aaggctcaga     1020
cacaactctcc aagaatggga cactttcttc ggtcacctca gcacgagctc tgcggccacc     1080
caaggctgct cctccaagac ctggcacatt tactccaca cccagtgtct ctagccaggc     1140
cctgtcctca ccaagactgc ccagggtaga tgaaccccca cctcaggcag tgtccctgac     1200
cccagggtggg gtttcttctt ctgttctgag ccgcatgggt gctgtgcctg tgatggtgcc     1260
tgcacagagt caggctgggt ctcttggtg atagcccagg cactcattag ctacatctgg     1320
tatctgacct ttctgtaaa gtctccttgt ggcacagagg actcaatctt gggaggatgc     1380
ccacattcta gacctccagt cctttgctcc tacctccttc tattgttgga atactgggoc     1440
tcagtaagac taaaatctgg gtcaaaggac aaaaggagga aatggacctg aggtaggggg     1500
ttgggagtga ggaggcttca ctctctccct gcttctccct gaagccagat gaatgctgcg     1560
gaagatcggc taccctccaa gggctctgga ggagactgcc agtcagtgat gcccctggct     1620
ctgtgatctg tacaacaccc ttatctaatt ctgtcctttg ccgttcgctc catctccctg     1680
tattaatata acctgtcctg ctggcttggc tgggttttgt tgtagcaggg ggataggaaa     1740
gacattttta aatctgactt gaaattgatg tttttgtttt tattttgcaa atttcaataa     1800
agatacatcg catttgcatg gaaaaaaaaa aaaaaagggc ggccgc      1846

```

&lt;210&gt; 150

&lt;211&gt; 245

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 150

Met Arg Leu Phe Val Arg Pro Ser Val Arg Pro Ala Met Ala Ala Pro

1	5	10	15
Ala Pro Ser	Pro Trp Thr Leu Ser	Leu Leu Leu Leu Leu Leu	Leu Leu Pro
	20	25	30
Ser Pro Gly	Ala His Gly Glu Leu Cys Arg	Pro Phe Gly Glu Asp Asn	
	35	40	45
Ser Ile Pro	Glu Ser Cys Pro Asp Phe Cys Cys	Gly Ser Cys Ser Ser	
	50	55	60
Gln Tyr Cys	Cys Ser Asp Val Leu Lys Lys Ile	Gln Trp Asn Glu Glu	
	65	70	75
Met Cys Pro	Glu Pro Glu Ser Ser Arg Phe Ser	Ala His Pro Glu Thr	
	85	90	95
Pro Glu Gln	Leu Gly Ser Val Leu Lys Tyr Gln	Ser Ser Leu Asp Ser	
	100	105	110
Asp Asn Met	Pro Gly Phe Gly Ala Thr Val Ala	Ile Gly Leu Thr Val	
	115	120	125
Phe Val Val	Phe Ile Ala Thr Ile Ile Val Cys	Phe Thr Cys Ser Cys	
	130	135	140
Cys Cys Leu	Tyr Lys Met Cys Cys Arg Pro Arg	Pro Val Val Ser Asn	
	145	150	155
Thr Thr Thr	Thr Thr Val Val His Thr Ala Tyr	Pro Gln Pro Gln Pro	
	165	170	175
Val Ala Pro	Ser Tyr Pro Gly Pro Thr Tyr Gln	Gly Tyr His Pro Met	
	180	185	190
Pro Pro Gln	Pro Gly Met Pro Ala Ala Pro Tyr	Pro Thr Gln Tyr Pro	
	195	200	205
Pro Pro Tyr	Leu Ala Gln Pro Thr Gly Pro Pro	Ala Tyr His Glu Thr	
	210	215	220
Leu Ala Gly	Ala Ser Gln Pro Pro Tyr Asn Pro	Ala Tyr Met Asp Pro	
	225	230	235
Pro Lys Ala	Val Pro		240
	245		

&lt;210&gt; 151

&lt;211&gt; 1801

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 151

gtcgaccac	gcgtccggcg	gaggttggtg	ctgcaccgtg	gtcctgggct	tggtcctggg	60
cttgatgcgt	ctgtttgtcc	gtccgtccgt	ccgtcccgcc	atggctgcgc	cggcgccctc	120
tccgtggacc	ctttcgctgc	tgtgttggt	gctactgccg	tctccgggtg	cccatggcga	180
gctgtgcagg	cccttcggtg	aagacaattc	gatcccagag	tctgtcctg	acttctgttg	240
tggtcctgt	tccagccaat	actgctgctc	tgacgtgctg	aagaaaatcc	agtggaatga	300
ggaaatgtgc	cctgagccag	agtccagcag	attttccgcc	cacccggaga	caccagaaca	360
gctgggttca	gtgctgaagt	atcagtcag	tcttgacagt	gacaacatgc	cagggttcgg	420
agcgaccgtg	gccatcggcc	tgaccgtctt	cgtgggtgtt	atcgctacca	tcattgtgtg	480
ctttacctgc	tcctgctgct	gtctatataa	gatgtgctgc	cgcccacgac	ctgtcgtgtc	540
caacaccaca	actactaccg	tggttcacac	cgcttaccct	cagcctcaac	ctgtggcccc	600
cagctatcct	ggaccaacat	accagggcta	ccatccccatg	cccccccagc	caggaatgcc	660
agcagcacc	taccaacgc	agtaccctcc	accctacctg	gcccagccca	cagggccacc	720
agcctatcat	gagacgttg	ctggagccag	ccagcctcca	tacaacccgg	cctacatgga	780
tccccaaag	gcagttccct	gagcctgccc	ccagcctctt	tggttaacat	ttgattatgt	840
catgtgtgtg	tgagtgtct	gcagagttct	ttactgctgt	ctgtggtgcg	tgtgccttgt	900
ctagacatgt	ggcttcctct	gctgatgacc	aggtaggcac	aaatcttacc	agtgtggtt	960
gggaccaatc	tggtttcttc	ctcacttgaa	attgtaattt	ctgaaatttc	aagtaaatta	1020
aaaacaatag	ggtaggaggt	atttcccgct	tcaccccaag	gtgaccagcc	atagcctgcc	1080
acacatagga	gagcaagctt	tttgtgggtc	catgtcctgc	tttggggagt	agccagctag	1140
ctgctgctat	gggtttatcc	ccagggcttg	gctgcattta	gctggacaga	gaacaagggg	1200

```

cctcagtggc agtggggtcag tgactgatgt cagagcacac taggcagaga gccccgtccg 1260
tctccatcag ctgtctgtct ggacgggtccc actgtctttc ctgggactat gtagagggcc 1320
acatgtattc actattcagg ctccagtggc ttccaggcca ggggcctctg tctactacac 1380
actctggttt ctccctacag tgtcttttta cgattagcca aacatattgc ctgttttttg 1440
tatccagatg tgtgataatt ggtgagggtg aaatccttgg ttcttgaga acaggaaacc 1500
tgacctctga cagtccgttt cccttgacac cagcttcata gaatacctga ctctgtact 1560
acagtccagt ttgttccagt agcaggggaca ccaggggccag gggttatctg gaccaagggt 1620
gggggtggag agcctggatg gtagctctgg accagatgtg aatgcctcca tattccctgt 1680
tggttctgt ttcactggct gttttagttt tgtgttaatt ggtgtttctg agcattcaaa 1740
ctccgcaccc tcgtttataa taaatgaata tttggaaaaa aaaaaaaaaa aaaaaaaaaa 1800
a 1801

```

&lt;210&gt; 152

&lt;211&gt; 245

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 152

```

Met Arg Leu Phe Val Arg Pro Ser Val Arg Pro Ala Met Ala Ala Pro
1          5          10          15
Ala Pro Ser Pro Trp Thr Leu Ser Leu Leu Leu Leu Leu Leu Leu Pro
20          25          30
Ser Pro Gly Ala His Gly Glu Leu Cys Arg Pro Phe Gly Glu Asp Asn
35          40          45
Ser Ile Pro Glu Ser Cys Pro Asp Phe Cys Cys Gly Ser Cys Ser Ser
50          55          60
Gln Tyr Cys Cys Ser Asp Val Leu Lys Lys Ile Gln Trp Asn Glu Glu
65          70          75          80
Met Cys Pro Glu Pro Glu Ser Ser Arg Phe Ser Ala His Pro Glu Thr
85          90          95
Pro Glu Gln Leu Gly Ser Ala Leu Lys Tyr Gln Ser Ser Leu Asp Ser
100         105         110
Asp Asn Met Pro Gly Phe Gly Ala Thr Val Ala Ile Gly Leu Thr Val
115         120         125
Phe Val Val Phe Ile Ala Thr Ile Ile Val Cys Phe Thr Cys Ser Cys
130         135         140
Cys Cys Leu Tyr Lys Met Cys Cys Arg Pro Arg Pro Val Val Ser Asn
145         150         155         160
Thr Thr Thr Thr Thr Ala Val His Thr Ala Tyr Pro Gln Pro Gln Pro
165         170         175
Val Ala Pro Ser Tyr Pro Gly Pro Thr Tyr Gln Gly Tyr His Pro Met
180         185         190
Pro Pro Gln Pro Gly Met Pro Ala Ala Pro Tyr Pro Thr Gln Tyr Pro
195         200         205
Pro Pro Tyr Leu Ala Gln Pro Thr Gly Pro Pro Ala Tyr His Glu Thr
210         215         220
Leu Ala Gly Ala Ser Gln Pro Pro Tyr Asn Pro Ala Tyr Met Asp Pro
225         230         235         240
Pro Lys Ala Val Pro
245

```

&lt;210&gt; 153

&lt;211&gt; 1801

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 153

```

gtcgaccac gcgtccggcg gaggttgtgg ctgcaccgtg gtcctgggct tggctctggg 60

```

```

cttgatgcgt ctgtttgtcc gtccgtccgt ccgtcccgcc atggctgcgc cggcgccctc 120
tccgtggacc ctttcgctgc tgcgtgtgtt gctactgccg tctccgggtg cccatggcga 180
gctgtgcagg cccttcgggtg aagacaattc gatcccagag tccgtgcctg acttctgttg 240
tggctcctgt tccagccaat actgctgctc tgacgtgctg aagaaaatcc agtggaaatga 300
ggaaatgtgc cctgagccag agtccagcag attttccgcc caccgggaga caccagaaca 360
gctgggttca gcgctgaagt atcagtcag tcttgacagt gacaacatgc cagggttcgg 420
agcgaccgtg gccatcggcc tgaccgtctt cgtgggtgtt atcgctacca tcattgtgtg 480
ctttacctgc tccgtgctgt gtctatataa gatgtgctgc cgcccacgac ctgtcgtgtc 540
caacaccaca actactaccg cggttcacac cgcttaccct cagcctcaac ctgtggcccc 600
cagctatcct ggaccaacat accagggcta ccatcccag ccccccagc caggaatgcc 660
agcagcacc caccacacgc agtaccctcc accctacctg gccagccca cagggccacc 720
agcctatcat gagacgttgg ctggagccag ccagcctcca tacaaccgg cctacatgga 780
tccccaaag gcagttccct gagcctgcc ccagcctctt tggctaacat ttgattatgt 840
catgtgtgtg tgagtgtat gcagagttct ttactgctgt ctgtggtgcg tgtgccttgt 900
ctagacatgt ggcttcctct gctgatgacc aggtaggcac aaatcttacc agtgcctggt 960
gggaccaatc tgttttcttc ctcacttgaa attgtaattt ctgaaatttc aagtaaatta 1020
aaaacaatag ggtaggaggt atttcccgct tcacccaag gtgaccagcc atagcctgcc 1080
acacatagga gagcaagctt tttgtgggtc catgtcctgc tttggggagt agccagctag 1140
ctgctgctat gggtttatcc ccagggcttg gctgcattta gctggacaga gaacaagggg 1200
cctcagtggc agtgggtcag tgactgatgt cagagcacac taggcagaga gcccgtccg 1260
tctccatcag ctgtctgtct ggacggtccc actgtcttct ctgggactat gtagagggcc 1320
acatgtattc actattcagg ctccagtggc ttccaggcca ggggcctctg tctactacac 1380
actctggttt ctccctacag tgtcttttta cgattagcca aacatattgc ctgttttttg 1440
tatccagatg tgtgataatt ggtgaggttg aaatccttgg ttccctggaga acaggaaacc 1500
tgacctctga cagtccgttt cccttgacac cagcttcata gaatacctga ctctgtact 1560
acagtccagt ttgttccagt agcagggaca ccagggccag gggttatctg gaccaaggg 1620
gggggtggag agcctggatg gtagctctgg accagatgtg aatgcctcca tattccctgt 1680
tggttcctgt ttcactggct gtttttagttt tgtgttaatt ggtgtttctg agcattcaaa 1740
ctccgcaccc tcgtttataa taaatgaata tttggaaaaa aaaaaaaaaa aaaaaaaaaa 1800
a 1801

```

&lt;210&gt; 154

&lt;211&gt; 245

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 154

```

Met Arg Leu Phe Val Arg Pro Ser Val Arg Pro Ala Met Ala Ala Pro
 1           5           10          15
Ala Pro Ser Pro Trp Thr Leu Ser Leu Leu Leu Leu Leu Leu Leu Pro
          20          25          30
Ser Pro Gly Ala His Gly Glu Leu Cys Arg Pro Phe Gly Glu Asp Asn
          35          40          45
Ser Ile Pro Glu Ser Cys Pro Asp Phe Cys Cys Gly Ser Cys Ser Ser
          50          55          60
Gln Tyr Cys Cys Ser Asp Val Leu Lys Lys Ile Gln Trp Asn Glu Glu
65          70          75          80
Met Cys Pro Glu Pro Glu Ser Ser Arg Phe Ser Ala His Pro Glu Thr
          85          90          95
Pro Glu Gln Leu Gly Ser Ala Leu Lys Tyr Gln Ser Ser Leu Asp Ser
          100         105         110
Asp Asn Met Pro Gly Phe Gly Ala Thr Val Ala Ile Gly Leu Thr Val
          115         120         125
Phe Val Val Phe Ile Ala Thr Ile Ile Val Cys Phe Thr Cys Ser Cys
          130         135         140
Cys Cys Leu Tyr Lys Met Cys Cys Arg Pro Arg Pro Val Val Ser Asn
145         150         155         160
Thr Thr Thr Thr Thr Val Val His Thr Ala Tyr Pro Gln Pro Gln Pro

```

[illegible]

```
<210> 155
<211> 1801
<212> DNA
<213> Homo sapiens
```

[illegible]

```
<210> 156
<211> 245
<212> PRT
<213> Homo sapiens
```

```
<400> 156
Met Arg Leu Phe Val Arg Pro Ser Val Arg Pro Ala Met Ala Ala Pro
 1           5           10           15
```

```
<210> 157
<211> 1801
<212> DNA
<213> Homo sapiens
```

102

```

tctccatcag ctgtctgtct ggacgggtccc actgtctttc ctgggactat gtagagggcc 1320
acatgtattc actattcagg ctccagtggc ttccaggcca ggggcctctg tctactacac 1380
actctggttt ctccctacag tgtcttttta cgattagcca aacatattgc ctgttttttg 1440
tatccagatg tgtgataatt ggtgaggttg aaatccttgg ttcctggaga acaggaaacc 1500
tgacctctga cagtccgttt cccttgacac cagcttcata gaatacctga ctctgtact 1560
acagtccagt ttgttccagt agcagggaca ccagggccag gggttatctg gaccaaggg 1620
gggggtggag agcctggatg gtagctctgg accagatgtg aatgcctcca tattccctgt 1680
tggttcctgt ttcactggct gttttagttt tgtgttaatt ggtgtttctg agcattcaaa 1740
ctccgcaccc tcgtttataa taaatgaata tttggaaaaa aaaaaaaaaa aaaaaaaaaa 1800
a 1801

```

&lt;210&gt; 158

&lt;211&gt; 213

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 158

```

Met Ala Ala Pro Ala Pro Ser Leu Trp Thr Leu Leu Leu Leu Leu Leu
 1          5          10          15
Leu Leu Pro Pro Pro Pro Gly Ala His Gly Glu Leu Cys Arg Pro Phe
      20          25          30
Gly Glu Asp Asn Ser Ile Pro Val Phe Cys Pro Asp Phe Cys Cys Gly
      35          40          45
Ser Cys Ser Asn Gln Tyr Cys Cys Ser Asp Val Leu Arg Lys Ile Gln
      50          55          60
Trp Asn Glu Glu Met Cys Pro Glu Pro Glu Ser Ser Arg Phe Ser Thr
      65          70          75          80
Pro Ala Glu Glu Thr Pro Glu His Leu Gly Ser Ala Leu Lys Phe Arg
      85          90          95
Ser Ser Phe Asp Ser Asp Pro Met Ser Gly Phe Gly Ala Thr Val Ala
      100          105          110
Ile Gly Val Thr Met Phe Val Val Phe Ile Ala Thr Ile Ile Ile Cys
      115          120          125
Phe Thr Cys Ser Cys Cys Cys Leu Tyr Lys Met Cys Cys Pro Gln Arg
      130          135          140
Pro Val Val Thr Asn Thr Thr Thr Thr Val Val His Ala Pro Tyr
      145          150          155          160
Pro Gln Pro Gln Pro Gln Pro Val Ala Pro Ser Tyr Pro Gly Pro Thr
      165          170          175
Tyr Gln Gly Tyr His Pro Met Pro Pro Pro Ala Arg Asn Ala Ser Ser
      180          185          190
Thr Leu Pro Asn Ala Val Pro Thr Thr Leu Pro Gly Pro Ala His Arg
      195          200          205
Ala Ala Thr Leu Pro
      210

```

&lt;210&gt; 159

&lt;211&gt; 1858

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 159

```

gtcgaccac gcgtccgcgc ggaggttgcg gcggcacctg ggtcttgggc ttggtccgtc 60
tgttcgctcg tccgttggtc tgccccgcca tggtgcgcc ggcgccctct ctgtggaccc 120
tattgctgct gctgttgctg ctgccgcgcg ctccgggtgc ccatggtgag ctgtgcaggc 180
cctttggtga agacaattcg atcccagtg tctgtcctga tttctgttgt ggttccctgt 240
ccaaccaata ctgctgctcg gacgtgctga ggaaatcca gtggaatgag gaaatgtgtc 300
ctgagccaga gtccagcaga ttttccaccc ccgcggagga gacacccgaa catctgggtt 360

```

```

cagcgctgaa atttcgatcc agttttgaca gtagccctat gtcaggggttc ggagcgaccg      420
tcgccattgg cgtgaccatg tttgtgggtg ttattgccac tatcatcatc tgcttcacct      480
gctcctgctg ctgtctgtat aagatgtgct gcccccaacg cctgtcgtg accaacacca      540
caactactac cgtgggttcat gccccttacc ctcagcctca acctcaacct gtggcccccac      600
gctatcctgg accaacatac caggggtacc atcccatgcc cccccagcc aggaatgcca      660
gcagcacctt acccaacgca gtaccaccca ccctacctgg cccagcccac agggccgcca      720
ccctaccatg agtccttggc tggagccagc cagcctccat acaacccgac ctacatggat      780
tcctaaaga caattccctg aacctgcccc cagcctcttt ggctgccatt tatgtcgtgt      840
gtgagtgagt gatacgcaga gttctttact gctgtctgtg gtgtgtgtgc cttgtctaga      900
catgtggctt cctctgtgtg tgaccaggta ggcgcaagtc ttaccagtgt gggctgggac      960
caacctgttt tcttctcac ttgaaattgt actttctgaa atttcaagca aattaaaaaac     1020
aataaggtag gaggtatttc ccacgtcacc ccaaggtgac cagccatggc ctgtcatact     1080
taggagagca agctttttgc gggtagagag caggctttgg ggggtaacca gctagctgct     1140
gctaggcctt tattccagg gtttggctgc attggcagtg aggcaggtgg ctgggggtga     1200
caccaggtga caaggggact cagtggcagg gggtcacacc aggcagaaca ccatacactc     1260
tccatcagct gtctgtctgg atgtcactgt ccttcccggg gctgtataga gggccacatg     1320
tgttcactat tcaggctcca ctgggggaat tttctacct ttgctggctt ggctcctgct     1380
cccaggccag ggacctcggt ctgtctacta cacactctgg tttctccctg cactgtcttt     1440
ttactgttag ccaaacattt tgctgtttt ctgtctccag atgtgtgata attggtgtga     1500
gggtgaaatc cctggttcct ggaggacaga caacctgacc tccgactgtc agtttccctt     1560
gacaccatct tcatagaaat acctgactcc tgtaccacag tccagtttgt cccagtagca     1620
gggacaccaa ggccaatggg ttatctggac caaaggtggg gtggagggcc tagatggtat     1680
ctccggccca gatgtgaata cctccatatt ccctgttggg tcctgtttca ctggctgttt     1740
tagctttgtg ttgattggtg tttctgagca ttcagactcc gcaccctcat ttctaataaa     1800
tgcaacattg gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaagg gcggccgc      1858

```

&lt;210&gt; 160

&lt;211&gt; 213

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 160

```

Met Ala Ala Pro Ala Pro Ser Leu Trp Thr Leu Leu Leu Leu Leu Leu
 1              5              10              15
Leu Leu Pro Pro Pro Pro Gly Ala His Gly Glu Leu Cys Arg Pro Phe
 20              25              30
Gly Glu Asp Asn Ser Ile Pro Val Phe Cys Pro Asp Phe Cys Cys Gly
 35              40              45
Ser Cys Ser Asn Gln Tyr Cys Cys Ser Asp Val Leu Arg Lys Ile Gln
 50              55              60
Trp Asn Glu Glu Met Cys Pro Glu Pro Glu Ser Ser Arg Phe Ser Thr
 65              70              75              80
Pro Ala Glu Glu Thr Pro Glu His Leu Gly Ser Ala Leu Lys Phe Arg
 85              90              95
Ser Ser Phe Asp Ser Asp Pro Met Ser Gly Phe Gly Ala Thr Val Ala
 100             105             110
Ile Gly Val Thr Ile Phe Val Val Phe Ile Val Thr Ile Ile Ile Cys
 115             120             125
Phe Thr Cys Ser Cys Cys Cys Leu Tyr Lys Met Cys Cys Pro Gln Arg
 130             135             140
Pro Val Val Thr Asn Thr Thr Thr Thr Val Val His Ala Pro Tyr
 145             150             155             160
Pro Gln Pro Gln Pro Gln Pro Val Ala Pro Ser Tyr Pro Gly Pro Thr
 165             170             175
Tyr Gln Gly Tyr His Pro Met Pro Pro Pro Ala Arg Asn Ala Ser Ser
 180             185             190
Thr Leu Pro Asn Ala Val Pro Thr Thr Leu Pro Gly Pro Ala His Arg
 195             200             205

```

Ala Ala Thr Leu Pro

210

&lt;210&gt; 161

&lt;211&gt; 1858

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 161

```

gtcgacccac gcggtccgcgc ggaggttgcg gcggcaccgt ggtcttgggc ttggtccgtc      60
tggtcggtccg tccgttggtc tgtcccgcca tggctgcgcc ggcgccctct ctgtggaccc      120
tattgctgct gctgttgctg ctgccgcgcg ctcggggtgc ccatggtgag ctgtgcaggc      180
cctttggtga agacaattcg atcccagtg tctgtcctga tttctgttgt ggttcctggt      240
ccaaccaata ctgctgctcg gacgtgctga ggaaaatcca gtggaatgag gaaatgtgtc      300
ctgagccaga gtccagcaga ttttccaccc ccgcggagga gacacccgaa catctgggtt      360
cagcgctgaa atttcgatcc agttttgaca gtgaccctat gtcagggttc ggagcgaccg      420
tcgccattgg cgtgaccatc tttgtggtgt ttattgtcac tatcatcatc tgcttcacct      480
gtcctgtctg ctgtctgtat aagatgtgct gccccaaacg ccctgtcgtg accaacacca      540
caactactac cgtgggtcat gccccttacc ctcagcctca acctcaacct gtggccccc      600
gctatcctgg accaacatac cagggctacc atcccatgcc cccccagcc aggaatgcc      660
gcagcacctt acccaacgca gtaccaccca cctacctgg ccagcccac agggccgcc      720
ccctaccatg agtccttggc tggagccagc cagcctccat acaacccgac ctacatggat      780
tcctaaaga caattccctg aacctgccc cagcctcttt ggctgccatt tatgtcgtgt      840
gtgagtgagt gatacgaga gttctttact gctgtctgtg gtgtgtgtgc cttgtctaga      900
catgtggctt cctctgctgt tgaccaggta ggcgcaagtc ttaccagtgt gggtcgggac      960
caacctgttt tcttcctcac ttgaaattgt actttctgaa atttcaagca aattaaaaac     1020
aataaggtag gaggtatttc ccacgtcacc ccaaggtgac cagccatggc ctgtcatact     1080
taggagagca agctttttgc gggtagagag caggctttgg ggggtaacca gctagctgct     1140
gctaggcctt tattcccagg gtttggtcgc attggcagtg aggcagggtg ctgggggtga     1200
caccaggtga caaggggact cagtggcagg gggtcacacc aggcagaaca ccatacactc     1260
tccatcagct gtctgtctgg atgtcactgt ccttcccggg gctgtataga gggccacatg     1320
tgttcactat tcaggetcca ctgggggaat tttcctacct ttgctggctt ggctcctgct     1380
cccaggccag ggacctcggg ctgtctacta cacactctgg tttctccctg cactgtcttt     1440
ttactgttag ccaaacattt tgccgtgttt ctgtctccag atgtgtgata attggtgtga     1500
ggttgaaatc cctggttcct ggaggacaga caacctgacc tccgactgtc agtttcctt     1560
gacaccatct tcatagaaat acctgactcc tgtaccacag tccagtttgt ccagtagca     1620
gggacacca ggccaatggg ttatctggac caaaggtggg gtggagggcc tagatggtat     1680
ctccggccca gatgtgaata cctccatatt cctgtttggg tctgtttca ctggctgttt     1740
tagctttgtg ttgattggtg tttctgagca ttcagactcc gcacctcat ttctaataaa     1800
tgcaacattg gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaagg gcggccgc     1858

```

&lt;210&gt; 162

&lt;211&gt; 213

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 162

```

Met Ala Ala Pro Ala Pro Ser Leu Trp Thr Leu Leu Leu Leu Leu Leu
 1              5              10              15
Leu Leu Pro Pro Pro Pro Gly Ala His Gly Glu Leu Cys Arg Pro Phe
 20              25              30
Gly Glu Asp Asn Ser Ile Pro Val Phe Cys Pro Asp Phe Cys Cys Gly
 35              40              45
Ser Cys Ser Asn Gln Tyr Cys Cys Ser Asp Val Leu Arg Lys Ile Gln
 50              55              60
Trp Asn Glu Glu Met Cys Pro Glu Pro Glu Ser Ser Arg Phe Ser Thr
 65              70              75              80
Pro Ala Glu Glu Thr Pro Glu His Leu Gly Ser Ala Leu Lys Phe Arg

```

```
<210> 163
<211> 1858
<212> DNA
<213> Mus musculus
```

<210> 164  
<211> 213

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 164

```

Met Ala Ala Pro Ala Pro Ser Leu Trp Thr Leu Leu Leu Leu Leu Leu
 1          5          10          15
Leu Leu Pro Pro Pro Pro Gly Ala His Gly Glu Leu Cys Arg Pro Phe
          20          25          30
Gly Glu Asp Asn Ser Ile Pro Val Phe Cys Pro Asp Phe Cys Cys Gly
          35          40          45
Ser Cys Ser Asn Gln Tyr Cys Cys Ser Asp Val Leu Arg Lys Ile Gln
          50          55          60
Trp Asn Glu Glu Met Cys Pro Glu Pro Glu Ser Ser Arg Phe Ser Thr
65          70          75          80
Pro Ala Glu Glu Thr Pro Glu His Leu Gly Ser Ala Leu Lys Phe Arg
          85          90          95
Ser Ser Phe Asp Ser Asp Pro Met Ser Gly Phe Gly Ala Thr Val Ala
          100          105          110
Ile Gly Val Thr Ile Phe Val Val Phe Ile Ala Thr Ile Ile Ile Cys
          115          120          125
Phe Thr Cys Ser Cys Cys Cys Leu Tyr Lys Met Cys Cys Pro Gln Arg
          130          135          140
Pro Val Val Thr Asn Thr Thr Thr Thr Thr Val Val His Ala Pro Tyr
145          150          155          160
Pro Gln Pro Gln Pro Gln Pro Val Ala Pro Ser Tyr Pro Gly Pro Thr
          165          170          175
Tyr Gln Gly Tyr His Pro Met Pro Pro Pro Ala Arg Asn Ala Ser Ser
          180          185          190
Thr Leu Pro Asn Val Val Pro Thr Thr Leu Pro Gly Pro Ala His Arg
          195          200          205
Ala Ala Thr Leu Pro
          210

```

&lt;210&gt; 165

&lt;211&gt; 1858

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 165

```

gtcgacccac gcgtccgcgc ggaggttgcg gcggcacccgt ggtcttgggc ttgggtccgtc      60
tggtcggtccg tccgttggtc tgtcccgcca tggtcgcgcc ggcgcctct ctgtggaccc      120
tattgctgct gctgttgctg ctgccgcgc ctccgggtgc ccatggtgag ctgtgcaggc      180
cctttggtga agacaattcg atcccagtg tctgtcctga tttctgtgtt ggttctgtt      240
ccaaccaata ctgctgctcg gacgtgctga ggaaaatcca gtggaatgag gaaatgtgtc      300
ctgagccaga gtccagcaga ttttccaccc ccgcggagga gacaccgaa catctgggtt      360
cagcgctgaa atttcgatcc agttttgaca gtgaccctat gtcagggttc ggagcgaccg      420
tcgccattgg cgtgaccatc tttgtggtgt ttattgccac tatcatcatc tgcttcacct      480
gctcctgctg ctgtctgtat aagatgtgct gcccccaacg ccctgtcgtg accaacacca      540
caactactac cgtgggttcat gccccttacc ctcagcctca acctcaacct gtggccccca      600
gctatcctgg accaacatac cagggctacc atcccagtc ccccccagcc aggaatgcc      660
gcagcacct acccaacgta gtaccacca ccctacctgg ccagcccac agggccgcc      720
ccctaccatg agtccttggc tggagccagc cagcctccat acaaccgac ctacatggat      780
tcctaaaga caattccctg aacctgcccc cagcctcttt ggctgccatt tatgtcgtgt      840
gtgagtgagt gatacgcaga gttctttact gctgtctgtg gtgtgtgtgc cttgtctaga      900
catctggctt cctctgtgtg tgaccaggta ggcgcaagtc ttaccagtgt gggtcgggac      960
caacctgttt tcttcctcac ttgaaattgt actttctgaa atttcaagca aattaaaaac      1020
aataaggtag gaggtatttc ccacgtcacc ccaaggtgac cagccatggc ctgtcatact      1080
taggagagca agctttttgc gggtagagag caggctttgg ggggtaacca gctagctgct      1140

```

gctaggcctt	tattcccagg	gtttggctgc	attggcágtg	aggcaggtgg	ctgggggtga	1200
caccaggtga	caaggggact	cagtggcagg	gggtcacacc	aggcagaaca	ccatacactc	1260
tccatcagct	gtctgtctgg	atgtcactgt	ccttcccggg	gctgtataga	gggccacatg	1320
tgttcaactat	tcaggctcca	ctgggggaat	tttctacct	ttgctggctt	ggctcctgct	1380
cccaggccag	ggacctcggt	ctgtctacta	cacactctgg	tttctccctg	cactgtcttt	1440
ttactgttag	ccaaacattt	tgcctgtttt	ctgtctccag	atgtgtgata	attggtgtga	1500
ggttgaaatc	cctggttcct	ggaggacaga	caacctgacc	tccgactgtc	agtttccctt	1560
gacaccatct	tcatagaaat	acctgactcc	tgtaccacag	tccagtttgt	cccagtagca	1620
gggacaccaa	ggccaatggg	ttatctggac	caaaggtggg	gtggagggcc	tagatgggat	1680
ctccggccca	gatgtgaata	cctccatatt	ccctgttggg	tcctgtttca	ctggctgttt	1740
tagctttgtg	ttgattgggt	tttctgagca	ttcagactcc	gcaccctcat	ttctaataaa	1800
tgcaacattg	gaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaag	gcggccgc	1858

&lt;210&gt; 166

&lt;211&gt; 639

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 166

atggctgctg	cggcgccttc	tctgtggacc	ctattgctgc	tgtgtgtgct	gctgccgcgc	60
cctccgggtg	cccatggtga	gctgtgcagg	ccctttgggtg	aagacaattc	gatcccagtg	120
ttctgtcctg	atttctgttg	tggttcctgt	tccaaccaat	actgctgctc	ggacgtgctg	180
aggaaaatcc	agtggaatga	ggaaatgtgt	cctgagccag	agtccagcag	attttccacc	240
cccgcggagg	agacaccgga	acatctgggt	tcagcgtga	aatttcgata	cagttttgac	300
agtgacccta	tgtcagggtt	cggagcgacc	gtcgccattg	gcgtgaccat	gtttgtgggtg	360
tttattgcca	ctatcatcat	ctgcttcacc	tgtcctgct	gctgtctgta	taagatgtgc	420
tgcccccaac	gccctgtcgt	gaccaacacc	acaactacta	ccgtgggttca	tgcccccttac	480
cctcagcctc	aacctcaacc	tgtggccccc	agctatcctg	gaccaacata	ccaggggtac	540
catcccattg	cccccccagc	caggaatgcc	agcagcacc	tacccaacgc	agtaccacc	600
accctacctg	gccagccca	cagggccgcc	accctacca			639

&lt;210&gt; 167

&lt;211&gt; 639

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 167

atggctgctg	cggcgccttc	tctgtggacc	ctattgctgc	tgtgtgtgct	gctgccgcgc	60
cctccgggtg	cccatggtga	gctgtgcagg	ccctttgggtg	aagacaattc	gatcccagtg	120
ttctgtcctg	atttctgttg	tggttcctgt	tccaaccaat	actgctgctc	ggacgtgctg	180
aggaaaatcc	agtggaatga	ggaaatgtgt	cctgagccag	agtccagcag	attttccacc	240
cccgcggagg	agacaccgga	acatctgggt	tcagcgtga	aatttcgata	cagttttgac	300
agtgacccta	tgtcagggtt	cggagcgacc	gtcgccattg	gcgtgaccat	ctttgtgggtg	360
tttattgtca	ctatcatcat	ctgcttcacc	tgtcctgct	gctgtctgta	taagatgtgc	420
tgcccccaac	gccctgtcgt	gaccaacacc	acaactacta	ccgtgggttca	tgcccccttac	480
cctcagcctc	aacctcaacc	tgtggccccc	agctatcctg	gaccaacata	ccaggggtac	540
catcccattg	cccccccagc	caggaatgcc	agcagcacc	tacccaacgc	agtaccacc	600
accctacctg	gccagccca	cagggccgcc	accctacca			639

&lt;210&gt; 168

&lt;211&gt; 639

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 168

atggctgctg	cggcgccttc	tctgtggacc	ctattgctgc	tgtgtgtgct	gctgccgcgc	60
cctccgggtg	cccatggtga	gctgtgcagg	ccctttgggtg	aagacaattc	gatcccagtg	120
ttctgtcctg	atttctgttg	tggttcctgt	tccaaccaat	actgctgctc	ggacgtgctg	180

aggaaaatcc	agtggaatga	ggaaatgtgt	cctgagccag	agtccagcag	attttccacc	240
ccgcgcggagg	agacacccga	acatctgggt	tcagcgctga	aatttcgatc	cagttttgac	300
agtgacccta	tgtcagggtt	cggagcgacc	gtcgccattg	gcgtgaccat	ctttgtggtg	360
tttattgcca	ctatcatcat	ctgcttcacc	tgctcctgct	gctgtctgta	taagatgtgc	420
tgcccccaac	gccctgtcgt	gaccaacacc	acaactacta	ccgtggctca	tgcccccttac	480
cctcagcctc	aacctcaacc	tgtggccccc	agctatcctg	gaccaacata	ccagggttac	540
catcccatgc	cccccccagc	caggaatgcc	agcagcacc	tacccaacgc	agtaccacc	600
accctacctg	gcccagccca	cagggccgcc	accctacca			639

&lt;210&gt; 169

&lt;211&gt; 639

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 169

atggctgcgc	cggcgccctc	tctgtggacc	ctattgctgc	tgtgtttgt	gctgccgcgc	60
cctccgggtg	cccatggtga	gctgtgcagg	ccctttggtg	aagacaattc	gatcccagtg	120
ttctgtcctg	atcttctgtt	tgttccctgt	tccaaccaat	actgctgctc	ggacgtgctg	180
aggaaaatcc	agtggaatga	ggaaatgtgt	cctgagccag	agtccagcag	attttccacc	240
ccgcgcggagg	agacacccga	acatctgggt	tcagcgctga	aatttcgatc	cagttttgac	300
agtgacccta	tgtcagggtt	cggagcgacc	gtcgccattg	gcgtgaccat	ctttgtggtg	360
tttattgcca	ctatcatcat	ctgcttcacc	tgctcctgct	gctgtctgta	taagatgtgc	420
tgcccccaac	gccctgtcgt	gaccaacacc	acaactacta	ccgtgggttca	tgcccccttac	480
cctcagcctc	aacctcaacc	tgtggccccc	agctatcctg	gaccaacata	ccagggttac	540
catcccatgc	cccccccagc	caggaatgcc	agcagcacc	tacccaacgt	agtaccacc	600
accctacctg	gcccagccca	cagggccgcc	accctacca			639

&lt;210&gt; 170

&lt;211&gt; 1218

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 170

atggggccca	gcacccctct	cctcatcttg	ttccttttgt	catggtcggg	acccctccaa	60
ggacagcagc	accaccttgt	ggagtacatg	gaacgccgac	tagctgcttt	agaggaacgg	120
ctggcccagt	gccaggacca	gagtagtcgg	catgctgctg	agctgcggga	cttcaagaac	180
aagatgctgc	cactgctgga	ggtggcagag	aaggagcggg	aggcactcag	aactgaggcc	240
gacaccatct	ccgggagagt	ggatcgtctg	gagcgggagg	cagactatct	ggagacccag	300
aacccagctc	tgccctgtgt	agagtttgat	gagaagggtga	ctggaggccc	tgggacccaa	360
ggcaaggga	gaaggaatga	gaagtacgat	atggtgacag	actgtggcta	cacaatctct	420
caagtgaat	caatgaagat	tctgaagcga	tttgggtggc	cagctggtct	atggaccaag	480
gatccactgg	ggcaaacaga	gaagatctac	gtgttagatg	ggacacagaa	tgacacagcc	540
tttgtcttcc	caaggctgcg	tgacttcacc	cttgccatgg	ctgcccggaa	agcttcccga	600
gtccgggtgc	ccttcccctg	ggtaggcaca	gggcagctgg	tatatggtgg	ctttctttat	660
tttgtctcga	ggcctcctgg	aagacctggt	ggagggtggtg	agatggagaa	cactttgcag	720
ctaatacaat	tccacctggc	aaaccgaaca	gtggtggaca	gctcagtatt	cccagcagag	780
gggctgatcc	ccccctacgg	cttgacagca	gacacctaca	tcgacctggc	agctgatgag	840
gaaggtcttt	gggctgtcta	tgccacccgg	gaggatgaca	ggcacttgtg	tctggccaag	900
ttagatccac	agacactgga	cacagagcag	cagtgggaca	caccatgtcc	cagagagaat	960
gctgaggctg	cctttgtcat	ctgtgggacc	ctctatgtcg	tctataaacac	ccgtcctgcc	1020
agtcgggccc	gcacccagtg	ctcctttgat	gccagcggca	ccctgacccc	tgaacgggca	1080
gcactccctt	attttccccg	cagatatggt	gcccattgcca	gcctccgcta	taacccccga	1140
gaacgccagc	tctatgcctg	ggatgatggc	taccagattg	tctataagct	ggagatgagg	1200
aagaaagagg	aggaggtt					1218

&lt;210&gt; 171

&lt;211&gt; 1218

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 171

atggggccca	gcacccctct	cctcatcttg	ttccttttgt	catgggtcggg	acccctccaa	60
ggacagcagc	accaccttgt	ggagtacatg	gaacgccgac	tagctgcttt	agaggaacgg	120
ctggcccagt	gccaggacca	gagtagtcgg	catgctgctg	agctgcggga	cttcaagaac	180
aagatgctgc	cactgctgga	ggtggcagag	aaggagcggg	aggcactcag	aactgaggcc	240
gacaccatct	ccgggagagt	ggatcgtctg	gagcgggagg	tagactatct	ggagacccag	300
aacccagctc	tgccctgtgt	agagtttgat	gagaagggtg	ctggaggccc	tgggacccaa	360
ggcaaggga	gaaggaatga	gaagtacgat	atgggtgacag	actgtggcta	cacaatctct	420
caagtgagat	caatgaagat	tctgaagcga	tttgggtggc	cagctgggtct	atggaccaag	480
gatccactgg	ggcaaacaga	gaagatctac	gtgttagatg	ggacacagaa	tgacacagcc	540
tttgtcttcc	caaggctgcg	tgacttcacc	cttgccatgg	ctgcccggaa	agcttcccga	600
gtccgggtgc	ccttcccctg	ggtaggcaca	gggcagctgg	tatatgggtg	ctttctttat	660
tttgtctcga	ggcctcctgg	aagacctggg	ggaggtgggt	agatggagaa	cactttgcag	720
ctaatacaat	tccacctggc	aaaccgaaca	gtggtggaca	gctcagtatt	cccagcagag	780
gggtgatcc	ccccctacgg	cttgacagca	gacacctaca	tcgacctggc	agctgatgag	840
gaaggtcttt	gggtgtgtct	tgccaccggg	gaggatgaca	ggcacttgtg	tctggccaag	900
ttagatccac	agacactgga	cacagagcag	cagtgggaca	caccatgtcc	cagagagaat	960
gctgaggctg	cctttgtcat	ctgtgggacc	ctctatgtcg	tctataacac	ccgtcctgcc	1020
agtcggggccc	gcatccagtg	ctcctttgat	gccagcggca	ccctgacccc	tgaacgggca	1080
gcactccctt	attttccccg	cagatatggg	gcccattgcca	gcctccgcta	taacccccga	1140
gaacgcccagc	tctatgcctg	ggatgatggc	taccagattg	tctataagct	ggagatgagg	1200
aagaaagagg	aggaggtt					1218

&lt;210&gt; 172

&lt;211&gt; 1219

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 172

catggggccc	agcacccttc	tcctcatctt	gttccttttg	tcattggtcgg	gaccctccca	60
aggacagcag	caccaccttg	tggagtacat	ggaacgccga	ctagctgctt	tagaggaacg	120
gctggcccag	tgccaggacc	agagtagtcg	gcatgctgct	gagctgcggg	acttcaagaa	180
caagatgctg	ccactgctgg	aggtggcaga	gaaggagcgg	gaggcactca	gaactgaggc	240
cgacaccatc	tccgggagag	tggatcgtct	ggagcgggag	gtagactatc	tggagaccca	300
gaacccagct	ctgccctgtg	tagagtttga	tgagaagggtg	actggaggcc	ctgggaccaa	360
aggcaaggga	agaaggaatg	agaagtacga	tatgggtgaca	gactgtggct	acacaatctc	420
tcaagtgaga	tcaatgaaga	ttctgaagcg	atttgggtggc	ccagctggta	tatggaccaa	480
ggatccactg	gggcaaacag	agaagatcta	cgtgttagat	gggacacaga	atgacacagc	540
ctttgtcttc	ccaaggctgc	gtgacttcac	ccttgccatg	gctgcccggg	aagcttcccg	600
agtccgggtg	cccttcccct	gggtaggcac	agggcagctg	gtatatgggtg	gctttcttta	660
ttttgctcgg	aggcctcctg	gaagacctgg	tggaggtggg	gagatggaga	acactttgca	720
gctaatacaa	ttccacctgg	caaaccgaac	agtgggtggac	agctcagtat	ttccagcaga	780
ggggctgatc	ccccctacg	gcttgacagc	agacacctac	atcgacctgg	cagctgatga	840
ggaagggtctt	tgggctgtct	atgccaccgg	ggaggatgac	aggcacttgt	gtctggccaa	900
gttagatcca	cagacactgg	acacagagca	gcagtgggac	acaccatgtc	ccagagagaa	960
tgctgaggct	gcctttgtca	tctgtgggac	cctctatgtc	gtctataaca	ccgctcctgc	1020
cagtcggggcc	cgcattccagt	gtccttttga	tgccagcggc	accctgaccc	ctgaacgggc	1080
agcactccct	tattttcccc	gcagatatgg	tgcccatgcc	agcctccgct	ataacccccg	1140
agaacgccag	ctctatgcct	gggatgatgg	ctaccagatt	gtctataagc	tggagatgag	1200
gaagaaagag	gaggaggtt					1219

&lt;210&gt; 173

&lt;211&gt; 1218

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 173

atggggccca	gcacccctct	cctcatcttg	ttccttttgt	catggtcggg	acccctccaa	60
ggacagcagc	accaccttgt	ggagtacatg	gaacgccgac	tagctgcttt	agaggaacgg	120
ctggcccagt	gccaggacca	gagtagtcgg	catgctgctg	agctgcggga	cttcaagaac	180
aagatgctgc	cactgctgga	ggtggcagag	aaggagcggg	aggcactcag	aactgaggcc	240
gacaccatct	ccgggagagt	ggatcgtctg	gagcgggagg	tagactatct	ggagaccag	300
aaccagctc	tgcctgtgt	agagtttgat	gagaagggtga	ctggaggccc	tgggaccaa	360
ggcaaggga	gaaggaatga	gaagtacgat	atggtgacag	actgtggcta	cacaatctct	420
caagtgaat	caatgaagat	tctgaagcga	tttgggtggc	cagctggtct	atggaccaag	480
gatccactgg	ggcaaacaga	gaagatctac	gtgttagatg	ggacacagaa	tgacacagtc	540
tttgtcttcc	caaggctgcg	tgacttcacc	cttgccatgg	ctgcccggaa	agcttcccga	600
gtccgggtgc	ccttcccctg	ggtaggcaca	gggcagctgg	tatatggtgg	ctttctttat	660
tttgtctgga	ggcctcctgg	aagacctggt	ggaggtggtg	agatggagaa	cactttgcag	720
ctaatacaat	tccacctggc	aaaccgaaca	gtggtggaca	gtcagatatt	cccagcagag	780
gggctgatcc	ccccctacgg	cttgacagca	gacacctaca	tcgacctggc	agctgatgag	840
gaaggtcttt	gggctgtcta	tgccacccgg	gaggatgaca	ggcacttggt	tctggccaag	900
ttagatccac	agacactgga	cacagagcag	cagtgggaca	caccatgtcc	cagagagaat	960
gctgaggctg	cctttgtcat	ctgtgggacc	ctctatgtcg	tctataacac	ccgtcctgcc	1020
agtccggccc	gcactcagtg	ctcctttgat	gccagcggca	ccctgacccc	tgaacgggca	1080
gcactccctt	atcttcccgc	cagatatggt	gcccattgcca	gcctccgcta	taacccccga	1140
gaacgccagc	tctatgcctg	ggatgatggc	taccagattg	tctataagct	ggagatgagg	1200
aagaaagagg	aggagggtt					1218

&lt;210&gt; 174

&lt;211&gt; 729

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 174

atgaggccac	ttcttgccct	tctgcttctg	ggtctggtgt	caggctctcc	tcctctggac	60
gacaacaaga	tccccagcct	gtgtcccggg	cagcccggcc	ttccaggcac	accaggtcac	120
catggcagcc	aaggcctgcc	tggccgtgac	ggccgtgatg	gccgcgacgg	tgaccccgga	180
gctccgggag	agaaaggcga	gggcgggaga	ccgggactac	ctggcccacg	tggggagccc	240
gggccgcgtg	gagaggtagg	gcccattggg	gctatcgggc	ctgcggggga	gtgctcggtg	300
ccccacgat	cagccttcag	tgccaagcga	tccgagagcc	gggtacctcc	gccagccgac	360
acaccctac	ctttcgaccg	tgtgctgcta	aatgagcagg	gccattacga	ccccactact	420
ggcaagttca	ctgcacaagt	gcctggcgct	tactactttg	ctgtgcacgc	cactgtctac	480
cgggccagct	tgcagtttga	tcttgtcaaa	aacgggcagt	ccatcgccct	tttcttccag	540
tattttgggg	ggtggcccaa	gccagcctcg	ctctcagggg	gtgcgatggg	aaggctagaa	600
cctgaggacc	aggtgtgggt	gcaggtgggc	gtgggtgatt	acattggcat	ctatgccagc	660
atcaagacag	acagtacctt	ctctggattt	ctcgctctatt	ctgactggca	cagctcccca	720
gtcttcgct						729

&lt;210&gt; 175

&lt;211&gt; 729

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 175

atgaggccac	ttcttgccct	tctgcttctg	ggtctggtgt	caggctctcc	tcctctggac	60
gacaacaaga	tccccagcct	gtgtcccggg	cagcccggcc	ttccaggcac	accaggtcac	120
catggcagcc	aaggcctgcc	tggccgtgac	ggccgtgatg	gccgcgacgg	tgaccccgga	180
gctccgggag	agaaaggcga	gggcgggaga	ccgggactac	ctggcccacg	tggggagccc	240
gggccgcgtg	gagaggcagg	gcccattggg	gctatcgggc	ctgcggggga	gtgctcggtg	300
ccccacgat	cagtcttcag	tgccaagcga	tccgagagcc	gggtacctcc	gccagccgac	360
acaccctac	ctttcgaccg	tgtgctgcta	aatgagcagg	gccattacga	ccccactact	420
ggcaagttca	cctgccaagt	gcctggcgct	tactactttg	ctgtgcacgc	cactgtctac	480
cgggccagct	tgcaagttga	tcttgtcaaa	aacgggcagt	ccatcgccct	tttcttccag	540

tat	ttt	tg	ggg	ggt	ggcccaa	gcc	agcctcg	ctctc	agggg	gtg	cgatggt	aagg	ctagaa	600
cct	gagg	acc	aggt	gtgggt	gcaggt	gggc	gtgggtgatt	acatt	ggcat	ctat	gccagc			660
atca	agacag	acagt	acctt	ctctg	gattt	ctcgt	ctatt	ctgact	ggca	cagct	cccca			720
gtctt	cgct													729

&lt;210&gt; 176

&lt;211&gt; 729

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 176

atg	aggccac	ttctt	gccct	tct	gcttctg	ggt	ctggtgt	cagg	ctctcc	tcct	ctggac			60
gaca	acaaga	tcccc	agcct	gtg	tcccggg	cag	cccggcc	ttcc	aggcac	acc	aggtcac			120
cat	ggcagcc	aagg	cctgcc	tgg	ccgtgac	ggc	cgatg	gcc	gcgacgg	tgc	acccgga			180
gct	ccgggag	agaa	aggcga	ggg	cgggaga	ccg	ggactac	ctg	ggccacg	tgg	ggagccc			240
ggg	ccgcgtg	gag	aggcagg	gccc	atgggg	gct	atcgggc	ctg	cggggga	gtg	ctcggtta			300
cccc	cacgat	cagc	cttcag	tgcc	aagcga	tcc	gagagcc	ggg	tacctcc	gcc	agccgac			360
acac	ccctac	ctttc	gaccg	tgc	gctgcta	aat	gagcagg	gcc	attacga	cccc	actact			420
ggca	agttca	cctg	ccaagt	gcct	ggcgctc	tact	actttg	ctgt	gcacgc	cact	gtctac			480
cggg	ccagct	tgc	agtttga	tctt	gtcaaa	aac	gggcagt	ccat	cgcctc	ttt	cttccag			540
tat	tttgggg	ggt	ggcccaa	gcc	agcctcg	ctctc	agggg	gtg	cgatggt	aagg	ctagaa			600
cct	gaggacc	aggt	gtgggt	gcaggt	gggc	gtgggt	gatt	acatt	ggcat	ctat	gccagc			660
atca	agacag	acagt	acctt	ctctg	gattt	ctcgt	ctatt	ctgact	ggca	cagct	cccca			720
gtctt	cgct													729

&lt;210&gt; 177

&lt;211&gt; 729

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 177

atg	aggccac	ttctt	gccct	tct	gcttctg	ggt	ctggtgt	cagg	ctctcc	tcct	ctggac			60
gaca	acaaga	tcccc	agcct	gtg	tcccggg	cag	cccggcc	ttcc	aggcac	acc	aggtcac			120
cat	ggcagcc	aagg	cctgcc	tgg	ccgtgac	ggc	cgatg	gcc	gcgacgg	tgc	acccgga			180
gct	ccgggag	agaa	aggcga	ggg	cgggaga	ccg	ggactac	ctg	ggccacg	tgg	ggagccc			240
ggg	ccgcgtg	gag	aggcagg	gccc	atgggg	gct	atcgggc	ctg	cggggga	gtg	ctcggtta			300
cccc	cacgat	cagc	cttcag	tgcc	aagcga	tcc	gagagcc	ggg	tacctcc	gcc	agccgac			360
acac	ccctac	ctttc	gaccg	tgt	gctgcta	aat	gagcagg	gcc	attacga	cccc	actact			420
ggca	agttca	cctg	ccaagt	gcct	ggcgctc	tact	actttg	ctgt	gcacgc	cact	gtctac			480
cggg	ccagct	tgc	agtttga	tatt	gtcaaa	aac	gggcagt	ccat	cgcctc	ttt	cttccag			540
tat	tttgggg	ggt	ggcccaa	gcc	agcctcg	ctctc	agggg	gtg	cgatggt	aagg	ctagaa			600
cct	gaggacc	aggt	gtgggt	gcaggt	gggc	gtgggt	gatt	acatt	ggcat	ctat	gccagc			660
atca	agacag	acagt	acctt	ctctg	gattt	ctcgt	ctatt	ctgact	ggca	cagct	cccca			720
gtctt	cgct													729

&lt;210&gt; 178

&lt;211&gt; 1218

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 178

atg	gggcccc	gtg	ctcctct	gct	gctcctc	ttct	ttttt	gt	cat	ggac	ggg	acc	cttcag	60
ggac	agcagc	acc	acctt	gt	ggagt	acat	g	gaac	gcgcag	tag	ctgcctt	agag	gaacgg	120
ctg	ggcccaat	ccc	aggatca	gag	tagtcgg	cat	gctgcgcg	ag	cttcggga	ctt	caaaaac			180
aag	atgtttgc	ctct	cctgga	gg	tggcagag	aag	gagcggg	ag	accctcag	aact	gaagca			240
gact	ccatct	cag	gaagagt	gg	accgtatt	gaa	aggggag	tag	actatct	gg	agacacag			300
aacc	cagctt	tgc	cctgtgt	ag	agctggat	gaga	aggtga	ctg	gaggtcc	tgg	agccaaa			360
ggca	agggcc	ga	agaaatga	gaa	atacgat	atg	gtgacgg	act	gtagcta	cac	agtcgct			420

caggtgaggt	caatgaagat	cctgaagcgg	tttgggtggt	cagttggcct	atggaccaag	480
gatccgctgg	ggccagcaga	gaagatctac	gtgttagacg	gcaccagaa	cgacacggct	540
tttgtcttcc	caaggctgcg	tgacttcacc	cttgccatgg	ctgcccggaa	agcttcccga	600
attcgggtgc	ccttcccctg	ggtaggcacg	gggcagctgg	tgtacggtgg	cttcctttat	660
tatgctcgaa	ggcctcctgg	aggacctgga	gggggtggtg	aattggagaa	cactctgcag	720
ctgatcaaat	ttcacttggc	aaaccgaaca	gtggtggata	gctcagtgtt	ccctgcagag	780
agcctgatac	ccccctacgg	cctgacagca	gatacatata	tcgacctggc	agctgatgag	840
gagggcctgt	gggctgtcta	tgccactcga	gatgatgaca	ggcatttgtg	tctagccaag	900
ttagaccac	agacacttga	cacagagcag	cagtgggaca	caccatgtcc	cagagagaac	960
gcagaggctg	cgtttgtcat	ctgtgggacc	ctgtacgttg	tctataaacac	ccgccctgcc	1020
agtagggctc	gtattcagtg	ttccttcgat	gccagtggta	ctctcgcccc	tgaaagggca	1080
gcactctcct	attttccacg	ccgatatggt	gcccattgcca	gccttcgcta	taacccccgt	1140
gagcgccagc	tgtatgcctg	ggatgatggc	taccagattg	tctacaaatt	ggagatgaag	1200
aagaaggagg	aggaagtt					1218

&lt;210&gt; 179

&lt;211&gt; 1218

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 179

atggggccca	gtgctcctct	gctgctcctc	ttctttttgt	catggacggg	accccttcag	60
ggacagcagc	accaccttgt	ggagtacatg	gaacgccgac	tagctgcctt	agaggaacgg	120
ctggcccaat	gccaggatca	gagtagtcgg	catgctgccg	agcttcggga	cttcaaaaac	180
aagatgttgc	ctctcctgga	ggtggcagag	aaggagcggg	agaccctcag	aactgaagca	240
gactccatct	caggaagagt	ggaccgtctt	gaaagggagg	tagactatct	ggagacacag	300
aaccagctt	tgccctgtgt	agagctggat	gagaagggtga	ctggagggtcc	tggagccaaa	360
ggcaagggcc	gaagaaatga	gaaatacgat	atagtacgag	actgtagcta	cacagtcgct	420
caggtgaggt	caatgaagat	cctgaagcgg	tttgggtggt	cagttggcct	atggaccaag	480
gatccgctgg	ggccagcaga	gaagatctac	gtgttagacg	gcaccagaa	cgacacggct	540
tttgtcttcc	caaggctgcg	tgacttcacc	cttgccatgg	ctgcccggaa	agcttcccga	600
attcgggtgc	ccttcccctg	ggtaggcacg	gggcagctgg	tgtacggtgg	cttcctttat	660
tatgctcgaa	ggcctcctgg	aggacctgga	gggggtggtg	aattggagaa	cactctgcag	720
ctgatcaaat	ttcacttggc	aaaccgaaca	gtggtggata	gctcagtgtt	ccctgcagag	780
agcctgatac	ccccctacgg	cctgacagca	gatacatata	tcgacctggc	agctgatgag	840
gagggcctgt	gggctgtcta	tgccactcga	gatgatgaca	ggcatttgtg	tctagccaag	900
ttagaccac	agacacttga	cacagagcag	cagtgggaca	caccatgtcc	cagagagaac	960
gcagaggctg	cgtttgtcat	ctgtgggacc	ctgtacgttg	tctataaacac	ccgccctgcc	1020
agtagggctc	gtattcagtg	ttccttcgat	gccagtggta	ctctcgcccc	tgaaagggca	1080
gcactctcct	attttccacg	ccgatatggt	gcccattgcca	gccttcgcta	taacccccgt	1140
gagcgccagc	tgtatgcctg	ggatgatggc	taccagattg	tctacaaatt	ggagatgaag	1200
aagaaggagg	aggaagtt					1218

&lt;210&gt; 180

&lt;211&gt; 1218

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 180

atggggccca	gtgctcctct	gctgctcctc	ttctttttgt	catggacggg	accccttcag	60
ggacagcagc	accaccttgt	ggagtacatg	gaacgccgac	tagctgcctt	agaggaacgg	120
ctggcccaat	gccaggatca	gagtagtcgg	catgctgccg	agcttcggga	cttcaaaaac	180
aagatgttgc	ctctcctgga	ggtggcagag	aaggagcggg	agaccctcag	aactgaagca	240
gactccatct	caggaagagt	ggaccgtctt	gaaagggagg	tagactatct	ggagacacag	300
aaccagctt	tgccctgtgt	agagctggat	gagaagggtga	ctggagggtcc	tggagccaaa	360
ggcaagggcc	gaagaaatga	gaaatacgat	atggtagcgg	actgtagcta	cacagtcgct	420
caggtgaggt	caatgaagat	cctgaagcgg	tttgggtggt	cagttggcct	atggaccaag	480
gatccgctgg	ggccagcaga	gaagatctac	gcgttagacg	gcaccagaa	cgacacggct	540

tttgtcttcc	caaggctgcg	tgacttcacc	cttgccatgg	ctgcccggaa	agcttcccga	600
attcgggtgc	ccttcccctg	ggtaggcacg	gggcagctgg	tgtacggtgg	cttcctttat	660
tatgctcgaa	ggcctcctgg	aggacctgga	gggggtggtg	aattggagaa	cactctgcag	720
ctgatcaaat	ttcacttggc	aaaccgaaca	gtggtggata	gctcagtgtt	ccctgcagag	780
agcctgatac	ccccctacgg	cctgacagca	gatacatata	tcgacctggc	agctgatgag	840
gagggcctgt	gggctgtcta	tgccactcga	gatgatgaca	ggcatttgtg	tctagccaag	900
ttagaccac	agacacttga	cacagagcag	cagtgggaca	caccatgtcc	cagagagaac	960
gcagaggctg	cgtttgtcat	ctgtgggacc	ctgtacgttg	tctataacac	ccgccctgcc	1020
agtagggctc	gtattcagtg	ttccttcgat	gccagtggta	ctctcgcccc	tgaaagggca	1080
gcactctcct	attttccacg	ccgatatggg	gcccattgcca	gccttcgcta	taacccccgt	1140
gagcgccagc	tgtatgcctg	ggatgatggc	taccagattg	tctacaaatt	ggagatgaag	1200
aagaaggagg	aggaagtt					1218

&lt;210&gt; 181

&lt;211&gt; 1218

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 181

atggggccca	gtgctcctct	gctgctcctc	ttctttttgt	catggacggg	accccttcag	60
ggacagcagc	accaccttgt	ggagtacatg	gaacgccgac	tagctgcctt	agaggaacgg	120
ctggcccaat	gccaggatca	gagtagtcgg	catgctgccg	agcttcggga	cttcaaaaac	180
aagatgttgc	ctctcctgga	ggtggcagag	aaggagcggg	agaccctcag	aactgaagca	240
gactccatct	caggaagagt	ggaccgtctt	gaaagggagg	tagactatct	ggagacacag	300
aacccagctt	tgccctgtgt	agagctggat	gagaagggtga	ctggaggtcc	tggagccaaa	360
ggcaagggcc	gaagaaatga	gaaatacgat	atggtgacgg	actgtagcta	cacagtcgct	420
caggtgaggt	caatgaagat	cctgaagcgg	tttggtggtt	cagttggcct	atggaccaag	480
gatccgctgg	ggccagcaga	gaagatctac	gtgttagacg	gcaccagaa	cgacacggct	540
tttgtcttcc	caaggctgcg	tgacttcacc	cttgtcatgg	ctgcccggaa	agcttcccga	600
attcgggtgc	ccttcccctg	ggtaggcacg	gggcagctgg	tgtacggtgg	cttcctttat	660
tatgctcgaa	ggcctcctgg	aggacctgga	gggggtggtg	aattggagaa	cactctgcag	720
ctgatcaaat	ttcacttggc	aaaccgaaca	gtggtggata	gctcagtgtt	ccctgcagag	780
agcctgatac	ccccctacgg	cctgacagca	gatacatata	tcgacctggc	agctgatgag	840
gagggcctgt	gggctgtcta	tgccactcga	gatgatgaca	ggcatttgtg	tctagccaag	900
ttagaccac	agacacttga	cacagagcag	cagtgggaca	caccatgtcc	cagagagaac	960
gcagaggctg	cgtttgtcat	ctgtgggacc	ctgtacgttg	tctataacac	ccgccctgcc	1020
agtagggctc	gtattcagtg	ttccttcgat	gccagtggta	ctctcgcccc	tgaaagggca	1080
gcactctcct	attttccacg	ccgatatggg	gcccattgcca	gccttcgcta	taacccccgt	1140
gagcgccagc	tgtatgcctg	ggatgatggc	taccagattg	tctacaaatt	ggagatgaag	1200
aagaaggagg	aggaagtt					1218

&lt;210&gt; 182

&lt;211&gt; 1110

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; all "n" positions

&lt;223&gt; n=a, c, g, or t

&lt;400&gt; 182

atgatttccc	tccccggggc	cctggtgacc	aacttgntgc	ggtttttgtt	cctggggctg	60
agtgcctcgc	cgccccctc	gcgggcccag	ctgcaactgc	acttgcccgc	caaccgggtg	120
caggcgggtg	aggaggggga	aagtgggtgct	tcagcatggt	acaccttgca	caggagggcg	180
tcttcacccc	agccatggga	ggtgcccttt	gtgatgtggt	tcttcaaaca	gaaagaaaag	240
gaggatcagg	tgttgtccta	catcaatggg	gtcacaacaa	gcaaacctgg	agtatccttg	300
gtctactcca	tgcctccccg	gaacctgtcc	ctgcgggtgg	agggtctcca	ggagaaagac	360

tctggcccct	acagctgctc	cgtgaatgtg	caagacaaac	aaggcaaadc	tagggggccac	420
agcatcaaaa	ccttagaact	caatgtactg	gttcctccag	ctcctccatc	ctgccgtctc	480
caggggtgtg	cccatgtggg	ggcaaacgtg	accctgagct	gccagtctcc	aaggagtaag	540
cccgtgtgcc	aataccagt	ggatcggcag	cttccatcct	tccagacttt	ctttgcacca	600
gcattagatg	tcatccgtgg	gtctttaagc	ctcaccaacc	tttcgtcttc	catggctgga	660
gtctatgtct	gcaaggccca	caatgaggtg	ggcactgccc	aatgtaatgt	gacgctggaa	720
gtgagcacag	ggcctggagc	tgcagtgggt	gctgaagctg	ttgtgggtac	cctgggtgga	780
ctgggggttg	tggctgggct	ggctctcttg	taccaccgcc	ggggcaaggc	cctggaggag	840
ccagccaatg	atatcaagga	ggatgccatt	gctccccgga	ccctgccctg	gccaagagc	900
tcagacacaa	tctccaagaa	tgggaccctt	tcctctgtca	cctccgcacg	agccctccgg	960
ccaccccatg	gccctcccag	gcctgggtgca	ttgaccccca	cgcccagctc	atccagccag	1020
gccctgccct	caccaagaca	tgcccacgac	agatggggcc	caccctcaac	caatatcccc	1080
catccctggt	gggggttttt	cctttggcct				1110

&lt;210&gt; 183

&lt;211&gt; 1110

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; all "n" positions

&lt;223&gt; n=a, c, g, or t

&lt;400&gt; 183

atgatttccc	tcccggggcc	cctggtgacc	aacttgntgc	ggtttttgtt	cctggggctg	60
agtgcctcgc	cgccccctc	gcggggcccag	ctgcaactgc	acttgcccgc	caaccgggtg	120
cagggcggtg	aggaggggga	aagtgggtgct	tcagcatggt	acaccttgca	cagggaggtg	180
tcttcatccc	agccatggga	ggtgcccttt	gtgatgtggt	tcttcaaaca	gaaagaaaag	240
gaggatcagg	tgttgctccta	catcaatggg	gtcacacaac	gcaaacctgg	agtatccttg	300
gcctactcca	tgccctcccgc	gaacctgtcc	ctgcgggtgg	agggctctcca	ggagaaagac	360
tctggcccct	acagctgctc	cgtgaatgtg	caagacaaac	aaggcaaadc	tagggggccac	420
agcatcaaaa	ccttagaact	caatgtactg	gttcctccag	ctcctccatc	ctgccgtctc	480
caggggtgtg	cccatgtggg	ggcaaacgtg	accctgagct	gccagtctcc	aaggagtaag	540
cccgtgtgcc	aataccagt	ggatcggcag	cttccatcct	tccagacttt	ctttgcacca	600
gcattagatg	tcatccgtgg	gtctttaagc	ctcaccaacc	tttcgtcttc	catggctgga	660
gtctatgtct	gcaaggccca	caatgaggtg	ggcactgccc	aatgtaatgt	gacgctggaa	720
gtgagcacag	ggcctggagc	tgcagtgggt	gctgaagctg	ttgtgggtac	cctgggtgga	780
ctgggggttg	tggctgggct	ggctctcttg	taccaccgcc	ggggcaaggc	cctggaggag	840
ccagccaatg	atatcaagga	ggatgccatt	gctccccgga	ccctgccctg	gccaagagc	900
tcagacacaa	tctccaagaa	tgggaccctt	tcctctgtca	cctccgcacg	agccctccgg	960
ccaccccatg	gccctcccag	gcctgggtgca	ttgaccccca	cgcccagctc	atccagccag	1020
gccctgccct	caccaagaca	tgcccacgac	agatggggcc	caccctcaac	caatatcccc	1080
catccctggt	gggggttttt	cctttggcct				1110

&lt;210&gt; 184

&lt;211&gt; 1110

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; all "n" positions

&lt;223&gt; n=a, c, g, or t

&lt;400&gt; 184

atgatttccc	tcccggggcc	cctggtgacc	aacttgntgc	ggtttttgtt	cctggggctg	60
agtgcctcgc	cgccccctc	gcggggcccag	ctgcaactgc	acttgcccgc	caaccgggtg	120

caggcggtgg	aggaggggga	aagtgggtgct	tcagcatggt	acaccttgca	cagggaggtg	180
tcttcatccc	agccatggga	ggtgcccttt	gtgatgtggt	tcttcaaaca	gaaagaaaag	240
gaggatcagg	tggtgtccta	catcaatggg	gtcacaacaa	gcaaacctgg	agtatccttg	300
gtctactcca	tgccctcccg	gaacctgtcc	ctgcgggtgg	agggctctcca	ggagaaagac	360
tctggcccct	acagctgctc	cgtgaatgtg	caagacaaac	aaggcaaate	taggggccac	420
agcatcaaaa	ccttagaact	caatgtactg	gttcctccag	ctcctccatc	ctgccgtatc	480
caggggtgtgc	cccatgtggg	ggcaaactg	accctgagct	gccagtctcc	aaggagtaag	540
cccgtgtgcc	aataccagtg	ggatcggcag	cttccatcct	tccagacttt	ctttgcacca	600
gcattagatg	tcacccgtgg	gtctttaagc	ctcaccaacc	tttcgtcttc	catggctgga	660
gtctatgtct	gcaaggccca	caatgaggtg	ggcactgccc	aatgtaatgt	gacgctggaa	720
gtgagcacag	ggcctggagc	tgcatgtggt	gctgaagctg	ttgtgggtac	cctggttggg	780
ctgggggttg	tggtctgggt	ggtcctcttg	taccaccgcc	ggggcaaggc	cctggaggag	840
ccagccaatg	atatcaagga	ggatgccatt	gctccccgga	ccctgccctg	gccaagagac	900
tcagacacaa	tctccaagaa	tgggaccctt	tcctctgtca	cctccgcacg	agccctccgg	960
ccaccccatg	gccctcccag	gcctggtgca	ttgaccccca	cgcccagtct	atccagccag	1020
gccctgccct	caccaagaca	tgcccacgac	agatggggcc	caccctcaac	caatatcccc	1080
catccctggt	gggggttttt	cctttggctt				1110

&lt;210&gt; 185

&lt;211&gt; 1110

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; all "n" positions

&lt;223&gt; n=a, c, g, or t

&lt;400&gt; 185

atgatttccc	tcccggggcc	cctggtgacc	aacttgntgc	ggtttttgtt	cctggggctg	60
agtgcctcgc	cgccccctc	gcggggcccag	ctgcaactgc	acttgcccgc	caaccgggtg	120
caggcggtgg	aggaggggga	aagtgggtgct	tcagcatggt	acaccttgca	cagggaggtg	180
tcttcatccc	agccatggga	ggtgcccttt	gtgatgtggt	tcttcaaaca	gaaagaaaag	240
gaggatcagg	tggtgtccta	catcaatggg	gtcacaacaa	gcaaacctgg	agtatccttg	300
gtctactcca	tgccctcccg	gaacctgtcc	ctgcgggtgg	agggctctcca	ggagaaagac	360
tctggcccct	acagctgctc	cgtgaatgtg	caagacaaac	aaggcaaate	taggggccac	420
agcatcaaaa	ccttagaact	caatgtactg	gttcctccag	ctcctccatc	ctgccgtctc	480
caggggtgtgc	cccatgtggg	ggcaaactg	accctgagct	gccagtctcc	aaggagtaag	540
cccgttgtcc	aataccagtg	ggatcggcag	cttccatcct	tccagacttt	ctttgcacca	600
gcattagatg	tcacccgtgg	gtctttaagc	ctcaccaacc	tttcgtcttc	catggctgga	660
gtctatgtct	gcaaggccca	caatgaggtg	ggcactgccc	aatgtaatgt	gacgctggaa	720
gtgagcacag	ggcctggagc	tgcatgtggt	gctgaagctg	ttgtgggtac	cctggttggg	780
ctgggggttg	tggtctgggt	ggtcctcttg	taccaccgcc	ggggcaaggc	cctggaggag	840
ccagccaatg	atatcaagga	ggatgccatt	gctccccgga	ccctgccctg	gccaagagac	900
tcagacacaa	tctccaagaa	tgggaccctt	tcctctgtca	cctccgcacg	agccctccgg	960
ccaccccatg	gccctcccag	gcctggtgca	ttgaccccca	cgcccagtct	atccagccag	1020
gccctgccct	caccaagaca	tgcccacgac	agatggggcc	caccctcaac	caatatcccc	1080
catccctggt	gggggttttt	cctttggctt				1110

&lt;210&gt; 186

&lt;211&gt; 1182

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 186

atgattcttc	aggctggaac	ccccgagacc	agcttgctgc	gggttttgtt	cctgggactg	60
agtacccttg	ctgccttctc	ccgagctcag	atggagttgc	acgtgcccc	gggcctcaac	120
aaattggaag	cggtagaggg	agaagaagtg	gtgctccccg	cctggtacac	gatggcacgg	180

gaggagtcgt	ggtcccaccc	ccgggaggtg	cccatcatga	tctggttctt	ggaacaagaa	240
gggaaggaac	caaaccaggt	gttgtcttac	attaatggag	tcatgacaaa	taaacctgga	300
acagccctgg	tccactctat	ctcttcacgg	aatgtgtccc	tgcgccctggg	ggcactccag	360
gagggagact	ctgggactta	ccgctgttct	gtcaatgtgc	agaatgatga	aggcaaaaagt	420
ataggccaca	gcatacaaaag	catagagctc	aaagtgtctg	ttcctccagc	tcctccatcc	480
tgtagtcttac	aggggtgtacc	ctatgtcggg	accaatgtga	ccctgaactg	caagtcccca	540
aggagtaaac	ctactgctca	gtaccagtg	gagaggctgg	ccccatcctc	ccagggtcttc	600
tttgaccag	ccttagatgc	tgttcgtgga	tctttaaagc	tactaacct	ttccattgcc	660
atgtctggag	tctatgtctg	caaggctcaa	aacagagtgg	gctttgcca	gtgcaacgtg	720
accttgacg	tgatgacagg	gtccaaggct	gcagtggctg	ctggagcagt	tgtgggcact	780
tttggtgggt	tgggtgctgat	agctgggctg	gtcctgttgt	accagcgccg	gagcaagacc	840
ttggaagagc	tggccaatga	tatcaaggaa	gatgccattg	ctccccggac	cttgccctgg	900
accaaaggct	cagacacaat	ctccaagaat	gggacacttt	cttcgggtcac	ctcagcacga	960
gctctgcggc	cacccaaggc	tgctcctcca	agacctggca	catttactcc	cacacccagt	1020
gtctctagcc	aggccctgtc	ctcaccaaga	ctgcccagg	tagatgaacc	cccacctcag	1080
gcagtgtccc	tgaccccagg	tggggtttct	tcttctgtct	tgagccgcac	gggtgctgtg	1140
cctgtgatgg	tgccctgcaca	gagtcaggct	gggtctcttg	tg		1182

&lt;210&gt; 187

&lt;211&gt; 1182

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 187

atgattcttc	aggctggaac	ccccgagacc	agcttgctgc	gggttttgtt	cctgggactg	60
agtacccttg	ctgccttctc	ccgagctcag	atggagtgtg	acgtgcccc	gggcctcaac	120
aaattggaag	cggtagaggg	agaagaagtg	gtgctccccg	cctggtacac	gatggcacgg	180
gaggagtcgt	ggtcccaccc	ccgggaggtg	cccatcctga	tctggttctt	ggaacaagaa	240
gggaaggaac	caaaccaggt	gttgtcttac	attaatggag	tcatgacaaa	taaacctgga	300
acagccctgg	tccactctat	ctcttcacgg	aatgtgtccc	tgcgccctggg	ggcactccag	360
gagggagact	ctgggactta	ccgctgttct	gtcaatgtgc	agaatgatga	aggcaaaaagt	420
ataggccaca	gcatacaaaag	catagagctc	aaagcgctgg	ttcctccagc	tcctccatcc	480
tgtagtcttac	aggggtgtacc	ctatgtcggg	accaatgtga	ccctgaactg	caagtcccca	540
aggagtaaac	ctactgctca	gtaccagtg	gagaggctgg	ccccatcctc	ccagggtcttc	600
tttgaccag	ccttagatgc	tgttcgtgga	tctttaaagc	tactaacct	ttccattgcc	660
atgtctggag	tctatgtctg	caaggctcaa	aacagagtgg	gctttgcca	gtgcaacgtg	720
accttgacg	tgatgacagg	gtccaaggct	gcagtggctg	ctggagcagt	tgtgggcact	780
tttggtgggt	tgggtgctgat	agctgggctg	gtcctgttgt	accagcgccg	gagcaagacc	840
ttggaagagc	tggccaatga	tatcaaggaa	gatgccattg	ctccccggac	cttgccctgg	900
accaaaggct	cagacacaat	ctccaagaat	gggacacttt	cttcgggtcac	ctcagcacga	960
gctctgcggc	cacccaaggc	tgctcctcca	agacctggca	catttactcc	cacacccagt	1020
gtctctagcc	aggccctgtc	ctcaccaaga	ctgcccagg	tagatgaacc	cccacctcag	1080
gcagtgtccc	tgaccccagg	tggggtttct	tcttctgtct	tgagccgcac	gggtgctgtg	1140
cctgtgatgg	tgccctgcaca	gagtcaggct	gggtctcttg	tg		1182

&lt;210&gt; 188

&lt;211&gt; 1182

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 188

atgattcttc	aggctggaac	ccccgagacc	agcttgctgc	gggttttgtt	cctgggactg	60
agtacccttg	ctgccttctc	ccgagctcag	atggagtgtg	acgtgcccc	gggcctcaac	120
aaattggaag	cggtagaggg	agaagaagtg	gtgctccccg	cctggtacac	gatggcacgg	180
gaggagtcgt	ggtcccaccc	ccgggaggtg	cccatcctga	tctggttctt	ggaacaagaa	240
gggaaggaac	caaaccaggt	gttgtcttac	attaatggag	tcatgacaaa	taaacctgga	300
acagccctgg	tccactctat	ctcttcacgg	aatgtgtccc	tgcgccctggg	ggcactccag	360
gagggagact	ctgggactta	ccgctgttct	gtcaatgtgc	agaatgatga	aggcaaaaagt	420

atagggccaca	gcatcaaaag	catagagctc	aaagtgtctg	ttcctccagc	tctccatcc	480
tgtagtttac	agggtgtacc	ctatgtcggg	accaatgtga	ccctgaactg	caagtcccca	540
aggagtaaac	ctactgctca	gtaccagtgg	gagaggctgg	tcccatcctc	ccagggtcttc	600
tttggaccag	ccttagatgc	tgttcgtgga	tctttaaagc	tcactaacct	ttccattgcc	660
atgtctggag	tctatgtctg	caaggctcaa	aacagagtgg	gctttgccaa	gtgcaacgtg	720
accttggacg	tgatgacagg	gtccaaggct	gcagtggctg	ctggagcagt	tgtgggcact	780
tttgttgggt	tggtgctgat	agctgggctg	gtcctgttgt	accagcgccg	gagcaagacc	840
ttggaagagc	tggccaatga	tatcaaggaa	gatgccattg	ctccccggac	cttgcccttg	900
accaaaggct	cagacacaat	ctccaagaat	gggacacttt	cttcggtcac	ctcagcacga	960
gctctgcggc	cacccaaggc	tgctcctcca	agacctggca	catttactcc	cacacccagt	1020
gtctctagcc	aggccctgtc	ctcaccaaga	ctgcccaggg	tagatgaacc	cccacctcag	1080
gcagtgtccc	tgaccccagg	tggggtttct	tcttctgtct	tgagccgcat	gggtgctgtg	1140
cctgtgatgg	tgcttgacac	gagtcaggct	gggtctcttg	tg		1182

&lt;210&gt; 189

&lt;211&gt; 1182

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 189

atgattcttc	aggctggaac	ccccgagacc	agcttgtctg	gggttttgtt	cctgggactg	60
agtacccttg	ctgccttctc	ccgagctcag	atggagttgc	acgtgcccc	gggcctcaac	120
aaattggaag	cggtagaggg	agaagaagtg	gtgctcccc	cctggtacac	gatggcacgg	180
gaggagtctg	gggtccaccc	ccgggagggtg	cccattcctga	tctggttctt	ggaacaagaa	240
gggaagggaac	caaaccagggt	gttgtcttac	attaatggag	tcatgacaaa	taaacctgga	300
acagccctgg	tccactctat	ctcttcacgg	aatgtgtccc	tgcgccctggg	ggcactccag	360
gagggagact	ctgggactta	ccgctgttct	gtcaatgtgc	agaatgatga	aggcaaaagt	420
atagggccaca	gcatcaaaag	catagagctc	aaagtgtctg	ttcctccagc	tctccatcc	480
tgtagtttac	agggtgtacc	ctatgtcggg	accaatgtga	ccctgaactg	caagtcccca	540
aggagtaaac	ctactgctca	gtaccagtgg	gagaggctgg	ccccatcctc	ccagggtcttc	600
tttggaccag	ccttagatgc	tgttcgtgga	tctttaaagc	tcactaacct	ttccattgcc	660
atgtctggag	tctatgtctg	caaggctcaa	aacagagtgg	gctttgccaa	gtgcaacgtg	720
accttggacg	tgatgacagg	gtccaaggct	gcagtggctg	ctggagcagt	tgtgggcact	780
tttgttgggt	tggtgctgat	agctgggctg	gtcctgttgt	accagcgccg	gagcaagacc	840
ttggaagagc	tggccaatga	tatcaaggaa	gatgccattg	ctccccggac	cttgcccttg	900
accaaaggct	cagacacaat	ctccaagaat	gggacacttt	cttcggtcac	ctcagcacga	960
gctctgcggc	cacccaaggc	tgctcctcca	agacctggca	catttactcc	cacacccagt	1020
gtctctagcc	aggccctgtc	ctcaccaaga	ctgcccaggg	tagatgaacc	cccacctcag	1080
gcagtgtccc	tgaccccagg	tggggtttct	tcttctgttc	tgagccgcat	gggtgctgtg	1140
cctgtgatgg	tgcttgacac	gagtcaggct	gggtctcttg	tg		1182

&lt;210&gt; 190

&lt;211&gt; 735

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 190

atgcgtctgt	ttgtccgtcc	gtccgtccgt	cccgccatgg	ctgcgccggc	gccctctccg	60
tggacccttt	cgctgctgct	gttgttgcta	ctgccgtctc	cgggtgccc	tggcgagctg	120
tgcaggccct	tgggtgaaga	caattcgatc	ccagagtcct	gtcctgactt	ctgttgtggc	180
tctgttcca	gccaatactg	ctgctctgac	gtgctgaaga	aaatccagtg	gaatgaggaa	240
atgtgccctg	agccagagtc	cagcagattt	tccgccacc	cggagacacc	agaacagctg	300
ggttcagtc	tgaagtatca	gtccagtctt	gacagtga	acatgccagg	gttcggagcg	360
accgtggcca	tgggcctgac	cgtcttcgtg	gtgtttatcg	ctaccatcat	tgtgtgcttt	420
acctgtcct	gctgctgtct	atataagatg	tgctgccgcc	cacgacctgt	cgtgtccaac	480
accacaacta	ctaccgtggg	tcacaccgct	tacctcagc	ctcaacctgt	ggccccagc	540
tatcctggac	caacatacca	gggtaccat	cccatgcccc	cccagccagg	aatgccagca	600
gcaccctacc	caacgcagta	ccctccacc	tacctggccc	agccacagg	gccaccagcc	660

tatcatgaga	cgttggctgg	agccagccag	cctccataca	acccggccta	catggatccc	720
ccaaaggcag	ttccc					735

&lt;210&gt; 191

&lt;211&gt; 735

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 191

atgcgtctgt	ttgtccgtcc	gtccgtccgt	cccgccatgg	ctgcgccggc	gccctctccg	60
tggacccttt	cgctgctgct	gttggtgcta	ctgccgtctc	cgggtgcca	tggcgagctg	120
tgcaggccct	tcggtgaaga	caattcgatc	ccagagtcct	gtcctgactt	ctgttggtggc	180
tcctgttcca	gccaatactg	ctgctctgac	gtgctgaaga	aaatccagtg	gaatgaggaa	240
atgtgccctg	agccagagtc	cagcagattt	tccgcccacc	cggagacacc	agaacagctg	300
ggttcagcgc	tgaagtatca	gtccagtctt	gacagtgaca	acatgccagg	gttcggagcg	360
accgtggcca	tcggcctgac	cgtcttcgtg	gtgtttatcg	ctaccatcat	tgtgtgcttt	420
acctgtctct	gctgctgtct	atataagatg	tgctgccggc	cacgacctgt	cgtgtccaac	480
accacaacta	ctaccgcggt	tcacaccgct	taccctcagc	ctcaacctgt	ggcccccagc	540
tatcctggac	caacatacca	gggctaccat	cccatgcccc	cccagccagg	aatgccagca	600
gcaccctacc	caacgcagta	ccctccacc	tacctggccc	agcccacagg	gccaccagcc	660
tatcatgaga	cgttggctgg	agccagccag	cctccataca	acccggccta	catggatccc	720
ccaaaggcag	ttccc					735

&lt;210&gt; 192

&lt;211&gt; 735

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 192

atgcgtctgt	ttgtccgtcc	gtccgtccgt	cccgccatgg	ctgcgccggc	gccctctccg	60
tggacccttt	cgctgctgct	gttggtgcta	ctgccgtctc	cgggtgcca	tggcgagctg	120
tgcaggccct	tcggtgaaga	caattcgatc	ccagagtcct	gtcctgactt	ctgttggtggc	180
tcctgttcca	gccaatactg	ctgctctgac	gtgctgaaga	aaatccagtg	gaatgaggaa	240
atgtgccctg	agccagagtc	cagcagattt	tccgcccacc	cggagacacc	agaacagctg	300
ggttcagcgc	tgaagtatca	gtccagtctt	gacagtgaca	acatgccagg	gttcggagcg	360
accgtggcca	tcggcctgac	cgtcttcgtg	gtgtttatcg	ctaccatcat	tgtgtgcttt	420
acctgtctct	gctgctgtct	atataagatg	tgctgccggc	cacgacctgt	cgtgtccaac	480
accacaacta	ctaccgtggt	tcacaccgct	taccctcagc	ctcaacctgt	ggcccccagc	540
tatcctggac	caacatacca	gggctaccat	cccatgcccc	cccagccagg	aatgccagca	600
gtaccctacc	caacgcagta	ccctccacc	tacctggccc	agcccacagg	gccaccagcc	660
tatcatgaga	cgttggctgg	agccagccag	cctccataca	acccggccta	catggatccc	720
ccaaaggcag	ttccc					735

&lt;210&gt; 193

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; forward primer

&lt;400&gt; 193

caaagtgagc	tcattgctctc	ac	22
------------	-------------	----	----

&lt;210&gt; 194

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<220>  
<223> reverse primer

<400> 194  
ctctgtgtctt gggcagaaat c 21

<210> 195  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> forward primer

<400> 195  
ggagtatcct tgggtctactc c 21

<210> 196  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> reverse primer

<400> 196  
gaaagtctgg aaggatggaa gct 23

<210> 197  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> forward primer

<400> 197  
ggatgatggc taccagattg tc 22

<210> 198  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> reverse primer

<400> 198  
ggaacattga gggttttgac tc 22

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/16883

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07K 14/47; C07H 21/04; C12N 15/63, 1/21; C12P 21/02

US CL : 530/350; 536/23.5; 435/320.1, 252.3, 361, 69.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 536/23.5; 435/320.1, 252.3, 361, 69.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	WO 99/10492 A1 (ZYMOGENETICS, INC.) 04 March 1999 (04.03.99), see entire document, especially SEQ ID NOS: 1 and 2, page 4, line 16 to page 5, line 24, page 6, line 7 to page 8, line 17.	1-10 and 12 ----- 18
X	Database EST, National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index, AN AI481222. 'vh21h07.x1 Soares_mammary_gland_NbMMG Mus musculus cDNA clone IMAGE:876157 3' similar to SW:CA28_HUMAN P25067 COLLAGEN ALPHA 2(VIII) CHAIN :, mRNA sequence'. 09 March 1999.	1, 3-5



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

06 SEPTEMBER 2000

Date of mailing of the international search report

22 SEP 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EILEEN B. O'HARA

Telephone No. (703) 308-0196

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-10, 12 and 18

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

Commercial Sequence Databases: GenEmbl, N\_Geneseq\_36, Issued\_Patents\_NA, EST, a-geneseq36, swiss-prot38, stremb112, pir64, a-issued  
Sequences searched: SEQ ID NOS: 1-3 and 8-10

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-10, 12 and 18, in so far as they are drawn to human and mouse Tango 253, polynucleotides of SEQ ID NOS: 1, 2, 8 and 9, vector, host cell, method of producing a protein and polypeptides of SEQ ID NOS: 3-5 and 10-12.

Groups II-IV, claim(s) 1-10, 12 and 18, in so far as they are drawn to the polynucleotides of distinct cDNA clones and encoded proteins of human and mouse Intercept 258, Tango 281 and Tango 257, listed in Tables 1-4, pages 59-63.

Groups V-VIII, claim(s) 11 and 15, in so far as they are drawn to antibodies and binding compounds to the polypeptides listed in groups I-IV, respectively.

Groups IX-XII, claim(s) 13, 14, 19, 20 and 22, in so far as they are drawn to a method for detecting the presence of a polypeptide or a method for identifying a compound which binds to or modulates the activity of a polypeptide listed in groups I-IV, respectively.

Groups XIII-XVI, claim(s) 16 and 17, in so far as they are drawn to a method for detecting the presence of a nucleic acid molecule listed in groups I-IV, respectively.

Groups XVII-XX, claim 21, in so far as it is drawn to a method for modulating the activity of a polypeptide listed in groups I-IV, respectively.

The inventions listed as Groups I-XX do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Group I corresponds to the first invention wherein the first product is the polynucleotide and the first method of using is the method of making the protein. Note that there is no method of making the polynucleotide. The invention also includes the protein made. Each of groups II-IV does not share the same or corresponding special technical feature because each group is drawn to a different polynucleotide and encoded protein, and each of groups V-XX does not share the same or corresponding special technical feature because each group is drawn to different compounds or methods of using the four polynucleotides and encoded proteins. This Authority therefore considers that the several inventions do not share a special technical feature within the meaning of PCT Rule 13.2 and thus do not relate to a single general inventive concept within the meaning of PCT Rule 13.1.